TWI822055B - 共軛生物分子、醫藥組成物及方法 - Google Patents
共軛生物分子、醫藥組成物及方法 Download PDFInfo
- Publication number
- TWI822055B TWI822055B TW111119282A TW111119282A TWI822055B TW I822055 B TWI822055 B TW I822055B TW 111119282 A TW111119282 A TW 111119282A TW 111119282 A TW111119282 A TW 111119282A TW I822055 B TWI822055 B TW I822055B
- Authority
- TW
- Taiwan
- Prior art keywords
- cancer
- twenty
- antibody
- drug conjugate
- obi
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 107
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 12
- 229940049595 antibody-drug conjugate Drugs 0.000 claims abstract description 249
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 247
- 239000000611 antibody drug conjugate Substances 0.000 claims abstract description 247
- 238000009739 binding Methods 0.000 claims abstract description 100
- 201000011510 cancer Diseases 0.000 claims abstract description 99
- 230000027455 binding Effects 0.000 claims abstract description 97
- 239000003814 drug Substances 0.000 claims abstract description 56
- 229940079593 drug Drugs 0.000 claims abstract description 51
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 23
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 23
- 208000005718 Stomach Neoplasms Diseases 0.000 claims abstract description 20
- 206010017758 gastric cancer Diseases 0.000 claims abstract description 20
- 201000011549 stomach cancer Diseases 0.000 claims abstract description 20
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 16
- 201000005202 lung cancer Diseases 0.000 claims abstract description 16
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 16
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract description 15
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims abstract description 15
- 201000002528 pancreatic cancer Diseases 0.000 claims abstract description 15
- 208000008443 pancreatic carcinoma Diseases 0.000 claims abstract description 15
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 11
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims abstract description 11
- 206010025323 Lymphomas Diseases 0.000 claims abstract description 11
- 206010039491 Sarcoma Diseases 0.000 claims abstract description 11
- 206010060862 Prostate cancer Diseases 0.000 claims abstract description 10
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 10
- 201000007270 liver cancer Diseases 0.000 claims abstract description 10
- 208000014018 liver neoplasm Diseases 0.000 claims abstract description 10
- 206010005003 Bladder cancer Diseases 0.000 claims abstract description 9
- 208000003174 Brain Neoplasms Diseases 0.000 claims abstract description 9
- 208000008839 Kidney Neoplasms Diseases 0.000 claims abstract description 9
- 206010033128 Ovarian cancer Diseases 0.000 claims abstract description 9
- 206010061535 Ovarian neoplasm Diseases 0.000 claims abstract description 9
- 206010038389 Renal cancer Diseases 0.000 claims abstract description 9
- 208000000453 Skin Neoplasms Diseases 0.000 claims abstract description 9
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims abstract description 9
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims abstract description 9
- 201000010881 cervical cancer Diseases 0.000 claims abstract description 9
- 201000010536 head and neck cancer Diseases 0.000 claims abstract description 9
- 208000014829 head and neck neoplasm Diseases 0.000 claims abstract description 9
- 201000010982 kidney cancer Diseases 0.000 claims abstract description 9
- 201000000849 skin cancer Diseases 0.000 claims abstract description 9
- 201000005112 urinary bladder cancer Diseases 0.000 claims abstract description 9
- 206010014733 Endometrial cancer Diseases 0.000 claims abstract description 8
- 206010014759 Endometrial neoplasm Diseases 0.000 claims abstract description 8
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims abstract description 8
- 208000003445 Mouth Neoplasms Diseases 0.000 claims abstract description 8
- 208000006990 cholangiocarcinoma Diseases 0.000 claims abstract description 8
- 201000004101 esophageal cancer Diseases 0.000 claims abstract description 8
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims abstract description 8
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims abstract description 7
- 206010023825 Laryngeal cancer Diseases 0.000 claims abstract description 7
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims abstract description 7
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims abstract description 7
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims abstract description 7
- 201000010175 gallbladder cancer Diseases 0.000 claims abstract description 7
- 208000005017 glioblastoma Diseases 0.000 claims abstract description 7
- 201000002313 intestinal cancer Diseases 0.000 claims abstract description 7
- 206010023841 laryngeal neoplasm Diseases 0.000 claims abstract description 7
- 201000006958 oropharynx cancer Diseases 0.000 claims abstract description 7
- 206010031096 Oropharyngeal cancer Diseases 0.000 claims abstract description 6
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims abstract description 4
- 239000000126 substance Substances 0.000 claims description 103
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims description 77
- 241000282414 Homo sapiens Species 0.000 claims description 76
- 238000011282 treatment Methods 0.000 claims description 59
- 239000000203 mixture Substances 0.000 claims description 54
- 239000002904 solvent Substances 0.000 claims description 44
- 238000002360 preparation method Methods 0.000 claims description 33
- 238000009472 formulation Methods 0.000 claims description 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 20
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 13
- 239000003153 chemical reaction reagent Substances 0.000 claims description 11
- 201000005787 hematologic cancer Diseases 0.000 claims description 10
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 8
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 7
- 230000001093 anti-cancer Effects 0.000 claims description 7
- 108010044540 auristatin Proteins 0.000 claims description 7
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 6
- 206010057644 Testis cancer Diseases 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 201000003120 testicular cancer Diseases 0.000 claims description 6
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims description 3
- 230000028993 immune response Effects 0.000 claims description 3
- 239000013067 intermediate product Substances 0.000 claims description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 3
- 230000002924 anti-infective effect Effects 0.000 claims 2
- 230000001506 immunosuppresive effect Effects 0.000 claims 2
- 239000000427 antigen Substances 0.000 abstract description 164
- 108091007433 antigens Proteins 0.000 abstract description 164
- 102000036639 antigens Human genes 0.000 abstract description 164
- 210000004027 cell Anatomy 0.000 abstract description 127
- 239000012634 fragment Substances 0.000 abstract description 32
- 201000009030 Carcinoma Diseases 0.000 abstract description 8
- 238000011275 oncology therapy Methods 0.000 abstract description 3
- 206010004593 Bile duct cancer Diseases 0.000 abstract description 2
- 208000026900 bile duct neoplasm Diseases 0.000 abstract description 2
- 208000032839 leukemia Diseases 0.000 abstract 1
- 230000003442 weekly effect Effects 0.000 description 127
- 238000012360 testing method Methods 0.000 description 99
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 78
- 238000011580 nude mouse model Methods 0.000 description 78
- 108010093470 monomethyl auristatin E Proteins 0.000 description 74
- 239000003981 vehicle Substances 0.000 description 66
- 241000699660 Mus musculus Species 0.000 description 61
- 241001465754 Metazoa Species 0.000 description 48
- 230000000259 anti-tumor effect Effects 0.000 description 48
- 101001062093 Homo sapiens RNA-binding protein 15 Proteins 0.000 description 45
- 102100029244 RNA-binding protein 15 Human genes 0.000 description 45
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 43
- 241000699670 Mus sp. Species 0.000 description 41
- 238000002474 experimental method Methods 0.000 description 41
- 239000011780 sodium chloride Substances 0.000 description 38
- 108090000623 proteins and genes Proteins 0.000 description 37
- 239000001509 sodium citrate Substances 0.000 description 37
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 37
- 108060003951 Immunoglobulin Proteins 0.000 description 31
- 102000018358 immunoglobulin Human genes 0.000 description 31
- 235000018102 proteins Nutrition 0.000 description 30
- 102000004169 proteins and genes Human genes 0.000 description 30
- 201000010099 disease Diseases 0.000 description 28
- 108090000765 processed proteins & peptides Proteins 0.000 description 28
- 150000001875 compounds Chemical class 0.000 description 27
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 24
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 24
- -1 glycoproteome Proteins 0.000 description 24
- 230000037396 body weight Effects 0.000 description 23
- 102000004196 processed proteins & peptides Human genes 0.000 description 20
- 210000004881 tumor cell Anatomy 0.000 description 20
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- 238000011316 allogeneic transplantation Methods 0.000 description 19
- 238000004458 analytical method Methods 0.000 description 19
- 238000005516 engineering process Methods 0.000 description 19
- 238000002347 injection Methods 0.000 description 19
- 239000007924 injection Substances 0.000 description 19
- 235000001014 amino acid Nutrition 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 17
- 241000124008 Mammalia Species 0.000 description 16
- 229940024606 amino acid Drugs 0.000 description 15
- 208000035475 disorder Diseases 0.000 description 15
- 125000005647 linker group Chemical group 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 14
- 239000000562 conjugate Substances 0.000 description 14
- 229940002612 prodrug Drugs 0.000 description 14
- 239000000651 prodrug Substances 0.000 description 14
- 230000001225 therapeutic effect Effects 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 13
- 230000004071 biological effect Effects 0.000 description 12
- 150000004676 glycans Chemical class 0.000 description 12
- 238000010171 animal model Methods 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- 150000001720 carbohydrates Chemical class 0.000 description 11
- 235000014633 carbohydrates Nutrition 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- 230000000445 cytocidal effect Effects 0.000 description 10
- 230000004927 fusion Effects 0.000 description 10
- 229940072221 immunoglobulins Drugs 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 238000001990 intravenous administration Methods 0.000 description 10
- 230000004614 tumor growth Effects 0.000 description 10
- 241001529936 Murinae Species 0.000 description 9
- 230000021615 conjugation Effects 0.000 description 9
- 231100000409 cytocidal Toxicity 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 108010082117 matrigel Proteins 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 241000894007 species Species 0.000 description 9
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 230000005856 abnormality Effects 0.000 description 8
- 229940127089 cytotoxic agent Drugs 0.000 description 8
- 238000002054 transplantation Methods 0.000 description 8
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 125000000524 functional group Chemical group 0.000 description 7
- 238000010253 intravenous injection Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000002207 metabolite Substances 0.000 description 7
- 229920001282 polysaccharide Polymers 0.000 description 7
- 239000005017 polysaccharide Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 239000003053 toxin Substances 0.000 description 7
- 231100000765 toxin Toxicity 0.000 description 7
- 108700012359 toxins Proteins 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 125000003342 alkenyl group Chemical group 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000004663 cell proliferation Effects 0.000 description 6
- 238000004587 chromatography analysis Methods 0.000 description 6
- 238000002648 combination therapy Methods 0.000 description 6
- 229920001577 copolymer Polymers 0.000 description 6
- 238000010494 dissociation reaction Methods 0.000 description 6
- 230000005593 dissociations Effects 0.000 description 6
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 6
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 6
- 238000013401 experimental design Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 239000003094 microcapsule Substances 0.000 description 6
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 208000031648 Body Weight Changes Diseases 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 101100149252 Caenorhabditis elegans sem-5 gene Proteins 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 230000004579 body weight change Effects 0.000 description 5
- 239000001569 carbon dioxide Substances 0.000 description 5
- 229910002092 carbon dioxide Inorganic materials 0.000 description 5
- 230000002354 daily effect Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 239000007941 film coated tablet Substances 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 230000002062 proliferating effect Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 238000007492 two-way ANOVA Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 101100042265 Caenorhabditis elegans sem-2 gene Proteins 0.000 description 4
- 101100149246 Caenorhabditis elegans sem-4 gene Proteins 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- 108090000848 Ubiquitin Proteins 0.000 description 4
- 102400000757 Ubiquitin Human genes 0.000 description 4
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 4
- 125000004450 alkenylene group Chemical group 0.000 description 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 229930195731 calicheamicin Natural products 0.000 description 4
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 4
- 230000009702 cancer cell proliferation Effects 0.000 description 4
- 239000012829 chemotherapy agent Substances 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 125000006575 electron-withdrawing group Chemical group 0.000 description 4
- 238000001962 electrophoresis Methods 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 201000000050 myeloid neoplasm Diseases 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 238000010647 peptide synthesis reaction Methods 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 238000010149 post-hoc-test Methods 0.000 description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
- 230000002285 radioactive effect Effects 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 239000011550 stock solution Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
- 238000009423 ventilation Methods 0.000 description 4
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 3
- BTOVVHWKPVSLBI-UHFFFAOYSA-N 2-methylprop-1-enylbenzene Chemical compound CC(C)=CC1=CC=CC=C1 BTOVVHWKPVSLBI-UHFFFAOYSA-N 0.000 description 3
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 3
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 3
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 238000010152 Bonferroni least significant difference Methods 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 3
- 108090000994 Catalytic RNA Proteins 0.000 description 3
- 102000053642 Catalytic RNA Human genes 0.000 description 3
- 108010001857 Cell Surface Receptors Proteins 0.000 description 3
- 102000000844 Cell Surface Receptors Human genes 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108010067787 Proteoglycans Proteins 0.000 description 3
- 102000016611 Proteoglycans Human genes 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 206010041067 Small cell lung cancer Diseases 0.000 description 3
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 238000011374 additional therapy Methods 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- 229960002749 aminolevulinic acid Drugs 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 239000004037 angiogenesis inhibitor Substances 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 239000007859 condensation product Substances 0.000 description 3
- 229960004397 cyclophosphamide Drugs 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 3
- 238000000556 factor analysis Methods 0.000 description 3
- 229940087476 femara Drugs 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 3
- 230000005861 gene abnormality Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 229960001101 ifosfamide Drugs 0.000 description 3
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 125000000468 ketone group Chemical group 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 229940043355 kinase inhibitor Drugs 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- DHMTURDWPRKSOA-RUZDIDTESA-N lonafarnib Chemical compound C1CN(C(=O)N)CCC1CC(=O)N1CCC([C@@H]2C3=C(Br)C=C(Cl)C=C3CCC3=CC(Br)=CN=C32)CC1 DHMTURDWPRKSOA-RUZDIDTESA-N 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
- 229960000485 methotrexate Drugs 0.000 description 3
- 229960001156 mitoxantrone Drugs 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 150000002772 monosaccharides Chemical class 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000000269 nucleophilic effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 238000002428 photodynamic therapy Methods 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 239000003909 protein kinase inhibitor Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 108091092562 ribozyme Proteins 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 208000000587 small cell lung carcinoma Diseases 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 239000008399 tap water Substances 0.000 description 3
- 235000020679 tap water Nutrition 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- 238000013414 tumor xenograft model Methods 0.000 description 3
- LLDWLPRYLVPDTG-UHFFFAOYSA-N vatalanib succinate Chemical compound OC(=O)CCC(O)=O.C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 LLDWLPRYLVPDTG-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QCXJFISCRQIYID-IAEPZHFASA-N 2-amino-1-n-[(3s,6s,7r,10s,16s)-3-[(2s)-butan-2-yl]-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-10-propan-2-yl-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]-4,6-dimethyl-3-oxo-9-n-[(3s,6s,7r,10s,16s)-7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propa Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N=C2C(C(=O)N[C@@H]3C(=O)N[C@H](C(N4CCC[C@H]4C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]3C)=O)[C@@H](C)CC)=C(N)C(=O)C(C)=C2O2)C2=C(C)C=C1 QCXJFISCRQIYID-IAEPZHFASA-N 0.000 description 2
- AOPRXJXHLWYPQR-UHFFFAOYSA-N 2-phenoxyacetamide Chemical class NC(=O)COC1=CC=CC=C1 AOPRXJXHLWYPQR-UHFFFAOYSA-N 0.000 description 2
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 2
- FDKRLXBXYZKWRZ-UWJYYQICSA-N 3-[(21S,22S)-16-ethenyl-11-ethyl-4-hydroxy-12,17,21,26-tetramethyl-7,23,24,25-tetrazahexacyclo[18.2.1.15,8.110,13.115,18.02,6]hexacosa-1,4,6,8(26),9,11,13(25),14,16,18(24),19-undecaen-22-yl]propanoic acid Chemical compound CCC1=C(C2=NC1=CC3=C(C4=C(CC(=C5[C@H]([C@@H](C(=CC6=NC(=C2)C(=C6C)C=C)N5)C)CCC(=O)O)C4=N3)O)C)C FDKRLXBXYZKWRZ-UWJYYQICSA-N 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 238000009010 Bradford assay Methods 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 2
- 101710095468 Cyclase Proteins 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000003951 Erythropoietin Human genes 0.000 description 2
- 108090000394 Erythropoietin Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 229930189413 Esperamicin Natural products 0.000 description 2
- UOACKFBJUYNSLK-XRKIENNPSA-N Estradiol Cypionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H](C4=CC=C(O)C=C4CC3)CC[C@@]21C)C(=O)CCC1CCCC1 UOACKFBJUYNSLK-XRKIENNPSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 206010015548 Euthanasia Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 102000009465 Growth Factor Receptors Human genes 0.000 description 2
- 108010009202 Growth Factor Receptors Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 108010000521 Human Growth Hormone Proteins 0.000 description 2
- 102000002265 Human Growth Hormone Human genes 0.000 description 2
- 239000000854 Human Growth Hormone Substances 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102100020880 Kit ligand Human genes 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 2
- 108010000817 Leuprolide Proteins 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- LYPFDBRUNKHDGX-SOGSVHMOSA-N N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 Chemical compound N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 LYPFDBRUNKHDGX-SOGSVHMOSA-N 0.000 description 2
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 108010013639 Peptidoglycan Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 102000003946 Prolactin Human genes 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108010039445 Stem Cell Factor Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 102000036693 Thrombopoietin Human genes 0.000 description 2
- 108010041111 Thrombopoietin Proteins 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 2
- 229960003437 aminoglutethimide Drugs 0.000 description 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- 230000002280 anti-androgenic effect Effects 0.000 description 2
- 230000001772 anti-angiogenic effect Effects 0.000 description 2
- 230000003388 anti-hormonal effect Effects 0.000 description 2
- 239000000051 antiandrogen Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229940087620 aromasin Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229940120638 avastin Drugs 0.000 description 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229960000397 bevacizumab Drugs 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 2
- 201000000053 blastoma Diseases 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 108700002839 cactinomycin Proteins 0.000 description 2
- 229950002826 canertinib Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 229930188550 carminomycin Natural products 0.000 description 2
- XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 2
- XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229950001725 carubicin Drugs 0.000 description 2
- 108010047060 carzinophilin Proteins 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012412 chemical coupling Methods 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 229960004630 chlorambucil Drugs 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- ZYVSOIYQKUDENJ-WKSBCEQHSA-N chromomycin A3 Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1OC(C)=O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@@H](C)[C@H](OC(C)=O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@@H]1C[C@@H](O)[C@@H](OC)[C@@H](C)O1 ZYVSOIYQKUDENJ-WKSBCEQHSA-N 0.000 description 2
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 2
- 229960002286 clodronic acid Drugs 0.000 description 2
- 229940047120 colony stimulating factors Drugs 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 239000012084 conversion product Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000002716 delivery method Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 2
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 description 2
- 229930188854 dolastatin Natural products 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 201000008184 embryoma Diseases 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 208000037828 epithelial carcinoma Diseases 0.000 description 2
- 208000010932 epithelial neoplasm Diseases 0.000 description 2
- 229940105423 erythropoietin Drugs 0.000 description 2
- LJQQFQHBKUKHIS-WJHRIEJJSA-N esperamicin Chemical compound O1CC(NC(C)C)C(OC)CC1OC1C(O)C(NOC2OC(C)C(SC)C(O)C2)C(C)OC1OC1C(\C2=C/CSSSC)=C(NC(=O)OC)C(=O)C(OC3OC(C)C(O)C(OC(=O)C=4C(=CC(OC)=C(OC)C=4)NC(=O)C(=C)OC)C3)C2(O)C#C\C=C/C#C1 LJQQFQHBKUKHIS-WJHRIEJJSA-N 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 229960005416 estradiol cypionate Drugs 0.000 description 2
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 2
- MTZQAGJQAFMTAQ-UHFFFAOYSA-N ethyl benzoate Chemical compound CCOC(=O)C1=CC=CC=C1 MTZQAGJQAFMTAQ-UHFFFAOYSA-N 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000008191 folinic acid Nutrition 0.000 description 2
- 239000011672 folinic acid Substances 0.000 description 2
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- CHPZKNULDCNCBW-UHFFFAOYSA-N gallium nitrate Chemical compound [Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O CHPZKNULDCNCBW-UHFFFAOYSA-N 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000007614 genetic variation Effects 0.000 description 2
- 229940080856 gleevec Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 239000003966 growth inhibitor Substances 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 238000001114 immunoprecipitation Methods 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- DBIGHPPNXATHOF-UHFFFAOYSA-N improsulfan Chemical compound CS(=O)(=O)OCCCNCCCOS(C)(=O)=O DBIGHPPNXATHOF-UHFFFAOYSA-N 0.000 description 2
- 229950008097 improsulfan Drugs 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 229940084651 iressa Drugs 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 2
- 229960001691 leucovorin Drugs 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 229940040129 luteinizing hormone Drugs 0.000 description 2
- 210000004324 lymphatic system Anatomy 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- 229960001428 mercaptopurine Drugs 0.000 description 2
- 229960005558 mertansine Drugs 0.000 description 2
- ANZJBCHSOXCCRQ-FKUXLPTCSA-N mertansine Chemical compound CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCS)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ANZJBCHSOXCCRQ-FKUXLPTCSA-N 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 2
- 108010059074 monomethylauristatin F Proteins 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- QZGIWPZCWHMVQL-UIYAJPBUSA-N neocarzinostatin chromophore Chemical compound O1[C@H](C)[C@H](O)[C@H](O)[C@@H](NC)[C@H]1O[C@@H]1C/2=C/C#C[C@H]3O[C@@]3([C@@H]3OC(=O)OC3)C#CC\2=C[C@H]1OC(=O)C1=C(O)C=CC2=C(C)C=C(OC)C=C12 QZGIWPZCWHMVQL-UIYAJPBUSA-N 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
- NSFSLUUZQIAOOX-LDCXZXNSSA-N pheophorbide a Chemical compound N1C(C=C2[C@H]([C@H](CCC(O)=O)C(=N2)C2=C3NC(=C4)C(C)=C3C(=O)[C@@H]2C(=O)OC)C)=C(C)C(C=C)=C1C=C1C(C)=C(CC)C4=N1 NSFSLUUZQIAOOX-LDCXZXNSSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920002643 polyglutamic acid Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 229940097325 prolactin Drugs 0.000 description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 150000008518 pyridopyrimidines Chemical class 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 229960004622 raloxifene Drugs 0.000 description 2
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- KZUNJOHGWZRPMI-AKLPVKDBSA-N samarium-153 Chemical compound [153Sm] KZUNJOHGWZRPMI-AKLPVKDBSA-N 0.000 description 2
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 229960003787 sorafenib Drugs 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- PVYJZLYGTZKPJE-UHFFFAOYSA-N streptonigrin Chemical compound C=1C=C2C(=O)C(OC)=C(N)C(=O)C2=NC=1C(C=1N)=NC(C(O)=O)=C(C)C=1C1=CC=C(OC)C(OC)=C1O PVYJZLYGTZKPJE-UHFFFAOYSA-N 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229940034785 sutent Drugs 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- 229960002197 temoporfin Drugs 0.000 description 2
- 125000004187 tetrahydropyran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 229960001196 thiotepa Drugs 0.000 description 2
- 229960003087 tioguanine Drugs 0.000 description 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 229960000241 vandetanib Drugs 0.000 description 2
- 229950000578 vatalanib Drugs 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- 229960004355 vindesine Drugs 0.000 description 2
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 229940053867 xeloda Drugs 0.000 description 2
- 229950009268 zinostatin Drugs 0.000 description 2
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
- OYINILBBZAQBEV-UWJYYQICSA-N (17s,18s)-18-(2-carboxyethyl)-20-(carboxymethyl)-12-ethenyl-7-ethyl-3,8,13,17-tetramethyl-17,18,22,23-tetrahydroporphyrin-2-carboxylic acid Chemical compound N1C2=C(C)C(C=C)=C1C=C(N1)C(C)=C(CC)C1=CC(C(C)=C1C(O)=O)=NC1=C(CC(O)=O)C([C@@H](CCC(O)=O)[C@@H]1C)=NC1=C2 OYINILBBZAQBEV-UWJYYQICSA-N 0.000 description 1
- LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 1
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 1
- WOWDZACBATWTAU-FEFUEGSOSA-N (2s)-2-[[(2s)-2-(dimethylamino)-3-methylbutanoyl]amino]-n-[(3r,4s,5s)-1-[(2s)-2-[(1r,2r)-3-[[(1s,2r)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-n,3-dimethylbutanamide Chemical compound CC(C)[C@H](N(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)C1=CC=CC=C1 WOWDZACBATWTAU-FEFUEGSOSA-N 0.000 description 1
- FLWWDYNPWOSLEO-HQVZTVAUSA-N (2s)-2-[[4-[1-(2-amino-4-oxo-1h-pteridin-6-yl)ethyl-methylamino]benzoyl]amino]pentanedioic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1C(C)N(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FLWWDYNPWOSLEO-HQVZTVAUSA-N 0.000 description 1
- DLKUYSQUHXBYPB-NSSHGSRYSA-N (2s,4r)-4-[[2-[(1r,3r)-1-acetyloxy-4-methyl-3-[3-methylbutanoyloxymethyl-[(2s,3s)-3-methyl-2-[[(2r)-1-methylpiperidine-2-carbonyl]amino]pentanoyl]amino]pentyl]-1,3-thiazole-4-carbonyl]amino]-2-methyl-5-(4-methylphenyl)pentanoic acid Chemical compound N([C@@H]([C@@H](C)CC)C(=O)N(COC(=O)CC(C)C)[C@H](C[C@@H](OC(C)=O)C=1SC=C(N=1)C(=O)N[C@H](C[C@H](C)C(O)=O)CC=1C=CC(C)=CC=1)C(C)C)C(=O)[C@H]1CCCCN1C DLKUYSQUHXBYPB-NSSHGSRYSA-N 0.000 description 1
- CGMTUJFWROPELF-YPAAEMCBSA-N (3E,5S)-5-[(2S)-butan-2-yl]-3-(1-hydroxyethylidene)pyrrolidine-2,4-dione Chemical compound CC[C@H](C)[C@@H]1NC(=O)\C(=C(/C)O)C1=O CGMTUJFWROPELF-YPAAEMCBSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- XRBSKUSTLXISAB-XVVDYKMHSA-N (5r,6r,7r,8r)-8-hydroxy-7-(hydroxymethyl)-5-(3,4,5-trimethoxyphenyl)-5,6,7,8-tetrahydrobenzo[f][1,3]benzodioxole-6-carboxylic acid Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H](CO)[C@@H]2C(O)=O)=C1 XRBSKUSTLXISAB-XVVDYKMHSA-N 0.000 description 1
- XRBSKUSTLXISAB-UHFFFAOYSA-N (7R,7'R,8R,8'R)-form-Podophyllic acid Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C(CO)C2C(O)=O)=C1 XRBSKUSTLXISAB-UHFFFAOYSA-N 0.000 description 1
- AESVUZLWRXEGEX-DKCAWCKPSA-N (7S,9R)-7-[(2S,4R,5R,6R)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione iron(3+) Chemical compound [Fe+3].COc1cccc2C(=O)c3c(O)c4C[C@@](O)(C[C@H](O[C@@H]5C[C@@H](N)[C@@H](O)[C@@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO AESVUZLWRXEGEX-DKCAWCKPSA-N 0.000 description 1
- JXVAMODRWBNUSF-KZQKBALLSA-N (7s,9r,10r)-7-[(2r,4s,5s,6s)-5-[[(2s,4as,5as,7s,9s,9ar,10ar)-2,9-dimethyl-3-oxo-4,4a,5a,6,7,9,9a,10a-octahydrodipyrano[4,2-a:4',3'-e][1,4]dioxin-7-yl]oxy]-4-(dimethylamino)-6-methyloxan-2-yl]oxy-10-[(2s,4s,5s,6s)-4-(dimethylamino)-5-hydroxy-6-methyloxan-2 Chemical compound O([C@@H]1C2=C(O)C=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C2[C@@H](O[C@@H]2O[C@@H](C)[C@@H](O[C@@H]3O[C@@H](C)[C@H]4O[C@@H]5O[C@@H](C)C(=O)C[C@@H]5O[C@H]4C3)[C@H](C2)N(C)C)C[C@]1(O)CC)[C@H]1C[C@H](N(C)C)[C@H](O)[C@H](C)O1 JXVAMODRWBNUSF-KZQKBALLSA-N 0.000 description 1
- INAUWOVKEZHHDM-PEDBPRJASA-N (7s,9s)-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-7-[(2r,4s,5s,6s)-5-hydroxy-6-methyl-4-morpholin-4-yloxan-2-yl]oxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound Cl.N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1 INAUWOVKEZHHDM-PEDBPRJASA-N 0.000 description 1
- RCFNNLSZHVHCEK-IMHLAKCZSA-N (7s,9s)-7-(4-amino-6-methyloxan-2-yl)oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical compound [Cl-].O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)C1CC([NH3+])CC(C)O1 RCFNNLSZHVHCEK-IMHLAKCZSA-N 0.000 description 1
- NOPNWHSMQOXAEI-PUCKCBAPSA-N (7s,9s)-7-[(2r,4s,5s,6s)-4-(2,3-dihydropyrrol-1-yl)-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCC=C1 NOPNWHSMQOXAEI-PUCKCBAPSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- IEXUMDBQLIVNHZ-YOUGDJEHSA-N (8s,11r,13r,14s,17s)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one Chemical compound C1=CC(N(C)C)=CC=C1[C@@H]1C2=C3CCC(=O)C=C3CC[C@H]2[C@H](CC[C@]2(O)CCCO)[C@@]2(C)C1 IEXUMDBQLIVNHZ-YOUGDJEHSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- FONKWHRXTPJODV-DNQXCXABSA-N 1,3-bis[2-[(8s)-8-(chloromethyl)-4-hydroxy-1-methyl-7,8-dihydro-3h-pyrrolo[3,2-e]indole-6-carbonyl]-1h-indol-5-yl]urea Chemical compound C1([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C4=CC(O)=C5NC=C(C5=C4[C@H](CCl)C3)C)=C2C=C(O)C2=C1C(C)=CN2 FONKWHRXTPJODV-DNQXCXABSA-N 0.000 description 1
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 description 1
- APXRHPDHORGIEB-UHFFFAOYSA-N 1H-pyrazolo[4,3-d]pyrimidine Chemical class N1=CN=C2C=NNC2=C1 APXRHPDHORGIEB-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- BTOTXLJHDSNXMW-POYBYMJQSA-N 2,3-dideoxyuridine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(=O)NC(=O)C=C1 BTOTXLJHDSNXMW-POYBYMJQSA-N 0.000 description 1
- BOMZMNZEXMAQQW-UHFFFAOYSA-N 2,5,11-trimethyl-6h-pyrido[4,3-b]carbazol-2-ium-9-ol;acetate Chemical compound CC([O-])=O.C[N+]1=CC=C2C(C)=C(NC=3C4=CC(O)=CC=3)C4=C(C)C2=C1 BOMZMNZEXMAQQW-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- FDAYLTPAFBGXAB-UHFFFAOYSA-N 2-chloro-n,n-bis(2-chloroethyl)ethanamine Chemical compound ClCCN(CCCl)CCCl FDAYLTPAFBGXAB-UHFFFAOYSA-N 0.000 description 1
- CTRPRMNBTVRDFH-UHFFFAOYSA-N 2-n-methyl-1,3,5-triazine-2,4,6-triamine Chemical class CNC1=NC(N)=NC(N)=N1 CTRPRMNBTVRDFH-UHFFFAOYSA-N 0.000 description 1
- JIZRGGUCOQKGQD-UHFFFAOYSA-N 2-nitrothiophene Chemical group [O-][N+](=O)C1=CC=CS1 JIZRGGUCOQKGQD-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- YIMDLWDNDGKDTJ-QLKYHASDSA-N 3'-deamino-3'-(3-cyanomorpholin-4-yl)doxorubicin Chemical compound N1([C@H]2C[C@@H](O[C@@H](C)[C@H]2O)O[C@H]2C[C@@](O)(CC=3C(O)=C4C(=O)C=5C=CC=C(C=5C(=O)C4=C(O)C=32)OC)C(=O)CO)CCOCC1C#N YIMDLWDNDGKDTJ-QLKYHASDSA-N 0.000 description 1
- PYSRRFNXTXNWCD-UHFFFAOYSA-N 3-(2-phenylethenyl)furan-2,5-dione Chemical compound O=C1OC(=O)C(C=CC=2C=CC=CC=2)=C1 PYSRRFNXTXNWCD-UHFFFAOYSA-N 0.000 description 1
- PWMYMKOUNYTVQN-UHFFFAOYSA-N 3-(8,8-diethyl-2-aza-8-germaspiro[4.5]decan-2-yl)-n,n-dimethylpropan-1-amine Chemical compound C1C[Ge](CC)(CC)CCC11CN(CCCN(C)C)CC1 PWMYMKOUNYTVQN-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 1
- DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 description 1
- MVBCOYVJSZKRIV-UHFFFAOYSA-N 4-[10,15-diphenyl-20-(4-sulfophenyl)-2,3,22,24-tetrahydroporphyrin-5-yl]benzenesulfonic acid Chemical compound C1=CC(S(=O)(=O)O)=CC=C1C(C1=CC=C(N1)C(C=1C=CC=CC=1)=C1C=CC(=N1)C(C=1C=CC=CC=1)=C1C=CC(N1)=C1C=2C=CC(=CC=2)S(O)(=O)=O)=C2N=C1CC2 MVBCOYVJSZKRIV-UHFFFAOYSA-N 0.000 description 1
- XRYJULCDUUATMC-CYBMUJFWSA-N 4-[4-[[(1r)-1-phenylethyl]amino]-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenol Chemical compound N([C@H](C)C=1C=CC=CC=1)C(C=1C=2)=NC=NC=1NC=2C1=CC=C(O)C=C1 XRYJULCDUUATMC-CYBMUJFWSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- WYXSYVWAUAUWLD-SHUUEZRQSA-N 6-azauridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=N1 WYXSYVWAUAUWLD-SHUUEZRQSA-N 0.000 description 1
- 229960005538 6-diazo-5-oxo-L-norleucine Drugs 0.000 description 1
- YCWQAMGASJSUIP-YFKPBYRVSA-N 6-diazo-5-oxo-L-norleucine Chemical compound OC(=O)[C@@H](N)CCC(=O)C=[N+]=[N-] YCWQAMGASJSUIP-YFKPBYRVSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- HDZZVAMISRMYHH-UHFFFAOYSA-N 9beta-Ribofuranosyl-7-deazaadenin Natural products C1=CC=2C(N)=NC=NC=2N1C1OC(CO)C(O)C1O HDZZVAMISRMYHH-UHFFFAOYSA-N 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 101800002638 Alpha-amanitin Proteins 0.000 description 1
- CEIZFXOZIQNICU-UHFFFAOYSA-N Alternaria alternata Crofton-weed toxin Natural products CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
- 108090000644 Angiozyme Proteins 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- MBABCNBNDNGODA-LTGLSHGVSA-N Bullatacin Natural products O=C1C(C[C@H](O)CCCCCCCCCC[C@@H](O)[C@@H]2O[C@@H]([C@@H]3O[C@H]([C@@H](O)CCCCCCCCCC)CC3)CC2)=C[C@H](C)O1 MBABCNBNDNGODA-LTGLSHGVSA-N 0.000 description 1
- KGGVWMAPBXIMEM-JQFCFGFHSA-N Bullatacinone Natural products O=C(C[C@H]1C(=O)O[C@H](CCCCCCCCCC[C@H](O)[C@@H]2O[C@@H]([C@@H]3O[C@@H]([C@@H](O)CCCCCCCCCC)CC3)CC2)C1)C KGGVWMAPBXIMEM-JQFCFGFHSA-N 0.000 description 1
- KGGVWMAPBXIMEM-ZRTAFWODSA-N Bullatacinone Chemical compound O1[C@@H]([C@@H](O)CCCCCCCCCC)CC[C@@H]1[C@@H]1O[C@@H]([C@H](O)CCCCCCCCCC[C@H]2OC(=O)[C@H](CC(C)=O)C2)CC1 KGGVWMAPBXIMEM-ZRTAFWODSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 1
- VSEIDZLLWQQJGK-CHOZPQDDSA-N CCC1=C(C)C2=N\C\1=C/C1=C(C)C(C(O)=O)=C(N1)\C(CC(=O)N[C@@H](CC(O)=O)C(O)=O)=C1/N=C(/C=C3\N/C(=C\2)C(C=C)=C3C)[C@@H](C)[C@@H]1CCC(O)=O Chemical compound CCC1=C(C)C2=N\C\1=C/C1=C(C)C(C(O)=O)=C(N1)\C(CC(=O)N[C@@H](CC(O)=O)C(O)=O)=C1/N=C(/C=C3\N/C(=C\2)C(C=C)=C3C)[C@@H](C)[C@@H]1CCC(O)=O VSEIDZLLWQQJGK-CHOZPQDDSA-N 0.000 description 1
- YERZIAGTPZLUAO-UHFFFAOYSA-N CCCCCCCCCCCC(OCCOCC(C(C1OCCO)OCCC1OCCO)OCCO)=O Chemical compound CCCCCCCCCCCC(OCCOCC(C(C1OCCO)OCCC1OCCO)OCCO)=O YERZIAGTPZLUAO-UHFFFAOYSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- XCDXSSFOJZZGQC-UHFFFAOYSA-N Chlornaphazine Chemical compound C1=CC=CC2=CC(N(CCCl)CCCl)=CC=C21 XCDXSSFOJZZGQC-UHFFFAOYSA-N 0.000 description 1
- MKQWTWSXVILIKJ-LXGUWJNJSA-N Chlorozotocin Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](C=O)NC(=O)N(N=O)CCCl MKQWTWSXVILIKJ-LXGUWJNJSA-N 0.000 description 1
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 229930188224 Cryptophycin Natural products 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- AUGQEEXBDZWUJY-ZLJUKNTDSA-N Diacetoxyscirpenol Chemical compound C([C@]12[C@]3(C)[C@H](OC(C)=O)[C@@H](O)[C@H]1O[C@@H]1C=C(C)CC[C@@]13COC(=O)C)O2 AUGQEEXBDZWUJY-ZLJUKNTDSA-N 0.000 description 1
- AUGQEEXBDZWUJY-UHFFFAOYSA-N Diacetoxyscirpenol Natural products CC(=O)OCC12CCC(C)=CC1OC1C(O)C(OC(C)=O)C2(C)C11CO1 AUGQEEXBDZWUJY-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 229930193152 Dynemicin Natural products 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- 102100023471 E-selectin Human genes 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- AFMYMMXSQGUCBK-UHFFFAOYSA-N Endynamicin A Natural products C1#CC=CC#CC2NC(C=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C3)=C3C34OC32C(C)C(C(O)=O)=C(OC)C41 AFMYMMXSQGUCBK-UHFFFAOYSA-N 0.000 description 1
- SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- OBMLHUPNRURLOK-XGRAFVIBSA-N Epitiostanol Chemical compound C1[C@@H]2S[C@@H]2C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 OBMLHUPNRURLOK-XGRAFVIBSA-N 0.000 description 1
- DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 238000010155 Games-Howell test Methods 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229940125497 HER2 kinase inhibitor Drugs 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- 102000012214 Immunoproteins Human genes 0.000 description 1
- 108010036650 Immunoproteins Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102100025947 Insulin-like growth factor II Human genes 0.000 description 1
- 238000012695 Interfacial polymerization Methods 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102100039897 Interleukin-5 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102100021592 Interleukin-7 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 102000000585 Interleukin-9 Human genes 0.000 description 1
- 241000764238 Isis Species 0.000 description 1
- 108010044023 Ki-1 Antigen Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- JLERVPBPJHKRBJ-UHFFFAOYSA-N LY 117018 Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCC3)=CC=2)C2=CC=C(O)C=C2S1 JLERVPBPJHKRBJ-UHFFFAOYSA-N 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 206010024291 Leukaemias acute myeloid Diseases 0.000 description 1
- 229940123917 Lipid kinase inhibitor Drugs 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 239000004907 Macro-emulsion Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- VJRAUFKOOPNFIQ-UHFFFAOYSA-N Marcellomycin Natural products C12=C(O)C=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C=C2C(C(=O)OC)C(CC)(O)CC1OC(OC1C)CC(N(C)C)C1OC(OC1C)CC(O)C1OC1CC(O)C(O)C(C)O1 VJRAUFKOOPNFIQ-UHFFFAOYSA-N 0.000 description 1
- 229930126263 Maytansine Natural products 0.000 description 1
- IVDYZAAPOLNZKG-KWHRADDSSA-N Mepitiostane Chemical compound O([C@@H]1[C@]2(CC[C@@H]3[C@@]4(C)C[C@H]5S[C@H]5C[C@@H]4CC[C@H]3[C@@H]2CC1)C)C1(OC)CCCC1 IVDYZAAPOLNZKG-KWHRADDSSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102100026632 Mimecan Human genes 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- 101710204212 Neocarzinostatin Proteins 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- SYNHCENRCUAUNM-UHFFFAOYSA-N Nitrogen mustard N-oxide hydrochloride Chemical compound Cl.ClCC[N+]([O-])(C)CCCl SYNHCENRCUAUNM-UHFFFAOYSA-N 0.000 description 1
- 208000032234 No therapeutic response Diseases 0.000 description 1
- KGTDRFCXGRULNK-UHFFFAOYSA-N Nogalamycin Natural products COC1C(OC)(C)C(OC)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=C4C5(C)OC(C(C(C5O)N(C)C)O)OC4=C3C3=O)=C3C=C2C(C(=O)OC)C(C)(O)C1 KGTDRFCXGRULNK-UHFFFAOYSA-N 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 229930187135 Olivomycin Natural products 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 101800002327 Osteoinductive factor Proteins 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- VREZDOWOLGNDPW-ALTGWBOUSA-N Pancratistatin Chemical compound C1=C2[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)[C@@H]3NC(=O)C2=C(O)C2=C1OCO2 VREZDOWOLGNDPW-ALTGWBOUSA-N 0.000 description 1
- VREZDOWOLGNDPW-MYVCAWNPSA-N Pancratistatin Natural products O=C1N[C@H]2[C@H](O)[C@H](O)[C@H](O)[C@H](O)[C@@H]2c2c1c(O)c1OCOc1c2 VREZDOWOLGNDPW-MYVCAWNPSA-N 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010057150 Peplomycin Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-OUBTZVSYSA-N Phosphorus-32 Chemical compound [32P] OAICVXFJPJFONN-OUBTZVSYSA-N 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- 108010076181 Proinsulin Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 102000015537 Protein Kinase C-alpha Human genes 0.000 description 1
- 108010050276 Protein Kinase C-alpha Proteins 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- AHHFEZNOXOZZQA-ZEBDFXRSSA-N Ranimustine Chemical compound CO[C@H]1O[C@H](CNC(=O)N(CCCl)N=O)[C@@H](O)[C@H](O)[C@H]1O AHHFEZNOXOZZQA-ZEBDFXRSSA-N 0.000 description 1
- 108090000103 Relaxin Proteins 0.000 description 1
- 102000003743 Relaxin Human genes 0.000 description 1
- OWPCHSCAPHNHAV-UHFFFAOYSA-N Rhizoxin Natural products C1C(O)C2(C)OC2C=CC(C)C(OC(=O)C2)CC2CC2OC2C(=O)OC1C(C)C(OC)C(C)=CC=CC(C)=CC1=COC(C)=N1 OWPCHSCAPHNHAV-UHFFFAOYSA-N 0.000 description 1
- NSFWWJIQIKBZMJ-YKNYLIOZSA-N Roridin A Chemical compound C([C@]12[C@]3(C)[C@H]4C[C@H]1O[C@@H]1C=C(C)CC[C@@]13COC(=O)[C@@H](O)[C@H](C)CCO[C@H](\C=C\C=C/C(=O)O4)[C@H](O)C)O2 NSFWWJIQIKBZMJ-YKNYLIOZSA-N 0.000 description 1
- RXGJTYFDKOHJHK-UHFFFAOYSA-N S-deoxo-amaninamide Natural products CCC(C)C1NC(=O)CNC(=O)C2Cc3c(SCC(NC(=O)CNC1=O)C(=O)NC(CC(=O)N)C(=O)N4CC(O)CC4C(=O)NC(C(C)C(O)CO)C(=O)N2)[nH]c5ccccc35 RXGJTYFDKOHJHK-UHFFFAOYSA-N 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 229910052772 Samarium Inorganic materials 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 229920000519 Sizofiran Polymers 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- ISQRJFLLIDGZEP-CMWLGVBASA-N Sophoricoside Chemical group O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(C=2C(C3=C(O)C=C(O)C=C3OC=2)=O)C=C1 ISQRJFLLIDGZEP-CMWLGVBASA-N 0.000 description 1
- 108010088160 Staphylococcal Protein A Proteins 0.000 description 1
- 229920000147 Styrene maleic anhydride Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- BXFOFFBJRFZBQZ-QYWOHJEZSA-N T-2 toxin Chemical compound C([C@@]12[C@]3(C)[C@H](OC(C)=O)[C@@H](O)[C@H]1O[C@H]1[C@]3(COC(C)=O)C[C@@H](C(=C1)C)OC(=O)CC(C)C)O2 BXFOFFBJRFZBQZ-QYWOHJEZSA-N 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- CGMTUJFWROPELF-UHFFFAOYSA-N Tenuazonic acid Natural products CCC(C)C1NC(=O)C(=C(C)/O)C1=O CGMTUJFWROPELF-UHFFFAOYSA-N 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 1
- UMILHIMHKXVDGH-UHFFFAOYSA-N Triethylene glycol diglycidyl ether Chemical compound C1OC1COCCOCCOCCOCC1CO1 UMILHIMHKXVDGH-UHFFFAOYSA-N 0.000 description 1
- FYAMXEPQQLNQDM-UHFFFAOYSA-N Tris(1-aziridinyl)phosphine oxide Chemical compound C1CN1P(N1CC1)(=O)N1CC1 FYAMXEPQQLNQDM-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 241000813924 Verrucospora Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 description 1
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- PVNFMCBFDPTNQI-UIBOPQHZSA-N [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] acetate [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] 3-methylbutanoate [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] 2-methylpropanoate [(1S,2R,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl] propanoate Chemical compound CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(C)=O)[C@]2(C)OC2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2.CCC(=O)O[C@H]1CC(=O)N(C)c2cc(C\C(C)=C\C=C\[C@@H](OC)[C@@]3(O)C[C@H](OC(=O)N3)[C@@H](C)C3O[C@@]13C)cc(OC)c2Cl.CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)C(C)C)[C@]2(C)OC2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2.CO[C@@H]1\C=C\C=C(C)\Cc2cc(OC)c(Cl)c(c2)N(C)C(=O)C[C@H](OC(=O)CC(C)C)[C@]2(C)OC2[C@H](C)[C@@H]2C[C@@]1(O)NC(=O)O2 PVNFMCBFDPTNQI-UIBOPQHZSA-N 0.000 description 1
- SPJCRMJCFSJKDE-ZWBUGVOYSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] 2-[4-[bis(2-chloroethyl)amino]phenyl]acetate Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)C(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 SPJCRMJCFSJKDE-ZWBUGVOYSA-N 0.000 description 1
- IFJUINDAXYAPTO-UUBSBJJBSA-N [(8r,9s,13s,14s,17s)-17-[2-[4-[4-[bis(2-chloroethyl)amino]phenyl]butanoyloxy]acetyl]oxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-yl] benzoate Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4OC(=O)COC(=O)CCCC=1C=CC(=CC=1)N(CCCl)CCCl)C)CC2=CC=3OC(=O)C1=CC=CC=C1 IFJUINDAXYAPTO-UUBSBJJBSA-N 0.000 description 1
- IHGLINDYFMDHJG-UHFFFAOYSA-N [2-(4-methoxyphenyl)-3,4-dihydronaphthalen-1-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanone Chemical compound C1=CC(OC)=CC=C1C(CCC1=CC=CC=C11)=C1C(=O)C(C=C1)=CC=C1OCCN1CCCC1 IHGLINDYFMDHJG-UHFFFAOYSA-N 0.000 description 1
- XZSRRNFBEIOBDA-CFNBKWCHSA-N [2-[(2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]-2-oxoethyl] 2,2-diethoxyacetate Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)C(OCC)OCC)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 XZSRRNFBEIOBDA-CFNBKWCHSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 108010023617 abarelix Proteins 0.000 description 1
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 description 1
- 229960002184 abarelix Drugs 0.000 description 1
- 229940028652 abraxane Drugs 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- ZOZKYEHVNDEUCO-XUTVFYLZSA-N aceglatone Chemical compound O1C(=O)[C@H](OC(C)=O)[C@@H]2OC(=O)[C@@H](OC(=O)C)[C@@H]21 ZOZKYEHVNDEUCO-XUTVFYLZSA-N 0.000 description 1
- 229950002684 aceglatone Drugs 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 229930188522 aclacinomycin Natural products 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Chemical compound CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229950004955 adozelesin Drugs 0.000 description 1
- BYRVKDUQDLJUBX-JJCDCTGGSA-N adozelesin Chemical compound C1=CC=C2OC(C(=O)NC=3C=C4C=C(NC4=CC=3)C(=O)N3C[C@H]4C[C@]44C5=C(C(C=C43)=O)NC=C5C)=CC2=C1 BYRVKDUQDLJUBX-JJCDCTGGSA-N 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- JZMHCANOTJFLQJ-IEQBYLOXSA-A affinitac Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)CO)[C@@H](OP([S-])(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)C1 JZMHCANOTJFLQJ-IEQBYLOXSA-A 0.000 description 1
- 230000009824 affinity maturation Effects 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000004007 alpha amanitin Substances 0.000 description 1
- MXKCYTKUIDTFLY-ZNNSSXPHSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-D-Galp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O[C@H]3[C@H]([C@@H](CO)OC(O)[C@@H]3O)O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O MXKCYTKUIDTFLY-ZNNSSXPHSA-N 0.000 description 1
- CIORWBWIBBPXCG-SXZCQOKQSA-N alpha-amanitin Chemical compound O=C1N[C@@H](CC(N)=O)C(=O)N2C[C@H](O)C[C@H]2C(=O)N[C@@H]([C@@H](C)[C@@H](O)CO)C(=O)N[C@@H](C2)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@H]1C[S@@](=O)C1=C2C2=CC=C(O)C=C2N1 CIORWBWIBBPXCG-SXZCQOKQSA-N 0.000 description 1
- CIORWBWIBBPXCG-UHFFFAOYSA-N alpha-amanitin Natural products O=C1NC(CC(N)=O)C(=O)N2CC(O)CC2C(=O)NC(C(C)C(O)CO)C(=O)NC(C2)C(=O)NCC(=O)NC(C(C)CC)C(=O)NCC(=O)NC1CS(=O)C1=C2C2=CC=C(O)C=C2N1 CIORWBWIBBPXCG-UHFFFAOYSA-N 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- BBDAGFIXKZCXAH-CCXZUQQUSA-N ancitabine Chemical compound N=C1C=CN2[C@@H]3O[C@H](CO)[C@@H](O)[C@@H]3OC2=N1 BBDAGFIXKZCXAH-CCXZUQQUSA-N 0.000 description 1
- 229950000242 ancitabine Drugs 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 231100000659 animal toxin Toxicity 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 230000009831 antigen interaction Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- NMYKBZSMOUFOJV-FJSWQEPZSA-N aprinocarsen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)CO)[C@@H](OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)C1 NMYKBZSMOUFOJV-FJSWQEPZSA-N 0.000 description 1
- 150000008209 arabinosides Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229940078010 arimidex Drugs 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 150000001541 aziridines Chemical class 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 229950008548 bisantrene Drugs 0.000 description 1
- JCXGWMGPZLAOME-AKLPVKDBSA-N bismuth-212 Chemical compound [212Bi] JCXGWMGPZLAOME-AKLPVKDBSA-N 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 229950006844 bizelesin Drugs 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000037237 body shape Effects 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 239000012152 bradford reagent Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960005520 bryostatin Drugs 0.000 description 1
- MJQUEDHRCUIRLF-TVIXENOKSA-N bryostatin 1 Chemical compound C([C@@H]1CC(/[C@@H]([C@@](C(C)(C)/C=C/2)(O)O1)OC(=O)/C=C/C=C/CCC)=C\C(=O)OC)[C@H]([C@@H](C)O)OC(=O)C[C@H](O)C[C@@H](O1)C[C@H](OC(C)=O)C(C)(C)[C@]1(O)C[C@@H]1C\C(=C\C(=O)OC)C[C@H]\2O1 MJQUEDHRCUIRLF-TVIXENOKSA-N 0.000 description 1
- MUIWQCKLQMOUAT-AKUNNTHJSA-N bryostatin 20 Natural products COC(=O)C=C1C[C@@]2(C)C[C@]3(O)O[C@](C)(C[C@@H](O)CC(=O)O[C@](C)(C[C@@]4(C)O[C@](O)(CC5=CC(=O)O[C@]45C)C(C)(C)C=C[C@@](C)(C1)O2)[C@@H](C)O)C[C@H](OC(=O)C(C)(C)C)C3(C)C MUIWQCKLQMOUAT-AKUNNTHJSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- MBABCNBNDNGODA-LUVUIASKSA-N bullatacin Chemical compound O1[C@@H]([C@@H](O)CCCCCCCCCC)CC[C@@H]1[C@@H]1O[C@@H]([C@H](O)CCCCCCCCCC[C@@H](O)CC=2C(O[C@@H](C)C=2)=O)CC1 MBABCNBNDNGODA-LUVUIASKSA-N 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 229950009908 cactinomycin Drugs 0.000 description 1
- IVFYLRMMHVYGJH-PVPPCFLZSA-N calusterone Chemical compound C1C[C@]2(C)[C@](O)(C)CC[C@H]2[C@@H]2[C@@H](C)CC3=CC(=O)CC[C@]3(C)[C@H]21 IVFYLRMMHVYGJH-PVPPCFLZSA-N 0.000 description 1
- 229950009823 calusterone Drugs 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 229960002115 carboquone Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 229940045200 cardioprotective agent Drugs 0.000 description 1
- 239000012659 cardioprotective agent Substances 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- BBZDXMBRAFTCAA-AREMUKBSSA-N carzelesin Chemical compound C1=2NC=C(C)C=2C([C@H](CCl)CN2C(=O)C=3NC4=CC=C(C=C4C=3)NC(=O)C3=CC4=CC=C(C=C4O3)N(CC)CC)=C2C=C1OC(=O)NC1=CC=CC=C1 BBZDXMBRAFTCAA-AREMUKBSSA-N 0.000 description 1
- 229950007509 carzelesin Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229950008249 chlornaphazine Drugs 0.000 description 1
- 229960001480 chlorozotocin Drugs 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000005354 coacervation Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 108010006226 cryptophycin Proteins 0.000 description 1
- PSNOPSMXOBPNNV-VVCTWANISA-N cryptophycin 1 Chemical compound C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 PSNOPSMXOBPNNV-VVCTWANISA-N 0.000 description 1
- PSNOPSMXOBPNNV-UHFFFAOYSA-N cryptophycin-327 Natural products C1=C(Cl)C(OC)=CC=C1CC1C(=O)NCC(C)C(=O)OC(CC(C)C)C(=O)OC(C(C)C2C(O2)C=2C=CC=CC=2)CC=CC(=O)N1 PSNOPSMXOBPNNV-UHFFFAOYSA-N 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 229960005052 demecolcine Drugs 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 229950003913 detorubicin Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- WVYXNIXAMZOZFK-UHFFFAOYSA-N diaziquone Chemical compound O=C1C(NC(=O)OCC)=C(N2CC2)C(=O)C(NC(=O)OCC)=C1N1CC1 WVYXNIXAMZOZFK-UHFFFAOYSA-N 0.000 description 1
- 229950002389 diaziquone Drugs 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- ZWAOHEXOSAUJHY-ZIYNGMLESA-N doxifluridine Chemical compound O[C@@H]1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ZWAOHEXOSAUJHY-ZIYNGMLESA-N 0.000 description 1
- 229950005454 doxifluridine Drugs 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 229950004203 droloxifene Drugs 0.000 description 1
- NOTIQUSPUUHHEH-UXOVVSIBSA-N dromostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 1
- 229950004683 drostanolone propionate Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 229960005501 duocarmycin Drugs 0.000 description 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 description 1
- 229930184221 duocarmycin Natural products 0.000 description 1
- AFMYMMXSQGUCBK-AKMKHHNQSA-N dynemicin a Chemical compound C1#C\C=C/C#C[C@@H]2NC(C=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C3)=C3[C@@]34O[C@]32[C@@H](C)C(C(O)=O)=C(OC)[C@H]41 AFMYMMXSQGUCBK-AKMKHHNQSA-N 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- FSIRXIHZBIXHKT-MHTVFEQDSA-N edatrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CC(CC)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FSIRXIHZBIXHKT-MHTVFEQDSA-N 0.000 description 1
- 229950006700 edatrexate Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 description 1
- XOPYFXBZMVTEJF-PDACKIITSA-N eleutherobin Chemical compound C(/[C@H]1[C@H](C(=CC[C@@H]1C(C)C)C)C[C@@H]([C@@]1(C)O[C@@]2(C=C1)OC)OC(=O)\C=C\C=1N=CN(C)C=1)=C2\CO[C@@H]1OC[C@@H](O)[C@@H](O)[C@@H]1OC(C)=O XOPYFXBZMVTEJF-PDACKIITSA-N 0.000 description 1
- XOPYFXBZMVTEJF-UHFFFAOYSA-N eleutherobin Natural products C1=CC2(OC)OC1(C)C(OC(=O)C=CC=1N=CN(C)C=1)CC(C(=CCC1C(C)C)C)C1C=C2COC1OCC(O)C(O)C1OC(C)=O XOPYFXBZMVTEJF-UHFFFAOYSA-N 0.000 description 1
- 229950000549 elliptinium acetate Drugs 0.000 description 1
- 229940120655 eloxatin Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- JOZGNYDSEBIJDH-UHFFFAOYSA-N eniluracil Chemical compound O=C1NC=C(C#C)C(=O)N1 JOZGNYDSEBIJDH-UHFFFAOYSA-N 0.000 description 1
- 229950010213 eniluracil Drugs 0.000 description 1
- 229950011487 enocitabine Drugs 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 229950002973 epitiostanol Drugs 0.000 description 1
- 229930013356 epothilone Natural products 0.000 description 1
- 150000003883 epothilone derivatives Chemical class 0.000 description 1
- 229940082789 erbitux Drugs 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- GTTBEUCJPZQMDZ-UHFFFAOYSA-N erlotinib hydrochloride Chemical compound [H+].[Cl-].C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 GTTBEUCJPZQMDZ-UHFFFAOYSA-N 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- ITSGNOIFAJAQHJ-BMFNZSJVSA-N esorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 ITSGNOIFAJAQHJ-BMFNZSJVSA-N 0.000 description 1
- 229950002017 esorubicin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- DQJJMWZRDSGUJP-UHFFFAOYSA-N ethenoxyethene;furan-2,5-dione Chemical compound C=COC=C.O=C1OC(=O)C=C1 DQJJMWZRDSGUJP-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- QSRLNKCNOLVZIR-KRWDZBQOSA-N ethyl (2s)-2-[[2-[4-[bis(2-chloroethyl)amino]phenyl]acetyl]amino]-4-methylsulfanylbutanoate Chemical compound CCOC(=O)[C@H](CCSC)NC(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 QSRLNKCNOLVZIR-KRWDZBQOSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 229940116333 ethyl lactate Drugs 0.000 description 1
- 229960005237 etoglucid Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229950011548 fadrozole Drugs 0.000 description 1
- 229940043168 fareston Drugs 0.000 description 1
- 229940087861 faslodex Drugs 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 150000002224 folic acids Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012537 formulation buffer Substances 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 229940044658 gallium nitrate Drugs 0.000 description 1
- 229940020967 gemzar Drugs 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229940114119 gentisate Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- LZYXPFZBAZTOCH-UHFFFAOYSA-N hexyl 5-amino-4-oxopentanoate;hydron;chloride Chemical compound Cl.CCCCCCOC(=O)CCC(=O)CN LZYXPFZBAZTOCH-UHFFFAOYSA-N 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 229940015872 ibandronate Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 229960003685 imatinib mesylate Drugs 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 125000001905 inorganic group Chemical group 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- XMBWDFGMSWQBCA-YPZZEJLDSA-N iodane Chemical compound [125IH] XMBWDFGMSWQBCA-YPZZEJLDSA-N 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000005367 kimax Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229940118199 levulan Drugs 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 238000012594 liquid chromatography nuclear magnetic resonance Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 229950001750 lonafarnib Drugs 0.000 description 1
- 229960003538 lonidamine Drugs 0.000 description 1
- WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
- YROQEQPFUCPDCP-UHFFFAOYSA-N losoxantrone Chemical compound OCCNCCN1N=C2C3=CC=CC(O)=C3C(=O)C3=C2C1=CC=C3NCCNCCO YROQEQPFUCPDCP-UHFFFAOYSA-N 0.000 description 1
- 229950008745 losoxantrone Drugs 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 229940087857 lupron Drugs 0.000 description 1
- RVFGKBWWUQOIOU-NDEPHWFRSA-N lurtotecan Chemical compound O=C([C@]1(O)CC)OCC(C(N2CC3=4)=O)=C1C=C2C3=NC1=CC=2OCCOC=2C=C1C=4CN1CCN(C)CC1 RVFGKBWWUQOIOU-NDEPHWFRSA-N 0.000 description 1
- 229950002654 lurtotecan Drugs 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- MQXVYODZCMMZEM-ZYUZMQFOSA-N mannomustine Chemical compound ClCCNC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CNCCCl MQXVYODZCMMZEM-ZYUZMQFOSA-N 0.000 description 1
- 229950008612 mannomustine Drugs 0.000 description 1
- 241001515942 marmosets Species 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical compound CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004296 megestrol acetate Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229950009246 mepitiostane Drugs 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- VJRAUFKOOPNFIQ-TVEKBUMESA-N methyl (1r,2r,4s)-4-[(2r,4s,5s,6s)-5-[(2s,4s,5s,6s)-5-[(2s,4s,5s,6s)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-(dimethylamino)-6-methyloxan-2-yl]oxy-2-ethyl-2,5,7,10-tetrahydroxy-6,11-dioxo-3,4-dihydro-1h-tetracene-1-carboxylat Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=C(O)C=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1C[C@H](O)[C@H](O)[C@H](C)O1 VJRAUFKOOPNFIQ-TVEKBUMESA-N 0.000 description 1
- YUUAYBAIHCDHHD-UHFFFAOYSA-N methyl 5-aminolevulinate Chemical compound COC(=O)CCC(=O)CN YUUAYBAIHCDHHD-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 229960003539 mitoguazone Drugs 0.000 description 1
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
- VFKZTMPDYBFSTM-GUCUJZIJSA-N mitolactol Chemical compound BrC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-GUCUJZIJSA-N 0.000 description 1
- 229950010913 mitolactol Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 150000002751 molybdenum Chemical class 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- FOYWNSCCNCUEPU-UHFFFAOYSA-N mopidamol Chemical compound C12=NC(N(CCO)CCO)=NC=C2N=C(N(CCO)CCO)N=C1N1CCCCC1 FOYWNSCCNCUEPU-UHFFFAOYSA-N 0.000 description 1
- 229950010718 mopidamol Drugs 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000000318 mullerian duct Anatomy 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- NJSMWLQOCQIOPE-OCHFTUDZSA-N n-[(e)-[10-[(e)-(4,5-dihydro-1h-imidazol-2-ylhydrazinylidene)methyl]anthracen-9-yl]methylideneamino]-4,5-dihydro-1h-imidazol-2-amine Chemical compound N1CCN=C1N\N=C\C(C1=CC=CC=C11)=C(C=CC=C2)C2=C1\C=N\NC1=NCCN1 NJSMWLQOCQIOPE-OCHFTUDZSA-N 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 239000002088 nanocapsule Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229940086322 navelbine Drugs 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 210000005155 neural progenitor cell Anatomy 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 229940080607 nexavar Drugs 0.000 description 1
- 229960002653 nilutamide Drugs 0.000 description 1
- XWXYUMMDTVBTOU-UHFFFAOYSA-N nilutamide Chemical compound O=C1C(C)(C)NC(=O)N1C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 XWXYUMMDTVBTOU-UHFFFAOYSA-N 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- KGTDRFCXGRULNK-JYOBTZKQSA-N nogalamycin Chemical compound CO[C@@H]1[C@@](OC)(C)[C@@H](OC)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=C4[C@@]5(C)O[C@H]([C@H]([C@@H]([C@H]5O)N(C)C)O)OC4=C3C3=O)=C3C=C2[C@@H](C(=O)OC)[C@@](C)(O)C1 KGTDRFCXGRULNK-JYOBTZKQSA-N 0.000 description 1
- 229950009266 nogalamycin Drugs 0.000 description 1
- 229940085033 nolvadex Drugs 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 229950005848 olivomycin Drugs 0.000 description 1
- CZDBNBLGZNWKMC-MWQNXGTOSA-N olivomycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1)O[C@H]1O[C@@H](C)[C@H](O)[C@@H](OC2O[C@@H](C)[C@H](O)[C@@H](O)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@H](O)[C@H](OC)[C@H](C)O1 CZDBNBLGZNWKMC-MWQNXGTOSA-N 0.000 description 1
- 229950011093 onapristone Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002138 osteoinductive effect Effects 0.000 description 1
- 229940043515 other immunoglobulins in atc Drugs 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 125000005429 oxyalkyl group Chemical group 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 101710135378 pH 6 antigen Proteins 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- VREZDOWOLGNDPW-UHFFFAOYSA-N pancratistatine Natural products C1=C2C3C(O)C(O)C(O)C(O)C3NC(=O)C2=C(O)C2=C1OCO2 VREZDOWOLGNDPW-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- QIMGFXOHTOXMQP-GFAGFCTOSA-N peplomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
- 229950003180 peplomycin Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229940097886 phosphorus 32 Drugs 0.000 description 1
- 229940109328 photofrin Drugs 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 208000007578 phototoxic dermatitis Diseases 0.000 description 1
- 231100000018 phototoxicity Toxicity 0.000 description 1
- MCTOGTBIQBEIBZ-QHWUVJKOSA-K photrex Chemical compound CCOC(=O)C([C@@]1([C@H]2C)CC)=CC3=C1N([Sn](N14)(Cl)Cl)C2=CC(C(=C2C)CC)=NC2=CC1=C(CC)C(C)=C4C=C1C(CC)=C(C)C3=N1 MCTOGTBIQBEIBZ-QHWUVJKOSA-K 0.000 description 1
- IEQIEDJGQAUEQZ-UHFFFAOYSA-N phthalocyanine Chemical compound N1C(N=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N3)=N2)=C(C=CC=C2)C2=C1N=C1C2=CC=CC=C2C4=N1 IEQIEDJGQAUEQZ-UHFFFAOYSA-N 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- NUKCGLDCWQXYOQ-UHFFFAOYSA-N piposulfan Chemical compound CS(=O)(=O)OCCC(=O)N1CCN(C(=O)CCOS(C)(=O)=O)CC1 NUKCGLDCWQXYOQ-UHFFFAOYSA-N 0.000 description 1
- 229950001100 piposulfan Drugs 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000141 poly(maleic anhydride) Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 239000002745 poly(ortho ester) Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 210000004896 polypeptide structure Anatomy 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 229940087463 proleukin Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 108010087851 prorelaxin Proteins 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 229950003776 protoporphyrin Drugs 0.000 description 1
- WOLQREOUPKZMEX-UHFFFAOYSA-N pteroyltriglutamic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(=O)NC(CCC(=O)NC(CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)C=C1 WOLQREOUPKZMEX-UHFFFAOYSA-N 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- JOZPEVMCAKXSEY-UHFFFAOYSA-N pyrimido[5,4-d]pyrimidine Chemical class N1=CN=CC2=NC=NC=C21 JOZPEVMCAKXSEY-UHFFFAOYSA-N 0.000 description 1
- CIFRQDSGIHWJDO-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical compound c1cc2c(ccc3cccnnc23)n1.c1cc2c(ccc3cccnnc23)n1 CIFRQDSGIHWJDO-UHFFFAOYSA-N 0.000 description 1
- 150000004944 pyrrolopyrimidines Chemical class 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 150000003252 quinoxalines Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000012857 radioactive material Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229960002185 ranimustine Drugs 0.000 description 1
- 229940099538 rapamune Drugs 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- BMKDZUISNHGIBY-UHFFFAOYSA-N razoxane Chemical compound C1C(=O)NC(=O)CN1C(C)CN1CC(=O)NC(=O)C1 BMKDZUISNHGIBY-UHFFFAOYSA-N 0.000 description 1
- 229960000460 razoxane Drugs 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 125000006853 reporter group Chemical group 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 description 1
- OWPCHSCAPHNHAV-LMONGJCWSA-N rhizoxin Chemical compound C/C([C@H](OC)[C@@H](C)[C@@H]1C[C@H](O)[C@]2(C)O[C@@H]2/C=C/[C@@H](C)[C@]2([H])OC(=O)C[C@@](C2)(C[C@@H]2O[C@H]2C(=O)O1)[H])=C\C=C\C(\C)=C\C1=COC(C)=N1 OWPCHSCAPHNHAV-LMONGJCWSA-N 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 229950004892 rodorubicin Drugs 0.000 description 1
- MBABCNBNDNGODA-WPZDJQSSSA-N rolliniastatin 1 Natural products O1[C@@H]([C@@H](O)CCCCCCCCCC)CC[C@H]1[C@H]1O[C@@H]([C@H](O)CCCCCCCCCC[C@@H](O)CC=2C(O[C@@H](C)C=2)=O)CC1 MBABCNBNDNGODA-WPZDJQSSSA-N 0.000 description 1
- IMUQLZLGWJSVMV-UOBFQKKOSA-N roridin A Natural products CC(O)C1OCCC(C)C(O)C(=O)OCC2CC(=CC3OC4CC(OC(=O)C=C/C=C/1)C(C)(C23)C45CO5)C IMUQLZLGWJSVMV-UOBFQKKOSA-N 0.000 description 1
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 description 1
- 229930182947 sarcodictyin Natural products 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 1
- 229950003647 semaxanib Drugs 0.000 description 1
- WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- JACPFCQFVIAGDN-UHFFFAOYSA-M sipc iv Chemical compound [OH-].[Si+4].CN(C)CCC[Si](C)(C)[O-].C=1C=CC=C(C(N=C2[N-]C(C3=CC=CC=C32)=N2)=N3)C=1C3=CC([C]1C=CC=CC1=1)=NC=1N=C1[C]3C=CC=CC3=C2[N-]1 JACPFCQFVIAGDN-UHFFFAOYSA-M 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- 229950001403 sizofiran Drugs 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229950006315 spirogermanium Drugs 0.000 description 1
- ICXJVZHDZFXYQC-UHFFFAOYSA-N spongistatin 1 Natural products OC1C(O2)(O)CC(O)C(C)C2CCCC=CC(O2)CC(O)CC2(O2)CC(OC)CC2CC(=O)C(C)C(OC(C)=O)C(C)C(=C)CC(O2)CC(C)(O)CC2(O2)CC(OC(C)=O)CC2CC(=O)OC2C(O)C(CC(=C)CC(O)C=CC(Cl)=C)OC1C2C ICXJVZHDZFXYQC-UHFFFAOYSA-N 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- CIOAGBVUUVVLOB-OUBTZVSYSA-N strontium-89 Chemical compound [89Sr] CIOAGBVUUVVLOB-OUBTZVSYSA-N 0.000 description 1
- 229940006509 strontium-89 Drugs 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229950010924 talaporfin Drugs 0.000 description 1
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229940120982 tarceva Drugs 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 229960000874 thyrotropin Drugs 0.000 description 1
- 230000001748 thyrotropin Effects 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- YFTWHEBLORWGNI-UHFFFAOYSA-N tiamiprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC(N)=NC2=C1NC=N2 YFTWHEBLORWGNI-UHFFFAOYSA-N 0.000 description 1
- 229950011457 tiamiprine Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960005026 toremifene Drugs 0.000 description 1
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 1
- 229940043263 traditional drug Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 229950001353 tretamine Drugs 0.000 description 1
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- PXSOHRWMIRDKMP-UHFFFAOYSA-N triaziquone Chemical compound O=C1C(N2CC2)=C(N2CC2)C(=O)C=C1N1CC1 PXSOHRWMIRDKMP-UHFFFAOYSA-N 0.000 description 1
- 229960004560 triaziquone Drugs 0.000 description 1
- 229930013292 trichothecene Natural products 0.000 description 1
- 150000003327 trichothecene derivatives Chemical class 0.000 description 1
- 229960001670 trilostane Drugs 0.000 description 1
- KVJXBPDAXMEYOA-CXANFOAXSA-N trilostane Chemical compound OC1=C(C#N)C[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@@]32O[C@@H]31 KVJXBPDAXMEYOA-CXANFOAXSA-N 0.000 description 1
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
- 229960001099 trimetrexate Drugs 0.000 description 1
- 229950000212 trioxifene Drugs 0.000 description 1
- 229960000875 trofosfamide Drugs 0.000 description 1
- UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
- 229950010147 troxacitabine Drugs 0.000 description 1
- RXRGZNYSEHTMHC-BQBZGAKWSA-N troxacitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)OC1 RXRGZNYSEHTMHC-BQBZGAKWSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- HDZZVAMISRMYHH-LITAXDCLSA-N tubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O HDZZVAMISRMYHH-LITAXDCLSA-N 0.000 description 1
- 229930184737 tubulysin Natural products 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 229940094060 tykerb Drugs 0.000 description 1
- 229950009811 ubenimex Drugs 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229940099039 velcade Drugs 0.000 description 1
- ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N verteporfin Chemical compound C=1C([C@@]2([C@H](C(=O)OC)C(=CC=C22)C(=O)OC)C)=NC2=CC(C(=C2C=C)C)=NC2=CC(C(=C2CCC(O)=O)C)=NC2=CC2=NC=1C(C)=C2CCC(=O)OC ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N 0.000 description 1
- 229960003895 verteporfin Drugs 0.000 description 1
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229960001771 vorozole Drugs 0.000 description 1
- XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
- 229960005502 α-amanitin Drugs 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0058—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1054—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1057—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from liver or pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
Abstract
本文中揭露包含與抗體或其抗原結合片段複合的藥物之抗體藥物共軛物(ADC’s),該抗體或其抗原結合片段與Globo系列抗原結合,並揭露該些抗體藥物共軛物之使用方法。使用方法包括但不限於癌症治療與檢測。本文中揭露之抗體可與特定癌細胞表面結合。本文中揭露之抗體例示性結合標的包括上皮癌(carcinoma),如惡性肉瘤(sarcoma)、皮膚癌、血癌、淋巴癌、腦癌、膠質母細胞瘤(glioblastoma)、肺癌、乳癌、口腔癌、頭頸癌、鼻咽癌、食道癌、胃癌、肝癌、膽管癌、膽囊癌、膀胱癌、胰臟癌、腸癌、大腸直腸癌、腎臟癌、子宮頸癌、子宮內膜癌、卵巢癌、睪丸癌、頰癌、口咽癌、喉癌及前列腺癌等。
Description
本文中揭露之技術係針對抗體-藥物共軛物(ADC’s)組成物與使用該組成物治療癌症之方法。本文中亦揭露使用抗體-藥物共軛物治療與疾病狀態相關的哺乳動物細胞之方法。本文中揭露之技術係關於與Globo系列抗原(Globo H、SSEA-3及SSEA-4)結合之抗體與其結合片段,包括包含前述抗體及/或結合片段之醫藥組成物。本文中進一步提供對受試者施用有效量之抗體-藥物共軛物以抑制癌症細胞增生之方法
許多表面醣類皆表現於惡性腫瘤中。舉例而言,醣抗原Globo H(Fucα1→2 Galβ1→3 GalNAcβ1→3 Galα1→4 Galβ1→4 Glc)以神經醯胺鍵結之醣脂質形態存在,並於1984年首次分離自乳癌MCF-7細胞(Bremer E G,
et al. (1984) J Biol Chem 259:14773-14777)。先前研究也顯示,在乳癌細胞與乳癌幹細胞上觀察到Globo H與階段特異性胚胎抗原3(Galβ1→ 3GalNAcβ1→ 3Galα1→ 4Galβ1→ 4Glcβ1)(SSEA-3,又稱Gb5)(WW Chang
et al. (2008) Proc Natl Acad Sci USA, 105(33): 11667-11672)。此外,階段特異性胚胎抗原4(SSEA-4)(Neu5Acα2→ 3Galβ1→ 3GalNAcβ1→ 3Galα1→ 4Galβ1→ 4Glcβ1)係一般常用於多功能人類幹細胞上之細胞表面標記,亦用於分離間質幹細胞(mesenchymal stem cells)及富集神經前驅細胞(neural progenitor cells)(Kannagi R
et al. (1983) EMBO J 2:2355-2361)。上述研究支持了Globo系列抗原(Globo H、SSEA-3及SSEA-4)屬癌症療法所針對之特定目標,亦可用以引導治療劑有效針對癌症細胞進行治療。因此,辨識與癌症相關及/或可預測癌症之聚醣標記,並發展能與此類聚醣標記反應之抗體-藥物共軛物,以用於檢測及治療多種癌症,即為頗受重視之要務。可使用不同聯結劑將針對Globo系列抗原之特異性抗體與治療劑結合,以將Globo系列抗原設計為一抗體-藥物共軛物。
利用抗體-藥物共軛物局部施用胞殺劑(cytotoxic agent)或細胞生長抑制劑(cytostatic agent),譬如在癌症治療中用以殺死癌症細胞或抑制其增生之藥物(Syrigos and Epenetos (1999) Anticancer Research 19:605-614;Niculescu-Duvaz and (1997) Adv. Drg. Del. Rev. 26:151-172;美國專利第4975278號),理論上可使藥物基團被輸送到特定腫瘤部位,並於細胞內累積。而對全身施用此類未共軛藥劑時,可能會帶來能破壞普通細胞與欲消除之腫瘤細胞的偏高毒性(參考Baldwin et al., 1986, Lancet pp. (Mar. 15, 1986):603-05; Thorpe, 1985, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review," in Monoclonal Antibodies '84: Biological And Clinical Applications, A. Pinchera et al. (ed.s), pp. 475-506),因此,一般期待藥物能造成最小毒性並達到最大效果。研究指出,使用多株抗體和單株抗體皆有助於達成前述目標(Rowland et al., 1986, Cancer Immunol. Immunother. 21:183-87)。此類方法中所使用之藥物包括daunomycin(唐黴素注射劑)、doxorubicin(艾黴素注射劑)、methotrexate(滅殺除癌錠)、vindesine(長春地辛)(Rowland et al., 1986, supra)。某些胞殺藥物在和大型抗體或蛋白質受體之配體結合時,會變得無活性或活性較低。
奧瑞斯他丁胜肽(auristatin peptides),如奧瑞斯他丁E(auristatin E)與單甲基奧瑞斯他丁(monomethylauristatin, MMAE),其為dolastatin之合成類似物,先前係與以下種類抗體共軛結合:(i) 嵌合單株抗體cBR96(對上皮癌Lewis Y抗原具特異性);(ii) cAC10抗體,其對血液腫瘤所表現的CD30抗原具特異性(Klussman, et al. (2004), Bioconjugate Chemistry 15(4):765-773; Doronina et al. (2003) Nature Biotechnology 21(7):778-784; "Monomethylvaline Compounds Capable of Conjugation to Ligands"; Francisco et al. (2003));(iii) 抗CD20抗體,譬如RITUXAN
®(莫須瘤注射劑)(WO 04/032828),用於治療表現CD20抗原之腫瘤及免疫疾病;(iv) 抗EphB2抗體2H9及抗IL-8抗體,用於治療大腸直腸癌(Mao, et al. (2004) Cancer Research 64(3):781-788);(v) E-selectin 抗體(Bhaskar et al. (2003) Cancer Res. 63:6387-6394);及(vi) 其他抗CD30抗體(WO 03/043583)。
本文中所揭露之技術內容係基於以下發現:Globo系列抗原會在多種之癌症細胞上不正常表現,但在普通細胞上則否。表現Globo系列抗原之癌細胞可包括但不限於惡性肉瘤(sarcoma)、皮膚癌、血癌、淋巴癌、腦癌、肺癌、乳癌、口腔癌、頭頸癌、鼻咽癌、食道癌、胃癌、肝癌、膽管癌、膽囊癌、膀胱癌、胰臟癌、大腸癌、大腸直腸癌、腎臟癌、子宮頸癌、子宮內膜癌、卵巢癌、睪丸癌、頰癌、口咽癌、喉癌及前列腺癌。
根據本發明之一態樣,提供一種對Globo系列抗原具特異性之抗體或其結合片段。
在某些實施例中,該抗體可為抗Globo H抗體。
在某些實施例中,該抗Globo H抗體可為OBI-888。範例OBI抗體888如US 2017/0101462(WO2017/062792)專利所述,其全部內容以引用方式併入本文中。
在某些實施例中,該抗體可為抗SSEA-4抗體。
在某些實施例中,該抗SSEA-4抗體可為OBI-898。範例OBI抗體898如US 2017/283488(WO2017/172990)專利所述,其全部內容以引用方式併入本文中。
根據本發明之一態樣,提供一種抗體藥物共軛物,其包含與胞殺劑共軛之抗體,該胞殺劑種類如化療製劑、藥物、生長抑制劑、毒素(如經酵素活化之細菌源、真菌源、植物源、動物源毒素,或其片段)或放射性同位素(如放射性共軛物)。在某些實施例中,本文中揭露一種對Globo系列抗原具特異性之抗體藥物共軛物。
在某些實施例中,該藥物可為單甲基奧瑞斯他丁(MMAE)。
根據本發明之一態樣,提供一種抑制癌細胞增生的方法,其包含對有需要之受試者施用有效量之範例抗體藥物共軛物(OBI-999),其中癌細胞增生會被抑制。
在某些實施例中,本發明提供一種治療受試者體內癌症的方法,該方法包含對有需要之受試者施用本文所述之有效量的範例抗體藥物共軛物(OBI-999)。
在所揭露之組成物中,抗體藥物共軛物或任何其他相關成分皆具備免疫有效量。就各抗體藥物共軛物而言,其最佳免疫有效量應由實驗結果決定(並考慮病患及/或治療類型之特性)。一般而言,此有效量為每公斤體重含0.01 μg至250 mg之抗體,該抗體對Globo系列抗原具特異性。在某些實施例中,醫療組成物之治療有效量(如有效劑量)可介於大約0.001 μg/kg與大約 250 mg/kg之間、0.01 μg/kg至100 mg/kg之間,或0.1 μg/kg至50 mg/kg之間,或者大約或至少為 0.001、0.002、0.003、0.004、0.005、0.006、0.007、0.008、0.009; 0.01、0.02、0.03、0.04、0.05、0.06、0.07、0.08、0.09;0.1、0.2、0.3、0.4、0.5、0.6、0.7、0.8、0.9、1、2、3、4、5、6、7、8、9、10、11、12、13、14、15、16、17、18、19、20、21、22、23、24、25、26、27、28、29、30、31、32、33、34、35、36、37、38、39、40、41、42、43、45、46、47、48、49、50、51、52、53、54、55、56、57、58、59、60、61、62、63、64、65、66、67、68、69、70、71、72、73、74、75、76、77、78、79、80、81、82、83、84、85、86、87、88、89、90、91、92、93、94、95、96、97、98、99、100、125、150、175、200、225或250 g/kg病患體重或μg/kg病患體重,或任何介於上述任兩數字間之範圍,或者介於其他明顯且本發明所屬技術領域中具通常知識者未經過度實驗而可理解之其他範圍。本發明所屬技術領域中具通常知識者將理解,能影響有效治療受試者所需劑量及時間之特定因素,包括但不限於該疾病或病症之嚴重程度、先前接受之治療、該受試者之整體健康狀況或年齡,以及其他當下存在之疾病。
在某些實施例中,該癌症選自由惡性肉瘤、皮膚癌、血癌、淋巴癌、腦癌、膠質母細胞瘤、肺癌、乳癌、口腔癌、頭頸癌、鼻咽癌、食道癌、胃癌、肝癌、膽管癌、膽囊癌、膀胱癌、胰臟癌、大腸癌、大腸直腸癌、腎臟癌、子宮頸癌、子宮內膜癌、卵巢癌、睪丸癌、頰癌、口咽癌、喉癌及前列腺癌組成之群組。
本發明之一或多個實施例的具體細節,可參照以下詳細說明。本發明之其他特點或優點在參照以下圖式、說明書中多個實施例及所附之申請專利範圍後,將變得明顯。
根據前述,本文中提供數種抗體藥物共軛物實施方法與組成物,該些方法及組成物皆針對用於檢測、治療多種癌症之標記物。本文中開發並揭露一種抗體藥物共軛物,其包含與抗Globo系列抗原共軛結合之抗體或抗體結合片段,且其實施方式包括但不限於癌症治療與檢測。本文中所述之抗體藥物共軛物可與多種之表現Globo系列抗原的癌細胞結合,以使癌症檢測及治療更容易進行。該些抗體之目標細胞包括上皮癌細胞,如於皮膚、血液、淋巴結、大腦、肺臟、口腔、食道、胃、肝臟、膽囊、胰臟、直腸、腎臟、子宮頸、卵巢、前列腺中出現之上皮癌細胞。
定義
除非另外說明,否則實施本發明時將採用傳統分子生物學、微生物學、DNA重組及免疫學技術,以上技術皆屬習知技術,且皆於先前文獻中詳細說明,可見Sambrook, Fritsch and Maniatis編著之
Molecular Cloning A Laboratory Manual, 2nd Ed.,(Cold Spring Harbor Laboratory Press, 1989);DNA Cloning, Volumes I and II (D. N. Glover ed., 1985);Culture Of Animal Cells (R. I. Freshney, Alan R. Liss, Inc., 1987); Immobilized Cells And Enzymes (IRL Press, 1986);B. Perbal所著之A Practical Guide To Molecular Cloning (1984);the treatise, Methods In Enzymology (Academic Press, Inc., N.Y.);Gene Transfer Vectors For Mammalian Cells (J. H. Miller and M. P. Calos eds., 1987, Cold Spring Harbor Laboratory);Methods In Enzymology, Vols. 154 and 155 (Wu
et al. eds.);Immunochemical Methods In Cell And Molecular Biology (Mayer and Walker, eds., Academic Press, London, 1987);Antibodies: A Laboratory Manual, by Harlow and Lane s (Cold Spring Harbor Laboratory Press, 1988);及Handbook Of Experimental Immunology, Volumes I-IV (D. M. Weir and C. C. Blackwell, eds., 1986)。
本文中使用之「聚醣」(glycan)一詞,係指多醣(polysaccharide)或寡醣(oligosaccharide)。本文中亦使用聚醣一詞指稱醣類共軛物(glycoconjugate)之醣部位,例如醣蛋白(glycoprotein)、醣脂質(glycolipid)、醣胜肽(glycopeptide)、醣蛋白組(glycoproteome)、肽聚醣(peptidoglycan)、脂多醣(lipopolysaccharide)或蛋白聚醣(proteoglycan)。聚醣通常僅包含單醣(monosaccharides)之間的O-糖苷鍵。舉例而言,纖維素係由β(1,4)鍵結之D-葡萄糖(β-1,4-linked D-glucose)組成之聚醣(精確而言係葡聚醣(glucan)),而甲殼素(chitin)係由β(1,4)鍵結之N-乙醯基-D-葡萄糖胺(β-1,4-linked N-acetyl-D-glucosamine)組成之聚醣。聚醣可為由單醣殘基組成之同元或異質聚合物,亦可為直鏈型或支鏈型。聚醣容易附著於蛋白質上,形成醣蛋白和蛋白聚醣。一般而言,聚醣位於細胞外層表面。O-鍵結與N-鍵結聚醣在真核生物中十分常見,不過也可見於原核生物中,惟比例較前者低。N-鍵結聚醣容易與sequon序列中天門冬醯胺(asparagine)上官能基團的氮結合。Sequon序列係Asn-X-Ser或Asn-X-Thr序列,其中X為除脯胺酸(proline)外之任何胺基酸。
本文所使用之「抗原」一詞,係定義為任何能引發免疫反應之物質。
本文所使用之「免疫生成性」(immunogenicity)一詞,係指免疫原(immunogen)、抗原或疫苗所具備之激發免疫反應的能力。
本文所使用之「抗原表位」(epitope)一詞,定義為抗原分子上用以接觸抗體之抗原結合位置或T細胞受體之部位。
本文所使用之「疫苗」一詞係指包含抗原之製劑,該抗原包含死菌或減毒之致病生物整體(whole disease-causing organisms)或該些生物之成分,如蛋白質、胜肽或多醣,其可用於製造免疫性以抵抗該些生物帶來之疾病。疫苗製劑可為天然、人工合成,或衍生自DNA重組技術。
本文所使用之「抗原特異性」(antigen specific)一詞,係指一細胞群之特性,在提供特定抗原或抗原之片段時,會導致特定細胞增生。
本文所使用之「特異性結合」(specifically binding)一詞,係指可互相結合結構(如抗體與抗原)間之交互作用。在不同實例中,特異性結合程度可用親和力常數表示,如約 10
-6莫耳/升、約 10
-7莫耳/升 、約 10
-8莫耳/升或更低。
本文所使用之「實質相似」、「實質相同」、「等同」或「實質等同」等詞,係指兩數值(如與一分子相關之一數值,以及與參考/對照組分子相關之另一數值)高度相似,本發明所屬技術領域中具有通常知識者可認定此兩數值幾無差異,或認定以前述數值(如解離常數Kd、抗病毒效果等)測定生物特性時,此數值差異不具生物及/或統計顯著性。舉例而言,此二數值之差異作為一參考/對照組分子之函數值,可小於大約50%、小於大約40%、小於大約30%、小於大約20%及/或小於大約10%。
本文所使用之「實質減少」或「實質不同」等詞,係指兩數值(如與一分子相關之一數值,以及與一參考/對照組分子相關之另一數值)高度相異,本發明所屬技術領域中具有通常知識者可認定以前述數值(如解離常數Kd)測定生物特性時,此數值差異具統計顯著性。舉例而言,此二數值之差異可大於大約10%、大於大約20%、大於大約30%、大於大約40%及/或大於大約50%,亦作為一參考/對照組分子之函數值。
本文所使用之「結合親和力」(binding affinity)一詞,係指分子(如抗體)上之單一結合部位與其結合對象(如抗原)間之非共價鍵交互作用總和強度。除非另外說明,否則本文中使用之「結合親和力」一詞係指「內在結合親和力」(intrinsic binding affinity),即結合組合成分間(如抗體與抗原)之一對一交互作用。分子X相對於其結合對象Y之親和力,可以解離常數Kd表示。親和力可透過習知方法測定,包括本文中所述之方法。一般而言,低親和力抗體會與抗原緩慢結合,且容易與之解離,而高親和力抗體則會與抗原快速結合,且能長時間維持結合狀態。習知技術已包含多種測定結合親和力之方法,其中任一方法皆可用於達成本發明之目的。特定數種示例性實施例如下述。
「抗體(Abs)」與「免疫球蛋白(Igs)」皆為具同樣結構特性之醣蛋白。抗體具備結合特異性,會與特定抗原結合,而免疫球蛋白則同時包括抗體與其他不具抗原特異性之類抗體分子。以後者為例,其多肽結構由淋巴系統及骨髓瘤(myeloma)生成,由淋巴系統製造時產量低,而由骨髓瘤製造時產量高。
此處之「抗體」與「免疫球蛋白」二詞係屬廣義用法,可相互替代使用,且包括單株抗體(如長度完整或結構完整之單株抗體)、多株抗體、單價(monovalent)及多價(multivalent)抗體、多特異性抗體(如可表現出預期生物活性之雙特異性抗體),同時可包含特定抗體片段(如本文所詳述)。抗體可為嵌合、人源、仿人化及/或經親和力熟成。
抗體之「可變區域」(variable region)或「可變域」(variable domain)係指該抗體重鏈或輕鏈之胺端域(amino-terminal domain)。一般而言,該些區域皆為抗體上變異最大之區域,且包含抗原結合位置。
「可變」一詞,係指可變域中特定部分序列會與抗體其他部分呈現高度差異,且該些特定部分亦參與各抗體與其目標抗原結合之專一結合反應。然而,各抗體可變域具備之可變程度仍互有差距。輕鏈與重鏈可變域中三個稱為互補性決定區(complementarity-determining regions, CDRs)或高度變異區(hypervariable regions)之片段,為可變程度最高之區域。可變域中較為穩定之部分稱為骨架(framework, FR)。天然重鏈與輕鏈之可變域各自包含四塊骨架區,主要呈現β摺疊態(beta-sheet configuration),彼此由三個互補性決定區相互連接,互補性決定區又形成環狀連接結構,在某些情況下亦會形成β摺疊結構之一部分。骨架區使各鏈上的互補性決定區彼此緊鄰,並與其他鏈上之互補性決定區一同形成抗體之抗原結合位置(見Kabat
et al., Sequences of Proteins of Immunological Interest, Fifth Edition, National Institute of Health, Bethesda, Md. (1991))。固定域(constant domains)不直接參與抗體與抗原結合反應,但會表現出不同效應物功能(effector functions),譬如抗體會參與抗體依賴型細胞毒殺作用(antibody-dependent cellular toxicity)。
使用木瓜酵素(papain)分解抗體後,會產生兩個完全相同、各自具備一抗原結合位置之抗原結合片段,稱為「Fab」片段,同時亦會產生另一「Fc」片段,此命名呼應該片段易於結晶(crystallize)之能力。使用胃蛋白酶(pepsin)分解抗體後,則產生一F(ab’)
2片段,該片段具備兩個抗原結合位置,且仍可與抗原進行交聯反應。
「Fv」為最小抗體片段,其中包含完整抗原辨識與結合位置。在雙鏈Fv類(two-chain Fv species)片段上,抗原辨識與結合區包含由重鏈與輕鏈可變域組成之雙體,此二可變域以非共價鍵緊密結合。在單鏈Fv類(single-chain Fv species)片段上,重鏈與輕鏈可變域可經由彈性胜肽聯結分子(peptide linker)以共價鍵彼此相連,最後使各輕鏈與重鏈處於類似雙鏈Fv類片段上之「雙體」結構,於彼此之間產生連結。在此態樣中,每一可變域之三塊互補性決定區於彼此之間進行交互作用,以於輕鏈可變域-重鏈可變域雙體結構表面上劃定抗原結合位置。該六塊互補性決定區會一同賦予該抗體抗原結合特異性。然而,各單一可變域(或半個Fv片段,其中僅包含三塊具抗原特異性之互補性決定區)皆具備辨識與結合抗原之能力,惟其親和力較整體結合位置低。
該Fab片段亦包含該輕鏈之固定域及該重鏈之第一固定域(CH1)。Fab'片段與Fab片段之差異,在於前者為於後者重鏈第一固定域羧基端添加殘基,如來自抗體鉸鍊區(hinge region)之一或多個半胱胺酸(cysteines)。本文使用之Fab'-SH一詞用以指稱固定域之半胱胺酸殘基具有自由硫醇基(free thiol group)的Fab'片段。F(ab')
2抗體片段最初產生時,其形式為一對Fab'片段,其間具有作為鉸鏈之半胱胺酸。其他經化學耦合之抗體片段亦屬習知。
脊椎生物之抗體(免疫球蛋白)中的輕鏈可分為兩大類,一為κ(kappa)類,二為λ(lambda)類,分類方式依固定域胺基酸序列而定。
就重鏈固定域之胺基酸序列而言,可將抗體(免疫球蛋白)分為五大類型,包括IgA、IgD、IgE、IgG及IgM,而其中幾類則可再分出子類(同型),如IgG
1、IgG
2、IgG
3、IgG
4、IgA
1、IgA
2。對應不同免疫球蛋白分類之重鏈固定域則分別稱為α、δ、ε、γ及μ。各子類型結構及各類免疫球蛋白之三維樣態屬習知技術,並見於諸多文獻中,如Abbas
et al. Cellular and Mol. Immunology, 4th ed. (2000)。抗體可為大型融合分子之一部分,該分子由該抗體與一或多個其他蛋白質或胜肽分子以共價鍵或非共價鍵結合而成。
本文所使用之「完整長度抗體」、「完好抗體」、「完整抗體」等詞可替代使用,皆指形態實質完整之抗體,而非如以下所定義之抗體片段。該些詞彙尤其指具有包含Fc區之重鏈的抗體。
「抗體片段」僅包含完好抗體之一部分,其保留該部分存在於完好抗體中的至少一部分、幾乎全部或全部之片段功能。在某一實施例中,抗體片段包含該完好抗體之抗原結合位置,且因此保留抗原結合能力。在另一實施例中,抗體片段(如包含該Fc區之抗體片段)保留了該部分存在於完好抗體中的至少一項Fc區基本生物功能,譬如Fc受體結合(FcRn binding)、抗體半生期調節、抗體依賴型細胞毒殺作用(ADCC)、補體結合等功能。在某一實施例中,抗體片段為單價抗體,其於活體內之半生期與完好抗體實質相似。舉例而言,該抗體片段可包含抗原結合臂,而該結合臂與賦予該片段活體內穩定性之Fc序列連接。
本文所使用之「單株抗體」一詞,係指取自一實質同質抗體群之抗體,除自然產生的微量基因變異種類外,包含於該抗體群之個別抗體皆無二致。因此,「單株」一詞意指該抗體並非由不同的抗體相混而成。一般而言,單株抗體包括一抗體,此抗體包含與目標結合之多胜肽序列,其中與目標結合之多胜肽序列自一方法取得,該方法包括自複數個多胜肽序列中,挑選能與單一目標結合之多胜肽序列。舉例而言,該挑選方法可為自複數個細胞株挑選一特殊細胞株,該複數個細胞株可為一群融合瘤細胞株(hybridoma clones)、噬菌體細胞株(phage clones)或重組DNA細胞株。應了解,經挑選之目標結合序列可被進一步修改,以達到提高與目標結合之親和力、將該目標結合序列人源化、提升細胞培養產量、降低該序列於活體內實驗(
in vivo)之免疫原性、製造多特異性抗體等目的。同時應了解,包含該經修改目標結合序列之抗體,亦屬於本文所述之單株抗體。製備單株抗體與製備多株抗體不同,後者一般包含針對不同表位(detetminants (epitopes))之不同抗體,而前者則包含針對單一抗原表位之單株抗體。單株抗體製程除具特異性外,另一優點為不受其他免疫球蛋白汙染。「單株」一詞意指該抗體取自一同質性抗體群,不應被理解為需要透過特定方法生成該抗體。舉例而言,本文中所使用之單株抗體,可透過許多技術產製而成,譬如融合瘤方法(見Kohler
et al., Nature, 256: 495 (1975);Harlow
et al., Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988);Hammerling
et al., in: Monoclonal Antibodies and T-Cell hybridomas 563-681 (Elsevier, N.Y., 1981))、重組DNA方法(見美國專利第4,816,567號)、噬菌體呈現技術(見Clackson
et al., Nature, 352: 624-628 (1991);Marks
et al., J. Mol. Biol. 222: 581-597 (1992);Sidhu
et al., J. Mol. Biol. 338(2): 299-310 (2004); Lee
et al., J. Mol. Biol. 340(5): 1073-1093 (2004);Fellouse, Proc. Natl. Acad. Sci. USA 101(34): 12467-12472 (2004);及Lee
et al., J. Immunol. Methods 284(1-2): 119-132 (2004)),以及於動物體內製備人類抗體或類人抗體之技術,前述動物包含部分或全部人類免疫球蛋白基因座(human immunoglobulin loci)或編碼人類免疫球蛋白序列之基因(見國際專利第WO98/24893號;第WO96/34096號;第WO96/33735號;第WO91/10741號;Jakobovits
et al., Proc. Natl. Acad. Sci. USA 90: 2551 (1993);Jakobovits
et al., Nature 362: 255-258 (1993);Bruggemann
et al., Year in Immunol. 7:33 (1993);美國專利第5,545,807號;第5,545,806號;第5,569,825號;第5,625,126號;第5,633,425號;第5,661,016號;Marks
et al., Bio. Technology 10: 779-783 (1992);Lonberg
et al., Nature 368: 856-859 (1994);Morrison, Nature 368: 812-813 (1994);Fishwild
et al., Nature Biotechnol. 14: 845-851 (1996);Neuberger, Nature Biotechnol. 14: 826 (1996)及Lonberg and Huszar, Intern. Rev. Immunol. 13: 65-93 (1995))。
本文之單株抗體特別包括「嵌合」(chimeric)抗體,此類抗體重鏈及/或輕鏈之一部分,與衍生自特定物種之抗體或屬於一特定抗體類型或子類型之對應序列完全相同或者同源。至於重/輕鏈上其他部分,則與衍生自另一特定物種之抗體或屬於另一特定抗體類型或子類型之對應序列完全相同或者同源。只要該些嵌合抗體之片段表現出預期生物活性,嵌合抗體也包含前述抗體的片段(見美國專利第4,816,567號;及Morrison
et al., Proc. Natl. Acad. Sci. USA 81:6851-6855 (1984))。
本文中之抗體亦可包括衍生自本文中抗體、且經嵌合或人源化之單株抗體。
該些抗體可具備完整長度,或包含具抗原結合位置抗體之一個(或多個)片段,包括但不限於Fab、F(ab')
2、Fab'、F(ab)'、Fv、單鏈Fv(scFv)、雙價單鏈Fv(bi-scFv)、三價單鏈Fv(tri-scFv)、Fd、dAb片段(見Ward
et al ., Nature, 341 :544-546 (1989))、互補性決定區、雙鏈抗體(diabodies)、三鏈抗體(triabodies)、四鏈抗體(tetrabodies)、線性抗體(linear antibodies)、單鏈抗體分子,以及由抗體片段形成之多特異性抗體。本文中亦包含使用重組技術或合成聯結分子連接抗體片段所生成之單鏈抗體。見Bird
et al.Science, 1988, 242:423-426. Huston et al, Proc. Natl. Acad. Sci. USA, 1988, 85:5879-5883。
本文中之抗體或其上之抗原結合部分可為單一特異性、雙特異性或多特異性。
本文中涵蓋之所有同型抗體,包括IgG(如IgG
l、IgG
2、IgG
3、IgG
4)、IgM、IgA(IgA
l、IgA
2)、IgD或IgE(本文中涵蓋其所有類型或子類型)。本文中之抗體或抗原結合部分可為哺乳動物(如老鼠或人類)抗體或抗原結合部分。此類抗體之輕鏈可為κ型或λ型。
因此,本發明之抗癌抗體包含非鼠源之一重鏈或輕鏈可變域、一重鏈或輕鏈固定域、一骨架區或任何前述部分的結合,較佳為人源,可併入本發明之一抗體中。
抗體具備之重鏈可變域及輕鏈可變域,與自參考抗體產生抗體之重鏈可變域及輕鏈可變域至少大約70%、至少大約75%、至少大約80%、至少大約81%、至少大約82%、至少大約83%、至少大約84%、至少大約85%、至少大約86%、至少大約87%、至少大約88%、至少大約89%、至少大約90%、至少大約91%、至少大約92%、至少大約93%、至少大約94%、至少大約95%、至少大約96%、至少大約97%、至少大約98%、至少大約99%或至少大約100%同源。此類抗體亦可與Globo系列抗原(如Globo H、SSEA-3或SSEA-4)結合。同源性可以胺基酸或核苷酸序列呈現。
該些抗體或抗原結合部分可為胜肽。此類胜肽可包括胜肽之變異物、類似物、異種同源物(orthologs)、同源物及衍生物,其表現生物活性,如碳水化合物抗原之結合反應。該些胜肽可包含一或多個胺基酸類似物(包括,如非天然胺基酸、於不相關的生物系統中天然存在之胺基酸、來自哺乳動物的經改造之胺基酸等)、含經取代鍵結之胜肽,以及其他習知之修飾物。
本發明所涵蓋之範圍,亦包括特定胺基酸經取代、刪除或插入之抗體或其抗原結合部分。在某一範例實施例中,前述改變不會替胜肽之生物特性(如結合親和力)帶來實質影響。在另一範例實施例中,抗體可於骨架區中具備胺基酸取代物,以改善抗體對抗原之結合親和力。在又另一範例實施例中,經選定之少量受者骨架殘基(acceptor framework residues)可被對應之供者胺基酸(donor amino acids)取代。供者骨架可為成熟或性腺人類抗體骨架序列或共通序列(consensus sequence)。關於產製不表現性狀胺基酸取代之原則方法,可見Bowie et al., Science, 247: 1306-1310 (1990)、Cunningham et al, Science, 244: 1081-1085 (1989)、Ausubel (ed.), Current Protocols in Molecular Biology, John Wiley and Sons, Inc. (1994)、T. Maniatis, E. F. Fritsch and J. Sambrook, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor laboratory, Cold Spring Harbor, N.Y. (1989)、Pearson, Methods Mol. Biol. 243:307-31 (1994)、Gonnet et al., Science 256: 1443-45 (1992)。
該抗體或其抗原結合部分,可衍生化或鍵結至與另一官能分子。舉例而言,抗體可透過功能性連接(如化學耦合、基因融合、非共價鍵交互作用等)至一或多個其他分子結構,如另一抗體、可偵測製劑(detectable agent)、胞殺毒殺製劑(cytotoxic agent)、醫藥製劑、可以媒介與其他分子(如鏈黴親和素核心區(streptavidin core region)或聚組胺酸標籤(polyhistidine tag))連結之蛋白質或胜肽、胺基酸連結分子、訊號序列(signal sequences)、免疫生成載體(immunogenic carriers)或對蛋白質純化有助益之配體(ligand),如穀胱甘肽S轉移酶(glutathione-S-transferase)、組胺酸標籤及金黃色葡萄球菌A蛋白(staphylococcal protein A)。其中一種衍生蛋白係由二或多個蛋白(屬同類型或不同類型)交聯而成。合適之交聯劑包括異質雙功能性(heterobifunctional)交聯劑,其具備以適當分隔物(如馬來醯亞胺苯甲酸琥珀醯亞胺酯(m-maleimidobenzoyl-N-hydroxysuccinimide ester))分隔之兩個不同反應基,或包括同質雙功能性(homobifunctional)交聯劑(如雙琥珀醯亞胺辛二酸酯(disuccinimidyl suberate))。該些聯結分子可自Pierce Chemical Company, Rockford, 111取得。可衍生(或標示)蛋白質之有用的可偵測製劑,包括螢光化合物、多種酶、輔基(prosthetic groups)、發光材料、生物發光材料及放射性材料。範例螢光可偵測製劑包括且不限於螢光素(fluorescein)、螢光異硫氰酸鹽(fluorescein isothiocyanate)、羅丹明(rhodamine)及藻紅蛋白(phycoerythrin)。蛋白質或抗體亦可透過可偵測酶而衍生化,可偵測酶種類如鹼性磷酸酶(alkaline phosphatase)、辣根過氧化物酶(horseradish peroxidase)、β半乳糖苷酶(beta-galactosidase)、乙醯膽鹼酯酵素(acetylcholinesterase)、葡萄糖氧化酶(glucose oxidase)與類似物。蛋白質亦可透過輔基(如鏈黴親和素(streptavidin)/生物素(biotin)及抗生物素蛋白(avidin)/生物素)而衍生化。
編碼本文中所述抗體或其抗原結合部分之功能活性變異物的核酸,亦涵蓋於本申請案範圍內。該些核酸分子可與編碼本文中任一抗體或其抗原結合部分之核酸在中嚴格度(stringency)、高嚴格度或極高嚴格度條件下雜交。實施雜交反應之指南,可見於Current Protocols in Molecular Biology, John Wiley & Sons, N.Y. 6.3.1-6.3.6, 1989,其全部內容以引用方式併入本文中。本文所述之特定混成條件包括以下:(1)中嚴格度混成條件:於大約45°C下施以6 X SSC緩衝液,再於60°C下以0.2 X SSC緩衝液、0.1%十二烷基硫酸鈉(SDS)清洗一或多次;(2)高嚴格度混成條件:於大約45°C下施以6 X SSC緩衝液,再於65°C下以0.2 X SSC緩衝液、0.1% SDS清洗一或多次(3)極高嚴格度混成條件:於65°C下施以0.5M磷酸鈉(sodium phosphate)、7% SDS,再於65°C下以0.2 X SSC緩衝液、1% SDS清洗一或多次。
編碼本文中所述抗體或其抗原結合部分之核酸,可嵌入於表現載體中,而該表現載體可於合適表現系統中表現,再將表現出之抗體或其抗原結合部分分離或純化。視情況而定,編碼本文中抗體或其抗原結合部分之核酸可於無細胞轉譯系統(cell-free translation system)中進行轉譯。見美國專利第4,816,567號,及Queen et al, Proc Natl Acad Sci USA, 86: 10029-10033 (1989)。
本文中所述抗體或其抗原結合部分可透過宿主細胞製備而成,而該宿主細胞係以編碼目標抗體輕鏈與重鏈(或其部分)之DNA而轉型。抗體可自培養物上清液及/或細胞以標準技術分離並純化取得。舉例而言,宿主細胞可以編碼抗體輕鏈、重鏈或前述兩者之DNA而完成轉型。DNA重組技術亦可用於移除某些或所有編碼非結合反應必要元素之輕鏈、重鏈或前述兩者的DNA,如穩定區。
本文中所述之核酸可於各種合適細胞中表現,其包括原核與真核細胞,如細菌細胞(譬如大腸桿菌)、酵母菌細胞、植物細胞、昆蟲細胞及哺乳動物細胞。許多哺乳動物細胞株為本發明所屬技術領域中所習知,且包含可自美國典型菌種保存中心(American Type Culture Collection, ATCC)取得之不死細胞株。該些細胞包括且不限於所有源於哺乳動物或類哺乳動物之細胞株,包括但不限於猴腎細胞(COS,如COS-1、COS-7)、HEK293細胞、幼倉鼠腎細胞(BHK,如BHK21)、中國倉鼠卵巢細胞(CHO)、NSO細胞、PerC6細胞、BSC-1細胞、人類肝細胞癌細胞(如Hep G2)、SP2/0細胞、HeLa細胞、Madin-Darby牛腎細胞(Madin-Darby bovine kidney, MDBK)、骨髓癌細胞及淋巴癌細胞的母細胞、衍生物及/或其基因改造變異物。經基因改造之變異物包含如經醣鏈圖譜(glycan profile)改造及/或具位置特異性嵌入位置(site-specific integration site)之衍生物。
本文中亦提供包含本文中所述核酸之細胞。該細胞可為融合瘤或經轉染之細胞(transfectant)。
或者,本文中所述之抗體或其抗原結合部分可由本發明所屬技術領域中所習知之固相流程(solid phase procedures)技術合成。見Solid Phase Peptide Synthesis: A Practical Approach by E. Atherton and R. C. Sheppard, published by IRL at Oxford University Press (1989)、Methods in Molecular Biology, Vol. 35: Peptide Synthesis Protocols (ed. M. W.Pennington and B. M. Dunn), chapter 7. Solid Phase Peptide Synthesis, 2nd Ed., Pierce Chemical Co., Rockford, IL (1984)、G. Barany and R. B. Merrifield, The Peptides: Analysis, Synthesis, Biology, editors E. Gross and J. Meienhofer, Vol. 1 and Vol. 2, Academic Press, New York, (1980), pp. 3-254、M. Bodansky, Principles of Peptide Synthesis, Springer-Verlag, Berlin (1984)。
「人源化」(humanized)形式之非人(如鼠科)抗體屬於嵌合抗體,其中包含衍生自非人免疫球蛋白之最小序列。在某一實施例中,人源化抗體為人類免疫球蛋白(受者抗體),其中該受者抗體之高度可變域殘基會被非人物種(供者抗體)之高度可變域殘基取代,該非人物種可為具目標結合特異性、親和力及/或能力之小鼠、大鼠、兔子或非人靈長類動物。在某些實例中,該人類免疫球蛋白之骨架殘基會被對應之非人殘基取代。此外,人源化抗體可能包含不屬於該受者抗體或該供者抗體之殘基。以上進行之修飾,目的皆為進一步改善抗體表現。一般而言,該人源化抗體實質上會包含至少一組、通常兩組之完整可變域,其中整體或實質上整體之可變域環會對應至非人免疫球蛋白之可變域環,且其中整體或實質上整體之骨架具備人類免疫球蛋白序列。該人源化抗體會選擇性包含至少一部分之免疫蛋白固定域(Fc),一般為人類免疫球蛋白之固定域。更多詳細說明,可參考Jones
et al., Nature 321:522-525 (1986); Riechmann
et al., Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992). See also the following review articles and references cited therein: Vaswani and Hamilton, Ann. Allergy, Asthma & Immunol. 1:105-115 (1998); Harris, Biochem. Soc. Transactions 23:1035-1038 (1995); Hurle and Gross, Curr. Op. Biotech. 5:428-433 (1994)。
本文所使用之「高度可變域」(hypervariable region、HVR或HV)一詞,係指抗體可變域中序列出現高度變異及/或形成結構定義環(structurally defined loops)之區域。一般而言,抗體包含六個高度可變域,三個位於重鏈可變域(H1、H2、H3),另三個位於輕鏈可變域(L1、L2、L3)。本文使用並涵蓋多種高度可變域之敘述。Kabat互補性決定區係依據序列可變性而標定,且為最廣泛使用之類型(見Kabat
et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991))。不過,Chothia則認為環狀結構(structural loop)處為可變域(見Chothia and Lesk J. Mol. Biol. 196:901-917 (1987))。
「骨架」(framework)或「骨架」殘基為可變域殘基,但非本文定義之高度可變域殘基。
本文所使用之「Kabat可變域殘基編號」或「Kabat胺基酸位置編號」及其變異物等詞,係指用於Kabat
et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)所彙整之抗體重鏈或輕鏈可變域之編號系統。透過此編號系統,可使真實存在之線性胺基酸序列於該可變域之骨架或高度可變域長度縮短或納入新片段,而包含較少或額外之胺基酸。舉例而言,重鏈可變域可於H2之52號殘基後包括單獨插入胺基酸(Kabat所稱之52a號殘基),及於重鏈骨架82號殘基後包括多個插入殘基(如Kabat所稱之82a、82b、82c號等殘基)。針對一抗體使用Kabat殘基編號法時,可以「標準」Kabat編號序列與該抗體序列同源性區域進行比對,以決定編號方式。
「單鏈Fv」抗體片段包含抗體重鏈及輕鏈可變域,其中該些區域以單一多肽鏈呈現。一般而言,單鏈Fv多肽進一步於重鏈及輕鏈可變域之間包含一多肽聯結分子,該聯結分子可使該單鏈Fv形成期望之結合抗原的結構。單鏈Fv相關評論可參考 Pluckthun所著之The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994)。
「雙鏈抗體」一詞係指具備兩個抗原結合位置之小型抗體片段,該些片段包含在同一條多肽鏈(重鏈-輕鏈)上與某輕鏈可變域連接之重鏈可變域。透過利用一過短而無法使位於同一條鏈上之兩個可變域進行配對之聯結分子,便能強制使該些區域與另一鏈上之互補區域組合,並生成兩個抗原結合位置。關於雙鏈抗體之詳細描述可參考歐洲專利第EP 404,097號、國際專利第WO93/1161號以及Hollinger et al., Proc. Natl. Acad. Sci. USA 90: 6444-6448 (1993)。
「人類抗體」係為具備胺基酸序列之抗體,其中該胺基酸序列與人類所產生抗體之胺基酸序列相對應及/或該胺基酸序列係以任何本文中揭露的製造人類抗體之任何技術所製造。前述人類抗體之定義,特別排除包含非人抗原結合殘基之人源化抗體。
「親和力成熟」之抗體,係於一或多個高度可變域內具有一或多個變異之抗體,與未經過變異的親代抗體相比,經過變異後該抗體對抗原之親和力提升。在某一實施例中,親和力成熟抗體對目標抗原之親和力為10
-9莫耳,或甚至為10
-12莫耳。親和力成熟抗體由本發明所屬技術領域中習知流程所製備。Marks et al. Bio/Technology 10:779-783 (1992)以重鏈與輕鏈可變域改組解釋親和力成熟過程。互補性決定區及/或骨架殘基之隨機突變相關描述,可見Barbas
et al.Proc Nat. Acad. Sci. USA 91:3809-3813 (1994);Schier
et al.Gene 169:147-155 (1995);Yelton et al. J. Immunol. 155:1994-2004 (1995);Jackson
et al., J. Immunol. 154(7):3310-9 (1995);及Hawkins
et al., J. Mol. Biol. 226:889-896 (1992)。
「阻斷」(blocking)抗體或「拮抗」(antagonist)抗體,係抑制或減少所結合抗原生物活性之抗體。特定阻斷抗體或拮抗抗體會實質或完全抑制該抗原之生物活性。
本文所使用之「致效抗體」(agnoist antibody)一詞,係指模擬目標多肽所具備之至少一種功能活性的抗體。
「病症(disorder)」係指能因施用本文中所述之抗體而改善之任何狀態。此異常包括慢性與急性病症或疾病,包括使哺乳動物容易陷入所謂病症之病態條件。有待治療之病症包括但不限於癌症。
本文所使用之「細胞增生病症」及「增生病症」等詞,係指與某種程度異常之細胞增生現象有關之病症。在某一實施例中,該細胞增生病症為癌症。
本文所使用之「腫瘤」一詞,係指無論惡性或良性之所有贅生(neoplastic)細胞的生長及增生現象,及指所有癌前期(pre-cancerous)及癌症型(cancerous)細胞與組織。本文所使用之「癌症」、「癌症型」、「細胞增生病症」、「增生病症」及「腫瘤」等詞並非互斥。
「癌症」及「癌症型」係指或描述哺乳動物體內之生理現象,其特徵一般為細胞生長/增生不受控制。癌症種類包括但不限於上皮瘤、淋巴瘤(如何杰金(Hodgkin's)及非何杰金淋巴瘤)、胚細胞瘤(blastoma)、惡性肉瘤及血癌。此類特定癌症種類還包括鱗狀細胞癌(squamous cell cancer)、小細胞肺癌、肺腺癌(adenocarcinoma of the lung)、肺鱗狀上皮細胞癌(squamous carcinoma of the lung)、腹膜(peritoneum)、肝細胞癌、胃腸道癌(gastrointestinal cancer)、胰臟癌、膠質母細胞瘤、子宮頸癌、卵巢癌、肝臟癌、膀胱癌、肝癌(hepatoma)、乳癌、腸癌、結腸直腸癌、子宮內膜癌(endometrial carcinoma)或子宮癌(uterine carcinoma)、唾液腺癌、腎臟癌、肝臟癌、前列腺癌、外陰癌(vulval cancer)、甲狀腺癌、肝癌(hepatic carcinoma)、血癌與其他淋巴增生病症(lymphoproliferative disorders),以及多種類型之頭頸癌。
本文所使用之「治療」一詞,係指施用臨床介入以達改變被治療個體或細胞自然發展進程之目的,而治療亦可為預防疾病或於臨床症狀出現時施用。預期之治療效果包括預防疾病發作或復發、減輕症狀、使任何該疾病直接或間接導致之病理狀況消失、預防或減輕發炎及/或組織/器官傷害、降低疾病惡化速率、改善或緩和患病狀態,以及使病患復原或改善預後情況。在某些實施例中,本發明之抗體用於延緩疾病或病症之發展速率。
本文中之「個體」或「受試者」為脊椎動物。在特定實施例中,該脊椎動物為哺乳動物,包括但不限於農場動物(如牛)、競賽用動物、寵物(如貓、狗及馬)、靈長類動物、小鼠及大鼠。在特定實施例中,該脊椎動物為人類。
用於治療之「哺乳動物」係指任何屬於哺乳類之動物,包括人類、家庭或農場豢養之動物,以及動物園動物、競賽用動物或寵物動物,如狗、馬、貓、牛等。在特定實施例中,該哺乳動物為人類。
「有效量」係指能在劑量上及所需時間內持續有效之劑量,用以達到預期之治療及預後成果。
本文中所述之物質/分子之「治療有效量」可隨不同因素改變,包括個體之患病狀態、年齡、性別及體重,以及該物質/分子於該個體體內引起預期反應之能力。治療有效量亦指其正向治療效果高過該物質/分子具備之任何毒性或損壞效果。「預防有效量」係指能在劑量上及所需時間內持續有效之劑量,用以達到預期之預防結果。在一般但非必然情況下,由於預防劑量會在患病前或患病初期施用於受試者體內,故該預防有效量會低於該治療有效量。
「組成物」係指組合療法,其中該抗體藥物共軛物及/或其他生物或化學藥物共同施用時(即共同施用及/或共同配方之情形),無論為依序或同時施用、於治療周期內同一日或不同日施用,皆可形成具備高度療效、超越加成療效之增效作用。
「癌症」及「癌症型」係指或描述哺乳動物體內之一生理現象,其特徵一般為細胞生長/增生不受控制。「腫瘤」包含一或多個癌症細胞。癌症種類包括但不限於上皮瘤、淋巴瘤、胚細胞瘤、惡性肉瘤及血癌或淋巴惡性瘤。
本文所使用之「胞殺劑」一詞,係指能抑制或遏止細胞功能及/或破壞細胞之物質。該詞意圖包括放射性同位素(如砈-211、碘-131、碘-125、釔-90、錸-186、錸-188、釤-153、鉍-212、磷-32、碳-60,及鎦-117、鍶-89、釤(釤-153)之放射性同位素)、化療製劑及毒素,譬如小分子毒素或經酵素活化之細菌、真菌、植物或動物源毒素,包括合成類似物或其衍生物。
「光動力療法(photodynamic therapy, PDT)」,或稱光化學療法,為一種透過光與光敏感化學物質之光療法,搭配氧分子共同使用使細胞死亡(即光毒性)。光動力療法可用來治療多種之臨床症狀,包括溼性老年黃斑部病變(wet age-related macular degeneration)、乾癬(psoriasis)、動脈粥狀硬化(atherosclerotic),而用來治療帶狀皰疹等病毒性症狀亦具備一定療效。此療法亦可用來治療惡性腫瘤,包括頭頸癌、肺癌、膀胱癌、皮膚癌及攝護腺癌(參考Wang, SS et al. Cancer Journal. 8 (2): 154–63. 2002)。該「光動力療法製劑」選自福得靈(Photofrin)、他拉泊芬鈉注射液(Laserphyrin)、氨基酮戊酸(Aminolevulinic acid (ALA))、矽鈦菁4(Silicon Phthalocyanine Pc 4)、m-四羥甲基氯化膦(m-tetrahydroxyphenylchlorin (mTHPC))、二氫卟吩e6(chlorin e6 (Ce6))、Allumera、氨基乙醯丙酸(Levulan)、替莫泊芬注射劑(Foscan)、Metvix、Hexvix、光克洛(Photochlor)、Photosens、Photrex、Lumacan、Visonac、Amphinex、維視達凍晶注射劑(Verteporfin)、Purlytin、ATMPn、鋅鈦菁(Zinc phthalocyanine (ZnPc))、原紫質(Protoporphyrin IX (PpIX))、焦脫鎂葉綠酸鹽-a(Pyropheophorbide-a (PPa))或脫鎂葉綠酸鹽-a(Pheophorbide a (PhA))。
「化療製劑」為能有效治療癌症之化學化合物。範例化療製劑種類包括單甲基奧瑞斯他丁E(MMAE)、單甲基奧瑞斯他丁F(MMAF)、mertansine(又稱DM1)、蒽環黴素(anthracycline)、吡咯苯二氮平(pyrrolobenzodiazepine)、α-amanitin、tubulysin、苯二氮平(benzodiazepine)、得舒緩膜衣錠(erlotinib, (TARCEVA
®), Genetech/OSI Pharm.)、萬科注射劑(VELCADE
®, Millenium Pharm.)、法洛德注射液(FASLODEX
®, Astrazeneca)、紓癌特膠囊(SUTENT
®, SU11248, Pfizer)、復乳納膜衣錠(FEMARA
®, Novartis)、基利克膜衣錠(GLEEVEC
®, Novartis)、PTK787/ZK 222584(Novartis)、益樂鉑注射液(ELOXATIN
®, Sanofi)、亞葉酸(leucovorin)、斥消靈錠(Sirolimus, (RAPAMUNE
®), Wyeth)、泰嘉錠膜衣錠(TYKERB
®, GSK572016, GlaxoSmithKline)、lonafarnib(SARASAR
®, SCH 66336)、sorafenib(蕾莎瓦膜衣錠(NEXAVAR
®), BAY43-9006, Bayer Labs.)及艾瑞莎膜衣錠(IRESSA
®, Astrazeneca)、AG1478、AG1571(SU 5271;SUGEN)、烯烴基化劑如thiotepa及環磷醯胺(CYTOXAN
®)、烷基磺酸鹽例如busulfan(補束剋注射劑)、二丙胺磺酯(improsulfan)和呱泊舒凡(piposulfan);氮丙啶例如苄多巴(benzodopa)、卡巴醌(carboquone)、美妥多巴(meturedopa)及烏瑞多巴(uredopa);次乙亞胺(ethylenimine)及甲基三聚氰胺(methylamelamine),包括六甲蜜胺(altretamine)、曲他胺(triethylenemelamine)、三乙烯磷醯胺(triethylenephosphoramide)、三乙烯硫代磷醯胺(triethylenethiophosphoramide)及三甲基蜜胺(trimethylolomelamine);多聚乙醯(尤其bullatacin及bullatacinone);喜樹鹼(包括合成類似物托普樂肯(topotecan));bryostatin;callystatin;CC-1065(包括其阿多來新(adozelesin)、卡折來新(carzelesin)及比折來新(bizelesin)合成類似物);隱花素(cryptophycin)(尤其隱花素1及隱花素8);海兔毒素(dolastatin);多卡黴素(duocarmycin)(包括合成類似物KW-2189 及CB1-TM1);紅蔥甲素(eleutherobin);pancratistatin ;sarcodictyin;海綿抑素(spongistatin);氮芥類如苯丁酸氮芥(chlorambucil)、萘氮芥(chlornaphazine)、膽磷醯胺(cholophosphamide)、雌莫司汀(estramustine)、異環磷醯胺(ifosfamide)、氮芥(mechlorethamine)、氧氮芥鹽酸鹽(mechlorethamine oxide hydrochloride)、美法侖(melphalan)、新恩比興(novembichin)、苯乙醯膽固醇氮芥(phenesterine)、松龍苯芥(prednimustine)、三芥環磷醯胺(trofosfamide)、尿嘧啶芥(uracil mustard);亞硝基脲(nitrosurea)如亞硝基脲氮芥(carmustine)、氯脲黴素(chlorozotocin)、福莫司汀(fotemustine)、洛莫司汀(lomustine)、尼莫司汀(nimustine)和雷諾司汀(ranimustine);抗生素如烯二炔類抗生素(如卡奇黴素(calicheamicin),尤其卡奇黴素γlI和卡奇黴素ω Il ,參考Agnew Chem Intl. Ed. Engl. (1994) 33:183-186);蒽環類抗生素(dynemicin),包括 dynemicin A;雙膦酸鹽類,如氯膦酸鹽(clodronate);埃斯波黴素(esperamicin); 以及新制癌素(neocarzinostatin)發色團與相關之色蛋白烯二炔類抗生素發色團)、阿克拉黴素(aclacinomycin)、放線菌素(actinomycin)、氨茴黴素(authramycin)、偶氮絲氨酸(azaserine)、博來黴素(bleomycin)、放線菌素 C (cactinomycin)、卡拉比星(carabicin)、 洋紅黴素(carminomycin)、嗜癌黴素(carzinophilin)、色黴素(chromomycin)、放線菌素 D (dactinomycin)、唐黴素(daunorubicin)、地托比星(detorubicin)、6-二氮-5-氧-L-正亮氨酸(6-diazo-5-oxo-L-norleucine)、ADRIAMYCIN
®多柔比星(doxorubicin)(包括嗎啉代多柔比星(morpholino-doxorubicin)、氰基嗎啉代多柔比星(cyanomorpholino-doxorubicin)、2-吡咯代多柔比星及脫氧多柔比星(2-pyrrolino-doxorubicin and deoxydoxorubicin))、表柔比星(epirubicin)、 依索比星(esorubicin)、伊達比星(idarubicin)、麻西羅黴素(marcellomycin)、絲裂黴素類(mitomycins)如絲裂黴素C、黴酚酸(mycophenolic acid)、諾拉黴素(nogalamycin)、 橄欖黴素(olivomycin)、培洛黴素(peplomycin)、泊非黴素(potfiromycin)、嘌呤黴素(puromycin)、三鐵阿黴素(quelamycin)、羅多比星(rodorubicin)、鏈黑菌素(streptonigrin)、鏈佐星(streptozocin)、殺結核菌素(tubercidin)、烏苯美司 (ubenimex)、淨司他丁(zinostatin)、佐柔比星(zorubicin);抗代謝物類,如甲氨蝶呤 (methotrexate)及5-氟尿嘧啶(5-FU);葉酸類似物,如二甲葉酸(denopterin)、蝶羅呤(pteropterin)、三甲曲沙(trimetrexate);嘌呤類似物,如氟達拉濱(fludarabine)、6-巰嘌呤(6-mercaptopurine)、硫咪嘌呤(thiamiprine)、 硫鳥嘌呤(thioguanine);嘧啶類似物,如安西他濱(ancitabine)、阿紮胞苷 (azacitidine)、6-氮尿苷(6-azauridine)、卡莫氟(carmofur)、阿糖胞苷(cytarabine)、 雙脫氧尿苷(dideoxyuridine)、去氧氟尿苷(doxifluridine)、依諾他濱(enocitabine)、 氟尿苷(floxuridine);雄激素類,如卡魯睪酮(calusterone)、丙酸屈他雄酮 (dromostanolone propionate)、表硫雄醇(epitiostanol)、美雄烷 (mepitiostane)、 睪內酯(testolactone);抗腎上腺類,如氨魯米特(aminoglutethimide)、米托坦 (mitotane)、曲洛司坦(trilostane);葉酸補充劑,如亞葉酸(folinic acid);醋葡醛內酯(aceglatone);醛磷醯胺糖苷(aldophosphamide glycoside);胺基乙醯丙酸 (aminolevulinic acid);恩尿嘧啶(eniluracil);安吖啶(amsacrine);bestrabucil ; 比生群(bisantrene);依達曲沙(edatraxate);地磷醯胺(defofamide);地美可辛 (demecolcine);亞胺醌(diaziquone);elformithine ;依利醋銨(elliptinium acetate); 埃坡黴素(epothilone);依託格魯(etoglucid);硝酸鎵;羥脲(hydroxyurea);香菇多醣(lentinan);氯尼達明(lonidamine);美登木素生物鹼類(maytansinoids), 如美登素(maytansine)及安絲菌素(ansamitocin);米托胍腙(mitoguazone); 米托蒽醌(mitoxantrone);莫哌達醇(mopidamol) ; 根瘤菌劑(nitraerine);噴司他丁(pentostatin);蛋氨氮芥(phenamet);吡柔比星(pirarubicin);洛索蒽醌(losoxantrone);鬼臼酸(podophyllinic acid);2-乙基醯胼(2-ethylhydrazide);丙卡巴胼(procarbazine) ;PSK
®多糖複合物(JHS Natural Products, Eugene, OR);雷佐生(razoxane);根黴素(rhizoxin);西佐非蘭(sizofiran);螺旋鍺(spirogermanium);細交鏈孢菌酮酸(tenuazonic acid);三亞胺醌(triaziquone) ;2,2',2''-三氯三乙胺;單端孢菌素類(trichothecenes)(尤其T-2毒素、疣孢菌素A (verracurin A)、杆孢菌素A (roridin A)及蛇行菌素(anguidine));胺基甲酸乙酯(urethan);長春地辛(vindesine);達卡巴仁(dacarbazine);甘露莫司汀(mannomustine) ;二溴甘露醇(mitobronitol);二溴衛矛醇(mitolactol);哌泊溴烷(pipobroman) ;gacytosine ;阿拉伯糖苷(arabinoside, "Ara-C");環磷醯胺(cyclophosphamide);thiotepa;類紫杉醇類(taxoids),如TAXOL
®汰癌勝注射液(paclitaxel)(Bristol-Myers Squibb Oncology, Princeton, N. J.)、ABRAXANE
®聚氧乙烯蓖麻油(Cremophor)、清蛋白改造奈米顆粒劑型汰癌勝注射液(American Pharmaceutical Partners, Schaumberg, Illinois)及TAXOTERE
®剋癌易注射劑(doxetaxel)(Rhone -Poulenc Rorer, Antony, France);苯丁酸氮芥(chlorambucil);GEMZAR
®吉西他濱(gemcitabine);6-硫鳥嘌呤(6-thioguanine);巰基嘌呤 (mercaptopurine);甲氨蝶呤(methotrexate);鉬類似物,如順鉬(cisplatin)、奧沙利鉑(oxaliplatin)及卡鉑(carboplatin);長春鹼(vinblastine);鉑(platinum);依託泊苷(etoposide)(VP-16);異環磷醯胺(ifosfamide);米托蒽醌(mitoxantrone);長春新鹼(vincristine);NAVELBINE® 長春瑞濱(vinorelbine);雙羥蒽醌注射液(novantrone);替尼泊苷(teniposide);依達曲沙(edatrexate);唐黴素注射劑(daunomycin);氨喋呤(aminopterin);截瘤達錠(xeloda);吉利康注射液(ibandronate);CPT-11;拓撲異構酶抑制劑RFS 2000(topoisomerase inhibitor RFS 2000);二氟甲基鳥氨酸(difluoromethylornithine, DMFO);類視黃酸類(retinoids),如視黃酸(retinoic acid);截瘤達(capecitabine, XELODA, Roche
®);及任何上述物質之醫藥上可接受鹽、酸或衍生物。
此處「化療製劑」之定義亦包括:(i) 抗激素製劑,其可調控或抑制激素對腫瘤造成之作用,例如抗雌激素劑及選擇性雌激素受體調節劑(selective estrogen receptor modulators, SERMs),包括tamoxifen(包括諾瓦得士錠tamoxifen)、raloxifene(鈣穩膜衣錠)、droloxifene、4-hydroxytamoxifen、trioxifene、keoxifene、LY117018、onapristone及FARESTON toremifene(弗瑞斯錠);(ii) 芳香環酶抑制劑(aromatese inhibitor),其可抑制芳香環酶,以達到調控腎上腺中雌激素產量之效果,包括4(5)-咪唑(4(5)-imidazoles)、aminoglutethimide、麥格斯口服懸液劑(MEGASE
®, megestrol acetate)、諾曼癌素糖衣錠(AROMASIN
®, exemestane)、formestanie、fadrozole、RIVISOR
®(vorozole)、letrozole(復乳納膜衣錠(FEMARA
®))及安美達錠(ARIMIDEX
®, anastrozole);(iii) 抗雄激素劑,如flutamide(護腺寧錠)、nilutamide、bicalutamide(可蘇多錠)、leuprolide(柳菩林注射液)、goserelin(諾雷德持續性注射劑);以及troxacitabine(α-1,3-二氧戊環核苷胞嘧啶類似物(α-1,3-dioxolane nucleoside cytosine analog));(iv) 芳香環酶抑制劑;(v) 蛋白激酶抑制劑(protein kinase inhibitor);(vi) 脂質激酶抑制劑(lipid kinase inhibitor);(vii) 反義寡核苷酸(antisense oligonucleotide),尤其為細胞異常增生時,可抑制相關基因傳輸訊息之反義寡核苷酸,如蛋白激酶C-α、RALF及H-Ras基因;(viii) 核酶,如血管內皮生長因子蛋白質抑制劑(如ANGIOZYME
®核酶)及HER2抑制劑;(ix) 疫苗,如基因療法疫苗,例如ALLOVECTIN
®、LEUVECTIN
®、VAXID
®、PROLEUKIN
®rIL-2(普留淨注射劑)、LURTOTECAN
®拓樸異構酶1抑制劑;ABARELIX
®rmRH;(x) 抗血管新生製劑,如bevacizumab(癌思停注射劑(AVASTIN
®),Genentech);及 (xi) 前述任一之醫藥上可接受的鹽類、酸類或衍生物。
蛋白激酶抑制劑包括酪胺酸激酶抑制劑,可某種程度抑制如ErbB受體等酪胺酸激酶之活性。範例酪胺酸激酶抑制劑包括針對EGFR之藥物,如:(i) 與EGFR結合之抗體,包括MAb 579(ATCC CRL HB 8506)、MAb 455(ATCC CRL HB8507)、MAb 225(ATCC CRL 8508)、MAb 528(ATCC CRL 8509)(可參考美國專利第4,943,533號,Mendelsohn et al.)及其變異種類,如嵌合抗體225(C225或Cetuxim 爾必得舒注射液(ERBITUX),Imclone)及重構人類抗體225(H225)(WO 96/40210, Imclone Systems Inc.);與第二型突變EGFR結合之抗體(美國專利第5,212,290號);與EGFR結合之人源化及嵌合抗體(美國專利第5,891,996號);及與EGFR結合之人類抗體,如ABX-EGF(WO 98/50433);(ii) 與之胞殺劑共軛之抗EGFR抗體(EP 659439A2);及與EGFR結合之小分子,包括ZD1839或Gefitinib(艾瑞莎膜衣錠IRESSA™;Astra Zeneca)、Erlotinib HCl(CP-358774,得舒緩膜衣錠TARCEVA™;Genentech/OSI)及AG1478、AG1571(SU 5271;Sugen),吡啶並嘧啶(pyridopyrimidines)、嘧啶並嘧啶(pyrimidopyrimidines)、吡咯並嘧啶(pyrrolopyrimidines),例如CGP 59326、CGP 60261及CGP 62706,以及吡唑啉酮嘧啶(pyrazolopyrimidines)、4-(苯胺)-7H-吡咯並[2,3-d]嘧啶,薑黃色素(二阿魏醯甲烷,4,5-(4-氟苯胺基)苯鄰二甲醯亞胺),含硝基噻吩基團之tyrphostines;PD-0183805(Warner-Lamber);反義分子(例如與ErbB編碼核酸結合之分子);喹喔啉(美國專利第5,804,396號);tryphostins(美國專利第5,804,396號);ZD6474(Astra Zeneca);PTK-787(Novartis/Schering AG);泛-ErbB抑制劑例如CI-1033(Pfizer);Affinitac(ISIS 3521;Isis/Lilly);Imatinib mesylate(Gleevac;Novartis);PKI 166(Novartis);GW2016(Glaxo SmithKline);CI-1033(Pfizer);EKB-569(Wyeth);Semaxanib(Sugen);ZD6474(AstraZeneca);PTK-787(Novartis/Schering AG);INC-1C11(Imclone);或於以下專利中所述:美國專利第5,804,396號;WO 99/09016(American Cyanamid);WO 98/43960(American Cyanamid);WO 97/38983(Warner Lambert);WO 99/06378(Warner Lambert);WO 99/06396(Warner Lambert);WO 96/30347(Pfizer, Inc);WO 96/33978(Zeneca);WO 96/3397(Zeneca);及WO 96/33980(Zeneca)。
「抗血管新生製劑」(anti-angiogenic agent)指能阻斷或某種程度上干擾血管生成之化合物。舉例來說,抗血管新生因子可為會與生長因子結合或與促進血管新生之生長因子受體結合之小分子或抗體。抗血管新生製劑之範例為會與血管內皮生長因子結合之抗體,如bevacizumab(癌思停注射劑(AVASTIN),Genentech)。
「細胞激素」(cytokine)為一通稱詞,係指由一細胞群所釋放、可作用於另一細胞以進行細胞間調節之蛋白質。細胞激素之範例為淋巴激素、單核激素及傳統之多肽激素。細胞激素包括生長激素,如人類生長激素、N-甲硫氨醯人類生長激素及牛生長激素;副甲狀腺素;甲狀腺素;胰島素;胰島素原;鬆弛素;鬆弛素原;醣蛋白激素,如促濾泡激素(FSH)、促甲狀腺素(TSH)及黃體生成素(LH);肝生長激素;纖維細胞生長因子;催乳素;胎盤催乳激素;腫瘤壞死因子-α與-β;穆勒氏管抑制物質;小鼠促性腺激素相關胜肽;抑制素;活化素;血管內皮生長因子;整聯蛋白;血小板生成素(TPO);神經生長因子,如NGF-β;血小板生長因子;轉化生長因子(TGF),如TGF-α及TGF-β;類胰島素生長因子-I及-II;促紅血球生成素(EPO);骨誘導生長因子(osteoinductive factor);干擾素,如干擾素-α、-β及-γ;聚落刺激因子(CSF),如巨噬細胞-CSF(M-CSF);粒細胞-巨噬細胞-CSF(GM-CSF);及粒細胞-CSF(G-CSF);白細胞介素(IL),如IL-1、IL-1α、IL-2、IL-3、IL-4、IL-5、IL-6、IL-7、IL-8、IL-9、IL-10、IL-11、IL-12;腫瘤壞死因子,如TNF-α或TNF-β;及其他多胜肽因子,包括LIF及工具組配體(kit ligand, KL)。本文使用之細胞激素一詞,係包括天然或源於重組細胞培養物之蛋白質,以及具原生序列細胞激素之生物活性等價物。
本發明使用之「前體藥物」(prodrug)一詞,係指醫藥上具活性物質之前驅物或衍生物形式,而相較於母藥,該前驅物或衍生物對腫瘤細胞較無胞殺力,且可經酵素活化或轉換為活性更強之母藥形式。相關參考資料如Wilman, “Prodrugs in Cancer Chemotherapy” Biochemical Society Transactions, 14, pp. 375-382, 615th Meeting Belfast (1986) and Stella et al., “Prodrugs: A Chemical Approach to Targeted Drug Delivery,”
Directed Drug Delivery, Borchardt et al., (ed.), pp. 247-267, Humana Press (1985)。本發明之前體藥物包括但不限於含磷酸鹽前體藥物、含硫代磷酸鹽前體藥物、含肽前體藥物、經D-胺基酸修飾之前體藥物、醣基化前體藥物、含β-內醯胺前體藥物、含可選擇性被取代的苯氧基乙醯胺之前體藥物,或者含可選擇性被取代的苯基乙醯胺之前體藥物、5-氟胞嘧啶以及其他5-氟尿嘧啶前體藥物,其可被轉化為活性更強之細胞毒性藥物。用於本發明中的可衍生為前體藥物形式之細胞毒性藥物,其範例包括但不限於上述之化療製劑。
「脂質體」為不同類型的脂質、磷脂質及/或介面活性劑組成之囊泡,對哺乳動物而言,脂質體有助於運送藥物(如本文中揭露之抗ErbB2抗體或任選之化療製劑)。脂質體成分通常具雙層排列形式,類似生物膜上之脂質排列形式。
本文所使用之「醫藥上可接受之鹽類」一詞,係指自抗體藥物共軛物生成之醫藥上可接受有機或無機鹽。此類鹽之範例包括但不限於硫酸鹽、檸檬酸鹽、乙酸鹽、草酸鹽、亞硫酸鹽、酸式磷酸鹽、異煙酸、水楊酸鹽、酸式檸檬酸鹽、酒石酸鹽、油酸鹽、單寧酸鹽、泛酸鹽、酒石酸氫鹽、抗壞血酸鹽、琥珀酸鹽、馬來酸鹽、龍膽酸鹽、延胡索酸鹽、葡萄糖酸鹽、葡萄糖醛酸鹽、糖酸鹽、蟻酸鹽、苯甲酸鹽、麩氨酸鹽、甲磺酸鹽、乙磺酸鹽、苯磺酸鹽、對甲苯磺酸鹽及雙羥萘酸鹽(即1,1'-亞甲基-二-(2-羥基-3-萘甲酸鹽))。醫藥上可接受之鹽可包含另一分子,如乙酸離子、琥珀酸離子或其他反離子。該反離子可為任何能穩定母化合物上電荷之有機或無機基團。此外,就結構上而言,醫藥上可接受之鹽可具有大於一個帶電原子。當帶電原子屬於該醫藥上可接受鹽之一部份時,可具有多個離子。因此,醫藥上可接受之鹽可具有一或多個帶電原子及/或一或多個反離子。
「醫藥上可接受之溶質」係指一或多個溶劑分子與抗體藥物共軛物結合之情形。能形成醫藥上可接受溶質之溶劑,其範例包括但不限於水、異丙醇、乙醇、甲醇、二甲基亞碸(DMSO)、乙酸乙酯、醋酸及乙醇胺。
範例抗體藥物共軛物之特性
本發明中之化合物包括能提供抗癌活性功效之化合物。該些化合物尤其包括與藥物基團共軛(即透過聯結分子以共價鍵相連)之抗體,其中該藥物未與抗體共軛時具備胞殺或抑制細胞生長效果。因此,該藥物基團之生物活性會由與抗體共軛情形調節。本發明之抗體藥物共軛物可選擇性針對腫瘤組織生成具有效劑量之胞殺劑,因此藥物作用選擇性會提高,也就是可使有效劑量降低。
抗體藥物共軛物可以化學式(I)表示:
Ab-(L-D)
n(I)
或為醫藥上可接受之鹽類或其溶質,其中:
Ab為與Globo系列抗原結合之抗體,或與一或多個腫瘤相關抗原或細胞表面受體結合之抗體;n為藥物與抗體連結比例(drug-to-antibody ratio, DAR),數值範圍為1到8。
抗體藥物共軛物包含透過聯結分子以共價鍵和一或多個單甲基奧瑞斯他丁(MMAE)基團相連之抗體。抗體藥物共軛物可以化學式(I)表示:
Ab-(L-D)
n(I)
其中一或多個單甲基奧瑞斯他丁(MMAE)基團(D)透過L與抗體Ab以共價鍵相連。Ab為對Globo系列抗原具特異性之抗體,或與一或多個腫瘤相關抗原或細胞表面受體結合之抗體。聯結分子L可於細胞外(即胞外空間中)維持穩定狀態。
在某一實施例中,當該抗體藥物共軛物進入細胞,且該細胞表面之受體對該抗體藥物共軛物之抗體具特異性時,該共軛物之藥物基團才會自抗體分離,並提供實質劑量。當該抗體藥物共軛物確實進入細胞後,藥物基團才會真正自抗體分離。
在另一實施例中,該抗體藥物共軛物會與Globo系列抗原特異結合,如Globo H、SSEA-3或SSEA-4。該抗體藥物共軛物可與Globo H、SSEA-4、SSEA-3特異結合。該抗體藥物共軛物可抑制表現Globo系列抗原之腫瘤生長。
在另一實施例中,化學式(I)之抗體(Ab)為一人類、嵌合或人源化抗體。
根據本發明之另一態樣,提供一種醫藥組成物,其包括化學式(I)之化合物或醫藥上可接受之鹽類或其溶質,以及醫藥上可接受之稀釋劑、溶媒或賦形劑。
根據本發明之另一態樣,提供一種醫藥組合,其包括化學式(I)之化合物,以及具抗癌特性或其他療效之另一化合物。
根據本發明之另一態樣,本文所揭露之化合物及組成物包括可用於診斷及治療之使用方法。
根據本發明之另一態樣,提供一種殺死或抑制腫瘤或癌細胞增生之方法,其包含使用抗體藥物共軛物或醫藥上可接受之鹽類或其溶質,對該些細胞提供能殺死或抑制腫瘤或癌細胞增生之劑量。
根據本發明之另一態樣,提供多種治療癌症之方法,其包含對病患施用具化學式(I)化合物之配方。其中一種方法係用以治療哺乳類動物體內癌症,其中該癌症之特徵為表現Globo系列抗原。使用未共軛之抗Globo系列抗原抗體進行治療時,該哺乳動物選擇性不會產生治療反應,或僅產生微弱反應。該方法包含對該哺乳動物施用具治療有效量之抗體藥物共軛化合物。
根據本發明之另一態樣,提供一種能針對表現Globo系列抗原之腫瘤並抑制其增生之方法,其包含對病患施用抗體藥物共軛化合物,該共軛化合物與所述生長因子受體以及化療製劑特異結合,其中施用所述抗體藥物共軛物與所述化療製劑時,兩者皆具備能抑制病患體內腫瘤細胞生長之有效劑量。
根據本發明之另一態樣,提供一種治療人類病患之方法,該人類病患易罹患或經診斷罹患會表現Globo系列抗原之病症,該方法包含施用化學式(I)化合物之抗體藥物共軛物搭配化療製劑之組合。
根據本發明之另一態樣,提供一種用以偵測癌症細胞之測定方法,其包含:將多個細胞暴露於抗體藥物共軛物化合物,並判定該抗體藥物共軛物化合物與該些細胞之結合程度。
根據本發明之另一態樣,提供多種篩選抗體藥物共軛物候選物之方法以治療疾病或病症,其中該疾病或病症之特徵為表現Globo系列抗原。
本發明之另一態樣為包括多種製造物,即包含抗體藥物共軛物、容器及治療資訊仿單或標籤之工具組。
本發明之另一態樣為包括多種使用抗體藥物共軛化合物治療疾病或病症之方法,該疾病或病症之特徵為病患體內過量表現Globo系列抗原。
本發明之另一態樣為包括抗體藥物共軛化合物之製造方法、製備方法、合成方法、共軛方法及純化方法,以及包括製備、合成及共軛抗體藥物共軛物時之中間產物。
抗體藥物共軛物:抗體
化學式(I)之抗體單元之範圍,包括與受體、抗原或其他與特定目標細胞群相關之接受性基團結合或者反應性相關或複合之任何抗體單元。抗體可為任何蛋白質或類蛋白質分子,該分子會與預計由提供療效方法或其他生物方法改造之細胞群基團複合或反應。根據本發明之一態樣,該抗體單元能運送美登木素(maytansinoid)藥物基團至特定目標細胞群,而該抗體單元亦會與該目標細胞群產生反應。此類抗體包括但不限於大分子量蛋白質,如完整長度抗體及抗體片段。
包含本發明抗體藥物共軛物之抗體,較佳地保留原生及野生型抗體所具備之與抗原結合能力。因此,本發明之抗體較佳地能與抗原特異結合。
本文使用之「抗體」一詞係具備最廣之定義,且特別涵蓋能表現表現預期生物活性之單株抗體、多株抗體、二聚體、多聚體、多特異性抗體(如雙特異性抗體)以及抗體片段(見Miller et al (2003) Jour. of Immunology 170:4854-4861)。抗體可為鼠抗體、人類抗體、人源化抗體、嵌合抗體或衍生自其他物種之抗體。抗體為免疫系統製造之蛋白質,可辨識特定抗原並與之結合(見Janeway, C., Travers, P., Walport, M., Shlomchik (2001)
Immuno Biology,5th Ed., Garland Publishing, New York)。目標抗原一般具備無數結合位置,又稱抗原表位,可被多種抗體上之互補性決定區辨識。與特定抗原表位特異結合的抗體,各自具備不同結構。因此,單一抗原可具備一種以上之對應結合抗體。抗體結構包括完整免疫球蛋白分子或完整免疫球蛋白分子之一具免疫活性部位,即包含抗原結合位置之分子,其可與整體或部分目標之抗原進行免疫特異結合,目標包括但不限於癌症細胞,或會針對自體免疫疾病製造自體免疫抗體之細胞。本文所揭露之免疫球蛋白可為任一類型(如IgG、IgE、IgM、IgD及IgA)、任一類別(如IgG1、IgG2、IgG3、IgG4、IgA1及IgA2)或任一子類別之免疫球蛋白分子。免疫球蛋白分子可衍生自任何物種。然而,根據本發明之一態樣,免疫球蛋白為人源、鼠源或兔源。
舉例而言,該些抗體可具備完整長度,或包含具抗原結合位置抗體之一個(或多個)片段,包括但不限於Fab、F(ab')2、Fab'、F(ab)'、Fv、單鏈Fv(scFv)、雙價單鏈Fv(bi-scFv)、三價單鏈Fv(tri-scFv)、Fd、dAb片段(見Ward et al., Nature, 341:544-546 (1989))、經分離之互補性決定區、雙鏈抗體(diabodies)、三鏈抗體(triabodies)、四鏈抗體(tetrabodies)、線性抗體(linear antibodies)、單鏈抗體分子,以及由抗體片段形成之多特異性抗體。本文中亦包含使用重組技術或合成聯結分子連接抗體片段所生成之單鏈抗體。見Bird et al. Science, 1988, 242:423-426. Huston et al, Proc. Natl. Acad. Sci. USA, 1988, 85:5879-5883。
舉例而言,本文中之抗體或其抗原結合部分可為單一特異性、雙特異性或多特異性。多特異性或雙特異性抗體或其片段對於單一目標碳水化合物(如Globo H)之不同抗原表位可具備特異性,或具備對於一種以上目標碳水化合物具特異性之抗原結合區(如對於Globo H、SSEA-3及SSEA-4具特異性之抗原結合區)。在某一實施例中,多特異性抗體或其抗原結合部分包含至少兩種不同之可變區,其中各可變區可與單一碳水化合物抗原特異結合,或與同樣碳水化合物抗原上之不同抗原表位特異結合,可參考Tutt et al., 1991, J. Immunol. 147:60-69. Kufer et al., 2004, Trends Biotechnol. 22:238-244。本文中之抗體可與另一官能分子聯結或共同表現,如另一胜肽或蛋白質分子。舉例而言,抗體或其片段可透過官能基與一或多個其他分子結構,如另一抗體或抗體片段聯結(如經化學耦合、基因融合、非共價鍵連結或其他方式),以製造具備第二結合特異型之雙特異性或多特異性抗體。
本文中涵蓋所有同型抗體,包括IgG(如IgG1、IgG2、IgG3、IgG4)、IgM、IgA(IgA1、IgA2)、IgD或IgE(本文中涵蓋所有類別或子類別)。本文中之抗體或其抗原結合部分可為哺乳動物(如老鼠或人類)抗體或其抗原結合部分。此類抗體之輕鏈可為κ型或λ型。
本文中抗體或其抗原結合部分之可變區,可源於非人類或人類。本文中抗體或其抗原結合部分之骨架,可為人類、人源化、非人類(如經改造以降低人體抗原性之鼠骨架)或合成骨架(例如共通序列(consensus sequence))。
在某一實施例中,本文中之抗體或其抗原結合部分包含至少一個重鏈可變區及/或一個輕鏈可變區。
本文中之抗體或其抗原結合部分會與Globo H特異結合,且解離常數(K
D)為小於大約10
-7M、小於大約10
-8M、小於大約10
-9M、小於大約10
-10M、小於大約10
-11M或小於大約10
-12M。在某一實施例中,該抗體或抗體結合部分具1~10×10
-9或更小之解離常數(K
D)。在另一實施例中,解離常數由表面電漿共振程度決定。
包含本發明抗體藥物共軛物之抗體,較佳地保留原生及野生型抗體所具備之與抗原結合能力。因此,本發明之抗體較佳地能與抗原特異結合。前述抗原包括腫瘤相關抗原(TAA)、細胞表面受體蛋白質及其他細胞表面分子、細胞存活調節因子、細胞增生調節因子、與組織生長或分化相關(如確定或疑似能提供官能基)之分子、淋巴激素、細胞激素、細胞周期調節相關之分子、脈管生成(vasculogenesis)相關之分子,以及血管新生(angiogenesis)相關(如確定或疑似能提供官能基)之分子。腫瘤相關抗原可為分化群因子(即CD蛋白)。可與本文中抗體結合之抗原,可屬於前述任一分類下之某一子集合,其中所述分類之其他子集合包含具備顯著特性(相對目標抗原而言)之其他分子/抗原。
在某一實施例中,抗體藥物共軛物之抗體與Globo H、SSEA-3、SSEA-4等Globo系列抗原特異結合。
在某些實施例中,抗體或其抗原結合部分包括抗Globo系列抗原抗體(Globo H:OBI-888、SSEA-4:OBI-999)之重鏈可變區及/或輕鏈可變區,如表1所示。
在相關實施例中,範例抗體或其抗原結合部分包括抗Globo系列抗原抗體(Globo H:OBI-888、SSEA-4:OBI-898)之重鏈可變互補性決定區及/或輕鏈可變互補性決定區。自融合瘤選殖出之範例重鏈可變區及輕鏈可變區互補性決定區及骨架,皆詳列於表1中。
表1-1 抗Globo H抗體(OBI-888)胺基酸序列
[詳細說明可參考美國專利第2017/0101462號 (WO2017/062792)]
可變區 | 胺基酸序列 | SEQ ID NO. |
輕鏈 CDR1 | GFSLYTFDMGVG | 1 |
重鏈 CDR2 | HIWWDDDKYYNPALKS | 2 |
重鏈 CDR3 | VRGLHDYYYWFAY | 3 |
人源化重鏈 FW1 | QITLKESGPTLVKPTQTLTLTCTFS | 4 |
人源化重鏈FW2 | WIRQPPGKGLEWLA | 5 |
人源化重鏈FW3 | RLTISKDTSKNQVVLTMTNMDPVDTATYYCAR | 6 |
輕鏈 CDR1 | RASSSVSYMH | 7 |
輕鏈 CDR2 | ATSNLAS | 8 |
輕鏈 CDR3 | QQWSRNPFT | 9 |
人源化輕鏈FW1 | EIVLTQSPATLSLSPGERATLSC | 10 |
人源化輕鏈 FW2 | WYQQKPGKSPKPWIY | 11 |
人源化輕鏈 FW3 | GVPSRFSGSGSGTDFTFTISSLQPEDIATYYC | 12 |
人源化抗體之重鏈可變區 | QITLKESGPTLVKPTQTLTLTCTFSGFSLYTFDMGVGWIRQPPGKGLEWLAHIWWDDDKYYNPALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCARVRGLHDYYYWFAY | 13 |
人源化抗體之輕鏈可變區 | EIVLTQSPATLSLSPGERATLSCRASSSVSYMHWYQQKPGKSPKPWIYATSNLASGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQWSRNPFT | 14 |
嵌合抗體之重鏈可變區 | QVTLKESGPGILQPSQTLSLTCSFSGFSLYTFDMGVGWIRQPSGKGLEWLAHIWWDDDKYYNPALKSRLTVSKDTSKNQVFLKIPNVDTADSATYYCARVRGLHDYYYWFAY | 15 |
嵌合抗體之輕鏈可變區 | QIVLSQSPTILSASPGEKVTMTCRASSSVSYMHWYQQKPGSSPKPWIYATSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYFCQQWSRNPFT | 16 |
改造抗體(人源化R28 mAb)之重鏈可變區 | QITLKESGPTLVKPTQTLTLTCTFSGFSLYTFDMGVGWIRQPPGKGLEWLAHIWWDGDKYYNPALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCARVRGLHRYYYWFAYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK | 17 |
改造抗體(人源化R28 mAb)之輕鏈可變區 | EIVLTQSPATLSLSPGERATLSCRASSSVSYMHWYQQKPGKSPKPWIYATSNKASGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQWSRRPFTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC | 18 |
表1-2 抗SSEA-4抗體(OBI-898)胺基酸序列
[詳細說明可參考美國專利第2017/283488號 (WO2017/172990)]
可變區 | 胺基酸序列 | SEQ ID NO. |
重鏈可變區(VH) | QVQLKESGPGLVAPSQSLSITCTVSGFSLISYGVDWVRQPPGKGLEWLGVIWGGGNTNYNSSLMSRLSISKDNSKSQVFLKMNSLQTDDTAMYYCAKTGTGYALEYWGQGTSVTVSS | 19 |
輕鏈可變區(VL) | ENVLTQSPAIMSASPGEKVTMTCSARSSVSYMHWYQQKSTASPKLWIYDTSKLASGVPGRFSGSGSGNSYSLTISSMEAEDVATYYCFQASGYPLTFGAGTKLELKR | 20 |
VL FW1 | ENVLTQSPAIMSASPGEKVTMTC | 21 |
VL CDR1 | SARSSVSYMH | 22 |
VL FW2 | WYQQKSTASPKLWIY | 23 |
VL CDR2 | DTSKLAS | 24 |
VL FW3 | GVPGRFSGSGSGNSYSLTISSMEAEDVATYYC | 25 |
VL CDR3 | FQASGYPLT | 26 |
VL FW4 | FGAGTKLELKR | 27 |
VH FW1 | QVQLKESGPGLVAPSQSLSITCTVS | 28 |
VH CDR1 | GFSLISYGVD | 29 |
VH FW2 | WVRQPPGKGLEWLG | 30 |
VH CDR2 | VIWGGGNTNYNSSLMS | 31 |
VH FW3 | RLSISKDNSKSQVFLKMNSLQTDDTAMYYCAK | 32 |
VH CDR3 | TGTGYALEY | 33 |
VH FW4 | WGQGTSVTVSS | 34 |
抗體具備之重鏈可變區及輕鏈可變區,與自選殖抗體株2C2所產生的抗體之重鏈可變區及輕鏈可變區至少大約70%、至少大約75%、至少大約80%、至少大約81%、至少大約82%、至少大約83%、至少大約84%、至少大約85%、至少大約86%、至少大約87%、至少大約88%、至少大約89%、至少大約90%、至少大約91%、至少大約92%、至少大約93%、至少大約94%、至少大約95%、至少大約96%、至少大約97%、至少大約98%、至少大約99%或至少大約100%同源。此類抗體亦可與碳水化合物抗原(如Globo H)結合。同源性可以胺基酸或核苷酸序列中呈現。
針對
Globo
系列抗原之抗體藥物共軛物
根據本揭露內容之一態樣,其揭露該新抗體藥物共軛物(OBI-999)具對Globo H之特異性。該抗體藥物共軛物之抗Globo H抗體係結合至Fucα1→2 Galβ1→3 GalNAcβ1→3 Galα1→4 Galβ1→4 Glc。
本文描述之任一抗體皆可為完整長度抗體或其抗原結合片段。在某些範例中,該抗原結合片段為Fab片段、F(ab')
2片段或單鏈Fv片段。在某些範例中,該抗體為人類抗體、人源化抗體、嵌合抗體或單鏈抗體。
本文描述之任一抗體具以下一或多個特徵:(a)為重組抗體、單株抗體、嵌合抗體、人源化抗體、人類抗體、抗體片段、具雙特異性抗體、具單特異性抗體、單價抗體、IgG
1抗體、IgG
2抗體或抗體之衍生物;(b)為人類、鼠科、人源化或嵌合抗體、抗原結合片段或抗體之衍生物;(c)為單鏈抗體片段、多體、Fab片段及/或與IgG、IgM、IgA、IgE、IgD同型及/或其子類型之免疫球蛋白;(d)具以下一或多個特徵:(i)能調控癌細胞抗體依賴型細胞調節的細胞毒殺作用(ADCC)及/或補體依賴型細胞毒殺作用(CDC);(ii)能引發及/或促進癌細胞凋亡;(iii)能抑制目標癌細胞進行細胞增生;(iv)能引發及/或促進吞噬癌細胞作用;及/或(v)能引發及/或促進胞殺物質之釋放;(e)與該腫瘤關聯之醣類抗原專一結合,此抗原為具腫瘤特異性之醣類抗原;(f)不與表現於非癌細胞、非腫瘤細胞、良性癌細胞及/或良性腫瘤細胞上之抗原結合;及/或(g)與表現於癌症幹細胞及正常癌細胞上之腫瘤關聯之醣類抗原專一結合。
較佳地,該些抗體與各自目標抗原之結合反應具特異性。一般而言,「特異性」一詞係指一結合對中其中一方不會與其特異結合對象之外的其他分子明顯結合之情形,且與本文所詳述分子以外之其他分子少於約30%,較佳為20%、10%或1%會產生交叉反應。
抗體製造
製造單株抗體之方法相當多樣化。以融合瘤技術而言,該技術係使用不同來源之細胞,包括小鼠(鼠科)、倉鼠、大鼠及人類細胞,以篩選出一可製造單一種類抗體之選殖細胞株。其他製造單株抗體之方法,如製造嵌合及人源化抗體時,則使用基因工程技術,即DNA重組技術。
多株抗體可於動物體內生成,生成時使用注射或腹腔內注射將相關抗原及佐劑注入目標動物體內。單株抗體係取自一實質同質抗體群之抗體,除自然產生的微量基因變異種類外,包含該抗體群之個別抗體皆無二致。
相關文獻中亦已描述將人類骨髓瘤細胞株及小鼠-人類異骨髓瘤細胞株用於產製人類單株抗體(見Kozbor, (1984) J. Immunol., 133:3001, and Brodeur et al
., Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987))。對培養融合瘤細胞之培養基進行測定,以製備拮抗該抗原之單株抗體。融合瘤細胞所生成的單株抗體之結合特異性,可由免疫沉澱法或試管內結合測定法判定,如放射免疫分析法(radioimmunoassay, RIA)或酵素結合免疫吸附法(ELISA)。舉例而言,單株抗體之結合親和力可經由Scatchard分析法(見Munson et al (1980) Anal. Biochem. 107:220)判定。
使用傳統技術(如使用寡核苷酸探針,此探針可與編碼鼠科抗體重鏈與輕鏈之基因特異結合)可輕易將編碼單株抗體之DNA分離並定序。融合瘤細胞可作為此DNA之來源。此DNA經分離後可置於表現溶媒內,並轉染至宿主細胞中,如轉染至如大腸桿菌、猿猴COS細胞、中國倉鼠卵巢(CHO)細胞或骨髓瘤細胞等不會自行製造其他抗體蛋白質之宿主細胞,以合成重組宿主細胞內之單株細胞(參考美國專利第2005/0048572號、2004/0229310號)。針對編碼該抗體的DNA於細菌內之重組表現,相關評論文章包括Skerra et al (1993) Curr. Opinion in Immunol. 5:256-262 及 Plückthun (1992) Immunol. Revs. 130:151-188。
在另一實施例中,可自噬菌體抗體庫分離出單株抗體或抗體片段,噬菌體抗體庫之製造技術可參考McCafferty et al (1990) Nature 348:552-554; Clackson et al (1991) Nature 352:624-628;及Marks et al (1991) J. Mol. Biol., 222:581-597,以上文獻分別描述由噬菌體抗體庫分離出鼠科及人類抗體之技術。後續文獻描述透過鏈置換(chain shuffling)方法(參考Marks et al (1992) Bio/Technology 10:779-783)製造高親和力(nM等級)抗體之技術,亦描述使用組合感染(combinatorial infection)及活體內重組技術作為建構巨大噬菌體抗體庫之策略(參考Waterhouse et al (1993) Nuc. Acids. Res. 21:2265-2266)。因此,前述技術皆可替代用來分離單株抗體之單株抗體融合瘤傳統技術。
可使用不同方式改造DNA,如透過以人類重鏈及輕鏈固定域編碼序列取代同源鼠科序列之方式(參考美國專利第4,816,567號,以及Morrison et al (1984) Proc. Natl. Acad. Sci. USA 81:6851),或透過以共價鍵將非免疫球蛋白多胜肽的全部或部分編碼序列連接至免疫球蛋白編碼序列上之方式。
一般而言,此非免疫球蛋白多胜肽皆用以取代抗體固定域,或用以取代抗體抗原結合位置之可變域,以生成包含兩個抗原結合位置之嵌合雙價抗體,此兩個結合位置分別對不同抗原具特異性。
抗體藥物共軛物:聯結分子:
範例抗體藥物共軛物聯結分子
針對抗體藥物共軛物之合適範例聯結分子已於文獻中描述,例如美國專利第7595292號(WO2005/007197)。文獻中與聯結分子相關之段落,皆以引用方式直接併入本文中。聯結分子L將抗體以共價鍵連接至不包含二硫鍵基之藥物基團上。該聯結分子為一雙功能性或多功能性基團,可用以連接一或多個藥物基團(D)及抗體單元(Ab),以形成化學式(I)之抗體藥物共軛物。可使用具備與該藥物基團及該抗體單元結合的反應功能性之聯結分子,輕易製備抗體藥物共軛物。該抗體內之半胱氨酸硫氫基或胺基,如N端或離胺酸等胺基酸側鏈,可與聯結分子試劑、藥物基團或藥物聯結分子試劑之官能基形成鍵結。
較佳地,該些聯結分子於胞外作用。較佳地,該抗體藥物共軛物經運輸或輸送入細胞前維持穩定且完整狀態,即該抗體維持與該藥物基團連接之狀態。位於目標細胞外之聯結分子皆處於穩定狀態,且可於細胞內以某有效速率被切割。有效聯結分子之特性包括:(i) 維持該抗體之特異結合屬性;(ii) 使該共軛物或該藥物基團可於胞內輸送;(iii) 維持穩定且完整狀態,即未被切割狀態,直到該共軛物被輸送或運輸至目標位置;及(iv) 針對該美登木素(maytansinoid)藥物基團維持胞殺效果或抑制細胞生長效果。該抗體藥物共軛物之穩定性可由標準分析技術測定,如質譜儀、高效液相層析法及液相層析質譜分離/分析技術。
要使該抗體及該藥物基團建立共價鍵鍵結,該聯結分子必須具備兩個反應官能基,即反應時具備雙價性。有助於連結兩個或多個官能基或生物活性基團,如胜肽、核酸、藥物、毒素、抗體、半抗原及報導基團等之雙價性聯結分子試劑為習知技術,且其連結方法與其衍生共軛物已於相關文獻中描述(參考Hermanson, G. T. (1996)
Bioconjugate Techniques; Academic Press: New York, p234-242)。
範例抗體藥物共軛物聯結分子可包括化學通式(II)之生物活性化合物,其中X或X'其中之一代表聚合物(尤其為毒素),且另一符號代表氫原子;其中每個Q各自代表聯結基團;W代表拉電子基或可經由還原該拉電子基製備之基團;或者,若X'代表聚合物,則X-Q-W整體可代表拉電子基;此外,若X'代表聚合物,則X'與拉電子基W可與兩側相鄰之原子共同組成一環;Z
1與Z
2各自代表由一生物分子衍生之一基團,且分別與A及B透過親核基團互相連接;或者,Z
1與Z
2共同代表衍生自生物分子之單獨基團,兩者分別與A、B透過兩個親核基團連接;A為C
1-5烯基鏈或亞烯基鏈;且B為鍵結或C
1-4烯基鏈或亞烯基鏈;形成範例抗體藥物共軛物聯結分子時,可將合適聚合物與合適生物活性分子透過前述分子內之親核基團共軛,較佳地為透過一雙硫鍵共軛。
(II)
在某些實施例中,本揭露內容提供一如化學式(III)之蛋白質-聚合物共軛物。
(III)
其中X為一選自由聚烯烴基二醇(polyalkylene glycols)、聚乙烯吡咯烷酮、聚丙烯酸酯、聚噁唑啉(polyoxazolines)、聚乙烯醇、聚丙烯醯胺、聚甲基丙烯醯胺、水解聚馬來酸酐共聚物、聚酯、聚甲醛、聚原酸酯、聚碳酸酯、聚亞胺碳酸酯、聚醯胺、雙乙烯基醚順丁烯二酸酐(divinylether-maleic anhydride)與苯乙烯順丁烯二酸酐(styrene-maleic anhydride)之共聚物、多聚醣及聚麩胺酸組成群組之均聚物或共聚合物(尤其為毒素);Q為選自由直接鍵結、烯基、選擇性取代芳基與選擇性取代雜芳基組成群組之聯結基團,其中該烯基、芳基或雜芳基可被一或多個氧原子、硫原子、酮基、—O—CO— 基、—CO—O— 基、—NR 基終止或中斷反應;W選自由酮基、酯基、碸基、還原酮基、還原酯基與還原碸基組成之群組;X'-Q為氫;A為C
1-5烯基鏈或亞烯基鏈;B為鍵結或C
1-4烯基鏈或亞烯基鏈A;且Z為與A及B連接之單獨蛋白質,連接時透過經還原蛋白質內雙硫鍵而產生之兩個醇基。
顯示範例抗體藥物共軛物效力之活性測定
本文中所述抗體藥物共軛物(OBI-999)之物理/化學性質及生物功能,可使用習知測定技術加以定性。
抗體對醣類抗原之親和力,可透過實驗並使用任何合適方法測定(見Berzofsky et al, "Antibody- Antigen Interactions," In Fundamental Immunology, Paul, W. E., Ed., Raven Press: New York, N.Y. (1984);Kuby, Janis Immunology, W. H. Freeman and Company: New York, N.Y. (1992);及本發明描述之方法)。在不同條件下(如鹽度、pH),對特定抗體-醣類抗原交互作用測定親和力之結果會出現落差。因此,測定親和力及其他抗原結合參數(如 K
D、K
a、Ka)時,較佳之方法為使用抗體及抗原之標準化溶液,以及標準化緩衝溶液。
本文中所述抗體或其抗原結合部分,皆具備試管內及活體內治療、預防及/或診斷用途。舉例而言,該些抗體可被施用至培養細胞,如於試管內(
in vitio)或活體外(
ex vivo)培養之細胞,或可施用於受試者,如施用於該受試者體內,以達治療、抑制、預防復發及/或診斷癌症之目的。
經純化之抗體可進一步使用一系列測定方法定性,該些方法包括但不限於N端定序(N-terminal sequencing)、胺基酸分析、非變性大小排除高效液相層析法(non-denaturing size exclusion high pressure liquid chromatography)、質譜儀分析、離子交換層析法及木瓜蛋白酶分解法(papain digestion)。
必要時,可對抗體進行分析以測定其生物活性。在某些實施例中,對本文中所述抗體進行測試以測定其抗原結合活性。習知且可用於本文中之抗原結合測定方法,包括但不限於使用西方墨點法、放射免疫分析法、ELISA(酵素結合免疫吸附法)、三明治免疫分析法(“sandwich” immunoassays)、免疫沉澱分析法、螢光免疫分析法、化學冷光免疫分析法(chemiluminescent immunoassays)、奈米粒子免疫分析法(nanoparticle immunoassays)、適體免疫分析法(aptamer immunoassays)及蛋白A免疫分析法等技術之任何直接結合或競爭性結合(competitive binding)測定方法。
人源化抗體
本文係關於各種人源化抗體。多種將非人抗體人源化之方法皆屬習知技術。舉例而言,人源化抗體可具有一或多個自非人來源引入之胺基酸殘基。非人胺基酸殘基通稱為「輸入」殘基,一般而言取自「輸入」可變域。可透過Winter與其同事之方法(參考Jones
et al.(1986) Nature 321:522-525; Riechmann
et al. (1988) Nature 332:323-327; Verhoeyen
et al. (1988) Science 239:1534-1536),以高度可變域序列取代人類抗體中之對應序列進行抗體人源化。因此,該「人源化」抗體屬於嵌合抗體(參考美國專利第4,816,567號),其中實質上少於一完整人類抗體可變域已經被該非人抗體之對應序列取代。實際上,人源化抗體一般屬於人類抗體,其中某些高度可變域殘基與可能的某些骨架殘基被來自囓齒類動物抗體中類似位置之殘基所取代。
製造人源化抗體時,選擇人類抗體輕鏈或重鏈可變域皆對降低抗原性有關鍵影響。根據所謂「最適」(best-fit)方法,會將囓齒類抗體之可變域序列與習知資料庫中之所有人類抗體可變域序列逐一比對,並取最接近該囓齒類抗體序列之人類抗體序列,作為人類抗體(參考Sims
et al. (1993) J. Immunol. 151:2296; Chothia
et al. (1987) J. Mol. Biol. 196:901)。另一方法則使用一特殊骨架,其衍生自包含特定亞群輕鏈或重鏈的所有人類抗體之共通序列。此骨架可適用數種不同之人源化抗體(參考Carter
et al. (1992) Proc. Natl. Acad. Sci. USA, 89:4285; Presta
et al. (1993) J. Immunol., 151:2623)。
進一步而言,一般預期之情況為抗體經人源化後仍保留對抗原之高親和力,以及其他有益之生物特性。根據某一方法,若欲達成此目的,則須使用親代序列及人源化序列之三維模型,透過分析親代序列及多種概念型人源化產物製備人源化抗體。對本發明所屬技術領域中具有通常知識者而言,免疫球蛋白三維模型維容易取得且熟悉之工具。挑選出候選免疫球蛋白序列後,可使用現有電腦程式描繪並顯示可能出現之序列三維結構構型。可經由研究電腦程式顯示之圖像,針對候選免疫球蛋白序列中的殘基可能具備之功能進行分析;換言之,可分析殘基如何影響候選免疫球蛋白與抗原之結合能力。如此一來,即可由受者抗體及輸入序列中挑選並結合骨架殘基,以獲得目標抗體特性,如使與目標抗原結合之親和力增加。一般而言,高度可變域殘基會直接且高度實質影響抗原結合過程。
用途
本文中所述之抗體藥物共軛物(OBI-999)可用於如試管內、活體外及/或活體內之治療方法。本文中所述之抗體藥物共軛物(OBI-999)可作為拮抗抗體,用以於試管內、活體外及/或活體內部分或完全阻斷特定抗原活性。有鑑於此,本文中所述之抗體藥物共軛物(OBI-999)可用於如包含該抗原之細胞培養物中、於人類受試者體內,或於具可與該抗體產生交叉反應的抗原之其他哺乳動物受試者(如黑猩猩、狒狒、狨猴(marmoset)、食蟹獼猴(cynomolgus)、豬或小鼠)體內,以抑制特定抗原活性。在某一實施例中,本文中所述之抗體藥物共軛物(OBI-999)可用於抑制抗原活性,其方法為將該抗體藥物共軛物(OBI-999)與該抗原接觸,以使抗原活性受到抑制。在某一實施例中,該抗原為人類蛋白質分子。
在某一實施例中,本文中所述之抗體藥物共軛物(OBI-999)可用於一種抑制受試者體內的抗原之方法,其中該受試者處在抗原活性有害之病症下,該方法包含對該受試者施用本文中所述之抗體藥物共軛物(OBI-999),以使該受試者體內之該抗原活性被抑制。在某一實施例中,該抗原為人類蛋白質分子,且該受試者為人類受試者。另外,該受試者亦可為表現抗原之哺乳動物,該抗原與本文中所述之抗體藥物共軛物(OBI-999)結合。又,該受試者亦可為體內已注入該抗原之哺乳動物(注入方式包括施用該抗原或表現抗原基因轉殖)。本文中所述之抗體藥物共軛物(OBI-999)可被施用於人類受試者體內,以達治療效果。此外,本文中所述之抗體藥物共軛物(OBI-999)可被施用入非人類哺乳動物體內(如靈長類動物、豬或小鼠),該哺乳動物表現與該抗體藥物共軛物(OBI-999)交互反應之抗原,以達獸醫相關目的或針對人類疾病建立一動物模型。若目的為後者,則該些動物模型可用於評估本文中所述抗體藥物共軛物(OBI-999)之療效(如測試劑量多寡及施用時間長短)。本文中所述之抗體藥物共軛物(OBI-999)可用於疾病、病症或狀態之治療、抑制、延緩發展、預防/延緩復發、改善或預防,該些疾病、病症或狀態皆與Globo系列抗之異常表現及/或活性相關,包括但不限於癌症、肌肉異常、泛素途徑相關(ubiquitin-pathway-related)基因異常、免疫/發炎異常、神經異常,以及其他泛素途徑相關異常。
本文中所述之抗體藥物共軛物(OBI-999)可於實施治療方法時單獨使用或與其他組成物同時使用。舉例而言,本文中所述之抗體藥物共軛物(OBI-999)可與另一抗體及/或佐劑/治療劑(如類固醇)同時施用。舉例而言,本文中所述之抗體藥物共軛物(OBI-999)可於療程內與消炎劑及/或抗菌劑合併使用,譬如治療任何本文描述之疾病,包括癌症、肌肉異常、泛素途徑相關基因異常、免疫/發炎異常、神經異常,以及其他泛素途徑相關基因異常。前述合併療法包括合併施用(包含於相同或不同配方內之兩種或多種試劑)及分別施用,進行後者時,施用本文中所述抗體藥物共軛物(OBI-999)之時機可為施用該輔助療法或各種療法之前及/或之後。
本文中所述之抗體藥物共軛物(OBI-999)可以任何合適之方式施用,包括腸道外、皮下、腹膜腔內、胸膜腔內與鼻腔內施用,以及欲進行局部治療時可於病灶內施用。腸道外灌注方式包括肌肉內、靜脈內、動脈內、腹膜腔內或皮下施用。此外,該抗體藥物共軛物(OBI-999)適合透過脈衝灌注(pulse infusion)方式施用,特別是以逐步降低該抗體藥物共軛物(OBI-999)之劑量的方式。可透過任何合適路徑給藥,如靜脈注射或皮下注射等注射方式,且部分視施用形式為短時間或慢性而定。
治療應用
本文描述之治療方法,包含針對需要前述治療之受試者施用具備治療有效量之組成物,該組成物包含一或多個本文描述之抗體藥物共軛物(OBI-999)。
在某些實施例中,需要該治療之受試者(如人類病患)係被診斷出、疑似或有風險罹患癌症。該癌症種類包括但不限於惡性肉瘤、皮膚癌、血癌、淋巴癌、腦癌、膠質母細胞瘤、肺癌、乳癌、口腔癌、頭頸癌、鼻咽癌、食道癌、胃癌、肝癌、膽管癌、膽囊癌、膀胱癌、胰臟癌、腸癌、大腸直腸癌、腎臟癌、子宮頸癌、子宮內膜癌、卵巢癌、睪丸癌、頰癌、口咽癌、喉癌及前列腺癌。
在較佳實施例中,該抗體藥物共軛物(OBI-999)可針對表現Globo系列抗原之癌細胞。在某些實施例中,該抗體藥物共軛物(OBI-999)可針對癌細胞上之Globo系列抗原。在某些實施例中,該抗體藥物共軛物(OBI-999)可針對癌細胞內之Globo系列抗原。
該治療可使腫瘤大小減少、惡性腫瘤細胞消失、預防癌症轉移、預防癌症復發、減少或消滅擴散之癌細胞、延長存活期及/或拉長癌症腫瘤惡化所需時間。
在某些實施例中,該治療方式進一步包含於施用該些抗體藥物共軛物(OBI-999)期間或之後,對前述受試者施用一額外療法。在某些實施例中,該額外療法為使用化療製劑之療法。在某些實施例中,該額外療法為放射療法。
本文中所述之方法對於治療及預防早期腫瘤尤其有效,可藉此預防腫瘤持續惡化,使因腫瘤惡化引起之致病率及死亡率降低。本文中所述之方法對於預防腫瘤復發或再生,如原發腫瘤移除後持續存在之潛伏腫瘤,或者對於減少或預防腫瘤復發亦有效。
在某些實施例中,本文中所述揭露之方法可適用於治療或預防癌症,譬如特性為Globo H、SSEA-3及/或SSEA-4表現量增加之癌症。在某些實施例中,該癌症包含癌症幹細胞。在某些實施例中,該癌症為潛伏期癌(pre-cancer)及/或惡性癌及/或抗藥性癌。在某些實施例中,該癌症為腦癌。
待接受本文描述方法治療之受試者可為哺乳動物,較佳為人類。哺乳動物種類包括但不限於農場動物、競賽用動物、寵物、靈長類動物、馬、狗、貓、小鼠及大鼠。需要該治療之人類受試者,可為罹患、有風險罹患或疑似罹患癌症之人類病患,該癌症包括但不限於惡性肉瘤、皮膚癌、血癌、淋巴癌、腦癌、肺癌、乳癌、口腔癌、食道癌、胃癌、肝癌、膽管癌、胰臟癌、腸癌、腎臟癌、子宮頸癌、卵巢癌及前列腺癌。可使用常規醫學檢查測定出罹患癌症之受試者。
本文所使用之「有效量」一詞,係指使各活性試劑提供療效予該受試者所需之劑量,該活性試劑可單獨使用,或與一或多個其他活性試劑合併使用。本發明所屬技術領域中具通常知識者皆理解,有效量會隨接受治療之疾病條件、該疾病條件嚴重程度、個別病患相關參數(包括年齡、健康狀況、身材、性別及體重)、接受治療時間、同時接受療程之特性(如適用之情形)、詳細施用途徑,以及屬醫療人員知識及專業範圍內之因素而變化。對於本發明所屬技術領域中具通常知識者,該些因素皆為習知因素,且可僅透過常規實驗因應。一般認為,較佳應使用個別成分或組成物之最大劑量,即基於健全醫療判斷之最安全劑量。然而,本發明所屬技術領域中具通常知識者將理解,病患可能基於醫療、心理或任何其他可能方面之理由,堅持使用較低劑量或可容忍劑量。
本文所使用之「治療」一詞,係指應用或施用組成物,包括一或多個活性試劑予受試者,該受試者罹患癌症、癌症症狀或具罹癌體質,且意圖治癒、治療、減輕、紓解、調整、補救、補強、改善或影響癌症、癌症症狀或癌症體質。
癌症「發展」或「變化」係指癌症初期樣態及/或後續變化情形。癌症發展可使用習知標準臨床技術偵測並評估。然而,發展亦指可能無法偵測之變化。就本文中揭露內容而言,發展或變化係指該些症狀之生物歷程。「發展」包括發生、再現及起始。本文所使用之癌症「發生」或「起始」等詞,包括癌症最初之起始及/或再現。
視治療之疾病種類或病灶,醫療領域中具通常知識者習知之傳統方法,可用以施用醫藥組成物至該受試者。該組成物亦可透過其他傳統途徑施用,如口服、腸道外、吸入噴劑(inhalation spray)、局部施用,直腸、鼻腔、口腔、陰道內,或者植入型儲藥槽(implanted reservoir)。本文所使用之「腸道外」一詞,包括皮下、皮內、靜脈內、肌肉內、動脈內、滑膜內、胸骨內、脊髓腔內、病灶內及顱內注射或灌注技術。此外,該組成物可經由注射式之長效儲存施用途徑(injectable depot routes of administration)施用於該受試者,如使用一、三或六個月之長效儲存注射式或生物可分解之材料及方法。
注射式組成物可包含不同溶媒,如植物油、二甲基乙醯胺(dimethylactamide)、二甲基甲醯胺(dimethyformamide)、乳酸乙酯(ethyl lactate)、碳酸乙酯(ethyl carbonate)、十四酸異丙酯(isopropyl myristate)、乙醇及多元醇(polyols)(甘油、丙二醇(propylene glycol)、液態聚乙二醇及其類似物)。使用靜脈注射方法時,可以滴注法(drip method)施用水溶性抗體藥物共軛物(OBI-999),藉以灌注包含該抗體藥物共軛物(OBI-999)及生理可接受賦形劑(excipient)之醫藥配方。生理可接受賦形劑可包括5%右旋糖(dextrose)、0.9%食鹽水、林格氏液(Ringer’s solution)或其他合適之賦形劑。
施用抗體藥物共軛物之醫藥配方
施用治療用抗體藥物共軛物時,可經由任何適用待治療病症之途徑。一般而言,抗體藥物共軛物會透過腸道外途徑施用,即灌注、腹腔內、皮下、肌肉內、靜脈內、皮內、脊髓腔、一次全劑量、腫瘤內注射或硬膜外等途徑(參考Shire et al (2004) J. Pharm. Sciences 93(6):1390-1402)。製備治療用抗體藥物共軛物之醫藥配方時,通常會以腸道外施用為目標,再搭配醫藥上可接受之腸道外溶媒以及單位劑量形式。具預期純度之抗體藥物共軛物可選擇性地與醫藥上可接受之稀釋劑、溶媒、賦形劑或穩定劑混合,其形式為凍晶配方或水溶液(參考Remington's Pharmaceutical Sciences (1980) 16th edition, Osol, A. Ed.)。
施用可接受之腸道外溶媒、稀釋劑、溶媒、賦形劑及穩定劑時,其劑量及濃度對受者皆不具毒性,且包括緩衝液如磷酸鹽、檸檬酸鹽及其他有機酸;抗氧化劑包括抗壞血酸及甲硫胺酸;防腐劑(如十八烷基二甲基苄基氯化銨(octadecyldimethylbenzyl ammonium chloride);六甲基氯化銨(hexamethonium chloride);苯基氯卡銨(benzalkonium chloride)、苄索氯銨(benzethonium chloride);或酚、丁醇或苯甲醇;具烷基之對羥基苯甲酸酯,如對羥基苯甲酸甲酯或對羥基苯甲酸丙酯;鄰苯二酚、間苯二酚、環己醇;3-戊醇;及間-甲酚);低分子量(小於大約10個殘基);蛋白質,如血清白蛋白、明膠或免疫球蛋白;親水性聚合物如聚乙烯吡咯烷酮;胺基酸如甘胺酸、麩醯胺酸、天門冬醯胺、組胺酸、精胺酸或離胺酸;單醣、雙醣及其他碳水化合物包括葡萄糖、甘露糖或糊精;螯合劑如EDTA;糖如蔗糖、甘露醇、海藻糖或山梨糖醇;成鹽反離子如鈉;金屬組成物(如鋅-蛋白質組成物);及/或非離子性介面活性劑如TWEEN™、PLURONICS™或聚乙二醇。舉例而言,專利第WO 97/04801號描述凍晶抗-ErbB2抗體配方,其內容以引用方式具體併入本文中。抗體藥物共軛物之範例配方如trastuzumab-SMCC-DM1,於約pH 6環境下具有大約100 mg/ml之海藻糖(2-(羥甲基)-6-[3,4,5-三羥基-6-(羥甲基)四氫吡喃-2-基]氧基-四氫吡喃-3,4,5-三醇/2-(hydroxymethyl)-6-[3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-tetrahydropyran-3,4,5-triol;C
12H
22O
11 ;CAS 編號 99-20-7)及大約0.1%之TWEEN™ 20(吐溫20;十二烷酸2-[2-[3,4-二(2-羥基乙氧基)四氫吡喃-2-基]-2-(2-羥基乙氧基)乙氧基]乙酯/2-[2-[3,4-bis(2-hydroxyethoxy)tetrahydrofuran-2-yl]-2-(2-hydroxyethoxy)ethoxy]ethyl ester; C
26H
50O
10;CAS 編號 9005-64-5)。
治療用抗體藥物共軛物之醫藥配方可含有特定量之未反應藥物基團(D)、抗體-聯結分子中間產物(Ab-L),及/或藥物-聯結分子中間產物(D-L),此為製備抗體藥物共軛物過程中未完全純化及分離過量試劑、不純物、副產物之結果;或為貯藏大量抗體藥物共軛物或配方抗體藥物共軛物組成物時,根據時間或溫度條件產生的水解反應或降解反應之結果。
活性醫藥成分亦可包覆於微膠囊中,微膠囊種類包括羥丙甲纖維素或明膠微膠囊以及聚甲基丙烯酸甲酯微膠囊,可分別於膠體藥物傳輸系統(譬如脂質體、白蛋白微球、微滴乳狀液、奈米粒子及奈米膠囊)或粗滴乳狀液中經由譬如聚集技術(coacervation technique)或界面聚合法製備。上述技術揭露於Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)。
可製備持續釋放製劑。持續釋放製劑之合適範例,包括包含該抗體藥物共軛物的固態疏水性聚合物之半透膜基質,其具有成形產品之外形,如薄膜或微膠囊。持續釋放基質包括聚酯纖維、水凝膠(如聚甲基丙烯酸羥基乙酯或聚乙烯醇)、聚乳酸(美國專利第3,773,919號)、L-聚麩胺酸及γ-乙基-L-麩醯胺酸共聚物、不可降解之乙烯/醋酸乙烯酯共聚物、可降解之乳酸-甘醇酸共聚物如LUPRON DEPOT™(成分為乳酸-甘醇酸共聚物及柳菩林之可注射式微球),以及聚-D-(−)-3-羥基丁酸(poly-D-(−)-3-hydroxybutyric acid)。
預期於活體內施用之配方必須為無菌,使用無菌滲透膜實施滲透作用可輕易達成此目標。
該些配方包括適用前述施用途徑之配方。基於方便因素,可將配方以單位劑量形式呈現,且可使用製藥技術領域之任何習知技術製備。相關技術和配方可參考
Remington's Pharmaceutical Sciences(Mack Publishing Co., Easton, Pa.)。上述方法包括使活性成分與包含一或多個附加成分的溶媒結合之步驟。一般製備配方之方法,皆為使活性成分與液態溶媒或細緻切分的固態溶媒或兩者同步且緊密結合,接著於必要時替產物塑形。
水性懸浮液內含有活性材料與適用於製備水性懸浮液的賦形劑之混合物。上述賦形劑包括懸浮劑,如羧甲基纖維素、交聯羧甲基纖維素、甲基纖維素、羥丙甲纖維素、海藻酸鈉、聚乙烯吡咯烷酮(polyvinylpyrrolidone)、黃耆膠、阿拉伯膠以及分散劑或潤濕劑,如天然生成之甘油磷脂(如卵磷脂)、氧化烷基與脂肪酸之縮合產物(如聚氧乙烯硬脂酸酯)、氧化乙烯與長鏈脂肪醇之縮合產物(如十七烷乙烯氧基鯨蠟醇)、氧化乙烯與自脂肪酸及己糖醇酐(如聚乙烯脫水山梨醇單油酸酯)衍生的部分酯之縮合產物。水性懸浮液亦可含有一或多種防腐劑,如苯甲酸乙酯或對羥基苯甲酸丙酯;一或多種著色劑;一或多種調味劑;及一或多種甜味劑,如蔗糖或糖精。
抗體藥物共軛物之醫藥組成物可具備無菌注射式製劑之形式,如無菌水性或油性懸浮液。懸浮液可根據習知技術調配,即使用上述合適之分散劑或潤濕劑及懸浮劑。無菌注射式製劑亦可為無菌注射式溶液或懸浮液,其溶於無毒且腸道外可接受之稀釋劑或溶劑,如溶於1,3-丁二醇之溶液或製備為凍晶粉。可使用之接受溶媒及溶劑包括水、林格氏液及等滲氯化鈉溶液。此外,傳統上可使用無菌固定油作為溶劑或懸浮媒介。為達此目的,可使用任何無味固定油,包括合成單酸或雙酸甘油酯。另外,製備注射式製劑時亦可使用如油酸等脂肪酸。
可與溶媒材料結合以製備單劑量製劑之活性成分,其劑量會根據接受治療對象及施用模式變動。舉例而言,靜脈內灌注預計使用之水性懸浮液 內,每毫升可含有大約3到500 μg之活性成分,以使灌注合適體積之速率可達30 mL/hr。進行皮下(一次全劑量注射)施用時,用量可為大約1.5 mL或少於總體積之量,濃度可為每mL含大約100 mg之抗體藥物共軛物。對於需要經過頻繁、慢性施用之抗體藥物共軛物,可採用皮下注射方式,如透過預先充填之注射器或自動注射裝置。
一般而言,施用抗體藥物共軛物時,每劑之醫藥上具療效起始劑量介於大約0.01-100 mg/kg之間,即每日大約0.1至20 mg/每kg病患體重,而一般施用化合物之起始劑量為每日0.3至15 mg/kg。舉例而言,可對人類病患施用之起始劑量為大約1.5 mg抗體藥物共軛物/每kg病患體重。此劑量可加重至最大可容忍劑量。施用劑量之時程大約為每三周一次,但會根據病患身體症狀或反應調高或調低施用頻率。此劑量可進一步於治療過程中調整為等於或低於最大可容忍劑量,在多次施用之情形下,如大約四次或四次以上,便可使病患安全無虞。
適合腸道外施用之配方包括水性及非水性無菌注射溶液,其可包含抗氧化劑、緩衝液、抑菌劑及溶質,使配方與預期接受注射患者之血液滲透壓相等;以及可包含水性及非水性無菌懸浮液,可包括懸浮劑及增稠劑。
口服施用蛋白質藥物時,由於藥物在患者體內被吸收、水解、變性之程度有限,導致生物利用度偏低,一般較不傾向採取此施用途徑。不過,適合口服施用之抗體藥物共軛物配方可製成分裝形式,如膠囊、囊劑或錠劑,每一分裝單位皆含有預先決定之抗體藥物共軛物劑量。
可將配方包裝於單位劑量或多劑量容器內,例如封裝之安瓿或小瓶,且可貯藏於冷凍乾燥(凍晶)狀態下,使用前僅需要透過無菌液態溶媒,例如水,便可立即注射。即時注射液及懸浮液皆由先前描述之無菌粉末、顆粒、錠劑製備。範例單位劑量配方包含每日劑量或單位每日次劑量,或者合適小單位之之活性成分。
本發明進一步提供獸醫用組成物,其包含至少一種上述之活性成分,以及獸醫用溶媒。獸醫用溶媒為適用於施用獸醫用組成物之材料,其可為固態、液態或氣態材料,於獸醫領域中為惰性或可接受之材料,且與活性成分相容。獸醫用組成物之施用方式包括腸道外、口服或其他預期之途徑。
基於預防或治療疾病之目的,抗體藥物共軛物之合適劑量將取決於如上述之待治療疾病種類、疾病嚴重程度及進程、分子施用目的為預防或治療、先前療程、病患病史與對抗體之反應,以及主治醫師之裁量權。合適情況為對病患於一次治療或一系列療程中施用該分子。依病症種類及嚴重程度,分子之起始候選劑量為大約1 μg/kg至15 mg/kg(如0.1-20 mg/kg),無論是透過一或多次分別施用或連續灌注方式對病患施用分子。一般每日劑量可能介於大約1 μg/kg至100 mg/kg或以上,視上述因素而定。對病患施用的範例抗體藥物共軛物之劑量介於大約0.1至大約10 mg/每kg病患體重之間。
對於在數天或更長時間內反覆施用之情形,將視症狀而定,持續治療至症狀如預期受到抑制為止。範例給藥療程包含施用大約4 mg/kg之起始負荷劑量,接著每周固定施用大約2 mg/kg之抗ErbB2抗體。其他給藥療程亦可具療效。使用傳統技術及測定方式可輕易監測此療法之進度。
組合療法
在一醫藥組合配方或組合療法給藥療程中,抗體藥物共軛物可與具抗癌性質之第二化合物結合。較佳地,該醫藥組合配方或給藥療程之第二化合物具有和該組合的抗體藥物共軛物互補之活性,因此不會互相產生不良影響。
第二化合物可為化療製劑、胞殺製劑、細胞激素、生長抑制劑、抗激素製劑、芳香環酶抑制劑、蛋白激酶抑制劑、脂質激酶抑制劑、抗雄性激素、反義寡核苷酸、核酶、基因療法疫苗、抗血管新生製劑及/或心臟保護藥劑。上述分子可適當包含於組成物中,其劑量相對於預期目的具有療效。含有抗體藥物共軛物之醫藥組成物,亦可含有具治療有效量之化療製劑,如微管蛋白生成抑制劑、拓撲異構酶抑制劑或DNA結合劑。
界定代謝產物時,可透過製備被放射性標記(如
14C或
3H)之抗體藥物共軛物、於腸道外對大鼠、小鼠、豚鼠、猴子、人類等動物施用可偵測劑量(如大於約0.5 mg/kg)之抗體藥物共軛物、預留足夠時間使代謝發生(一般大約為30秒到30小時),並且將其轉化產物自尿液、血液或其他生物樣本分離。上述產物在被標記之後,即可被輕易分離(分離其他產物時,則透過能與仍存在代謝產物中的表位結合之抗體)。代謝產物結構會以傳統方式測定,如使用質譜儀、液相層析質譜儀或核磁共振分析法。一般而言,分析代謝產物之方法與本發明所屬領域中技術人員習知之傳統藥物代謝研究方法相同。當轉化產物不存在於活體內時,即可用於診斷測定過程,以便施用具療效劑量之抗體藥物共軛物化合物。
代謝產物包括於活體內切割抗體藥物共軛物之產物,其中藥物基團與抗體之鍵結會被切割。代謝切割可能因此產生裸露抗體或抗體片段。抗體代謝產物可與部分或全部之聯結分子連接。代謝切割亦可產生完整或部分藥物基團。藥物基團之代謝產物可與部分或全部之聯結分子連接。
製造物
在另一實施例中,提供一種製造物或「工具組」,其包含抗體藥物共軛物及可用於治療前述病症之材料。該製造物包含容器以及顯示於容器上或與容器相關之標籤或仿單。合適之容器包括瓶子、小瓶、針筒或泡罩包裝。容器可由許多材料形成,如玻璃或塑膠。容器內裝有抗體藥物共軛物組成物,其具備治癒疾病療效,且可具有無菌給藥通道(例如容器可為靜脈注射袋或小瓶,小瓶含有可以皮下注射針頭戳穿之塞子)。組成物中至少一種活性製劑為抗體藥物共軛物。根據標籤或仿單說明,組成物可用於治療任意指定之病症,如癌症。
無須進一步說明,對本發明所屬技術領域中具有通常知識者而言,一般皆可根據以上說明完全實現本發明。因此,以下提供之具體實施例僅作為例示性說明,不應被理解為具有任何限制本文後續揭露內容之意圖。本文引述之所有文獻皆以引用方式併入,以配合本文目的或涉及之主題。
實施例
實施例
1
:抗體與藥物之共軛
PolyTherics公司將單甲基奧瑞斯他丁反應試劑(MMAE)與OBI-888單株抗體共軛,以製備抗體藥物共軛物(OBI-999)。雙硫共軛物聯結分子如美國專利第7595292號(WO2005/007197)所揭露;OBI-888為抗Globo H之單株抗體,如美國專利第20170101462號(WO2017/062792)所揭露;單甲基奧瑞斯他丁反應試劑為市場上可購得之抗腫瘤劑。透過實施試驗級反應和純化步驟,以判定合適之條件。結果顯示,還原抗體不易聚合。篩選還原與共軛之條件後,即使共軛物產率顯著提升。OBI-999(藥物抗體比=4)之完整化學結構式如下所示:
實施例
2
:抗體藥物共軛物(
OBI-999
)之分析
2.1 外觀
以顏色與透明度等視覺效果檢視產物溶液之外觀。
2.2 疏水性交互作用層析法分析
使用與Dionex Ultimate 3000RS高效液相層析法系統連接之TOSOH之TSKgel丁基疏水性色譜柱(Butyl-NPR column,3.5 cm × 4.6 mm)進行疏水性交互作用層析法。流動相為緩衝液A(溶於50 mM磷酸鈉之1.5 M硫酸銨,pH 7.0)。使用緩衝液B(溶於50 mM磷酸鈉之20%異丙醇(v/v) ,pH 7.0)實施梯度沖提,自20%至86%(超過18.4分鐘,流速為1.2 mL/min)。分析過程中,管柱溫度皆維持30 °C,並於280 nm時進行紫外線偵測。每組分析皆注射10 µg之原生OBI-888或共軛產物。
2.3 粒徑篩析層析法分析
使用與Agilent Infinity 1260 Bioinert系統連接的TOSOH Bioscience之TSKgel Super SW 3000色譜柱(4.6 mm × 30 cm,4 µm)及保護管柱(4.6 mm × 4 cm)進行粒徑篩析層析法。流動相為0.2 M磷酸鉀緩衝液,pH 6.8(0.2 M氯化鉀、15%異丙醇)。流速穩定維持0.35 mL/min。分析過程中,管柱皆維持於室溫,並實施等位沖提20分鐘,於280 nm時偵測紫外線。每組分析皆注射10 µg之共軛產物。以主峰面積及初始沖提峰面積分別與總峰面積比較,以分別計算純度與聚合度百分比。
2.4 十二烷基硫酸鈉聚丙烯醯胺凝膠電泳(SDS-PAGE)分析
使用NuPAGE 4-12%之Bis-Tris膠(Invitrogen,Cat#NP0321BOX)搭配脂肪酸甲脂磺酸鈉,於還原條件下進行SDS-PAGE分析。分析時,將1 µg樣本(基於蛋白質)置於各泳道之電泳膠上方。於200 V下進行電泳35分鐘。電泳膠經InstantBlue染劑(Expedeon,Cat#ISB1LUK)染色以偵測蛋白質,並使用ImageQuant造影設備(GE Healthcare)分析電泳膠。
2.5 使用Bradford定量法與紫外線吸收度判定濃度
使用Bradford 微量滴定盤定量法,並與原生OBI-888標準曲線(0-100 µg/mL)比對後測定共軛物之濃度。進行Bradford定量法時,於96孔平底培養皿中將100 µL校準標準物及樣本與200 µL之Bradford試劑(Expedeon,BFU1L)混合,再取同樣三份之混合物。讀取595 nm之光密度,並與該原生OBI-888標準曲線比對以測定樣本濃度。共軛物(基於蛋白質)之濃度亦經由操作超微量光譜儀後之紫外線吸收度(A280)測定。取同樣三份之測量結果,並透過平均值計算抗體濃度:
c=Abs /ε. l
其中c為濃度(mg/mL);Abs為280 nm時之吸收度;ε為消光係數(mL/mg.cm);l為長度(cm)。
自大型共軛物分離出一抗體藥物共軛物樣本(OBI-999),該共軛物樣本之藥物對抗體值為4,且經分離出之抗體藥物共軛物(OBI-999)重量為14.5 mg(經Bradford法測定)。使用疏水性交互作用層析法分析藥物對抗體比值分布情形,如第一圖所示。第一圖(A)顯示使用疏水性交互作用層析法分析OBI-888之一單峰(100%),而第一圖(B)則顯示抗體藥物共軛物(OBI-999)之一主峰(82.3%),該抗體藥物共軛物之藥物對抗體值為4。OBI-888(第二圖A)及抗體藥物共軛物(OBI-999)(第二圖B)之純度經粒徑篩析層析法測定,兩者純度皆大於96%。最後,第三圖顯示針對OBI-888及抗體藥物共軛物(OBI-999)之SDS-PAGE分析結果。樣本為均相產物(單一藥物對抗體比值>82%),且聚合度低(<5%)。表2列出相關分析結果。
表2:抗體藥物共軛物(OBI-999)之分析結果
待分析特性 | 結果 |
外觀 | 清澈無色溶液 |
% 純度(疏水性交互作用層析法) | 藥物對抗體比值 = 3 : 13.4 % 藥物對抗體比值 = 4 : 82.3 % 藥物對抗體比值 => 4 : 4.3 % |
% 純度(粒徑篩析層析法) | 96.9% 單體 |
重量(Bradford法) | 14.5 mg |
實施例
3
:測量裸小鼠體內範例抗體之抗腫瘤活性(乳癌)
在一人類乳腺癌腫瘤異體移植模型中,MCF-7(ATCC HTB-22)細胞經皮下途徑(對每隻小鼠施打0.2 mL之matrigel/培養液1:1混合物,內含 2.0 × 10
7個細胞)接種至無胸腺母裸小鼠(nu/nu)身體右側。自細胞移植前一周至研究結束期間,每周於小鼠肩胛骨間經皮下施打雌二醇環戊基丙酸酯(estradiol cyclopentyl propionate)補充注射液(100 µg/每小鼠)兩次。將經植入腫瘤之小鼠分為十一組實驗組,每組包含六隻小鼠,細胞移植後隔天即開始施打測試試劑(標記為第1天)。
3.1 試驗物質及給藥模式
每天使用含25 mM檸檬酸鈉、100 mM NaCl緩衝液(pH 6.5)之稀釋原液製備抗體藥物共軛物(OBI-999)、OBI-888及MMAE等試驗物質,並透過靜脈(IV)每周對小鼠施打一次,為期兩周或六周。每周對兩組實驗組經靜脈施打溶媒(25 mM檸檬酸鈉、100 mM NaCl緩衝液)一次,分別為期六周(第一組)及兩周(第二組)。每周施打10 mg/kg抗體藥物共軛物(OBI-999)試驗物質一次,為期兩周,或每周施打0.3、1及3 mg/kg,為期六周。每周施打10 mg/kg OBI-888試驗物質一次,為期兩周,或每周施打0.3、1及3 mg/kg,為期六周。每周施打0.057 mg/kg MMAE試驗物質一次,為期六周。除抗體藥物共軛物(OBI-999)具12.5 mL/kg之劑量、以10 mg/kg施打之外,所有試驗物質皆具10 mL/kg之劑量。
表3:裸小鼠體內範例抗體之抗腫瘤活性之研究設計(乳癌)
組別 | 試驗物質 | 途徑 | 濃度 mg/mL | 劑量 | 小鼠 (nu/nu) | |
mL/kg | mg/kg | (母) | ||||
1 | 溶媒 a | IV | NA | 10 | 0 x 6c | 6 |
2 | 溶媒 a | IV | NA | 10 | 0 x 2b | 6 |
3 | 抗體藥物共軛物 (OBI-999) | IV | 0.8 | 12.5 | 10 x 2b | 6 |
4 | 抗體藥物共軛物 (OBI-999) | IV | 0.03 | 10 | 0.3 x 6c | 6 |
5 | 抗體藥物共軛物 (OBI-999) | IV | 0.1 | 10 | 1 x 6c | 6 |
6 | 抗體藥物共軛物 (OBI-999) | IV | 0.3 | 10 | 3 x 6c | 6 |
7 | OBI-888 | IV | 1 | 10 | 10 x 2b | 6 |
8 | OBI-888 | IV | 0.03 | 10 | 0.3 x 6c | 6 |
9 | OBI-888 | IV | 0.1 | 10 | 1 x 6c | 6 |
10 | OBI-888 | IV | 0.3 | 10 | 3 x 6c | 6 |
11 | MMAE | IV | 0.0057 | 10 | 0.057 x 6c | 6 |
a pH 6.5之25mM 檸檬酸鈉+100 mM NaCl b 給藥模式:自腫瘤植入後(第1天)每周一次,為期兩周 c 給藥模式:自腫瘤植入後(第1天)每周一次,為期六周 每周觀測並紀錄腫瘤尺寸及小鼠體重兩次,至第43天或腫瘤尺寸達500 mm 3為止。研究結束時替腫瘤攝影。 |
3.2 細胞株
人類乳腺癌腫瘤細胞株MCF-7(ATCC HTB乳腺癌)由贊助人提供。腫瘤細胞由贊助人製備培養(1 × 10
8個細胞/mL),而包含2 × 10
7個細胞之0.2 mL MCF-7腫瘤細胞接種源(1:1混合之matrigel與培養液)則以皮下注射方式植入每隻小鼠右側身體。
3.3 受試動物
實驗使用自台灣BioLasco公司(經Charles River Laboratories授權)購得之六至七周齡母裸小鼠(nu/nu)。受試動物皆飼養於個獨立通風籠中(IVC,36 Mini Isolator System)。分配給每3-5隻受試動物之空間大小為27 × 20 × 14 cm
3。所有受試動物皆於恆溫(20-24℃)、恆濕(30-70%)、亮暗各12小時之乾淨衛生環境中。小鼠可自由食用標準實驗飼料(Oriental Yeast Co., Ltd.,日本)並飲用高壓滅菌自來水。動物實驗之飼養、實驗與死後處置等流程,皆依據
Guide for the Care and Use of Laboratory Animals: Eighth Edition(National Academies Press, Washington, D.C., 2011)之規範,於實驗團隊經AAALAC認證之實驗動物設施中執行。此外,進行實驗之動物照護及使用申請表已由Eurofins Panlabs Taiwan, Ltd. 之實驗動物照護及使用委員會審核並核准。
3.4 實驗化學物質
本實驗使用益斯多注射液(Estol-Depot Inj.,estradiol cyclopentyl propionate)(Astar,台灣)及BD Matrigel 基質膠(BD Biosciences,美國)。
3.5 實驗器材
實驗器材包括游標尺(Mitutoyo,日本)、離心機 5810R(Eppendorf,德國)、二氧化碳培養箱(Forma Scientific Inc.,美國)、血球計數器(Hausser Scientific Horsham,美國)、獨立通風籠(36 Mini Isolator system,Tecniplast,義大利)、倒立顯微鏡 CK-40(Olympus,日本)、系統顯微鏡 E-400(Nikon,日本)及垂直無菌操作台(Tsao-Hsin,台灣)。
3.6 實驗方法
每周觀察兩次並紀錄小鼠腫瘤體積、體重、死亡率及明顯毒性作用徵兆,為期77天。腫瘤體積(mm
3)係根據長橢球體積公式計算:長度(mm)× [寬度(mm)]
2× 0.5。腫瘤生長抑制程度以T/C(治療/控制)× 100%計。T/C值≦42%即代表顯著抗腫瘤活性。使用雙因子變異數分析再進行Bonferroni 事後檢定,以判斷各實驗組相較於各溶媒對照組之統計顯著性(*
p< 0.05)。
3.7 實驗結果
表4-1:異體移植MCF-7乳癌腫瘤及裸小鼠體內腫瘤體積(第1天到第26天)
組別 | 治療方式 | 劑量 (mg/kg) (途徑) | 編號 | 腫瘤體積 (mm 3) | |||||||
第1天 | 第5天 | 第8天 | 第12天 | 第15天 | 第19天 | 第22天 | 第26天 | ||||
1 | 溶媒 (pH 6.5之25 mM 檸檬酸鈉+100 mM NaCl) | 10 mL/kg x 6 IV (每周一次) | 1 | 131 | 119 | 133 | 134 | 175 | 220 | 240 | 258 |
2 | 171 | 115 | 160 | 168 | 164 | 219 | 240 | 296 | |||
3 | 173 | 137 | 150 | 150 | 176 | 194 | 243 | 286 | |||
4 | 155 | 125 | 121 | 171 | 142 | 185 | 202 | 240 | |||
5 | 166 | 117 | 123 | 181 | 138 | 169 | 171 | 203 | |||
6 | 157 | 125 | 139 | 157 | 171 | 228 | 275 | 306 | |||
平均 | 159 | 123 | 138 | 160 | 161 | 203 | 229 | 265 | |||
SEM | 6 | 3 | 6 | 7 | 7 | 10 | 15 | 16 | |||
2 | 溶媒 (pH 6.5之25 mM 檸檬酸鈉+100 mM NaCl) | 10 mL/kg x 2 IV (每周一次) | 1 | 169 | 148 | 137 | 207 | 210 | 268 | 300 | 322 |
2 | 149 | 137 | 146 | 189 | 189 | 234 | 282 | 337 | |||
3 | 169 | 139 | 148 | 262 | 279 | 300 | 307 | 317 | |||
4 | 184 | 133 | 139 | 133 | 123 | 127 | 146 | 231 | |||
5 | 143 | 113 | 113 | 184 | 131 | 154 | 205 | 210 | |||
6 | 160 | 121 | 127 | 142 | 153 | 174 | 174 | 166 | |||
平均 | 162 | 132 | 135 | 186 | 181 | 210 | 236 | 264 | |||
SEM | 6 | 5 | 5 | 19 | 24 | 28 | 28 | 29 | |||
% T/C | 102 | 107 | 98 | 116 | 112 | 103 | 103 | 100 | |||
3 | 抗體藥物共軛物 (OBI-999) | 10 mg/kg x 2 IV (每周一次) | 1 | 155 | 126 | 119 | 168 | 104 | 97 | 108 | 89 |
2 | 139 | 123 | 115 | 123 | 90 | 89 | 89 | 94 | |||
3 | 164 | 117 | 121 | 131 | 89 | 76 | 85 | 74 | |||
4 | 152 | 119 | 110 | 88 | 100 | 97 | 85 | 75 | |||
5 | 166 | 110 | 108 | 87 | 94 | 57 | 56 | 54 | |||
6 | 127 | 125 | 118 | 129 | 101 | 104 | 93 | 85 | |||
平均 | 151 | 120 | 115 | 121 | 96 | 87 | 86 | 79 | |||
SEM | 6 | 2 | 2 | 12 | 3 | 7 | 7 | 6 | |||
% T/C | 93 | 91 | 85 | 65 | 53 | 41 | 36 | 30 | |||
4 | 抗體藥物共軛物(OBI-999) | 0.3 mg/kg x 6 IV (每周一次) | 1 | 139 | 117 | 113 | 159 | 123 | 160 | 160 | 152 |
2 | 176 | 139 | 131 | 143 | 141 | 144 | 176 | 195 | |||
3 | 146 | 121 | 143 | 155 | 125 | 174 | 187 | 220 | |||
4 | 153 | 119 | 126 | 168 | 156 | 186 | 198 | 197 | |||
5 | 148 | 117 | 94 | 146 | 130 | 154 | 155 | 124 | |||
6 | 135 | 103 | 113 | 141 | 143 | 145 | 163 | 166 | |||
平均 | 150 | 119 | 120 | 152 | 136 | 161 | 173 | 176 | |||
SEM | 6 | 5 | 7 | 4 | 5 | 7 | 7 | 14 | |||
% T/C | 94 | 97 | 87 | 95 | 84 | 79 | 76 | 66 | |||
5 | 抗體藥物共軛物 (OBI-999) | 1 mg/kg x 6 IV (每周一次) | 1 | 197 | 161 | 149 | 175 | 145 | 135 | 138 | 125 |
2 | 162 | 101 | 107 | 74 | 95 | 113 | 110 | 78 | |||
3 | 157 | 131 | 148 | 126 | 124 | 148 | 135 | 121 | |||
4 | 152 | 133 | 125 | 136 | 124 | 144 | 141 | 120 | |||
5 | 131 | 101 | 108 | 127 | 113 | 106 | 117 | 112 | |||
6 | 116 | 104 | 112 | 108 | 73 | 76 | 67 | 65 | |||
平均 | 153 | 122 | 125 | 124 | 112 | 120 | 118 | 104 | |||
SEM | 11 | 10 | 8 | 14 | 10 | 11 | 11 | 10 | |||
% T/C | 96 | 99 | 91 | 78 | 70 | 59 | 52 | 39 | |||
6 | 抗體藥物共軛物 (OBI-999) | 3 mg/kg x 6 IV (每周一次) | 1 | 156 | 129 | 129 | 117 | 98 | 89 | 93 | 79 |
2 | 194 | 108 | 108 | 125 | 88 | 86 | 88 | 70 | |||
3 | 129 | 112 | 83 | 72 | 44 | 38 | 24 | 21 | |||
4 | 139 | 108 | 94 | 88 | 81 | 82 | 51 | 37 | |||
5 | 143 | 111 | 108 | 80 | 74 | 76 | 55 | 45 | |||
6 | 139 | 108 | 94 | 88 | 81 | 88 | 83 | 55 | |||
平均 | 150 | 113 | 103 | 95 | 78 | 77 | 66 | 51 | |||
SEM | 9 | 3 | 7 | 9 | 8 | 8 | 11 | 9 | |||
% T/C | 94 | 92 | 75 | 59 | 48 | 38 | 29 | 19 | |||
7 | OBI-888 | 10 mg/kg x 2 IV (每周一次) | 1 | 123 | 94 | 123 | 100 | 162 | 161 | 154 | 137 |
2 | 155 | 114 | 141 | 123 | 161 | 207 | 207 | 214 | |||
3 | 150 | 97 | 127 | 111 | 104 | 115 | 133 | 145 | |||
4 | 144 | 125 | 123 | 113 | 109 | 106 | 106 | 101 | |||
5 | 159 | 125 | 100 | 120 | 145 | 187 | 202 | 213 | |||
6 | 141 | 110 | 110 | 117 | 108 | 130 | 133 | 125 | |||
平均 | 145 | 111 | 121 | 114 | 132 | 151 | 156 | 156 | |||
SEM | 5 | 5 | 6 | 3 | 11 | 17 | 17 | 19 | |||
% T/C | 90 | 84 | 90 | 61 | 73 | 74 | 68 | 59 | |||
8 | OBI-888 | 0.3 mg/kg x 6 IV (每周一次) | 1 | 154 | 110 | 111 | 106 | 119 | 131 | 133 | 98 |
2 | 231 | 123 | 104 | 106 | 111 | 141 | 157 | 197 | |||
3 | 129 | 104 | 137 | 123 | 117 | 167 | 189 | 203 | |||
4 | 153 | 119 | 117 | 106 | 113 | 113 | 119 | 115 | |||
5 | 157 | 98 | 123 | 121 | 108 | 142 | 181 | 180 | |||
6 | 150 | 101 | 127 | 101 | 104 | 109 | 121 | 164 | |||
平均 | 162 | 109 | 120 | 111 | 112 | 134 | 150 | 160 | |||
SEM | 14 | 4 | 5 | 4 | 2 | 9 | 12 | 18 | |||
% T/C | 102 | 89 | 87 | 69 | 70 | 66 | 66 | 60 | |||
9 | OBI-888 | 1 mg/kg x 6 IV (每周一次) | 1 | 146 | 133 | 113 | 115 | 83 | 97 | 92 | 86 |
2 | 164 | 113 | 127 | 113 | 119 | 146 | 141 | 133 | |||
3 | 127 | 63 | 69 | 80 | 69 | 81 | 89 | 88 | |||
4 | 146 | 139 | 108 | 129 | 94 | 144 | 122 | 119 | |||
5 | 215 | 136 | 115 | 130 | 145 | 200 | 198 | 206 | |||
6 | 146 | 119 | 106 | 109 | 93 | 119 | 119 | 122 | |||
平均 | 157 | 117 | 106 | 113 | 101 | 131 | 127 | 126 | |||
SEM | 12 | 12 | 8 | 7 | 11 | 17 | 16 | 18 | |||
% T/C | 99 | 95 | 77 | 71 | 63 | 65 | 55 | 48 | |||
10 | OBI-888 | 3 mg/kg x 6 IV (每周一次) | 1 | 146 | 108 | 127 | 87 | 88 | 96 | 92 | 115 |
2 | 137 | 125 | 131 | 125 | 115 | 124 | 137 | 153 | |||
3 | 126 | 94 | 109 | 94 | 93 | 95 | 99 | 119 | |||
4 | 136 | 119 | 125 | 124 | 124 | 143 | 138 | 114 | |||
5 | 135 | 84 | 89 | 91 | 69 | 85 | 86 | 77 | |||
6 | 181 | 108 | 129 | 121 | 91 | 103 | 108 | 102 | |||
平均 | 144 | 106 | 118 | 107 | 97 | 108 | 110 | 113 | |||
SEM | 8 | 6 | 7 | 7 | 8 | 9 | 9 | 10 | |||
% T/C | 91 | 86 | 86 | 67 | 60 | 53 | 48 | 43 | |||
11 | MMAE | 0.057 mg/kg x 6 IV (每周一次) | 1 | 162 | 145 | 139 | 133 | 127 | 125 | 137 | 119 |
2 | 186 | 104 | 131 | 115 | 105 | 121 | 138 | 154 | |||
3 | 152 | 106 | 131 | 103 | 137 | 148 | 164 | 179 | |||
4 | 188 | 128 | 146 | 129 | 121 | 135 | 143 | 144 | |||
5 | 141 | 110 | 121 | 101 | 102 | 137 | 123 | 135 | |||
6 | 139 | 123 | 125 | 104 | 101 | 113 | 137 | 127 | |||
平均 | 161 | 119 | 132 | 114 | 116 | 130 | 140 | 143 | |||
SEM | 9 | 6 | 4 | 6 | 6 | 5 | 5 | 9 | |||
% T/C | 101 | 97 | 96 | 71 | 72 | 64 | 61 | 54 |
表4-2:異體移植MCF-7乳癌腫瘤及裸小鼠體內腫瘤體積(第29天到第49天)
組別 | 治療方式 | 劑量 (mg/kg) (途徑) | 編號 | 腫瘤體積 (mm 3) | ||||||
第29天 | 第33天 | 第36天 | 第40天 | 第43天 | 第46天 | 第49天 | ||||
1 | 溶媒 (pH 6.5之25 mM 檸檬酸鈉+100 mM NaCl) | 10 mL/kg x 6 IV (每周一次) | 1 | 281 | 312 | 343 | 372 | 399 | 435 | 455 |
2 | 295 | 325 | 340 | 348 | 368 | 376 | 419 | |||
3 | 307 | 328 | 351 | 363 | 388 | 432 | 465 | |||
4 | 255 | 277 | 295 | 307 | 330 | 355 | 387 | |||
5 | 214 | 228 | 243 | 259 | 307 | 321 | 351 | |||
6 | 316 | 370 | 386 | 424 | 432 | 436 | 476 | |||
平均 | 278 | 307 | 326 | 346 | 371 | 393 | 426 | |||
SEM | 16 | 20 | 20 | 23 | 19 | 20 | 20 | |||
2 | 溶媒 (pH 6.5之25 mM 檸檬酸鈉+100 mM NaCl) | 10 mL/kg x 2 IV (每周一次) | 1 | 356 | 389 | 432 | 458 | 503 | 612 | 738 |
2 | 344 | 364 | 402 | 402 | 429 | 470 | 484 | |||
3 | 381 | 402 | 411 | 415 | 415 | 433 | 456 | |||
4 | 252 | 279 | 341 | 389 | 422 | 451 | 499 | |||
5 | 266 | 317 | 325 | 332 | 340 | 356 | 368 | |||
6 | 169 | 189 | 194 | 197 | 203 | 203 | 203 | |||
平均 | 295 | 323 | 351 | 366 | 385 | 421 | 458 | |||
SEM | 33 | 33 | 36 | 38 | 42 | 55 | 72 | |||
% T/C | 106 | 105 | 108 | 106 | 104 | 107 | 108 | |||
3 | 抗體藥物共軛物(OBI-999) | 10 mg/kg x 2 IV (每周一次) | 1 | 73 | 66 | 66 | 57 | 53 | 51 | 49 |
2 | 91 | 85 | 83 | 70 | 66 | 53 | 48 | |||
3 | 75 | 79 | 79 | 62 | 56 | 49 | 45 | |||
4 | 75 | 76 | 78 | 72 | 65 | 62 | 56 | |||
5 | 48 | 42 | 39 | 32 | 32 | 31 | 30 | |||
6 | 86 | 82 | 79 | 66 | 62 | 60 | 58 | |||
平均 | 75 | 72 | 71 | 60 | 56 | 51 | 48 | |||
SEM | 6 | 7 | 7 | 6 | 5 | 5 | 4 | |||
% T/C | 27 | 23 | 22 | 17 | 15 | 13 | 11 | |||
4 | 抗體藥物共軛物(OBI-999) | 0.3 mg/kg x 6 IV (每周一次) | 1 | 176 | 222 | 240 | 269 | 296 | 307 | 340 |
2 | 218 | 238 | 260 | 270 | 276 | 295 | 333 | |||
3 | 284 | 388 | 405 | 580 | 700 | 756 | 828 | |||
4 | 241 | 254 | 264 | 285 | 312 | 326 | 353 | |||
5 | 143 | 168 | 190 | 198 | 209 | 221 | 233 | |||
6 | 174 | 211 | 225 | 234 | 243 | 259 | 269 | |||
平均 | 206 | 247 | 264 | 306 | 339 | 361 | 393 | |||
SEM | 21 | 31 | 30 | 56 | 74 | 81 | 89 | |||
% T/C | 74 | 80 | 81 | 88 | 91 | 92 | 92 | |||
5 | 抗體藥物共軛物(OBI-999) | 1 mg/kg x 6 IV (每周一次) | 1 | 140 | 140 | 140 | 153 | 165 | 167 | 182 |
2 | 85 | 95 | 117 | 127 | 147 | 154 | 158 | |||
3 | 141 | 160 | 174 | 181 | 192 | 179 | 187 | |||
4 | 126 | 143 | 143 | 154 | 180 | 200 | 219 | |||
5 | 121 | 113 | 121 | 127 | 127 | 129 | 137 | |||
6 | 69 | 56 | 64 | 70 | 72 | 74 | 74 | |||
平均 | 114 | 118 | 127 | 135 | 147 | 151 | 160 | |||
SEM | 12 | 16 | 15 | 15 | 18 | 18 | 21 | |||
% T/C | 41 | 38 | 39 | 39 | 40 | 38 | 38 | |||
6 | 抗體藥物共軛物(OBI-999) | 3 mg/kg x 6 IV (每周一次) | 1 | 79 | 79 | 73 | 60 | 58 | 56 | 56 |
2 | 86 | 83 | 80 | 56 | 53 | 51 | 50 | |||
3 | 18 | 0 | 0 | 0 | 0 | 0 | 0 | |||
4 | 37 | 40 | 47 | 31 | 31 | 29 | 0 | |||
5 | 39 | 44 | 51 | 30 | 29 | 25 | 23 | |||
6 | 59 | 41 | 39 | 0 | 0 | 0 | 0 | |||
平均 | 53 | 48 | 48 | 30 | 29 | 27 | 22 | |||
SEM | 11 | 12 | 12 | 11 | 10 | 10 | 11 | |||
% T/C | 19 | 16 | 15 | 9 | 8 | 7 | 5 | |||
7 | OBI-888 | 10 mg/kg x 2 IV (每周一次) | 1 | 174 | 200 | 249 | 272 | 292 | 313 | 332 |
2 | 236 | 244 | 273 | 291 | 296 | 293 | 308 | |||
3 | 139 | 173 | 202 | 249 | 292 | 354 | 425 | |||
4 | 117 | 111 | 119 | 117 | 122 | 128 | 134 | |||
5 | 241 | 247 | 264 | 296 | 312 | 347 | 378 | |||
6 | 159 | 174 | 197 | 200 | 205 | 213 | 230 | |||
平均 | 178 | 192 | 217 | 238 | 253 | 275 | 301 | |||
SEM | 21 | 21 | 24 | 28 | 30 | 36 | 43 | |||
% T/C | 64 | 63 | 67 | 69 | 68 | 70 | 71 | |||
8 | OBI-888 | 0.3 mg/kg x 6 IV (每周一次) | 1 | 97 | 110 | 119 | 127 | 137 | 167 | 179 |
2 | 213 | 265 | 331 | 385 | 416 | 486 | 508 | |||
3 | 211 | 217 | 240 | 246 | 265 | 286 | 310 | |||
4 | 106 | 104 | 121 | 139 | 150 | 152 | 152 | |||
5 | 241 | 294 | 372 | 397 | 455 | 493 | 539 | |||
6 | 189 | 217 | 245 | 274 | 287 | 295 | 298 | |||
平均 | 176 | 201 | 238 | 261 | 285 | 313 | 331 | |||
SEM | 25 | 32 | 43 | 47 | 54 | 61 | 66 | |||
% T/C | 63 | 65 | 73 | 75 | 77 | 80 | 78 | |||
9 | OBI-888 | 1 mg/kg x 6 IV (每周一次) | 1 | 104 | 108 | 119 | 117 | 127 | 133 | 139 |
2 | 153 | 160 | 174 | 181 | 187 | 192 | 200 | |||
3 | 98 | 127 | 136 | 158 | 178 | 199 | 211 | |||
4 | 123 | 139 | 145 | 147 | 161 | 163 | 178 | |||
5 | 255 | 331 | 354 | 379 | 416 | 450 | 491 | |||
6 | 142 | 145 | 157 | 168 | 185 | 199 | 201 | |||
平均 | 146 | 168 | 181 | 192 | 209 | 223 | 237 | |||
SEM | 23 | 33 | 35 | 39 | 42 | 47 | 52 | |||
% T/C | 53 | 55 | 56 | 55 | 56 | 57 | 56 | |||
10 | OBI-888 | 3 mg/kg x 6 IV (每周一次) | 1 | 123 | 139 | 146 | 152 | 162 | 181 | 192 |
2 | 167 | 181 | 231 | 256 | 269 | 272 | 292 | |||
3 | 149 | 171 | 183 | 207 | 221 | 236 | 248 | |||
4 | 117 | 145 | 154 | 163 | 166 | 170 | 174 | |||
5 | 79 | 83 | 86 | 91 | 101 | 112 | 116 | |||
6 | 103 | 107 | 107 | 105 | 110 | 112 | 116 | |||
平均 | 123 | 138 | 151 | 162 | 172 | 181 | 190 | |||
SEM | 13 | 15 | 21 | 25 | 26 | 26 | 29 | |||
% T/C | 44 | 45 | 46 | 47 | 46 | 46 | 45 | |||
11 | MMAE | 0.057 mg/kg x 6 IV (每周一次) | 1 | 119 | 133 | 152 | 156 | 186 | 222 | 235 |
2 | 156 | 168 | 201 | 223 | 242 | 258 | 301 | |||
3 | 194 | 216 | 256 | 285 | 296 | 332 | 351 | |||
4 | 160 | 177 | 218 | 226 | 240 | 259 | 264 | |||
5 | 146 | 162 | 171 | 184 | 186 | 204 | 210 | |||
6 | 131 | 152 | 154 | 186 | 239 | 261 | 270 | |||
平均 | 151 | 168 | 192 | 210 | 232 | 256 | 272 | |||
SEM | 11 | 11 | 17 | 18 | 17 | 18 | 20 | |||
% T/C | 54 | 55 | 59 | 61 | 63 | 65 | 64 |
表4-3:異體移植MCF-7乳癌腫瘤及裸小鼠體內腫瘤體積(第53天到第77天)
組別 | 治療方式 | 劑量 (mg/kg) (途徑) | 編號 | 腫瘤體積 (mm 3) | |||||||
第53天 | 第56天 | 第60天 | 第63天 | 第67天 | 第70天 | 第74天 | 第77天 | ||||
1 | 溶媒 (pH 6.5之25 mM 檸檬酸鈉+100 mM NaCl) | 10 mL/kg x 6 IV (每周一次) | 1 | 489 | 519 | 535 | 565 | 645 | 684 | 744 | 853 |
2 | 445 | 469 | 509 | 519 | 557 | 579 | 584 | 601 | |||
3 | 519 | 578 | 688 | 785 | 890 | 972 | 986 | 1155 | |||
4 | 405 | 416 | 454 | 465 | 514 | 518 | 578 | 796 | |||
5 | 375 | 450 | 509 | 579 | 622 | 652 | 681 | 881 | |||
6 | 499 | 530 | 585 | 629 | 752 | 776 | 862 | 1032 | |||
平均 | 455 | 494 | 547 | 590 | 663 | 697 | 739 | 886 | |||
SEM | 23 | 24 | 33 | 45 | 56 | 66 | 66 | 78 | |||
2 | 溶媒 (pH 6.5之25 mM 檸檬酸鈉+100 mM NaCl) | 10 mL/kg x 2 IV (每周一次) | 1 | 803 | 950 | 1113 | 1247 | 1439 | 1509 | 1870 | 2222 |
2 | 488 | 528 | 547 | 575 | 597 | 627 | 663 | 780 | |||
3 | 465 | 494 | 515 | 525 | 578 | 583 | 647 | 828 | |||
4 | 605 | 708 | 793 | 877 | 968 | 1014 | 1030 | 1102 | |||
5 | 368 | 407 | 414 | 423 | 465 | 465 | 535 | 754 | |||
6 | 208 | 222 | 243 | 267 | 361 | 433 | 526 | 615 | |||
平均 | 490 | 552 | 604 | 652 | 735 | 772 | 879 | 1050 | |||
SEM | 83 | 103 | 125 | 145 | 164 | 170 | 212 | 243 | |||
% T/C | 108 | 112 | 110 | 111 | 111 | 111 | 119 | 119 | |||
3 | 抗體藥物共軛物(OBI-999) | 10 mg/kg x 2 IV (每周一次) | 1 | 48 | 47 | 46 | 45 | 44 | 42 | 42 | 40 |
2 | 46 | 45 | 44 | 42 | 41 | 41 | 41 | 43 | |||
3 | 45 | 43 | 41 | 39 | 37 | 37 | 37 | 37 | |||
4 | 55 | 56 | 55 | 48 | 46 | 45 | 44 | 43 | |||
5 | 29 | 55 | 55 | 23 | 23 | 23 | 23 | 25 | |||
6 | 58 | 29 | 29 | 55 | 53 | 51 | 51 | 50 | |||
平均 | 47 | 46 | 45 | 42 | 41 | 40 | 40 | 40 | |||
SEM | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 3 | |||
% T/C | 10 | 9 | 8 | 7 | 6 | 6 | 5 | 5 | |||
4 | 抗體藥物共軛物(OBI-999) | 0.3 mg/kg x 6 IV (每周一次) | 1 | 356 | 385 | 411 | 428 | 490 | 607 | 665 | 834 |
2 | 361 | 371 | 444 | 476 | 536 | 630 | 681 | 819 | |||
3 | 992 | 1120 | 1276 | 1299 | 1532 | 1882 | 1950 | 2177 | |||
4 | 400 | 484 | 530 | 575 | 641 | 725 | 849 | 1028 | |||
5 | 235 | 241 | 276 | 298 | 362 | 408 | 473 | 575 | |||
6 | 272 | 292 | 328 | 371 | 390 | 492 | 545 | 704 | |||
平均 | 436 | 482 | 544 | 575 | 659 | 791 | 861 | 1023 | |||
SEM | 114 | 132 | 151 | 150 | 180 | 223 | 224 | 239 | |||
% T/C | 96 | 98 | 99 | 97 | 99 | 113 | 117 | 115 | |||
5 | 抗體藥物共軛物(OBI-999) | 1 mg/kg x 6 IV (每周一次) | 1 | 188 | 197 | 205 | 222 | 237 | 264 | 292 | 373 |
2 | 160 | 176 | 183 | 205 | 217 | 245 | 256 | 277 | |||
3 | 197 | 200 | 219 | 228 | 228 | 233 | 233 | 231 | |||
4 | 236 | 257 | 296 | 331 | 409 | 497 | 552 | 770 | |||
5 | 145 | 172 | 195 | 224 | 259 | 291 | 304 | 368 | |||
6 | 70 | 73 | 74 | 76 | 77 | 77 | 78 | 78 | |||
平均 | 166 | 179 | 195 | 214 | 238 | 268 | 286 | 350 | |||
SEM | 23 | 25 | 29 | 33 | 43 | 55 | 63 | 95 | |||
% T/C | 36 | 36 | 36 | 36 | 36 | 38 | 39 | 40 | |||
6 | 抗體藥物共軛物(OBI-999) | 3 mg/kg x 6 IV (每周一次) | 1 | 54 | 52 | 52 | 51 | 51 | 51 | 51 | 52 |
2 | 49 | 47 | 46 | 44 | 42 | 42 | 42 | 41 | |||
3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
5 | 23 | 22 | 21 | 21 | 21 | 21 | 21 | 23 | |||
6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
平均 | 21 | 20 | 20 | 19 | 19 | 19 | 19 | 19 | |||
SEM | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | |||
% T/C | 5 | 4 | 4 | 3 | 3 | 3 | 3 | 2 | |||
7 | OBI-888 | 10 mg/kg x 2 IV (每周一次) | 1 | 377 | 399 | 420 | 496 | 940 | 1180 | 1250 | 1710 |
2 | 333 | 348 | 372 | 436 | 451 | 死亡 | 死亡 | 死亡 | |||
3 | 610 | 162 | 188 | 701 | 746 | 849 | 952 | 1476 | |||
4 | 160 | 462 | 519 | 194 | 198 | 265 | 313 | 402 | |||
5 | 441 | 239 | 242 | 547 | 605 | 609 | 677 | 768 | |||
6 | 233 | 657 | 682 | 262 | 268 | 271 | 284 | 325 | |||
平均 | 359 | 378 | 404 | 439 | 535 | 635 | 695 | 936 | |||
SEM | 65 | 71 | 74 | 76 | 116 | 175 | 186 | 281 | |||
% T/C | 79 | 77 | 74 | 74 | 81 | 91 | 94 | 106 | |||
8 | OBI-888 | 0.3 mg/kg x 6 IV (每周一次) | 1 | 181 | 202 | 213 | 243 | 284 | 350 | 419 | 658 |
2 | 528 | 573 | 711 | 717 | 744 | 781 | 955 | 1080 | |||
3 | 332 | 155 | 157 | 428 | 451 | 510 | 552 | 589 | |||
4 | 152 | 733 | 841 | 157 | 157 | 157 | 157 | 162 | |||
5 | 673 | 318 | 341 | 910 | 992 | 1138 | 1180 | 1392 | |||
6 | 307 | 372 | 381 | 353 | 378 | 436 | 475 | 616 | |||
平均 | 362 | 392 | 441 | 468 | 501 | 562 | 623 | 750 | |||
SEM | 83 | 91 | 112 | 118 | 127 | 142 | 153 | 175 | |||
% T/C | 80 | 79 | 81 | 79 | 76 | 81 | 84 | 85 | |||
9 | OBI-888 | 1 mg/kg x 6 IV (每周一次) | 1 | 147 | 161 | 163 | 168 | 183 | 194 | 201 | 221 |
2 | 259 | 265 | 322 | 360 | 385 | 429 | 475 | 596 | |||
3 | 220 | 226 | 248 | 337 | 365 | 379 | 443 | 579 | |||
4 | 213 | 653 | 784 | 254 | 321 | 335 | 341 | 377 | |||
5 | 632 | 210 | 217 | 847 | 883 | 932 | 962 | 1289 | |||
6 | 203 | 240 | 273 | 223 | 228 | 291 | 299 | 394 | |||
平均 | 279 | 293 | 335 | 365 | 394 | 427 | 454 | 576 | |||
SEM | 72 | 73 | 93 | 101 | 103 | 106 | 109 | 154 | |||
% T/C | 61 | 59 | 61 | 62 | 59 | 61 | 61 | 65 | |||
10 | OBI-888 | 3 mg/kg x 6 IV (每周一次) | 1 | 203 | 324 | 356 | 303 | 352 | 389 | 460 | 629 |
2 | 309 | 316 | 381 | 356 | 378 | 378 | 396 | 603 | |||
3 | 294 | 176 | 179 | 411 | 469 | 508 | 581 | 678 | |||
4 | 174 | 125 | 138 | 181 | 181 | 181 | 181 | 215 | |||
5 | 124 | 127 | 131 | 143 | 162 | 177 | 206 | 270 | |||
6 | 121 | 219 | 269 | 134 | 137 | 139 | 159 | 161 | |||
平均 | 204 | 215 | 242 | 255 | 280 | 295 | 331 | 426 | |||
SEM | 33 | 36 | 45 | 48 | 56 | 61 | 71 | 96 | |||
% T/C | 45 | 44 | 44 | 43 | 42 | 42 | 45 | 48 | |||
11 | MMAE | 0.057 mg/kg x 6 IV (每周一次) | 1 | 268 | 325 | 383 | 494 | 598 | 603 | 681 | 760 |
2 | 319 | 329 | 373 | 418 | 455 | 493 | 570 | 632 | |||
3 | 373 | 399 | 453 | 496 | 505 | 523 | 568 | 807 | |||
4 | 270 | 328 | 358 | 412 | 489 | 528 | 695 | 887 | |||
5 | 216 | 305 | 312 | 286 | 307 | 333 | 365 | 410 | |||
6 | 291 | 249 | 262 | 422 | 458 | 591 | 625 | 922 | |||
平均 | 290 | 323 | 357 | 421 | 469 | 512 | 584 | 736 | |||
SEM | 22 | 20 | 27 | 31 | 39 | 40 | 49 | 77 | |||
% T/C | 64 | 65 | 65 | 71 | 71 | 73 | 79 | 83 |
表5-1:異體移植MCF-7乳癌腫瘤及裸小鼠體重(第1天到第26天)
組別 | 治療方式 | 劑量 (mg/kg) (途徑) | 編號 | 體重 (g) | |||||||
第1天 | 第5天 | 第8天 | 第12天 | 第15天 | 第19天 | 第22天 | 第26天 | ||||
1 | 溶媒 (pH 6.5之25 mM 檸檬酸鈉+100 mM NaCl) | 10 mL/kg x 6 IV (每周一次) | 1 | 25 | 25 | 26 | 27 | 27 | 26 | 26 | 25 |
2 | 24 | 24 | 26 | 28 | 29 | 29 | 29 | 27 | |||
3 | 23 | 24 | 25 | 26 | 26 | 26 | 26 | 27 | |||
4 | 23 | 24 | 26 | 27 | 27 | 27 | 26 | 26 | |||
5 | 23 | 24 | 25 | 27 | 27 | 27 | 28 | 27 | |||
6 | 21 | 22 | 24 | 24 | 24 | 24 | 25 | 24 | |||
平均 | 23.2 | 23.8 | 25.3 | 26.5 | 26.7 | 26.5 | 26.7 | 26.0 | |||
SEM | 0.5 | 0.4 | 0.3 | 0.6 | 0.7 | 0.7 | 0.6 | 0.5 | |||
2 | 溶媒 (pH 6.5之25 mM 檸檬酸鈉+100 mM NaCl) | 10 mL/kg x 2 IV (每周一次) | 1 | 21 | 23 | 23 | 25 | 25 | 25 | 25 | 25 |
2 | 20 | 21 | 22 | 24 | 25 | 25 | 25 | 25 | |||
3 | 18 | 19 | 20 | 21 | 22 | 22 | 23 | 22 | |||
4 | 24 | 24 | 24 | 26 | 26 | 25 | 26 | 27 | |||
5 | 23 | 25 | 27 | 28 | 28 | 27 | 27 | 28 | |||
6 | 23 | 24 | 25 | 26 | 27 | 26 | 27 | 27 | |||
平均 | 21.5 | 22.7 | 23.5 | 25.0 | 25.5 | 25.0 | 25.5 | 25.7 | |||
SEM | 0.9 | 0.9 | 1.0 | 1.0 | 0.8 | 0.7 | 0.6 | 0.9 | |||
P<0.05 | |||||||||||
3 | 抗體藥物共軛物(OBI-999) | 10 mg/kg x 2 IV (每周一次) | 1 | 22 | 22 | 25 | 26 | 27 | 26 | 26 | 26 |
2 | 21 | 21 | 22 | 23 | 23 | 23 | 24 | 23 | |||
3 | 23 | 25 | 26 | 26 | 27 | 27 | 26 | 27 | |||
4 | 21 | 20 | 21 | 21 | 23 | 21 | 22 | 21 | |||
5 | 20 | 20 | 21 | 22 | 23 | 23 | 24 | 24 | |||
6 | 22 | 23 | 23 | 24 | 24 | 24 | 25 | 25 | |||
平均 | 21.5 | 21.8 | 23.0 | 23.7 | 24.5 | 24.0 | 24.5 | 24.3 | |||
SEM | 0.4 | 0.8 | 0.9 | 0.8 | 0.8 | 0.9 | 0.6 | 0.9 | |||
P<0.05 | |||||||||||
4 | 抗體藥物共軛物(OBI-999) | 0.3 mg/kg x 6 IV (每周一次) | 1 | 22 | 22 | 23 | 24 | 25 | 25 | 25 | 25 |
2 | 23 | 24 | 25 | 27 | 26 | 25 | 26 | 26 | |||
3 | 21 | 21 | 22 | 23 | 23 | 23 | 25 | 25 | |||
4 | 23 | 23 | 24 | 25 | 24 | 25 | 25 | 26 | |||
5 | 21 | 22 | 23 | 24 | 24 | 24 | 25 | 24 | |||
6 | 21 | 21 | 23 | 24 | 24 | 25 | 25 | 25 | |||
平均 | 21.8 | 22.2 | 23.3 | 24.5 | 24.3 | 24.5 | 25.2 | 25.2 | |||
SEM | 0.4 | 0.5 | 0.4 | 0.6 | 0.4 | 0.3 | 0.2 | 0.3 | |||
P<0.05 | |||||||||||
5 | 抗體藥物共軛物(OBI-999) | 1 mg/kg x 6 IV (每周一次) | 1 | 22 | 22 | 24 | 24 | 24 | 24 | 24 | 24 |
2 | 22 | 23 | 25 | 26 | 26 | 26 | 26 | 26 | |||
3 | 21 | 20 | 22 | 22 | 23 | 23 | 24 | 23 | |||
4 | 23 | 25 | 25 | 26 | 27 | 26 | 27 | 26 | |||
5 | 22 | 23 | 24 | 25 | 25 | 25 | 25 | 25 | |||
6 | 23 | 24 | 25 | 26 | 27 | 25 | 26 | 25 | |||
平均 | 22.2 | 22.8 | 24.2 | 24.8 | 25.3 | 24.8 | 25.3 | 24.8 | |||
SEM | 0.3 | 0.7 | 0.5 | 0.7 | 0.7 | 0.5 | 0.5 | 0.5 | |||
6 | 抗體藥物共軛物(OBI-999) | 3 mg/kg x 6 IV (每周一次) | 1 | 22 | 22 | 24 | 26 | 26 | 26 | 26 | 26 |
2 | 22 | 21 | 23 | 24 | 23 | 23 | 23 | 24 | |||
3 | 22 | 22 | 23 | 24 | 24 | 24 | 24 | 24 | |||
4 | 22 | 23 | 24 | 26 | 26 | 26 | 26 | 26 | |||
5 | 22 | 22 | 22 | 23 | 23 | 23 | 23 | 23 | |||
6 | 20 | 21 | 22 | 23 | 24 | 24 | 24 | 23 | |||
平均 | 21.7 | 21.8 | 23.0 | 24.3 | 24.3 | 24.3 | 24.3 | 24.3 | |||
SEM | 0.3 | 0.3 | 0.4 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | |||
P<0.05 | |||||||||||
7 | OBI-888 | 10 mg/kg x 2 IV (每周一次) | 1 | 21 | 21 | 22 | 23 | 24 | 23 | 24 | 24 |
2 | 24 | 24 | 25 | 26 | 27 | 27 | 28 | 28 | |||
3 | 21 | 22 | 23 | 24 | 25 | 24 | 24 | 24 | |||
4 | 22 | 24 | 24 | 25 | 26 | 26 | 26 | 26 | |||
5 | 21 | 21 | 22 | 23 | 25 | 25 | 25 | 25 | |||
6 | 21 | 22 | 24 | 23 | 25 | 24 | 25 | 24 | |||
平均 | 21.7 | 22.3 | 23.3 | 24.0 | 25.3 | 24.8 | 25.3 | 25.2 | |||
SEM | 0.5 | 0.6 | 0.5 | 0.5 | 0.4 | 0.6 | 0.6 | 0.7 | |||
P<0.05 | |||||||||||
8 | OBI-888 | 0.3 mg/kg x 6 IV (每周一次) | 1 | 21 | 23 | 23 | 25 | 25 | 25 | 25 | 24 |
2 | 19 | 19 | 21 | 22 | 22 | 22 | 23 | 22 | |||
3 | 19 | 19 | 21 | 22 | 23 | 23 | 24 | 24 | |||
4 | 20 | 21 | 22 | 23 | 23 | 23 | 24 | 23 | |||
5 | 21 | 23 | 23 | 23 | 24 | 24 | 24 | 24 | |||
6 | 21 | 22 | 23 | 22 | 22 | 20 | 19 | 21 | |||
平均 | 20.2 | 21.2 | 22.2 | 22.8 | 23.2 | 22.8 | 23.2 | 23.0 | |||
SEM | 0.4 | 0.7 | 0.4 | 0.5 | 0.5 | 0.7 | 0.9 | 0.5 | |||
P<0.05 | |||||||||||
9 | OBI-888 | 1 mg/kg x 6 IV (每周一次) | 1 | 20 | 21 | 23 | 24 | 25 | 25 | 25 | 25 |
2 | 20 | 20 | 21 | 22 | 23 | 22 | 23 | 23 | |||
3 | 18 | 19 | 20 | 21 | 21 | 21 | 22 | 21 | |||
4 | 21 | 23 | 25 | 25 | 26 | 26 | 26 | 26 | |||
5 | 22 | 22 | 23 | 24 | 25 | 25 | 25 | 25 | |||
6 | 21 | 23 | 25 | 26 | 26 | 26 | 26 | 26 | |||
平均 | 20.3 | 21.3 | 22.8 | 23.7 | 24.3 | 24.2 | 24.5 | 24.3 | |||
SEM | 0.6 | 0.7 | 0.8 | 0.8 | 0.8 | 0.9 | 0.7 | 0.8 | |||
10 | OBI-888 | 3 mg/kg x 6 IV (每周一次) | 1 | 20 | 20 | 22 | 22 | 23 | 23 | 24 | 24 |
2 | 22 | 23 | 23 | 24 | 25 | 24 | 25 | 25 | |||
3 | 22 | 23 | 24 | 25 | 25 | 25 | 26 | 26 | |||
4 | 22 | 23 | 24 | 26 | 26 | 26 | 26 | 26 | |||
5 | 21 | 22 | 23 | 24 | 25 | 24 | 25 | 24 | |||
6 | 22 | 23 | 25 | 27 | 27 | 27 | 27 | 27 | |||
平均 | 21.5 | 22.3 | 23.5 | 24.7 | 25.2 | 24.8 | 25.5 | 25.3 | |||
SEM | 0.3 | 0.5 | 0.4 | 0.7 | 0.5 | 0.6 | 0.4 | 0.5 | |||
P<0.05 | |||||||||||
11 | MMAE | 0.057 mg/kg x 6 IV (每周一次) | 1 | 23 | 24 | 26 | 26 | 27 | 26 | 27 | 27 |
2 | 22 | 22 | 23 | 24 | 25 | 24 | 25 | 25 | |||
3 | 22 | 22 | 24 | 25 | 25 | 25 | 24 | 24 | |||
4 | 24 | 24 | 25 | 25 | 26 | 25 | 26 | 26 | |||
5 | 21 | 22 | 23 | 24 | 25 | 25 | 25 | 24 | |||
6 | 23 | 24 | 24 | 25 | 25 | 25 | 26 | 25 | |||
平均 | 22.5 | 23.0 | 24.2 | 24.8 | 25.5 | 25.0 | 25.5 | 25.2 | |||
SEM | 0.4 | 0.4 | 0.5 | 0.3 | 0.3 | 0.3 | 0.4 | 0.5 | |||
P<0.05 |
表5-2:異體移植MCF-7乳癌腫瘤及裸小鼠體重(第29天到第49天)
組別 | 治療方式 | 劑量 (mg/kg) (途徑) | 編號 | 體重 (g) | ||||||
第29天 | 第33天 | 第36天 | 第40天 | 第43天 | 第46天 | 第49天 | ||||
1 | 溶媒 (pH 6.5之25 mM 檸檬酸鈉+100 mM NaCl) | 10 mL/kg x 6 IV (每周一次) | 1 | 26 | 26 | 26 | 26 | 26 | 26 | 26 |
2 | 28 | 28 | 28 | 28 | 28 | 28 | 29 | |||
3 | 27 | 28 | 28 | 28 | 27 | 27 | 27 | |||
4 | 26 | 26 | 27 | 26 | 26 | 27 | 27 | |||
5 | 28 | 28 | 28 | 29 | 28 | 28 | 28 | |||
6 | 24 | 23 | 23 | 23 | 22 | 23 | 24 | |||
平均 | 26.5 | 26.5 | 26.7 | 26.7 | 26 | 26.5 | 26.8 | |||
SEM | 0.6 | 0.8 | 0.8 | 0.9 | 1 | 0.8 | 0.7 | |||
2 | 溶媒 (pH 6.5之25 mM 檸檬酸鈉+100 mM NaCl) | 10 mL/kg x 2 IV (每周一次) | 1 | 25 | 25 | 25 | 25 | 26 | 26 | 26 |
2 | 25 | 23 | 23 | 24 | 24 | 23 | 23 | |||
3 | 23 | 22 | 24 | 23 | 23 | 24 | 23 | |||
4 | 28 | 28 | 28 | 28 | 27 | 27 | 28 | |||
5 | 28 | 29 | 29 | 29 | 29 | 28 | 29 | |||
6 | 27 | 27 | 28 | 28 | 27 | 28 | 29 | |||
平均 | 26.0 | 25.7 | 26.2 | 26.2 | 26 | 26.0 | 26.3 | |||
SEM | 0.8 | 1.1 | 1.0 | 1.0 | 1 | 0.9 | 1.1 | |||
P<0.05 | ||||||||||
3 | 抗體藥物共軛物(OBI-999) | 10 mg/kg x 2 IV (每周一次) | 1 | 26 | 26 | 27 | 27 | 27 | 26 | 28 |
2 | 24 | 24 | 24 | 25 | 24 | 24 | 24 | |||
3 | 27 | 28 | 28 | 27 | 28 | 27 | 28 | |||
4 | 22 | 22 | 23 | 23 | 23 | 23 | 23 | |||
5 | 24 | 24 | 24 | 24 | 25 | 25 | 25 | |||
6 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | |||
平均 | 24.7 | 24.8 | 25.2 | 25.2 | 25 | 25.0 | 25.5 | |||
SEM | 0.7 | 0.8 | 0.8 | 0.7 | 1 | 0.6 | 0.8 | |||
P<0.05 | ||||||||||
4 | 抗體藥物共軛物(OBI-999) | 0.3 mg/kg x 6 IV (每周一次) | 1 | 24 | 24 | 25 | 25 | 25 | 25 | 25 |
2 | 26 | 27 | 28 | 27 | 27 | 27 | 28 | |||
3 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | |||
4 | 25 | 25 | 26 | 26 | 26 | 26 | 27 | |||
5 | 25 | 24 | 25 | 25 | 25 | 25 | 25 | |||
6 | 26 | 26 | 27 | 26 | 26 | 26 | 27 | |||
平均 | 25.2 | 25.2 | 26.0 | 25.7 | 26 | 25.7 | 26.2 | |||
SEM | 0.3 | 0.5 | 0.5 | 0.3 | 0 | 0.3 | 0.5 | |||
P<0.05 | ||||||||||
5 | 抗體藥物共軛物(OBI-999) | 1 mg/kg x 6 IV (每周一次) | 1 | 24 | 24 | 24 | 24 | 24 | 24 | 24 |
2 | 26 | 26 | 26 | 26 | 26 | 26 | 27 | |||
3 | 24 | 25 | 25 | 25 | 25 | 25 | 25 | |||
4 | 27 | 27 | 27 | 27 | 27 | 28 | 28 | |||
5 | 26 | 25 | 26 | 26 | 25 | 25 | 26 | |||
6 | 26 | 26 | 27 | 26 | 25 | 26 | 26 | |||
平均 | 25.5 | 25.5 | 25.8 | 25.7 | 25.3 | 25.7 | 26.0 | |||
SEM | 0.5 | 0.4 | 0.5 | 0.4 | 0.4 | 0.6 | 0.6 | |||
6 | 抗體藥物共軛物(OBI-999) | 3 mg/kg x 6 IV (每周一次) | 1 | 27 | 26 | 27 | 26 | 27 | 27 | 28 |
2 | 24 | 24 | 25 | 24 | 24 | 24 | 24 | |||
3 | 24 | 24 | 25 | 24 | 24 | 24 | 25 | |||
4 | 26 | 24 | 24 | 25 | 24 | 25 | 27 | |||
5 | 23 | 23 | 24 | 24 | 24 | 24 | 24 | |||
6 | 24 | 24 | 25 | 25 | 25 | 24 | 24 | |||
平均 | 24.7 | 24.2 | 25.0 | 24.7 | 24.7 | 24.7 | 25.3 | |||
SEM | 0.6 | 0.4 | 0.4 | 0.3 | 0.5 | 0.5 | 0.7 | |||
P<0.05 | ||||||||||
7 | OBI-888 | 10 mg/kg x 2 IV (每周一次) | 1 | 24 | 25 | 25 | 24 | 24 | 24 | 25 |
2 | 28 | 28 | 28 | 27 | 28 | 28 | 28 | |||
3 | 24 | 24 | 24 | 24 | 25 | 24 | 25 | |||
4 | 26 | 26 | 26 | 22 | 21 | 22 | 24 | |||
5 | 25 | 25 | 26 | 26 | 26 | 26 | 28 | |||
6 | 25 | 25 | 25 | 25 | 23 | 25 | 24 | |||
平均 | 25.3 | 25.5 | 25.7 | 24.7 | 24.5 | 24.8 | 25.7 | |||
SEM | 0.6 | 0.6 | 0.6 | 0.7 | 1.0 | 0.8 | 0.8 | |||
P<0.05 | ||||||||||
8 | OBI-888 | 0.3 mg/kg x 6 IV (每周一次) | 1 | 25 | 25 | 25 | 25 | 25 | 25 | 26 |
2 | 23 | 22 | 23 | 22 | 23 | 23 | 24 | |||
3 | 24 | 25 | 24 | 25 | 24 | 24 | 26 | |||
4 | 24 | 23 | 24 | 24 | 24 | 24 | 24 | |||
5 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | |||
6 | 24 | 24 | 25 | 24 | 25 | 24 | 25 | |||
平均 | 24.0 | 23.8 | 24.2 | 24.0 | 24.2 | 24.0 | 24.8 | |||
SEM | 0.3 | 0.5 | 0.3 | 0.4 | 0.3 | 0.3 | 0.4 | |||
P<0.05 | ||||||||||
9 | OBI-888 | 1 mg/kg x 6 IV (每周一次) | 1 | 25 | 25 | 23 | 20 | 24 | 25 | 26 |
2 | 24 | 23 | 24 | 23 | 23 | 23 | 25 | |||
3 | 22 | 22 | 22 | 23 | 23 | 22 | 22 | |||
4 | 26 | 25 | 26 | 26 | 26 | 26 | 27 | |||
5 | 25 | 24 | 25 | 25 | 25 | 25 | 26 | |||
6 | 27 | 26 | 27 | 27 | 27 | 28 | 27 | |||
平均 | 24.8 | 24.2 | 24.5 | 24.0 | 24.7 | 24.8 | 25.5 | |||
SEM | 0.7 | 0.6 | 0.8 | 1.0 | 0.7 | 0.9 | 0.8 | |||
10 | OBI-888 | 3 mg/kg x 6 IV (每周一次) | 1 | 25 | 24 | 25 | 25 | 25 | 24 | 26 |
2 | 26 | 26 | 27 | 26 | 26 | 27 | 28 | |||
3 | 25 | 25 | 26 | 26 | 26 | 26 | 27 | |||
4 | 27 | 26 | 27 | 26 | 24 | 24 | 24 | |||
5 | 25 | 26 | 26 | 26 | 26 | 26 | 27 | |||
6 | 27 | 26 | 26 | 25 | 25 | 25 | 27 | |||
平均 | 25.8 | 25.5 | 26.2 | 25.7 | 25.3 | 25.3 | 26.5 | |||
SEM | 0.4 | 0.3 | 0.3 | 0.2 | 0.3 | 0.5 | 0.6 | |||
P<0.05 | ||||||||||
11 | MMAE | 0.057 mg/kg x 6 IV (每周一次) | 1 | 27 | 27 | 27 | 26 | 26 | 26 | 28 |
2 | 25 | 24 | 25 | 25 | 25 | 25 | 26 | |||
3 | 25 | 24 | 24 | 24 | 22 | 21 | 21 | |||
4 | 26 | 26 | 27 | 28 | 27 | 27 | 25 | |||
5 | 24 | 25 | 25 | 26 | 25 | 26 | 26 | |||
6 | 25 | 26 | 26 | 26 | 26 | 26 | 27 | |||
平均 | 25.3 | 25.3 | 25.7 | 25.8 | 25.2 | 25.2 | 25.5 | |||
SEM | 0.4 | 0.5 | 0.5 | 0.5 | 0.7 | 0.9 | 1.0 | |||
P<0.05 |
表5-1:異體移植MCF-7乳癌腫瘤及裸小鼠體重(第53天到第77天)
組別 | 治療方式 | 劑量 (mg/kg) (途徑) | 編號 | 體重 (g) | |||||||
第53天 | 第56天 | 第60天 | 第63天 | 第67天 | 第70天 | 第74天 | 第77天 | ||||
1 | 溶媒 (pH 6.5之25 mM 檸檬酸鈉+100 mM NaCl) | 10 mL/kg x 6 IV (每周一次) | 1 | 27 | 26 | 27 | 27 | 27 | 27 | 27 | 27 |
2 | 29 | 28 | 28 | 27 | 28 | 28 | 27 | 28 | |||
3 | 28 | 27 | 28 | 28 | 27 | 26 | 26 | 26 | |||
4 | 27 | 27 | 27 | 27 | 28 | 28 | 28 | 28 | |||
5 | 27 | 28 | 29 | 29 | 28 | 28 | 28 | 27 | |||
6 | 25 | 26 | 27 | 26 | 26 | 26 | 26 | 25 | |||
平均 | 27.2 | 27.0 | 27.7 | 27.3 | 27.3 | 27.2 | 27.0 | 26.8 | |||
SEM | 0.5 | 0.4 | 0.3 | 0.4 | 0.3 | 0.4 | 0.4 | 0.5 | |||
2 | 溶媒 (pH 6.5之25 mM 檸檬酸鈉+100 mM NaCl) | 10 mL/kg x 2 IV (每周一次) | 1 | 26 | 26 | 27 | 26 | 27 | 27 | 27 | 27 |
2 | 23 | 21 | 21 | 21 | 21 | 21 | 22 | 22 | |||
3 | 24 | 24 | 25 | 25 | 25 | 25 | 25 | 25 | |||
4 | 28 | 28 | 29 | 28 | 28 | 29 | 29 | 29 | |||
5 | 28 | 28 | 28 | 28 | 29 | 29 | 29 | 29 | |||
6 | 28 | 27 | 26 | 26 | 26 | 26 | 27 | 27 | |||
平均 | 26.2 | 25.7 | 26.0 | 25.7 | 26.0 | 26.2 | 26.5 | 26.5 | |||
SEM | 0.9 | 1.1 | 1.2 | 1.1 | 1.2 | 1.2 | 1.1 | 1.1 | |||
P<0.05 | |||||||||||
3 | 抗體藥物共軛物(OBI-999) | 10 mg/kg x 2 IV (每周一次) | 1 | 28 | 27 | 28 | 27 | 28 | 28 | 27 | 28 |
2 | 24 | 24 | 24 | 24 | 25 | 24 | 24 | 24 | |||
3 | 28 | 28 | 29 | 28 | 30 | 30 | 29 | 29 | |||
4 | 24 | 23 | 24 | 21 | 23 | 24 | 24 | 25 | |||
5 | 25 | 25 | 26 | 24 | 24 | 25 | 26 | 26 | |||
6 | 25 | 24 | 25 | 26 | 25 | 26 | 23 | 22 | |||
平均 | 25.7 | 25.2 | 26.0 | 25.0 | 25.8 | 26.2 | 25.5 | 25.7 | |||
SEM | 0.8 | 0.8 | 0.9 | 1.0 | 1.1 | 1.0 | 0.9 | 1.1 | |||
P<0.05 | |||||||||||
4 | 抗體藥物共軛物(OBI-999) | 0.3 mg/kg x 6 IV (每周一次) | 1 | 25 | 25 | 26 | 26 | 26 | 26 | 26 | 26 |
2 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | |||
3 | 26 | 26 | 26 | 25 | 23 | 24 | 21 | 22 | |||
4 | 28 | 28 | 28 | 27 | 28 | 28 | 28 | 28 | |||
5 | 23 | 24 | 26 | 25 | 26 | 27 | 28 | 27 | |||
6 | 27 | 27 | 29 | 28 | 29 | 27 | 27 | 28 | |||
平均 | 26.2 | 26.3 | 27.2 | 26.5 | 26.7 | 26.7 | 26.3 | 26.5 | |||
SEM | 0.8 | 0.7 | 0.5 | 0.6 | 0.9 | 0.6 | 1.1 | 1.0 | |||
P<0.05 | |||||||||||
5 | 抗體藥物共軛物(OBI-999) | 1 mg/kg x 6 IV (每周一次) | 1 | 24 | 24 | 24 | 22 | 23 | 23 | 23 | 23 |
2 | 28 | 27 | 29 | 27 | 29 | 29 | 25 | 25 | |||
3 | 25 | 24 | 25 | 25 | 27 | 26 | 25 | 25 | |||
4 | 28 | 27 | 28 | 28 | 28 | 28 | 29 | 28 | |||
5 | 26 | 26 | 27 | 26 | 26 | 27 | 27 | 26 | |||
6 | 26 | 26 | 27 | 27 | 27 | 27 | 29 | 28 | |||
平均 | 26.2 | 25.7 | 26.7 | 25.8 | 26.7 | 26.7 | 26.3 | 25.8 | |||
SEM | 0.7 | 0.6 | 0.8 | 0.9 | 0.8 | 0.8 | 1.0 | 0.8 | |||
P<0.05 | |||||||||||
6 | 抗體藥物共軛物(OBI-999) | 3 mg/kg x 6 IV (每周一次) | 1 | 28 | 27 | 28 | 28 | 29 | 29 | 30 | 29 |
2 | 24 | 22 | 22 | 21 | 22 | 21 | 22 | 22 | |||
3 | 25 | 25 | 26 | 26 | 26 | 26 | 26 | 26 | |||
4 | 26 | 27 | 28 | 28 | 28 | 28 | 28 | 27 | |||
5 | 24 | 24 | 25 | 24 | 24 | 25 | 24 | 24 | |||
6 | 24 | 23 | 24 | 23 | 23 | 23 | 23 | 23 | |||
平均 | 25.2 | 24.7 | 25.5 | 25.0 | 25.3 | 25.3 | 25.5 | 25.2 | |||
SEM | 0.7 | 0.8 | 1.0 | 1.2 | 1.1 | 1.2 | 1.3 | 1.1 | |||
P<0.05 | |||||||||||
7 | OBI-888 | 10 mg/kg x 2 IV (每周一次) | 1 | 25 | 25 | 27 | 26 | 26 | 26 | 26 | 26 |
2 | 28 | 28 | 29 | 29 | 28 | 死亡 | 死亡 | 死亡 | |||
3 | 24 | 24 | 26 | 21 | 23 | 24 | 24 | 24 | |||
4 | 25 | 27 | 28 | 27 | 27 | 27 | 26 | 25 | |||
5 | 27 | 22 | 23 | 27 | 28 | 31 | 35 | 26 | |||
6 | 23 | 22 | 21 | 24 | 24 | 24 | 22 | 20 | |||
平均 | 25.3 | 24.7 | 25.7 | 25.7 | 26.0 | 26.4 | 26.6 | 24.2 | |||
SEM | 0.8 | 1.0 | 1.3 | 1.1 | 0.9 | 1.3 | 2.2 | 1.1 | |||
P<0.05 | |||||||||||
8 | OBI-888 | 0.3 mg/kg x 6 IV (每周一次) | 1 | 26 | 26 | 26 | 26 | 27 | 27 | 28 | 27 |
2 | 24 | 23 | 24 | 25 | 26 | 26 | 27 | 26 | |||
3 | 26 | 24 | 25 | 25 | 25 | 25 | 26 | 26 | |||
4 | 24 | 24 | 25 | 25 | 25 | 26 | 26 | 25 | |||
5 | 24 | 25 | 27 | 25 | 24 | 25 | 25 | 25 | |||
6 | 26 | 25 | 26 | 26 | 26 | 26 | 26 | 26 | |||
平均 | 25.0 | 24.5 | 25.5 | 25.3 | 25.5 | 25.8 | 26.3 | 25.8 | |||
SEM | 0.4 | 0.4 | 0.4 | 0.2 | 0.4 | 0.3 | 0.4 | 0.3 | |||
P<0.05 | |||||||||||
9 | OBI-888 | 1 mg/kg x 6 IV (每周一次) | 1 | 26 | 26 | 26 | 26 | 25 | 26 | 26 | 24 |
2 | 24 | 25 | 25 | 24 | 26 | 26 | 24 | 25 | |||
3 | 22 | 27 | 28 | 20 | 21 | 21 | 22 | 21 | |||
4 | 27 | 25 | 26 | 26 | 27 | 27 | 24 | 24 | |||
5 | 25 | 26 | 26 | 26 | 26 | 26 | 26 | 26 | |||
6 | 26 | 19 | 19 | 26 | 26 | 27 | 27 | 27 | |||
平均 | 25.0 | 24.7 | 25.0 | 24.7 | 25.2 | 25.5 | 24.8 | 24.5 | |||
SEM | 0.7 | 1.2 | 1.3 | 1.0 | 0.9 | 0.9 | 0.7 | 0.8 | |||
P<0.05 | |||||||||||
10 | OBI-888 | 3 mg/kg x 6 IV (每周一次) | 1 | 26 | 24 | 26 | 26 | 27 | 27 | 26 | 27 |
2 | 26 | 27 | 27 | 24 | 23 | 21 | 23 | 24 | |||
3 | 26 | 23 | 23 | 25 | 22 | 25 | 25 | 25 | |||
4 | 24 | 26 | 28 | 23 | 24 | 22 | 23 | 25 | |||
5 | 27 | 26 | 27 | 27 | 27 | 27 | 27 | 28 | |||
6 | 26 | 25 | 27 | 26 | 26 | 27 | 27 | 28 | |||
平均 | 25.8 | 25.2 | 26.3 | 25.2 | 24.8 | 24.8 | 25.2 | 26.2 | |||
SEM | 0.4 | 0.6 | 0.7 | 0.6 | 0.9 | 1.1 | 0.7 | 0.7 | |||
P<0.05 | |||||||||||
11 | MMAE | 0.057 mg/kg x 6 IV (每周一次) | 1 | 28 | 26 | 28 | 29 | 27 | 25 | 24 | 23 |
2 | 26 | 26 | 27 | 26 | 26 | 26 | 27 | 27 | |||
3 | 22 | 23 | 24 | 24 | 25 | 25 | 25 | 24 | |||
4 | 24 | 25 | 26 | 27 | 28 | 28 | 28 | 27 | |||
5 | 26 | 24 | 27 | 27 | 27 | 27 | 27 | 28 | |||
6 | 26 | 27 | 27 | 26 | 28 | 28 | 29 | 29 | |||
平均 | 25.3 | 25.2 | 26.5 | 26.5 | 26.8 | 26.5 | 26.7 | 26.3 | |||
SEM | 0.8 | 0.6 | 0.6 | 0.7 | 0.5 | 0.6 | 0.8 | 1.0 | |||
P<0.05 |
第四圖顯示植入母裸小鼠(nu/nu)之MCF-7腫瘤生長曲線。每周使用靜脈注射施打抗體藥物共軛物(OBI-999)一次,劑量為10 mg/kg,為期兩周。相較於對應之溶媒對照組(第四圖A),植入腫瘤之實驗組自第19天至第77天呈現顯著抗腫瘤活性(T/C值≦42%)。此外,每周施打一次抗體藥物共軛物(OBI-999)、為期六周之實驗組呈現劑量依賴效應。實驗過程中,每周靜脈施打抗體藥物共軛物(OBI-999)0.3 mg/kg一次、為期六周之組別,並未呈現明顯抗腫瘤活性。然而,每周靜脈施打抗體藥物共軛物(OBI-999)1 mg/kg及3 mg/kg一次、為期六周之組別,相較於對應之溶媒對照組(第四圖B),則分別自第26天至第77天及自第19天至第77天呈現顯著(T/C 值≦42%)抗腫瘤活性。
每周靜脈施打OBI-888一次、為期六周、劑量10 mg/kg之組別,在實驗給藥期間及給藥後一小段時間內,相較於對應之溶媒對照組(第四圖A)呈現微弱至中等抗腫瘤活性。此外,每周施打一次OBI-888、為期六周之實驗組呈現劑量依賴效應。實驗過程中,每周靜脈施打OBI-888一次、為期六周、劑量0.3 mg/kg之組別呈現微弱抗腫瘤活性。實驗過程中,每周靜脈施打OBI-888一次、為期六周、劑量1 mg/kg之組別呈現中等抗腫瘤活性。每周靜脈施打OBI-888一次、為期六周、劑量3 mg/kg之組別於第67天及第70天呈現顯著(T/C 值≦42%)抗腫瘤活性,不過第26天時,抗腫瘤活性相較於對應之溶媒對照組(第四圖B)即已接近顯著程度(T/C 值≦42%)。
每周靜脈施打MMAE一次、為期六周、劑量0.057 mg/kg之組別,在實驗給藥期間及給藥後一小段時間內,相較於對應之溶媒對照組(第四圖B)呈現微弱至中等抗腫瘤活性。
第五圖顯示被植入MCF-7腫瘤之母裸小鼠(nu/nu)體重變化。所有試驗物質在所有劑量下皆可被受試動物容忍,且實驗過程中,施打試驗物質之組別皆未呈現顯著體重變化。實驗前後並未觀察到任何明顯毒性反應。相較於溶媒對照組,施打抗體藥物共軛物(OBI-999)、OBI-888及MMAE之組別顯然安全無虞。
實施例
4
:測量裸小鼠體內範例抗體之抗腫瘤活性(胃癌)
在一人類胃癌腫瘤異體移植模型中,NCI-N87(ATCC CRL-5822)活體細胞經皮下途徑(對每隻小鼠施打0.2 mL之matrigel(1:1),內含 2.5 × 10
6個細胞)接種至母裸小鼠(nu/nu)身體右側。將經植入腫瘤之小鼠分為七組實驗組,每組包含五隻小鼠,細胞移植後隔天即開始施打測試試劑(標記為第1天)。
4.1 試驗物質及給藥模式
使用含25 mM檸檬酸鈉、100 mM NaCl緩衝液(pH 6.5)之稀釋原液製備抗體藥物共軛物(OBI-999)、OBI-888及MMAE等試驗物質,並透過靜脈(IV)每周對小鼠施打一次,為期四周。每周經腹腔內(IP)對小鼠注射標準製劑、MMAE抗體及對應溶媒(PBS pH 7.4)一次,為期四周,劑量為0.191 mg/kg。某一實驗組接受試驗物質之組合療法,其中包括劑量10 mg/kg之OBI-888及劑量0.191 mg/kg之MMAE。
表6:裸小鼠體內範例抗體之抗腫瘤活性之研究設計(胃癌)
組別 | 試驗物質 | 途徑 | 劑量 | 小鼠 c,d (nu/nu) | |
mL/kg | mg/kg | (母) | |||
1 | 溶媒 a+溶媒 b | IP + IV | 10 | N/A | 8 |
2 | 抗體藥物共軛物 (OBI-999) b | IV | 10 | 1 | 8 |
3 | 抗體藥物共軛物 (OBI-999) b | IV | 10 | 3 | 8 |
4 | 抗體藥物共軛物 (OBI-999) b | IV | 10 | 10 | 8 |
5 | OBI-888 b | IV | 10 | 10 | 8 |
6 | 抗-CD30 抗體藥物共軛物 b(OBI-910) | IV | 10 | 3 | 5 |
7 | MMAE a+ OBI-888 b | IP + IV | 10 | 0.191 + 10 | 8 |
8 | MMAE a | IP | 10 | 0.191 | 8 |
apH 7.4之PBS(高濃度MMAE儲存於100% 二甲基亞碸中,接著被稀釋為pH 7.4之PBS) bpH 6.5之25mM 檸檬酸鈉+100 mM NaCl c每周施打溶媒及試驗物質一次,為期四周,且於細胞移植後隔天即開始施打(標記為第1天) d將200 µL含2.5 × 10 6個細胞、與matrigel混合(1:1)之NCI-N87經皮下途徑接種至母裸小鼠(nu/nu)身體右側 每周觀測並紀錄腫瘤尺寸及小鼠體重兩次,至第70天或溶媒對照組之平均腫瘤尺寸達2000 mm 3為止。小鼠犧牲時須攝影。 |
4.2 細胞株
人類胃癌活體腫瘤細胞株NCI-N87(ATCC CRL-5822)購自Eurofins Panlabs Taiwan, Ltd.,並同樣於Eurofins Panlabs Taiwan, Ltd.培養。於37 °C下,使用含有10%胎牛血清且置於5%二氧化碳培養箱中之RPMI-1640培養液培養腫瘤細胞,並將腫瘤細胞以皮下注射方式植入每隻小鼠右側身體。
4.3 受試動物
實驗使用自台灣BioLasco公司(經Charles River Laboratories授權)購得之五至六周齡母裸小鼠(nu/nu)。受試動物皆飼養於個獨立通風籠中(IVC,36 Mini Isolator System)。分配給每3隻受試動物之空間大小為27 × 20 × 14 cm
3。所有受試動物皆於恆溫(20-24℃)、恆濕(30-70%)、亮暗各12小時之乾淨衛生環境中。小鼠可自由食用標準實驗飼料 [MFG(Oriental Yeast Co., Ltd.,日本)]並飲用罐裝高壓滅菌自來水。動物實驗之飼養、實驗與死後處置等流程,皆依據
Guide for the Care and Use of Laboratory Animals: Eighth Edition(National Academies Press, Washington, D.C., 2011)之規範,於實驗團隊經AAALAC認證之實驗動物設施中執行。此外,進行實驗之動物照護及使用申請表已由Eurofins Panlabs Taiwan, Ltd. 之實驗動物照護及使用委員會審核並核准。
4.4 實驗化學物質
本實驗使用NaCl(Sin-Tong,台灣)、胎牛血清(Hyclone,美國)、Matrigel(BD,美國)及RPMI-1640(Hyclone,美國)。
4.5 實驗器材
實驗器材包括動物籠(Tecniplast,義大利)、1000 mL燒杯(Kimax,美國)、游標尺(Mitutoyo,日本)、第二類生物安全操作櫃(NuAire,美國)、獨立通風籠(IVC,36 Mini Isolator system)(Tecniplast,義大利)、小鼠磅秤 #Z-40(Taconic,美國)、不鏽鋼鉗(Klappenecker,德國)及垂直無菌操作台(Tsao-Hsin,台灣)。
4.6 實驗方法
每周觀察兩次並紀錄小鼠腫瘤體積、體重、死亡率及明顯毒性作用徵兆,為期100天。腫瘤生長抑制程度以T/C(治療/控制)× 100%計。相較於溶媒對照組,T/C值≦42%即代表顯著抗腫瘤活性。使用雙因子變異數分析再進行Bonferroni 事後檢定,以判斷各實驗組相較於各溶媒對照組之統計顯著性(*
p< 0.05)。
4.7 實驗結果
表7-1:異體移植NCI-N87胃癌腫瘤及母裸小鼠(nu/nu)體內腫瘤體積(第1天到第25天)
組別 | 治療方式 | 劑量 (mg/kg) (途徑) | 編號 | 腫瘤體積 (mm 3) | |||||||
第1天 | 第4天 | 第8天 | 第11天 | 第15天 | 第18天 | 第22天 | 第25天 | ||||
1 | 溶媒 (PBS, pH 7.4) + 溶媒 (pH 6.5之25 mM 檸檬酸鈉+100 mM NaCl) | 10 mL/kg x 4 (每周一次) IP+ IV | 1 | 93 | 100 | 137 | 258 | 372 | 453 | 635 | 613 |
2 | 118 | 117 | 131 | 166 | 175 | 216 | 219 | 225 | |||
3 | 108 | 141 | 177 | 333 | 392 | 432 | 600 | 704 | |||
4 | 99 | 123 | 146 | 332 | 332 | 375 | 442 | 498 | |||
5 | 103 | 157 | 162 | 289 | 292 | 335 | 455 | 493 | |||
6 | 96 | 124 | 146 | 303 | 325 | 514 | 560 | 664 | |||
7 | 86 | 106 | 144 | 268 | 271 | 321 | 329 | 489 | |||
8 | 98 | 123 | 133 | 296 | 344 | 406 | 510 | 510 | |||
平均 | 100 | 124 | 147 | 281 | 313 | 382 | 469 | 525 | |||
SEM | 3 | 6 | 5 | 19 | 24 | 32 | 50 | 52 | |||
2 | 抗體藥物共軛物 (OBI-999) | 1 mg/kg x 4 IV (每周一次) | 1 | 85 | 98 | 110 | 152 | 92 | 104 | 108 | 115 |
2 | 88 | 112 | 99 | 131 | 117 | 141 | 139 | 159 | |||
3 | 93 | 113 | 97 | 144 | 129 | 143 | 169 | 208 | |||
4 | 94 | 119 | 88 | 176 | 119 | 103 | 77 | 121 | |||
5 | 103 | 117 | 103 | 104 | 113 | 113 | 85 | 80 | |||
6 | 88 | 97 | 83 | 144 | 131 | 131 | 139 | 145 | |||
7 | 103 | 104 | 96 | 135 | 121 | 131 | 143 | 150 | |||
8 | 101 | 123 | 94 | 97 | 88 | 78 | 91 | 133 | |||
平均 | 94 | 110 | 96 | 135 | 114 | 118* | 119* | 139* | |||
SEM | 3 | 3 | 3 | 9 | 6 | 8 | 12 | 13 | |||
% T/C | - | 89 | 65 | 48 | 36 # | 31 # | 25 # | 26 # | |||
% TGI | - | 11 | 35 | 52 | 64 | 69 | 75 | 74 | |||
3 | 抗體藥物共軛物 (OBI-999) | 3 mg/kg x 4 IV (每周一次) | 1 | 80 | 102 | 121 | 91 | 60 | 60 | 68 | 73 |
2 | 96 | 131 | 89 | 91 | 79 | 79 | 79 | 65 | |||
3 | 97 | 125 | 89 | 96 | 99 | 79 | 69 | 66 | |||
4 | 97 | 93 | 71 | 93 | 94 | 86 | 77 | 76 | |||
5 | 90 | 131 | 80 | 89 | 84 | 77 | 53 | 57 | |||
6 | 127 | 160 | 77 | 81 | 91 | 70 | 43 | 68 | |||
7 | 94 | 127 | 101 | 87 | 108 | 85 | 79 | 77 | |||
8 | 77 | 88 | 60 | 72 | 93 | 99 | 69 | 70 | |||
平均 | 95 | 120 | 86 | 88 | 89 | 79* | 67* | 69* | |||
SEM | 5 | 8 | 7 | 3 | 5 | 4 | 5 | 2 | |||
% T/C | - | 97 | 59 | 31 # | 28 # | 21 # | 14 # | 13 # | |||
% TGI | - | 3 | 41 | 69 | 72 | 79 | 86 | 87 | |||
4 | 抗體藥物共軛物 (OBI-999) | 10 mg/kg x 4 IV (每周一次) | 1 | 93 | 89 | 82 | 66 | 61 | 86 | 54 | 68 |
2 | 110 | 115 | 97 | 85 | 72 | 71 | 51 | 73 | |||
3 | 88 | 125 | 85 | 86 | 93 | 51 | 41 | 58 | |||
4 | 94 | 104 | 101 | 86 | 93 | 89 | 73 | 85 | |||
5 | 96 | 86 | 73 | 81 | 74 | 40 | 41 | 69 | |||
6 | 87 | 127 | 96 | 104 | 101 | 86 | 53 | 57 | |||
7 | 82 | 108 | 110 | 82 | 86 | 73 | 70 | 70 | |||
8 | 96 | 115 | 88 | 85 | 77 | 68 | 66 | 62 | |||
平均 | 93 | 109 | 92 | 84 | 82 | 71* | 56* | 68* | |||
SEM | 3 | 5 | 4 | 4 | 5 | 6 | 4 | 3 | |||
% T/C | - | 88 | 63 | 30 # | 26 # | 19 # | 12 # | 13 # | |||
% TGI | - | 12 | 37 | 70 | 74 | 81 | 88 | 87 | |||
5 | OBI-888 | 10 mg/kg x 4 IV (每周一次) | 1 | 94 | 106 | 117 | 179 | 214 | 248 | 356 | 358 |
2 | 101 | 133 | 157 | 272 | 318 | 321 | 409 | 394 | |||
3 | 94 | 104 | 114 | 199 | 238 | 295 | 307 | 396 | |||
4 | 78 | 135 | 125 | 150 | 281 | 426 | 455 | 460 | |||
5 | 123 | 150 | 144 | 236 | 252 | 458 | 522 | 551 | |||
6 | 91 | 111 | 115 | 195 | 256 | 279 | 401 | 401 | |||
7 | 94 | 111 | 106 | 211 | 233 | 348 | 359 | 432 | |||
8 | 86 | 113 | 89 | 144 | 216 | 288 | 385 | 467 | |||
平均 | 95 | 120 | 121 | 198 | 251 | 333 | 399 | 432 | |||
SEM | 5 | 6 | 8 | 15 | 12 | 26 | 23 | 21 | |||
% T/C | - | 97 | 82 | 70 | 80 | 87 | 85 | 82 | |||
% TGI | - | 3 | 18 | 30 | 20 | 13 | 15 | 18 | |||
6 | 抗-CD30 抗體藥物共軛物 (OBI-910) | 3 mg/kg x 4 IV (每周一次) | 1 | 108 | 110 | 112 | 101 | 91 | 91 | 97 | 104 |
2 | 97 | 81 | 94 | 121 | 117 | 121 | 129 | 130 | |||
3 | 78 | 94 | 111 | 125 | 106 | 110 | 129 | 166 | |||
4 | 117 | 89 | 94 | 108 | 127 | 128 | 155 | 133 | |||
5 | 111 | 121 | 111 | 127 | 129 | 146 | 172 | 174 | |||
平均 | 102 | 99 | 104 | 116 | 114 | 119* | 136* | 141* | |||
SEM | 7 | 7 | 4 | 5 | 7 | 9 | 13 | 13 | |||
% T/C | - | 80 | 71 | 41 # | 36 # | 31 # | 29 # | 27 # | |||
% TGI | - | 20 | 29 | 59 | 67 | 69 | 71 | 73 | |||
7 | MMAE + OBI-888 | 0.191 mg/kg x 4 IP (每周一次) + 10 mg/kg x 4 IV (每周一次) | 1 | 99 | 104 | 146 | 164 | 214 | 214 | 222 | 243 |
2 | 111 | 121 | 112 | 146 | 161 | 211 | 243 | 269 | |||
3 | 121 | 88 | 103 | 103 | 159 | 145 | 119 | 130 | |||
4 | 112 | 99 | 119 | 119 | 163 | 233 | 320 | 415 | |||
5 | 83 | 125 | 112 | 146 | 164 | 186 | 237 | 236 | |||
6 | 87 | 74 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | |||
7 | 81 | 99 | 111 | 132 | 181 | 214 | 239 | 269 | |||
8 | 78 | 104 | 108 | 113 | 192 | 179 | 181 | 217 | |||
平均 | 97 | 102 | 116 | 132 | 176 | 197 | 223 | 254* | |||
SEM | 6 | 6 | 5 | 8 | 8 | 11 | 23 | 32 | |||
% T/C | - | 82 | 79 | 47 | 56 | 52 | 48 | 48 | |||
% TGI | - | 18 | 21 | 53 | 44 | 48 | 52 | 52 | |||
8 | MMAE | 0.191 mg/kg x 4 IP (每周一次) | 1 | 61 | 106 | 117 | 162 | 153 | 152 | 144 | 146 |
2 | 89 | 102 | 142 | 158 | 189 | 213 | 201 | 216 | |||
3 | 83 | 115 | 127 | 137 | 178 | 234 | 246 | 259 | |||
4 | 88 | 115 | 115 | 169 | 231 | 255 | 303 | 356 | |||
5 | 125 | 115 | 110 | 174 | 175 | 231 | 252 | 315 | |||
6 | 88 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | |||
7 | 110 | 104 | 125 | 187 | 208 | 228 | 322 | 353 | |||
8 | 121 | 109 | 119 | 166 | 189 | 211 | 296 | 296 | |||
平均 | 96 | 109 | 122 | 165 | 189 | 218 | 252 | 277 | |||
SEM | 8 | 2 | 4 | 6 | 9 | 12 | 24 | 29 | |||
% T/C | - | 88 | 83 | 59 | 60 | 57 | 54 | 53 | |||
% TGI | - | 12 | 17 | 41 | 40 | 43 | 46 | 47 |
表7-2:異體移植NCI-N87胃癌腫瘤及母裸小鼠(nu/nu)體內腫瘤體積(第29天到第53天)
組別 | 治療方式 | 劑量 (mg/kg) (途徑) | 編號 | 腫瘤體積 (mm 3) | |||||||
第29天 | 第32天 | 第36天 | 第39天 | 第43天 | 第46天 | 第50天 | 第53天 | ||||
1 | 溶媒 (PBS, pH 7.4) + 溶媒 (pH 6.5之25 mM 檸檬酸鈉+100 mM NaCl) | 10 mL/kg x 4 (每周一次) IP+ IV | 1 | 645 | 706 | 853 | 926 | 1062 | 1069 | 1116 | 1127 |
2 | 299 | 299 | 416 | 432 | 451 | 455 | 484 | 513 | |||
3 | 779 | 1079 | 1355 | 1479 | 1592 | 1862 | 2039 | 2546 | |||
4 | 623 | 628 | 719 | 756 | 792 | 792 | 798 | 811 | |||
5 | 702 | 864 | 895 | 1201 | 1309 | 1553 | 1800 | 2004 | |||
6 | 862 | 956 | 1034 | 1135 | 1236 | 1420 | 1849 | 2009 | |||
7 | 489 | 489 | 503 | 508 | 564 | 630 | 653 | 719 | |||
8 | 665 | 707 | 746 | 828 | 863 | 900 | 968 | 1036 | |||
平均 | 633 | 716 | 815 | 908 | 984 | 1085 | 1213 | 1346 | |||
SEM | 62 | 89 | 105 | 125 | 137 | 172 | 212 | 262 | |||
2 | 抗體藥物共軛物 (OBI-999) | 1 mg/kg x 4 IV (每周一次) | 1 | 113 | 73 | 72 | 72 | 64 | 58 | 53 | 51 |
2 | 164 | 192 | 228 | 234 | 258 | 299 | 324 | 346 | |||
3 | 222 | 240 | 243 | 252 | 275 | 310 | 345 | 345 | |||
4 | 121 | 121 | 121 | 125 | 125 | 113 | 死亡 | 死亡 | |||
5 | 94 | 110 | 112 | 97 | 96 | 96 | 104 | 108 | |||
6 | 145 | 148 | 152 | 168 | 183 | 202 | 208 | 225 | |||
7 | 152 | 176 | 184 | 199 | 216 | 218 | 248 | 271 | |||
8 | 133 | 133 | 137 | 148 | 152 | 187 | 208 | 231 | |||
平均 | 143* | 149* | 156* | 162* | 171* | 185* | 213* | 225* | |||
SEM | 14 | 19 | 21 | 23 | 27 | 33 | 40 | 42 | |||
% T/C | 23 # | 21 # | 19 # | 18 # | 17 # | 17 # | 18 # | 17 # | |||
% TGI | 77 | 79 | 81 | 82 | 83 | 83 | 82 | 83 | |||
3 | 抗體藥物共軛物 (OBI-999) | 3 mg/kg x 4 IV (每周一次) | 1 | 56 | 72 | 72 | 66 | 64 | 63 | 60 | 58 |
2 | 68 | 68 | 73 | 76 | 72 | 64 | 61 | 59 | |||
3 | 59 | 40 | 41 | 43 | 38 | 34 | 33 | 32 | |||
4 | 54 | 48 | 44 | 36 | 38 | 38 | 38 | 38 | |||
5 | 88 | 32 | 0 | 0 | 0 | 0 | 0 | 0 | |||
6 | 64 | 64 | 62 | 56 | 55 | 54 | 52 | 50 | |||
7 | 104 | 89 | 85 | 82 | 76 | 72 | 69 | 36 | |||
8 | 70 | 69 | 66 | 65 | 62 | 60 | 60 | 57 | |||
平均 | 70* | 60* | 55* | 53* | 51* | 48* | 47* | 42* | |||
SEM | 6 | 7 | 9 | 9 | 9 | 8 | 8 | 8 | |||
% T/C | 11 # | 8 # | 7 # | 6 # | 5 # | 4 # | 4 # | 3 # | |||
% TGI | 89 | 92 | 93 | 94 | 95 | 96 | 96 | 97 | |||
4 | 抗體藥物共軛物 (OBI-999) | 10 mg/kg x 4 IV (每周一次) | 1 | 66 | 61 | 51 | 51 | 50 | 49 | 48 | 47 |
2 | 56 | 57 | 64 | 61 | 59 | 59 | 58 | 58 | |||
3 | 44 | 47 | 46 | 40 | 38 | 0 | 0 | 0 | |||
4 | 77 | 69 | 65 | 65 | 64 | 64 | 61 | 61 | |||
5 | 52 | 59 | 56 | 54 | 52 | 51 | 49 | 46 | |||
6 | 70 | 59 | 53 | 53 | 53 | 52 | 50 | 49 | |||
7 | 67 | 68 | 68 | 62 | 60 | 60 | 60 | 57 | |||
8 | 66 | 77 | 66 | 61 | 60 | 57 | 55 | 54 | |||
平均 | 62* | 62* | 59* | 56* | 55* | 49* | 48* | 47* | |||
SEM | 4 | 3 | 3 | 3 | 3 | 7 | 7 | 7 | |||
% T/C | 10 # | 9 # | 7 # | 6 # | 6 # | 5 # | 4 # | 3 # | |||
% TGI | 90 | 91 | 93 | 94 | 94 | 95 | 96 | 97 | |||
5 | OBI-888 | 10 mg/kg x 4 IV (每周一次) | 1 | 418 | 583 | 605 | 612 | 698 | 801 | 819 | 926 |
2 | 590 | 689 | 694 | 694 | 773 | 845 | 1016 | 1074 | |||
3 | 460 | 466 | 508 | 588 | 668 | 770 | 828 | 1030 | |||
4 | 714 | 830 | 859 | 1040 | 1103 | 1359 | 1614 | 1885 | |||
5 | 739 | 744 | 835 | 886 | 968 | 1230 | 1238 | 1342 | |||
6 | 565 | 565 | 652 | 723 | 840 | 979 | 1012 | 1074 | |||
7 | 530 | 728 | 780 | 780 | 900 | 1057 | 1072 | 1258 | |||
8 | 533 | 652 | 719 | 722 | 869 | 958 | 1065 | 1065 | |||
平均 | 569 | 657 | 707 | 756 | 852 | 1000 | 1083 | 1207 | |||
SEM | 40 | 41 | 42 | 52 | 51 | 74 | 90 | 107 | |||
% T/C | 90 | 92 | 87 | 83 | 87 | 92 | 89 | 90 | |||
% TGI | 10 | 8 | 13 | 17 | 13 | 8 | 11 | 10 | |||
6 | 抗-CD30 抗體藥物共軛物 (OBI-910) | 3 mg/kg x 4 IV (每周一次) | 1 | 181 | 187 | 192 | 179 | 171 | 164 | 148 | 141 |
2 | 208 | 231 | 189 | 191 | 210 | 256 | 292 | 320 | |||
3 | 225 | 243 | 243 | 246 | 252 | 296 | 327 | 355 | |||
4 | 197 | 207 | 217 | 217 | 217 | 259 | 262 | 262 | |||
5 | 282 | 272 | 377 | 381 | 411 | 546 | 546 | 579 | |||
平均 | 219* | 228* | 244* | 243* | 252* | 304* | 315* | 331* | |||
SEM | 17 | 15 | 35 | 36 | 42 | 64 | 65 | 72 | |||
% T/C | 35 # | 32 # | 30 # | 27 # | 26 # | 28 # | 26 # | 25 # | |||
% TGI | 65 | 68 | 70 | 73 | 74 | 72 | 74 | 75 | |||
7 | MMAE + OBI-888 | 0.191 mg/kg x 4 IP (每周一次) + 10 mg/kg x 4 IV (每周一次) | 1 | 293 | 292 | 356 | 394 | 407 | 509 | 562 | 578 |
2 | 286 | 272 | 279 | 293 | 352 | 356 | 385 | 407 | |||
3 | 143 | 189 | 199 | 159 | 156 | 164 | 166 | 192 | |||
4 | 465 | 465 | 469 | 484 | 484 | 515 | 538 | 614 | |||
5 | 283 | 325 | 387 | 405 | 417 | 458 | 476 | 521 | |||
6 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | |||
7 | 325 | 405 | 515 | 514 | 540 | 617 | 688 | 819 | |||
8 | 314 | 293 | 289 | 292 | 295 | 360 | 372 | 432 | |||
平均 | 301* | 320* | 356* | 363* | 379* | 426* | 455* | 509* | |||
SEM | 36 | 34 | 42 | 47 | 48 | 56 | 63 | 74 | |||
% T/C | 48 | 45 | 44 | 40 # | 39 # | 39 # | 38 # | 38 # | |||
% TGI | 52 | 55 | 56 | 60 | 61 | 61 | 62 | 62 | |||
8 | MMAE | 0.191 mg/kg x 4 IP (每周一次) | 1 | 162 | 160 | 94 | 94 | 97 | 91 | 89 | 88 |
2 | 277 | 318 | 345 | 385 | 414 | 606 | 623 | 682 | |||
3 | 399 | 397 | 390 | 407 | 429 | 535 | 569 | 590 | |||
4 | 406 | 385 | 389 | 442 | 489 | 495 | 550 | 581 | |||
5 | 439 | 446 | 506 | 530 | 581 | 719 | 766 | 816 | |||
6 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | |||
7 | 525 | 584 | 658 | 671 | 780 | 878 | 936 | 1094 | |||
8 | 387 | 432 | 459 | 487 | 549 | 561 | 590 | 620 | |||
平均 | 371* | 389* | 406* | 431* | 477* | 555* | 589* | 639* | |||
SEM | 44 | 49 | 65 | 67 | 78 | 92 | 98 | 114 | |||
% T/C | 59 | 54 | 50 | 47 | 48 | 51 | 49 | 47 | |||
% TGI | 41 | 46 | 50 | 53 | 52 | 49 | 51 | 53 |
表7-3:異體移植NCI-N87胃癌腫瘤及母裸小鼠(nu/nu)體內腫瘤體積(第57天到第85天)
組別 | 治療方式 | 劑量 (mg/kg) (途徑) | 編號 | 腫瘤體積 (mm 3) | ||||||||
第57天 | 第60天 | 第64天 | 第67天 | 第70天 | 第74天 | 第78天 | 第81天 | 第85天 | ||||
1 | 溶媒 (PBS, pH 7.4) + 溶媒 (pH 6.5之25 mM 檸檬酸鈉+100 mM NaCl) | 10 mL/kg x 4 (每周一次) IP+IV | 1 | NA | NA | NA | NA | NA | NA | NA | NA | NA |
2 | NA | NA | NA | NA | NA | NA | NA | NA | NA | |||
3 | NA | NA | NA | NA | NA | NA | NA | NA | NA | |||
4 | NA | NA | NA | NA | NA | NA | NA | NA | NA | |||
5 | NA | NA | NA | NA | NA | NA | NA | NA | NA | |||
6 | NA | NA | NA | NA | NA | NA | NA | NA | NA | |||
7 | NA | NA | NA | NA | NA | NA | NA | NA | NA | |||
8 | NA | NA | NA | NA | NA | NA | NA | NA | NA | |||
平均 | - | - | - | - | - | - | - | - | - | |||
SEM | - | - | - | - | - | - | - | - | - | |||
2 | 抗體藥物共軛物 (OBI-999) | 1 mg/kg x 4 IV (每周一次) | 1 | 48 | 48 | 47 | 44 | 36 | 35 | 35 | 37 | 37 |
2 | 386 | 417 | 426 | 471 | 496 | 519 | 528 | 553 | 567 | |||
3 | 373 | 424 | 456 | 536 | 556 | 578 | 630 | 690 | 760 | |||
4 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | |||
5 | 104 | 104 | 101 | 101 | 94 | 91 | 97 | 97 | 94 | |||
6 | 231 | 206 | 223 | 229 | 254 | 277 | 292 | 298 | 306 | |||
7 | 328 | 396 | 455 | 521 | 544 | 593 | 658 | 684 | 778 | |||
8 | 251 | 309 | 347 | 489 | 529 | 570 | 680 | 717 | 833 | |||
平均 | 246 | 272 | 294 | 342 | 358 | 380 | 417 | 439 | 482 | |||
SEM | 49 | 58 | 65 | 80 | 85 | 92 | 103 | 110 | 127 | |||
% T/C | - | - | - | - | - | - | - | - | - | |||
3 | 抗體藥物共軛物 (OBI-999) | 3 mg/kg x 4 IV (每周一次) | 1 | 55 | 55 | 53 | 53 | 54 | 55 | 57 | 60 | 62 |
2 | 56 | 56 | 56 | 59 | 61 | 64 | 65 | 68 | 70 | |||
3 | 30 | 29 | 29 | 27 | 27 | 26 | 25 | 25 | 24 | |||
4 | 39 | 40 | 41 | 41 | 45 | 51 | 54 | 59 | 64 | |||
5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
6 | 50 | 51 | 53 | 55 | 58 | 60 | 63 | 63 | 64 | |||
7 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | |||
8 | 55 | 55 | 57 | 60 | 60 | 57 | 55 | 53 | 52 | |||
平均 | 41 | 41 | 41 | 42 | 44 | 45 | 46 | 47 | 48 | |||
SEM | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 9 | 10 | |||
% T/C | - | - | - | - | - | - | - | - | - | |||
4 | 抗體藥物共軛物 (OBI-999) | 10 mg/kg x 4 IV (每周一次) | 1 | 46 | 46 | 49 | 51 | 54 | 54 | 52 | 52 | 52 |
2 | 55 | 58 | 55 | 55 | 53 | 51 | 48 | 48 | 51 | |||
3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
4 | 61 | 61 | 64 | 65 | 65 | 65 | 62 | 60 | 57 | |||
5 | 45 | 45 | 45 | 44 | 42 | 40 | 38 | 38 | 36 | |||
6 | 46 | 45 | 45 | 45 | 44 | 44 | 42 | 40 | 40 | |||
7 | 57 | 57 | 60 | 62 | 62 | 57 | 55 | 53 | 40 | |||
8 | 54 | 53 | 51 | 51 | 48 | 46 | 45 | 45 | 45 | |||
平均 | 46 | 46 | 46 | 47 | 46 | 45 | 43 | 42 | 40 | |||
SEM | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 6 | |||
% T/C | - | - | - | - | - | - | - | - | - | |||
5 | OBI-888 | 10 mg/kg x 4 IV (每周一次) | 1 | 1005 | 1145 | 1152 | 1220 | 1281 | NA | NA | NA | NA |
2 | 1135 | 1369 | 1406 | 1458 | 1458 | NA | NA | NA | NA | |||
3 | 1048 | 1090 | 1146 | 1331 | 1371 | NA | NA | NA | NA | |||
4 | 2137 | 2313 | 2334 | 2669 | 2692 | NA | NA | NA | NA | |||
5 | 1429 | 1475 | 1483 | 1491 | 1491 | NA | NA | NA | NA | |||
6 | 1324 | 1371 | 1433 | 1571 | 1694 | NA | NA | NA | NA | |||
7 | 1302 | 1378 | 1468 | 1617 | 1628 | NA | NA | NA | NA | |||
8 | 1310 | 1371 | 1415 | 1553 | 1580 | NA | NA | NA | NA | |||
平均 | 1336 | 1439 | 1480 | 1614 | 1649 | - | - | - | - | |||
SEM | 126 | 133 | 131 | 158 | 156 | - | - | - | - | |||
% T/C | - | - | - | - | - | - | - | - | - | |||
6 | 抗-CD30 抗體藥物共軛物 (OBI-910) | 3 mg/kg x 4 IV (每周一次) | 1 | 135 | 133 | 127 | 123 | 119 | 117 | 115 | 113 | 113 |
2 | 360 | 437 | 467 | 610 | 631 | 733 | 862 | 905 | 999 | |||
3 | 427 | 453 | 503 | 634 | 634 | 706 | 854 | 928 | 1006 | |||
4 | 269 | 352 | 368 | 415 | 411 | 485 | 515 | 539 | 559 | |||
5 | 584 | 605 | 611 | 633 | 645 | 689 | 689 | 729 | 749 | |||
平均 | 355 | 396 | 415 | 483 | 488 | 546 | 607 | 643 | 685 | |||
SEM | 75 | 77 | 82 | 99 | 102 | 116 | 138 | 150 | 166 | |||
% T/C | - | - | - | - | - | - | - | - | - | |||
7 | MMAE + OBI-888 | 0.191 mg/kg x 4 IP (每周一次) + 10 mg/kg x 4 IV (每周一次) | 1 | 640 | 701 | 721 | 814 | 841 | 930 | 969 | 1065 | 1175 |
2 | 461 | 490 | 510 | 540 | 551 | 584 | 623 | 623 | 623 | |||
3 | 199 | 206 | 200 | 228 | 234 | 240 | 248 | 255 | 276 | |||
4 | 663 | 663 | 677 | 723 | 728 | 743 | 757 | 767 | 772 | |||
5 | 567 | 681 | 708 | 796 | 808 | 951 | 958 | 965 | 1064 | |||
6 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | |||
7 | 845 | 897 | 897 | 965 | 1044 | 1051 | 1111 | 1171 | 1171 | |||
8 | 436 | 409 | 409 | 404 | 420 | 467 | 477 | 477 | 482 | |||
平均 | 544 | 578 | 589 | 639 | 661 | 709 | 735 | 760 | 795 | |||
SEM | 77 | 86 | 88 | 98 | 104 | 111 | 116 | 125 | 134 | |||
% T/C | - | - | - | - | - | - | - | - | - | |||
8 | MMAE | 0.191 mg/kg x 4 IP (每周一次) | 1 | 85 | 83 | 82 | 79 | 76 | 74 | 74 | 77 | 77 |
2 | 694 | 745 | 765 | 883 | 943 | 1012 | 1042 | 1064 | 1097 | |||
3 | 663 | 783 | 788 | 827 | 870 | 909 | 955 | 961 | 1033 | |||
4 | 627 | 664 | 702 | 726 | 726 | 856 | 890 | 903 | 933 | |||
5 | 870 | 854 | 920 | 1070 | 1090 | 1117 | 1197 | 1197 | 1331 | |||
6 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | |||
7 | 1141 | 1234 | 1272 | 1300 | 1358 | 1422 | 1431 | 1517 | 1558 | |||
8 | 650 | 676 | 703 | 840 | 859 | 916 | 928 | 935 | 988 | |||
平均 | 676 | 720 | 747 | 818 | 846 | 901 | 931 | 951 | 1002 | |||
SEM | 120 | 129 | 134 | 143 | 150 | 156 | 160 | 166 | 175 | |||
% T/C | - | - | - | - | - | - | - | - | - |
表7-4:異體移植NCI-N87胃癌腫瘤及母裸小鼠(nu/nu)體內腫瘤體積(第88天到第100天)
組別 | 治療方式 | 劑量 (mg/kg) (途徑) | 編號 | 腫瘤體積 (mm 3) | ||||
第88天 | 第91天 | 第95天 | 第98天 | 第100天 | ||||
1 | 溶媒 (PBS, pH 7.4) + 溶媒 (pH 6.5之25 mM 檸檬酸鈉+100 mM NaCl) | 10 mL/kg x 4 (每周一次) IP+IV | 1 | NA | NA | NA | NA | NA |
2 | NA | NA | NA | NA | NA | |||
3 | NA | NA | NA | NA | NA | |||
4 | NA | NA | NA | NA | NA | |||
5 | NA | NA | NA | NA | NA | |||
6 | NA | NA | NA | NA | NA | |||
7 | NA | NA | NA | NA | NA | |||
8 | NA | NA | NA | NA | NA | |||
平均 | - | - | - | - | - | |||
SEM | - | - | - | - | - | |||
2 | 抗體藥物共軛物 (OBI-999) | 1 mg/kg x 4 IV (每周一次) | 1 | 36 | 36 | 34 | 34 | 34 |
2 | 588 | 719 | 817 | 832 | 881 | |||
3 | 814 | 841 | 868 | 898 | 959 | |||
4 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | |||
5 | 91 | 91 | 94 | 94 | 96 | |||
6 | 306 | 298 | 295 | 292 | 289 | |||
7 | 802 | 817 | 866 | 942 | 996 | |||
8 | 834 | 924 | 1163 | 1284 | 1338 | |||
平均 | 496 | 532 | 591 | 625 | 656 | |||
SEM | 132 | 143 | 167 | 182 | 193 | |||
% T/C | - | - | - | - | - | |||
3 | 抗體藥物共軛物 (OBI-999) | 3 mg/kg x 4 IV (每周一次) | 1 | 65 | 65 | 68 | 70 | 73 |
2 | 70 | 70 | 68 | 65 | 62 | |||
3 | 23 | 22 | 21 | 21 | 0 | |||
4 | 66 | 72 | 76 | 85 | 117 | |||
5 | 0 | 0 | 0 | 0 | 0 | |||
6 | 65 | 65 | 65 | 57 | 55 | |||
7 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | |||
8 | 52 | 52 | 51 | 50 | 49 | |||
平均 | 49 | 49 | 50 | 50 | 51 | |||
SEM | 10 | 10 | 11 | 11 | 16 | |||
% T/C | - | - | - | - | - | |||
4 | 抗體藥物共軛物 (OBI-999) | 10 mg/kg x 4 IV (每周一次) | 1 | 52 | 50 | 49 | 48 | 47 |
2 | 53 | 55 | 55 | 53 | 51 | |||
3 | 0 | 0 | 0 | 0 | 0 | |||
4 | 55 | 55 | 55 | 54 | 53 | |||
5 | 36 | 36 | 36 | 35 | 28 | |||
6 | 40 | 40 | 37 | 34 | 0 | |||
7 | NA | NA | NA | NA | NA | |||
8 | 43 | 42 | 40 | 37 | 24 | |||
平均 | 40 | 40 | 39 | 37 | 29 | |||
SEM | 7 | 7 | 7 | 7 | 9 | |||
% T/C | - | - | - | - | - | |||
5 | OBI-888 | 10 mg/kg x 4 IV (每周一次) | 1 | NA | NA | NA | NA | NA |
2 | NA | NA | NA | NA | NA | |||
3 | NA | NA | NA | NA | NA | |||
4 | NA | NA | NA | NA | NA | |||
5 | NA | NA | NA | NA | NA | |||
6 | NA | NA | NA | NA | NA | |||
7 | NA | NA | NA | NA | NA | |||
8 | NA | NA | NA | NA | NA | |||
平均 | - | - | - | - | - | |||
SEM | - | - | - | - | - | |||
% T/C | - | - | - | - | - | |||
6 | 抗-CD30 抗體藥物共軛物 (OBI-910) | 3 mg/kg x 4 IV (每周一次) | 1 | 112 | 110 | 106 | 103 | 99 |
2 | 1038 | 1183 | 1347 | 1408 | 1455 | |||
3 | 1014 | 1081 | 1176 | 1236 | 1311 | |||
4 | 573 | 597 | 657 | 693 | 719 | |||
5 | 804 | 888 | 895 | 856 | 942 | |||
平均 | 708 | 772 | 836 | 859 | 905 | |||
SEM | 171 | 193 | 217 | 228 | 240 | |||
% T/C | - | - | - | - | - | |||
7 | MMAE + OBI-888 | 0.191 mg/kg x 4 IP (每周一次) + 10 mg/kg x 4 IV (每周一次) | 1 | 1253 | 1329 | 1466 | 1595 | 1732 |
2 | 628 | 628 | 640 | 646 | 628 | |||
3 | 290 | 293 | 296 | 296 | 296 | |||
4 | 788 | 820 | 815 | 810 | 753 | |||
5 | 1087 | 1122 | 1226 | 1284 | 1301 | |||
6 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | |||
7 | 1171 | 1208 | 1217 | 1225 | 1242 | |||
8 | 468 | 454 | 436 | 408 | 386 | |||
平均 | 812 | 836 | 871 | 895 | 905 | |||
SEM | 140 | 150 | 167 | 184 | 201 | |||
% T/C | - | - | - | - | - | |||
8 | MMAE | 0.191 mg/kg x 4 IP (每周一次) | 1 | 74 | 72 | 68 | 68 | 62 |
2 | 1104 | 1122 | 1192 | 1215 | 1254 | |||
3 | 1117 | 1130 | 1184 | 1265 | 1273 | |||
4 | 933 | 933 | 947 | 1061 | 1076 | |||
5 | 1346 | 1346 | 1354 | 1398 | 1444 | |||
6 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | |||
7 | 1626 | 1636 | 1646 | 1656 | 1590 | |||
8 | 1023 | 1023 | 1029 | 1043 | 1043 | |||
平均 | 1032 | 1037 | 1060 | 1101 | 1106 | |||
SEM | 182 | 183 | 186 | 189 | 189 | |||
% T/C | - | - | - | - | - |
表8-1:異體移植NCI-N87胃癌腫瘤及母裸小鼠(nu/nu)體重(第1天到第25天)
組別 | 治療方式 | 劑量 (mg/kg) (途徑) | 編號 | 體重 (g) | |||||||
第1天 | 第4天 | 第8天 | 第11天 | 第15天 | 第18天 | 第22天 | 第25天 | ||||
1 | 溶媒 (PBS, pH 7.4) + 溶媒 (pH 6.5之25 mM 檸檬酸鈉+100 mM NaCl) | 10 mL/kg x 4 (每周一次) IP+IV | 1 | 22 | 24 | 24 | 25 | 24 | 24 | 25 | 25 |
2 | 23 | 24 | 25 | 25 | 24 | 24 | 24 | 25 | |||
3 | 21 | 22 | 23 | 24 | 24 | 24 | 24 | 25 | |||
4 | 22 | 24 | 22 | 22 | 23 | 24 | 24 | 24 | |||
5 | 22 | 23 | 24 | 25 | 26 | 26 | 26 | 25 | |||
6 | 23 | 24 | 25 | 26 | 25 | 26 | 25 | 25 | |||
7 | 23 | 23 | 24 | 25 | 24 | 25 | 25 | 24 | |||
8 | 24 | 24 | 25 | 26 | 25 | 25 | 25 | 26 | |||
平均 | 22.5 | 23.5 | 24.0 | 24.8 | 24.4 | 24.8 | 24.8 | 24.9 | |||
SEM | 0.3 | 0.3 | 0.4 | 0.5 | 0.3 | 0.3 | 0.3 | 0.2 | |||
2 | 抗體藥物共軛物 (OBI-999) | 1 mg/kg x 4 IV (每周一次) | 1 | 22 | 23 | 23 | 24 | 24 | 24 | 24 | 24 |
2 | 22 | 24 | 25 | 25 | 24 | 24 | 24 | 24 | |||
3 | 21 | 22 | 23 | 24 | 23 | 23 | 23 | 23 | |||
4 | 22 | 23 | 24 | 24 | 23 | 23 | 22 | 24 | |||
5 | 23 | 23 | 26 | 26 | 27 | 27 | 27 | 27 | |||
6 | 20 | 22 | 23 | 23 | 24 | 24 | 24 | 24 | |||
7 | 22 | 22 | 24 | 25 | 24 | 23 | 24 | 24 | |||
8 | 23 | 23 | 24 | 24 | 24 | 24 | 24 | 24 | |||
平均 | 21.9 | 22.8 | 24.0 | 24.4 | 24.1 | 24.0 | 24.0 | 24.3 | |||
SEM | 0.4 | 0.3 | 0.4 | 0.3 | 0.4 | 0.5 | 0.5 | 0.4 | |||
3 | 抗體藥物共軛物 (OBI-999) | 3 mg/kg x 4 IV (每周一次) | 1 | 22 | 23 | 23 | 24 | 23 | 24 | 24 | 24 |
2 | 21 | 22 | 23 | 24 | 25 | 25 | 25 | 26 | |||
3 | 23 | 22 | 22 | 23 | 22 | 23 | 24 | 24 | |||
4 | 23 | 23 | 23 | 22 | 22 | 23 | 24 | 23 | |||
5 | 23 | 24 | 25 | 24 | 24 | 24 | 24 | 24 | |||
6 | 22 | 22 | 23 | 24 | 24 | 24 | 24 | 24 | |||
7 | 21 | 22 | 23 | 24 | 25 | 25 | 25 | 25 | |||
8 | 22 | 22 | 21 | 21 | 22 | 22 | 23 | 22 | |||
平均 | 22.1 | 22.5 | 22.9 | 23.3 | 23.4 | 23.8 | 24.1 | 24.0 | |||
SEM | 0.3 | 0.3 | 0.4 | 0.4 | 0.5 | 0.4 | 0.2 | 0.4 | |||
4 | 抗體藥物共軛物 (OBI-999) | 10 mg/kg x 4 IV (每周一次) | 1 | 22 | 22 | 22 | 22 | 23 | 24 | 23 | 24 |
2 | 21 | 21 | 23 | 23 | 24 | 23 | 24 | 24 | |||
3 | 22 | 23 | 23 | 22 | 22 | 23 | 23 | 24 | |||
4 | 21 | 21 | 22 | 22 | 23 | 23 | 23 | 23 | |||
5 | 23 | 24 | 24 | 24 | 23 | 23 | 24 | 24 | |||
6 | 22 | 23 | 24 | 24 | 24 | 24 | 24 | 24 | |||
7 | 21 | 22 | 22 | 23 | 22 | 23 | 23 | 22 | |||
8 | 23 | 23 | 25 | 26 | 26 | 25 | 26 | 26 | |||
平均 | 21.9 | 22.4 | 23.1 | 23.3 | 23.4 | 23.5 | 23.8 | 23.9 | |||
SEM | 0.3 | 0.4 | 0.4 | 0.5 | 0.5 | 0.3 | 0.4 | 0.4 | |||
5 | OBI-888 | 10 mg/kg x 4 IV (每周一次) | 1 | 21 | 21 | 22 | 23 | 24 | 24 | 23 | 24 |
2 | 22 | 23 | 24 | 24 | 25 | 25 | 25 | 26 | |||
3 | 19 | 19 | 19 | 20 | 21 | 22 | 22 | 23 | |||
4 | 22 | 22 | 22 | 23 | 23 | 23 | 23 | 24 | |||
5 | 21 | 22 | 23 | 23 | 22 | 22 | 23 | 23 | |||
6 | 21 | 21 | 22 | 23 | 23 | 23 | 24 | 24 | |||
7 | 20 | 22 | 22 | 22 | 21 | 21 | 22 | 22 | |||
8 | 21 | 21 | 22 | 22 | 21 | 21 | 22 | 22 | |||
平均 | 20.9 | 21.4 | 22.0 | 22.5 | 22.5 | 22.6 | 23.0 | 23.5 | |||
SEM | 0.4 | 0.4 | 0.5 | 0.4 | 0.5 | 0.5 | 0.4 | 0.5 | |||
6 | 抗-CD30 抗體藥物共軛物 (OBI-910) | 3 mg/kg x 4 IV (每周一次) | 1 | 21 | 22 | 23 | 23 | 23 | 24 | 24 | 22 |
2 | 20 | 21 | 22 | 22 | 22 | 23 | 23 | 22 | |||
3 | 21 | 22 | 22 | 23 | 22 | 23 | 24 | 24 | |||
4 | 22 | 22 | 22 | 23 | 24 | 24 | 25 | 25 | |||
5 | 22 | 23 | 23 | 23 | 24 | 25 | 25 | 26 | |||
平均 | 21.2 | 22.0 | 22.4 | 22.8 | 23.0 | 23.8 | 24.2 | 23.8 | |||
SEM | 0.4 | 0.3 | 0.2 | 0.2 | 0.4 | 0.4 | 0.4 | 0.8 | |||
7 | MMAE + OBI-888 | 0.191 mg/kg x 4 IP (每周一次) + 10 mg/kg x 4 IV (每周一次) | 1 | 20 | 18 | 22 | 21 | 23 | 24 | 24 | 23 |
2 | 21 | 20 | 22 | 22 | 21 | 22 | 23 | 23 | |||
3 | 21 | 20 | 22 | 22 | 22 | 22 | 22 | 22 | |||
4 | 21 | 20 | 22 | 23 | 23 | 22 | 23 | 22 | |||
5 | 23 | 21 | 24 | 24 | 25 | 24 | 25 | 26 | |||
6 | 23 | 21 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | |||
7 | 22 | 22 | 24 | 23 | 24 | 23 | 24 | 24 | |||
8 | 22 | 21 | 23 | 23 | 23 | 24 | 24 | 25 | |||
平均 | 21.6 | 20.4 | 22.7 | 22.6 | 23.0 | 23.0 | 23.6 | 23.6 | |||
SEM | 0.4 | 0.4 | 0.4 | 0.4 | 0.5 | 0.4 | 0.4 | 0.6 | |||
8 | MMAE | 0.191 mg/kg x 4 IP (每周一次) | 1 | 20 | 18 | 22 | 22 | 24 | 24 | 24 | 24 |
2 | 20 | 19 | 22 | 22 | 23 | 22 | 22 | 22 | |||
3 | 22 | 22 | 22 | 23 | 23 | 23 | 24 | 24 | |||
4 | 24 | 21 | 23 | 25 | 25 | 26 | 25 | 25 | |||
5 | 22 | 20 | 23 | 24 | 24 | 24 | 25 | 24 | |||
6 | 21 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | |||
7 | 24 | 24 | 24 | 23 | 23 | 24 | 25 | 25 | |||
8 | 22 | 19 | 19 | 19 | 22 | 22 | 24 | 24 | |||
平均 | 21.9 | 20.4 | 22.1 | 22.6 | 23.4 | 23.6 | 24.1 | 24.0 | |||
SEM | 0.5 | 0.8 | 0.6 | 0.7 | 0.4 | 0.5 | 0.4 | 0.4 |
表8-2:異體移植NCI-N87胃癌腫瘤及母裸小鼠(nu/nu)體重(第29天到第53天)
組別 | 治療方式 | 劑量 (mg/kg) (途徑) | 編號 | 體重 (g) | |||||||
第29天 | 第32天 | 第36天 | 第39天 | 第43天 | 第46天 | 第50天 | 第53天 | ||||
1 | 溶媒 (PBS, pH 7.4) + 溶媒 (pH 6.5之25 mM 檸檬酸鈉+100 mM NaCl) | 10 mL/kg x 4 (每周一次) IP+ IV | 1 | 27 | 26 | 26 | 27 | 26 | 27 | 27 | 29 |
2 | 26 | 26 | 26 | 27 | 26 | 27 | 28 | 29 | |||
3 | 26 | 27 | 27 | 27 | 27 | 27 | 28 | 28 | |||
4 | 25 | 25 | 26 | 26 | 26 | 26 | 27 | 28 | |||
5 | 27 | 27 | 28 | 28 | 28 | 29 | 29 | 29 | |||
6 | 25 | 25 | 26 | 26 | 26 | 27 | 25 | 27 | |||
7 | 25 | 26 | 26 | 27 | 26 | 26 | 26 | 27 | |||
8 | 27 | 27 | 27 | 27 | 27 | 27 | 27 | 28 | |||
平均 | 26.0 | 26.1 | 26.5 | 26.9 | 26.5 | 27.0 | 27.1 | 28.1 | |||
SEM | 0.3 | 0.3 | 0.3 | 0.2 | 0.3 | 0.3 | 0.4 | 0.3 | |||
2 | 抗體藥物共軛物 (OBI-999) | 1 mg/kg x 4 IV (每周一次) | 1 | 24 | 24 | 26 | 25 | 25 | 25 | 25 | 25 |
2 | 26 | 26 | 26 | 27 | 26 | 27 | 26 | 27 | |||
3 | 24 | 24 | 25 | 26 | 26 | 26 | 26 | 26 | |||
4 | 23 | 24 | 24 | 23 | 20 | 19 | 死亡 | 死亡 | |||
5 | 28 | 28 | 28 | 29 | 29 | 30 | 29 | 29 | |||
6 | 25 | 25 | 26 | 27 | 27 | 28 | 27 | 28 | |||
7 | 25 | 25 | 26 | 26 | 25 | 26 | 26 | 28 | |||
8 | 26 | 25 | 26 | 27 | 26 | 27 | 27 | 28 | |||
平均 | 25.1 | 25.1 | 25.9 | 26.3 | 25.5 | 26.0 | 26.6 | 27.3 | |||
SEM | 0.5 | 0.5 | 0.4 | 0.6 | 0.9 | 1.1 | 0.5 | 0.5 | |||
3 | 抗體藥物共軛物 (OBI-999) | 3 mg/kg x 4 IV (每周一次) | 1 | 25 | 25 | 26 | 26 | 26 | 27 | 27 | 28 |
2 | 27 | 27 | 29 | 29 | 25 | 24 | 26 | 27 | |||
3 | 24 | 24 | 25 | 26 | 26 | 27 | 26 | 27 | |||
4 | 24 | 24 | 24 | 25 | 25 | 25 | 25 | 26 | |||
5 | 26 | 25 | 26 | 27 | 27 | 27 | 27 | 27 | |||
6 | 25 | 25 | 26 | 26 | 26 | 26 | 26 | 27 | |||
7 | 26 | 26 | 25 | 24 | 23 | 21 | 18 | 17 | |||
8 | 23 | 23 | 24 | 25 | 23 | 24 | 24 | 25 | |||
平均 | 25.0 | 24.9 | 25.6 | 26.0 | 25.1 | 25.1 | 24.9 | 25.5 | |||
SEM | 0.5 | 0.4 | 0.6 | 0.5 | 0.5 | 0.7 | 1.0 | 1.3 | |||
4 | 抗體藥物共軛物 (OBI-999) | 10 mg/kg x 4 IV (每周一次) | 1 | 24 | 25 | 26 | 26 | 26 | 26 | 27 | 28 |
2 | 25 | 25 | 25 | 25 | 26 | 25 | 26 | 26 | |||
3 | 24 | 25 | 25 | 26 | 26 | 26 | 26 | 26 | |||
4 | 24 | 25 | 25 | 26 | 25 | 26 | 26 | 26 | |||
5 | 25 | 24 | 25 | 26 | 26 | 26 | 26 | 26 | |||
6 | 26 | 26 | 27 | 28 | 27 | 27 | 27 | 27 | |||
7 | 23 | 24 | 25 | 25 | 24 | 26 | 25 | 25 | |||
8 | 28 | 28 | 27 | 28 | 27 | 28 | 28 | 29 | |||
平均 | 24.9 | 25.3 | 25.6 | 26.3 | 25.9 | 26.3 | 26.4 | 26.6 | |||
SEM | 0.5 | 0.5 | 0.3 | 0.4 | 0.4 | 0.3 | 0.3 | 0.5 | |||
5 | OBI-888 | 10 mg/kg x 4 IV (每周一次) | 1 | 24 | 25 | 25 | 26 | 26 | 27 | 26 | 27 |
2 | 27 | 25 | 27 | 28 | 28 | 29 | 29 | 30 | |||
3 | 23 | 23 | 24 | 26 | 25 | 26 | 25 | 27 | |||
4 | 25 | 25 | 26 | 27 | 27 | 27 | 27 | 28 | |||
5 | 24 | 24 | 24 | 24 | 24 | 25 | 25 | 26 | |||
6 | 25 | 25 | 26 | 26 | 27 | 26 | 26 | 27 | |||
7 | 23 | 23 | 23 | 24 | 24 | 25 | 25 | 26 | |||
8 | 22 | 23 | 24 | 24 | 25 | 25 | 25 | 26 | |||
平均 | 24.1 | 24.1 | 24.9 | 25.6 | 25.8 | 26.3 | 26.0 | 27.1 | |||
SEM | 0.5 | 0.4 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | |||
6 | 抗-CD30 抗體藥物共軛物 (OBI-910) | 3 mg/kg x 4 IV (每周一次) | 1 | 23 | 24 | 25 | 27 | 26 | 26 | 25 | 26 |
2 | 22 | 23 | 24 | 25 | 25 | 26 | 26 | 27 | |||
3 | 25 | 25 | 25 | 26 | 26 | 27 | 27 | 28 | |||
4 | 26 | 26 | 26 | 26 | 26 | 27 | 27 | 28 | |||
5 | 26 | 26 | 27 | 28 | 27 | 27 | 26 | 25 | |||
平均 | 24.4 | 24.8 | 25.4 | 26.4 | 26.0 | 26.6 | 26.2 | 26.8 | |||
SEM | 0.8 | 0.6 | 0.5 | 0.5 | 0.3 | 0.2 | 0.4 | 0.6 | |||
7 | MMAE + OBI-888 | 0.191 mg/kg x 4 IP (每周一次) + 10 mg/kg x 4 IV (每周一次) | 1 | 24 | 24 | 24 | 26 | 26 | 26 | 26 | 27 |
2 | 23 | 23 | 24 | 24 | 24 | 24 | 24 | 25 | |||
3 | 23 | 23 | 23 | 24 | 22 | 23 | 23 | 25 | |||
4 | 24 | 24 | 25 | 25 | 24 | 25 | 24 | 25 | |||
5 | 28 | 27 | 27 | 29 | 28 | 29 | 29 | 30 | |||
6 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | |||
7 | 25 | 25 | 26 | 26 | 25 | 26 | 25 | 26 | |||
8 | 25 | 24 | 25 | 26 | 25 | 26 | 26 | 27 | |||
平均 | 24.6 | 24.3 | 24.9 | 25.7 | 24.9 | 25.6 | 25.3 | 26.4 | |||
SEM | 0.6 | 0.5 | 0.5 | 0.6 | 0.7 | 0.7 | 0.7 | 0.7 | |||
8 | MMAE | 0.191 mg/kg x 4 IP (每周一次) | 1 | 25 | 25 | 26 | 26 | 26 | 26 | 26 | 27 |
2 | 24 | 23 | 24 | 24 | 24 | 25 | 24 | 24 | |||
3 | 25 | 24 | 25 | 26 | 26 | 27 | 26 | 27 | |||
4 | 26 | 27 | 25 | 26 | 26 | 27 | 26 | 27 | |||
5 | 26 | 26 | 26 | 26 | 26 | 27 | 27 | 27 | |||
6 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | |||
7 | 25 | 26 | 25 | 26 | 26 | 26 | 26 | 26 | |||
8 | 26 | 25 | 25 | 26 | 26 | 26 | 27 | 28 | |||
平均 | 25.3 | 25.1 | 25.1 | 25.7 | 25.7 | 26.3 | 26.0 | 26.6 | |||
SEM | 0.3 | 0.5 | 0.3 | 0.3 | 0.3 | 0.3 | 0.4 | 0.5 |
表8-3:異體移植NCI-N87胃癌腫瘤及母裸小鼠(nu/nu)體重(第57天到第85天)
組別 | 治療方式 | 劑量 (mg/kg) (途徑) | 編號 | 體重 (g) | ||||||||
第57天 | 第60天 | 第64天 | 第67天 | 第70天 | 第74天 | 第78天 | 第81天 | 第85天 | ||||
1 | 溶媒 (PBS, pH 7.4) + 溶媒 (pH 6.5之25 mM 檸檬酸鈉+100 mM NaCl) | 10 mL/kg x 4 (每周一次) IP+IV | 1 | NA | NA | NA | NA | NA | NA | NA | NA | NA |
2 | NA | NA | NA | NA | NA | NA | NA | NA | NA | |||
3 | NA | NA | NA | NA | NA | NA | NA | NA | NA | |||
4 | NA | NA | NA | NA | NA | NA | NA | NA | NA | |||
5 | NA | NA | NA | NA | NA | NA | NA | NA | NA | |||
6 | NA | NA | NA | NA | NA | NA | NA | NA | NA | |||
7 | NA | NA | NA | NA | NA | NA | NA | NA | NA | |||
8 | NA | NA | NA | NA | NA | NA | NA | NA | NA | |||
平均 | - | - | - | - | - | - | - | - | - | |||
SEM | - | - | - | - | - | - | - | - | - | |||
2 | 抗體藥物共軛物 (OBI-999) | 1 mg/kg x 4 IV (每周一次) | 1 | 25 | 25 | 26 | 26 | 26 | 26 | 26 | 26 | 27 |
2 | 27 | 28 | 28 | 28 | 28 | 28 | 28 | 28 | 29 | |||
3 | 27 | 27 | 27 | 27 | 27 | 28 | 28 | 29 | 30 | |||
4 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | |||
5 | 29 | 28 | 28 | 30 | 28 | 29 | 28 | 28 | 29 | |||
6 | 28 | 28 | 28 | 28 | 28 | 30 | 29 | 29 | 30 | |||
7 | 27 | 26 | 25 | 26 | 25 | 27 | 29 | 28 | 27 | |||
8 | 28 | 28 | 28 | 29 | 28 | 28 | 29 | 29 | 30 | |||
平均 | 27.3 | 27.1 | 27.1 | 27.7 | 27.1 | 28.0 | 28.1 | 28.1 | 28.9 | |||
SEM | 0.5 | 0.5 | 0.5 | 0.6 | 0.5 | 0.5 | 0.4 | 0.4 | 0.5 | |||
3 | 抗體藥物共軛物 (OBI-999) | 3 mg/kg x 4 IV (每周一次) | 1 | 27 | 28 | 27 | 27 | 28 | 28 | 28 | 28 | 28 |
2 | 27 | 28 | 29 | 29 | 29 | 29 | 30 | 31 | 31 | |||
3 | 26 | 27 | 27 | 27 | 27 | 28 | 27 | 27 | 27 | |||
4 | 26 | 26 | 26 | 26 | 26 | 26 | 27 | 26 | 27 | |||
5 | 27 | 27 | 27 | 27 | 27 | 27 | 27 | 27 | 28 | |||
6 | 26 | 27 | 26 | 26 | 26 | 27 | 27 | 27 | 28 | |||
7 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | |||
8 | 25 | 26 | 25 | 26 | 25 | 26 | 26 | 26 | 26 | |||
平均 | 26.3 | 27.0 | 26.7 | 26.9 | 26.9 | 27.3 | 27.4 | 27.4 | 27.9 | |||
SEM | 0.3 | 0.3 | 0.5 | 0.4 | 0.5 | 0.4 | 0.5 | 0.6 | 0.6 | |||
4 | 抗體藥物共軛物 (OBI-999) | 10 mg/kg x 4 IV (每周一次) | 1 | 27 | 28 | 28 | 29 | 28 | 29 | 29 | 28 | 29 |
2 | 27 | 27 | 28 | 28 | 28 | 28 | 27 | 28 | 26 | |||
3 | 26 | 28 | 27 | 27 | 28 | 26 | 26 | 25 | 26 | |||
4 | 27 | 25 | 26 | 28 | 27 | 27 | 28 | 27 | 28 | |||
5 | 27 | 27 | 26 | 27 | 27 | 27 | 26 | 26 | 27 | |||
6 | 28 | 28 | 28 | 28 | 27 | 27 | 26 | 25 | 26 | |||
7 | 24 | 24 | 22 | 22 | 21 | 19 | 19 | 19 | 15 | |||
8 | 28 | 29 | 28 | 28 | 28 | 29 | 28 | 27 | 28 | |||
平均 | 26.8 | 27.0 | 26.6 | 27.1 | 26.8 | 26.5 | 26.1 | 25.6 | 25.6 | |||
SEM | 0.5 | 0.6 | 0.7 | 0.8 | 0.8 | 1.1 | 1.1 | 1.0 | 1.6 | |||
5 | OBI-888 | 10 mg/kg x 4 IV (每周一次) | 1 | 27 | 28 | 27 | 28 | 27 | NA | NA | NA | NA |
2 | 29 | 30 | 30 | 30 | 30 | NA | NA | NA | NA | |||
3 | 26 | 26 | 26 | 27 | 28 | NA | NA | NA | NA | |||
4 | 27 | 28 | 27 | 28 | 28 | NA | NA | NA | NA | |||
5 | 25 | 26 | 26 | 26 | 26 | NA | NA | NA | NA | |||
6 | 26 | 26 | 27 | 27 | 27 | NA | NA | NA | NA | |||
7 | 26 | 26 | 26 | 27 | 26 | NA | NA | NA | NA | |||
8 | 26 | 26 | 26 | 26 | 26 | NA | NA | NA | NA | |||
平均 | 26.5 | 27.0 | 26.9 | 27.4 | 27.3 | - | - | - | - | |||
SEM | 0.4 | 0.5 | 0.5 | 0.5 | 0.5 | - | - | - | - | |||
6 | 抗-CD30 抗體藥物共軛物 (OBI-910) | 3 mg/kg x 4 IV (每周一次) | 1 | 25 | 27 | 27 | 27 | 27 | 27 | 27 | 27 | 27 |
2 | 26 | 28 | 27 | 28 | 28 | 28 | 29 | 29 | 29 | |||
3 | 26 | 27 | 27 | 28 | 27 | 27 | 27 | 27 | 27 | |||
4 | 27 | 28 | 29 | 29 | 30 | 29 | 30 | 29 | 31 | |||
5 | 24 | 25 | 25 | 25 | 25 | 24 | 26 | 26 | 26 | |||
平均 | 25.6 | 27.0 | 27.0 | 27.4 | 27.4 | 27.0 | 27.8 | 27.6 | 28.0 | |||
SEM | 0.5 | 0.5 | 0.6 | 0.7 | 0.8 | 0.8 | 0.7 | 0.6 | 0.9 | |||
7 | MMAE + OBI-888 | 0.191 mg/kg x 4 IP (每周一次) + 10 mg/kg x 4 IV (每周一次) | 1 | 27 | 27 | 27 | 28 | 28 | 28 | 28 | 28 | 29 |
2 | 25 | 25 | 25 | 26 | 25 | 24 | 24 | 24 | 25 | |||
3 | 24 | 25 | 26 | 26 | 25 | 25 | 25 | 24 | 24 | |||
4 | 24 | 25 | 24 | 25 | 23 | 24 | 24 | 24 | 25 | |||
5 | 30 | 30 | 30 | 31 | 30 | 31 | 32 | 31 | 32 | |||
6 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | |||
7 | 26 | 26 | 26 | 26 | 26 | 26 | 26 | 26 | 26 | |||
8 | 26 | 27 | 27 | 27 | 26 | 27 | 27 | 27 | 26 | |||
平均 | 26.0 | 26.4 | 26.4 | 27.0 | 26.1 | 26.4 | 26.6 | 26.3 | 26.7 | |||
SEM | 0.8 | 0.7 | 0.7 | 0.8 | 0.9 | 0.9 | 1.1 | 1.0 | 1.1 | |||
8 | MMAE | 0.191 mg/kg x 4 IP (每周一次) | 1 | 27 | 27 | 27 | 27 | 26 | 27 | 28 | 28 | 27 |
2 | 24 | 25 | 24 | 25 | 25 | 24 | 25 | 25 | 25 | |||
3 | 27 | 28 | 28 | 28 | 27 | 28 | 28 | 28 | 28 | |||
4 | 27 | 26 | 27 | 28 | 27 | 28 | 28 | 28 | 29 | |||
5 | 27 | 28 | 27 | 28 | 27 | 28 | 28 | 27 | 28 | |||
6 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | |||
7 | 26 | 27 | 27 | 27 | 26 | 24 | 25 | 24 | 23 | |||
8 | 27 | 27 | 27 | 28 | 27 | 27 | 29 | 28 | 28 | |||
平均 | 26.4 | 26.9 | 26.7 | 27.3 | 26.4 | 26.6 | 27.3 | 26.9 | 26.9 | |||
SEM | 0.4 | 0.4 | 0.5 | 0.4 | 0.3 | 0.7 | 0.6 | 0.6 | 0.8 |
表8-4:異體移植NCI-N87胃癌腫瘤及母裸小鼠(nu/nu)體重(第88天到第100天)
組別 | 治療方式 | 劑量 (mg/kg) (途徑) | 編號 | 體重 (g) | ||||
第88天 | 第91天 | 第95天 | 第98天 | 第100天 | ||||
1 | 溶媒 (PBS, pH 7.4) + 溶媒 (pH 6.5之25 mM 檸檬酸鈉+100 mM NaCl) | 10 mL/kg x 4 (每周一次) IP+IV (每周一次) | 1 | NA | NA | NA | NA | NA |
2 | NA | NA | NA | NA | NA | |||
3 | NA | NA | NA | NA | NA | |||
4 | NA | NA | NA | NA | NA | |||
5 | NA | NA | NA | NA | NA | |||
6 | NA | NA | NA | NA | NA | |||
7 | NA | NA | NA | NA | NA | |||
8 | NA | NA | NA | NA | NA | |||
平均 | - | - | - | - | - | |||
SEM | - | - | - | - | - | |||
2 | 抗體藥物共軛物 (OBI-999) | 1 mg/kg x 4 IV (每周一次) | 1 | 27 | 26 | 27 | 27 | 28 |
2 | 29 | 28 | 28 | 29 | 29 | |||
3 | 29 | 29 | 29 | 29 | 30 | |||
4 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | |||
5 | 29 | 29 | 30 | 29 | 29 | |||
6 | 30 | 29 | 30 | 29 | 30 | |||
7 | 26 | 26 | 26 | 26 | 27 | |||
8 | 30 | 29 | 30 | 30 | 31 | |||
平均 | 28.6 | 28.0 | 28.6 | 28.4 | 29.1 | |||
SEM | 0.6 | 0.5 | 0.6 | 0.5 | 0.5 | |||
3 | 抗體藥物共軛物 (OBI-999) | 3 mg/kg x 4 IV (每周一次) | 1 | 29 | 29 | 28 | 29 | 29 |
2 | 31 | 31 | 31 | 31 | 31 | |||
3 | 28 | 28 | 28 | 28 | 28 | |||
4 | 27 | 27 | 27 | 27 | 28 | |||
5 | 27 | 28 | 28 | 27 | 29 | |||
6 | 27 | 27 | 28 | 27 | 28 | |||
7 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | |||
8 | 26 | 26 | 27 | 26 | 26 | |||
平均 | 27.9 | 28.0 | 28.1 | 27.9 | 28.4 | |||
SEM | 0.6 | 0.6 | 0.5 | 0.6 | 0.6 | |||
4 | 抗體藥物共軛物 (OBI-999) | 10 mg/kg x 4 IV (每周一次) | 1 | 28 | 28 | 28 | 29 | 29 |
2 | 27 | 28 | 28 | 28 | 29 | |||
3 | 26 | 25 | 26 | 25 | 25 | |||
4 | 28 | 27 | 27 | 27 | 28 | |||
5 | 26 | 25 | 25 | 23 | 23 | |||
6 | 26 | 26 | 28 | 29 | 30 | |||
7 | NA | NA | NA | NA | NA | |||
8 | 27 | 27 | 27 | 26 | 26 | |||
平均 | 26.9 | 26.6 | 27.0 | 26.7 | 27.1 | |||
SEM | 0.3 | 0.5 | 0.4 | 0.8 | 1.0 | |||
5 | OBI-888 | 10 mg/kg x 4 IV (每周一次) | 1 | NA | NA | NA | NA | NA |
2 | NA | NA | NA | NA | NA | |||
3 | NA | NA | NA | NA | NA | |||
4 | NA | NA | NA | NA | NA | |||
5 | NA | NA | NA | NA | NA | |||
6 | NA | NA | NA | NA | NA | |||
7 | NA | NA | NA | NA | NA | |||
8 | NA | NA | NA | NA | NA | |||
平均 | - | - | - | - | - | |||
SEM | - | - | - | - | - | |||
6 | 抗-CD30 抗體藥物共軛物 (OBI-910) | 3 mg/kg x 4 IV (每周一次) | 1 | 27 | 27 | 27 | 27 | 28 |
2 | 29 | 29 | 30 | 30 | 30 | |||
3 | 26 | 25 | 25 | 25 | 25 | |||
4 | 31 | 31 | 31 | 30 | 32 | |||
5 | 26 | 25 | 25 | 25 | 25 | |||
平均 | 27.8 | 27.4 | 27.6 | 27.4 | 28.0 | |||
SEM | 1.0 | 1.2 | 1.2 | 1.1 | 1.4 | |||
7 | MMAE + OBI-888 | 0.191 mg/kg x 4 IP (每周一次) + 10 mg/kg x 4 IV (每周一次) | 1 | 29 | 28 | 29 | 29 | 30 |
2 | 26 | 26 | 26 | 25 | 25 | |||
3 | 24 | 23 | 22 | 21 | 21 | |||
4 | 26 | 25 | 25 | 26 | 25 | |||
5 | 32 | 32 | 33 | 32 | 33 | |||
6 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | |||
7 | 25 | 25 | 25 | 24 | 24 | |||
8 | 27 | 25 | 26 | 25 | 25 | |||
平均 | 27.0 | 26.3 | 26.6 | 26.0 | 26.1 | |||
SEM | 1.0 | 1.1 | 1.3 | 1.3 | 1.5 | |||
8 | MMAE | 0.191 mg/kg x 4 IP (每周一次) | 1 | 28 | 28 | 28 | 29 | 28 |
2 | 25 | 26 | 26 | 27 | 27 | |||
3 | 29 | 29 | 29 | 29 | 30 | |||
4 | 29 | 29 | 29 | 29 | 29 | |||
5 | 28 | 28 | 29 | 29 | 30 | |||
6 | 死亡 | 死亡 | 死亡 | 死亡 | 死亡 | |||
7 | 23 | 23 | 22 | 22 | 22 | |||
8 | 28 | 28 | 29 | 28 | 29 | |||
平均 | 27.1 | 27.3 | 27.4 | 27.6 | 27.9 | |||
SEM | 0.9 | 0.8 | 1.0 | 1.0 | 1.1 |
第十七圖顯示植入母裸小鼠(nu/nu)之NCI-N87腫瘤生長曲線。實驗過程中,經靜脈注射劑量為1 mg/kg的抗體藥物共軛物(OBI-999)之實驗組,相較於溶媒對照組呈現強效抗腫瘤活性。實驗組自第15天起即呈現顯著抗腫瘤活性(T/C值≦42%)並持續至第53天,TGI百分比於第53天達最大值83%。實驗過程中,經靜脈注射劑量為3 mg/kg的抗體藥物共軛物(OBI-999)之實驗組,相較於溶媒對照組呈現強效抗腫瘤活性。實驗組自第11天起即呈現顯著抗腫瘤活性(T/C值≦42%)並持續至第53天,TGI百分比於第53天達最大值97%。實驗過程中,經靜脈注射劑量為10 mg/kg的抗體藥物共軛物(OBI-999)之實驗組,相較於溶媒對照組呈現強效抗腫瘤活性。實驗組自第11天起即呈現顯著抗腫瘤活性(T/C值≦42%)並持續至第53天,TGI百分比於第53天達最大值97%。
實驗過程中,每周經靜脈注射劑量為10 mg/kg的OBI-888之實驗組,相較於溶媒對照組呈現微弱抗腫瘤活性(第十七圖)。
實驗過程中,每周經靜脈注射劑量為10 mg/kg的試驗物質抗-CD 30抗體藥物共軛物(OBI-910)之實驗組,相較於溶媒對照組呈現強效抗腫瘤活性。實驗組自第11天起即呈現顯著抗腫瘤活性(T/C值≦42%)並持續至第53天,TGI百分比於第53天達最大值75%。
實驗過程中,每周經腹腔內注射劑量為0.191 mg/kg的標準製劑MMAE之實驗組,相較於溶媒對照組呈現中等抗腫瘤活性,TGI百分比於第53天達最大值53%。
實驗過程中,施打包含10 mg/kg試驗物質OBI-888及0.191 mg/kg標準製劑MMAE的組合療法之實驗組,相較於溶媒對照組呈現顯著抗腫瘤生長效果。實驗組自第11天起即呈現顯著抗腫瘤活性(T/C值≦42%)並持續至第53天,TGI百分比於第53天達最大值62%(第十七圖)。
第十八圖顯示被植入NCI-N87腫瘤之母裸小鼠(nu/nu)體重變化。所有試驗物質皆可被受試動物容忍,且實驗過程中,施打試驗物質之組別皆未呈現顯著體重變化。
實施例
5
:測量裸小鼠體內範例抗體之抗腫瘤活性(肺癌)
在一人類小細胞肺癌腫瘤異體移植模型中,將NCI-H526第E期上皮癌活體細胞;變異小細胞肺癌細胞(ATCC CRL-5811)經皮下途徑(對每隻小鼠施打0.2 mL之matrigel(1:0.8),內含 1 × 10
6個細胞)接種至母裸小鼠(nu/nu)身體右側。將經植入腫瘤之小鼠分為五組實驗組,每組包含八隻小鼠,細胞移植後隔天即開始施打測試試劑(標記為第1天)。
4.1 試驗物質及給藥模式
使用含25 mM檸檬酸鈉、100 mM NaCl緩衝液(pH 6.5)之稀釋原液製備抗體藥物共軛物(OBI-999)、OBI-888及MMAE等試驗物質,並透過靜脈(IV)每周對小鼠施打一次,為期四周。每周經腹腔內(IP)對小鼠注射標準製劑、MMAE抗體及對應溶媒(PBS pH 7.4)一次,為期四周,劑量為0.191 mg/kg。某一實驗組接受試驗物質之組合療法,其中包括劑量10 mg/kg之OBI-888及劑量0.191 mg/kg之MMAE。
表9:裸小鼠體內範例抗體之抗腫瘤活性之研究設計(肺癌)
組別 | 試驗物質 | 途徑 | 劑量 | 小鼠 c,d (nu/nu) | |
mL/kg | mg/kg | (母) | |||
1 | 溶媒 a+溶媒 b | IP + IV | 10 | N/A | 8 |
2 | 抗體藥物共軛物 (OBI-999) b | IV | 10 | 10 | 8 |
3 | OBI-888 b | IV | 10 | 10 | 8 |
4 | MMAE a+ OBI-888 b | IP + IV | 10 | 0.191 + 10 | 8 |
5 | MMAE a | IP | 10 | 0.191 | 8 |
apH 7.4之PBS(高濃度MMAE儲存於100% 二甲基亞碸中,接著被稀釋為pH 7.4之PBS) bpH 6.5之25mM 檸檬酸鈉+100 mM NaCl c每周施打溶媒及試驗物質一次,為期四周,且於細胞移植後隔天即開始施打(標記為第1天) d將200 µL含1 × 10 6個細胞、與matrigel混合(1:0.8)之NCI-H526經皮下途徑接種至母裸小鼠(nu/nu)身體右側 每周觀測並紀錄腫瘤尺寸及小鼠體重兩次,至第70天或溶媒對照組之平均腫瘤尺寸達2000 mm 3為止。小鼠犧牲時須攝影。 |
5.2 細胞株
NCI-H526肺癌腫瘤細胞株購自美國典型菌種保護中心(American Type Culture Collection)(ATCC CRL-5811,變異小細胞肺癌上皮癌),並於Eurofins Panlabs Taiwan, Ltd.培養。於37 °C下,使用含有10%胎牛血清且置於5%二氧化碳培養箱中之RPMI-1640培養液培養腫瘤細胞,並將腫瘤細胞以皮下注射方式植入每隻小鼠右側身體。
5.3 受試動物
實驗使用自台灣BioLasco公司(經Charles River Laboratories授權)購得之六至七周齡母裸小鼠(nu/nu)。受試動物皆飼養於個獨立通風籠中(IVC,36 Mini Isolator System)。分配給每5隻受試動物之空間大小為27 × 20 × 14 cm
3。所有受試動物皆於恆溫(20-24℃)、恆濕(30-70%)、亮暗各12小時之乾淨衛生環境中。小鼠可自由食用標準實驗飼料 [MFG(Oriental Yeast Co., Ltd.,日本)]並飲用高壓滅菌自來水。動物實驗之飼養、實驗與死後處置等流程,皆依據
Guide for the Care and Use of Laboratory Animals: Eighth Edition(National Academies Press, Washington, D.C., 2011)之規範,於實驗團隊經AAALAC認證之實驗動物設施中執行。此外,進行實驗之動物照護及使用申請表已由Eurofins Panlabs Taiwan, Ltd. 之實驗動物照護及使用委員會審核並核准。
5.4 實驗化學物質
本實驗使用胎牛血清(Hyclone,美國)、RPMI-1640培養液(ThermoFisher,美國)及Matrigel(Corning,美國)。
5.5 實驗器材
實驗器材包括游標尺(Mitutoyo,日本)、離心機 5810R(Eppendorf,德國)、二氧化碳培養箱(Forma Scientific Inc.,美國)、血球計數器(Hausser Scientific Horsham,美國)、獨立通風籠架(36 Mini Isolator system,Tecniplast,義大利)、倒立顯微鏡 CK-40(Olympus,日本)、系統顯微鏡 E-400(Nikon,日本)及垂直無菌操作台(Tsao-Hsin,台灣)。
5.6 實驗方法
每周觀察兩次並紀錄小鼠腫瘤體積、體重、死亡率及明顯毒性作用徵兆,為期45天。腫瘤生長抑制程度以T/C(治療/控制)× 100%計。相較於溶媒對照組,T/C值≦42%即代表顯著抗腫瘤活性。使用雙因子變異數分析再進行Bonferroni 事後檢定,以判斷各實驗組相較於各溶媒對照組之統計顯著性(*
p< 0.05)。
5.7 實驗結果
表10-1:異體移植NCI-H526肺癌腫瘤及母裸小鼠(nu/nu)體內腫瘤體積(第1天到第25天)
組別 | 治療方式 | 劑量 (mg/kg) (途徑) | 編號 | 腫瘤體積 (mm 3) | |||||||
第1天 | 第4天 | 第8天 | 第11天 | 第15天 | 第18天 | 第22天 | 第25天 | ||||
1 | 溶媒 (PBS, pH 7.4) + 溶媒 (pH 6.5之25 mM 檸檬酸鈉+100 mM NaCl) | 10 mL/kg x 4 (每周一次) IP+IV | 1 | 66 | 61 | 92 | 104 | 159 | 536 | 942 | 1548 |
2 | 86 | 91 | 86 | 111 | 101 | 157 | 190 | 428 | |||
3 | 71 | 76 | 85 | 99 | 157 | 368 | 949 | 1578 | |||
4 | 89 | 103 | 137 | 164 | 180 | 401 | 965 | 1383 | |||
5 | 80 | 80 | 80 | 172 | 221 | 474 | 757 | 1303 | |||
6 | 70 | 73 | 69 | 123 | 189 | 356 | 615 | 920 | |||
7 | 90 | 89 | 99 | 121 | 203 | 490 | 647 | 787 | |||
8 | 65 | 82 | 72 | 133 | 183 | 449 | 760 | 1004 | |||
平均 | 77 | 82 | 90 | 128 | 174 | 404 | 728 | 1119 | |||
SEM | 4 | 4 | 8 | 9 | 13 | 41 | 91 | 143 | |||
2 | 抗體藥物共軛物 (OBI-999) | 10 mg/kg x 4 IV (每周一次) | 1 | 66 | 31 | 92 | 104 | 159 | 536 | 942 | 1548 |
2 | 86 | 91 | 86 | 111 | 101 | 157 | 190 | 428 | |||
3 | 71 | 76 | 85 | 99 | 157 | 368 | 949 | 1578 | |||
4 | 89 | 103 | 137 | 164 | 180 | 401 | 965 | 1383 | |||
5 | 80 | 80 | 80 | 172 | 221 | 474 | 757 | 1303 | |||
6 | 70 | 73 | 69 | 123 | 189 | 356 | 615 | 920 | |||
7 | 90 | 89 | 99 | 121 | 203 | 490 | 647 | 787 | |||
8 | 65 | 82 | 72 | 133 | 183 | 449 | 760 | 1004 | |||
平均 | 77 | 82 | 90 | 128 | 174 | 404 | 728 | 1119 | |||
SEM | 5 | 9 | 4 | 4 | 5 | 11 | 33 | 46 | |||
% TGI | N/A | -24 | -8 | 34 | 49 | 76 | 83 | 85 | |||
% T/C | 99 | 124 | 108 | 66 | 51 | 24 # | 17 # | 15 # | |||
3 | OBI-888 | 10 mg/kg x 4 IV (每周一次) | 1 | 66 | 101 | 94 | 108 | 171 | 216 | 551 | 981 |
2 | 86 | 87 | 81 | 99 | 113 | 183 | 504 | 725 | |||
3 | 80 | 121 | 81 | 91 | 136 | 201 | 415 | 681 | |||
4 | 66 | 97 | 104 | 127 | 135 | 222 | 511 | 913 | |||
5 | 86 | 93 | 98 | 96 | 166 | 170 | 483 | 756 | |||
6 | 86 | 86 | 81 | 93 | 62 | 76 | 113 | 289 | |||
7 | 94 | 94 | 79 | 79 | 89 | 77 | 87 | 99 | |||
8 | 71 | 99 | 69 | 89 | 82 | 99 | 93 | 83 | |||
平均 | 79 | 97 | 86 | 98 | 119 | 156 | 345 | 566* | |||
SEM | 4 | 4 | 4 | 5 | 14 | 22 | 74 | 126 | |||
% TGI | NA | -18 | 4 | 23 | 32 | 61 | 53 | 49 | |||
% T/C | 103 | 118 | 96 | 77 | 68 | 39 # | 47 | 51 | |||
4 | MMAE + OBI-888 | 0.191 mg/kg x 4 IP (每周一次) + 10 mg/kg x 4 IV (每周一次) | 1 | 82 | 86 | 93 | 119 | 112 | 179 | 323 | 511 |
2 | 63 | 82 | 83 | 69 | 69 | 66 | 68 | 118 | |||
3 | 68 | 108 | 94 | 83 | 61 | 95 | 148 | 346 | |||
4 | 87 | 80 | 79 | 148 | 142 | 181 | 525 | 938 | |||
5 | 97 | 81 | 93 | 96 | 121 | 141 | 402 | 590 | |||
6 | 101 | 111 | 88 | 93 | 98 | 98 | 119 | 171 | |||
7 | 93 | 99 | 89 | 99 | 115 | 137 | 388 | 540 | |||
8 | 87 | 94 | 94 | 88 | 115 | 122 | 333 | 507 | |||
平均 | 85 | 93 | 89 | 99 | 104 | 127 | 288* | 465* | |||
SEM | 5 | 4 | 2 | 9 | 10 | 14 | 57 | 92 | |||
% TGI | NA | -13 | 1 | 23 | 40 | 69 | 60 | 58 | |||
% T/C | 110 | 113 | 99 | 77 | 60 | 31 # | 40 # | 42 # | |||
5 | MMAE | 0.191 mg/kg x 4 IP (每周一次) | 1 | 75 | 80 | 94 | 74 | 82 | 80 | 74 | 70 |
2 | 108 | 127 | 74 | 86 | 133 | 199 | 618 | 1163 | |||
3 | 81 | 101 | 94 | 89 | 137 | 246 | 530 | 1095 | |||
4 | 83 | 88 | 83 | 104 | 101 | 169 | 337 | 483 | |||
5 | 99 | 115 | 70 | 121 | 144 | 187 | 317 | 525 | |||
6 | 60 | 85 | 82 | 67 | 89 | 101 | 152 | 249 | |||
7 | 68 | 80 | 121 | 77 | 172 | 281 | 621 | 1078 | |||
8 | 91 | 108 | 74 | 79 | 123 | 202 | 401 | 535 | |||
平均 | 83 | 98 | 87 | 87 | 123 | 183 | 381 | 650* | |||
SEM | 6 | 6 | 6 | 6 | 11 | 24 | 72 | 146 | |||
% TGI | NA | -20 | 3 | 32 | 29 | 55 | 48 | 42 | |||
% T/C | 108 | 120 | 97 | 68 | 71 | 45 | 52 | 58 |
表10-2:異體移植NCI-H526肺癌腫瘤及母裸小鼠(nu/nu)體內腫瘤體積(第29天到第45天)
組別 | 治療方式 | 劑量 (mg/kg) (途徑) | 編號 | 腫瘤體積 (mm 3) | |||||
第29天 | 第31天 | 第36天 | 第39天 | 第43天 | 第45天 | ||||
1 | 溶媒 (PBS, pH 7.4) + 溶媒 (pH 6.5之25 mM 檸檬酸鈉+100 mM NaCl) | 10 mL/kg x 4 (每周一次) IP+IV | 1 | 1968 | 2452 | NA | NA | NA | NA |
2 | 968 | 1251 | NA | NA | NA | NA | |||
3 | 2579 | 3369 | NA | NA | NA | NA | |||
4 | 2218 | 2803 | NA | NA | NA | NA | |||
5 | 2342 | 2329 | NA | NA | NA | NA | |||
6 | 1594 | 1794 | NA | NA | NA | NA | |||
7 | 1561 | 2022 | NA | NA | NA | NA | |||
8 | 1942 | 2363 | NA | NA | NA | NA | |||
平均 | 1897 | 2298 | - | - | - | - | |||
SEM | 181 | 226 | - | - | - | - | |||
2 | 抗體藥物共軛物 (OBI-999) | 10 mg/kg x 4 IV (每周一次) | 1 | 517 | 717 | 922 | 死亡 | 死亡 | 死亡 |
2 | 207 | 289 | 612 | 615 | 953 | 1095 | |||
3 | 811 | 983 | 1886 | 2403 | 3693 | 4092 | |||
4 | 99 | 79 | 0 | 0 | 0 | 0 | |||
5 | 507 | 644 | 1349 | 1798 | 2982 | 3948 | |||
6 | 231 | 333 | 789 | 1094 | 1727 | 2190 | |||
7 | 150 | 265 | 461 | 702 | 1109 | 1369 | |||
8 | 80 | 111 | 144 | 218 | 318 | 395 | |||
平均 | 325* | 428* | 770 | 976 | 1540 | 1870 | |||
SEM | 92 | 113 | 220 | 305 | 482 | 575 | |||
% TGI | 83 | 81 | - | - | - | - | |||
% T/C | 17 # | 19 # | - | - | - | - | |||
3 | OBI-888 | 10 mg/kg x 4 IV (每周一次) | 1 | 1640 | 1837 | 3370 | 3941 | NA | NA |
2 | 1227 | 1519 | 2820 | 3803 | NA | NA | |||
3 | 931 | 1246 | 2045 | 2174 | NA | NA | |||
4 | 1318 | 1714 | 2856 | 3617 | NA | NA | |||
5 | 1176 | 1539 | 1998 | 2177 | NA | NA | |||
6 | 500 | 550 | 1159 | 1802 | NA | NA | |||
7 | 120 | 214 | 322 | 410 | NA | NA | |||
8 | 77 | 101 | 70 | 63 | NA | NA | |||
平均 | 874* | 1090* | 1830 | 2248 | - | - | |||
SEM | 205 | 246 | 429 | 526 | - | - | |||
% TGI | 54 | 53 | - | - | - | - | |||
% T/C | 46 | 47 | - | - | - | - | |||
4 | MMAE + OBI-888 | 0.191 mg/kg x 4 IP (每周一次) + 10 mg/kg x 4 IV (每周一次) | 1 | 747 | 866 | 1514 | 2347 | NA | NA |
2 | 184 | 321 | 877 | 1485 | NA | NA | |||
3 | 632 | 887 | 1897 | 2822 | NA | NA | |||
4 | 1654 | 2176 | 3764 | 5272 | NA | NA | |||
5 | 1150 | 1437 | 2654 | 3181 | NA | NA | |||
6 | 389 | 636 | 982 | 1333 | NA | NA | |||
7 | 1046 | 1204 | 2056 | 3536 | NA | NA | |||
8 | 1034 | 1367 | 2251 | 3438 | NA | NA | |||
平均 | 855* | 1112* | 1999 | 2927 | - | - | |||
SEM | 165 | 202 | 331 | 446 | - | - | |||
% TGI | 55 | 52 | - | - | - | - | |||
% T/C | 45 | 48 | - | - | - | - | |||
5 | MMAE | 0.191 mg/kg x 4 IP (每周一次) | 1 | 90 | 173 | 126 | 56 | NA | NA |
2 | 1756 | 1901 | 3047 | 4380 | NA | NA | |||
3 | 1410 | 1682 | 2480 | 2713 | NA | NA | |||
4 | 853 | 1172 | 2090 | 2836 | NA | NA | |||
5 | 522 | 657 | 759 | 841 | NA | NA | |||
6 | 431 | 550 | 1032 | 1304 | NA | NA | |||
7 | 1313 | 1595 | 2538 | 3040 | NA | NA | |||
8 | 845 | 1044 | 1318 | 1339 | NA | NA | |||
平均 | 903* | 1097* | 1674 | 2064 | - | - | |||
SEM | 198 | 215 | 359 | 499 | - | - | |||
% TGI | 52 | 52 | - | - | - | - | |||
% T/C | 48 | 48 | - | - | - | - |
表11-1:異體移植NCI-H526肺癌腫瘤及母裸小鼠(nu/nu)體重(第1天到第25天)
組別 | 治療方式 | 劑量 (mg/kg) (途徑) | 編號 | 體重 (g) | |||||||
第1天 | 第4天 | 第8天 | 第11天 | 第15天 | 第18天 | 第22天 | 第25天 | ||||
1 | 溶媒 (PBS, pH 7.4) + 溶媒 (pH 6.5之25 mM 檸檬酸鈉+100 mM NaCl) | 10 mL/kg x 4 (每周一次) IP+IV | 1 | 23 | 24 | 24 | 23 | 24 | 25 | 26 | 27 |
2 | 23 | 25 | 26 | 25 | 26 | 25 | 25 | 26 | |||
3 | 23 | 24 | 24 | 25 | 25 | 26 | 25 | 26 | |||
4 | 25 | 25 | 25 | 24 | 24 | 25 | 26 | 27 | |||
5 | 24 | 24 | 24 | 24 | 24 | 26 | 26 | 27 | |||
6 | 25 | 26 | 26 | 25 | 26 | 26 | 27 | 27 | |||
7 | 24 | 25 | 26 | 25 | 24 | 26 | 26 | 26 | |||
8 | 22 | 23 | 22 | 22 | 23 | 24 | 24 | 25 | |||
平均 | 23.6 | 24.5 | 24.6 | 24.1 | 24.5 | 25.4 | 25.6 | 26.4 | |||
SEM | 0.4 | 0.3 | 0.5 | 0.4 | 0.4 | 0.3 | 0.3 | 0.3 | |||
2 | 抗體藥物共軛物 (OBI-999) | 10 mg/kg x 4 IV (每周一次) | 1 | 24 | 25 | 25 | 25 | 25 | 26 | 26 | 26 |
2 | 24 | 24 | 25 | 25 | 25 | 25 | 25 | 25 | |||
3 | 26 | 26 | 28 | 28 | 27 | 28 | 28 | 28 | |||
4 | 24 | 25 | 24 | 24 | 25 | 27 | 27 | 27 | |||
5 | 25 | 26 | 28 | 28 | 28 | 28 | 28 | 29 | |||
6 | 24 | 25 | 26 | 26 | 25 | 26 | 25 | 26 | |||
7 | 23 | 24 | 25 | 24 | 24 | 24 | 24 | 24 | |||
8 | 24 | 24 | 25 | 25 | 25 | 25 | 25 | 26 | |||
平均 | 24.3 | 24.9 | 25.8 | 25.6 | 25.5 | 26.1 | 26.0 | 26.4 | |||
SEM | 0.3 | 0.3 | 0.5 | 0.6 | 0.5 | 0.5 | 0.5 | 0.6 | |||
3 | OBI-888 | 10 mg/kg x 4 IV (每周一次) | 1 | 25 | 25 | 27 | 27 | 27 | 28 | 28 | 29 |
2 | 24 | 24 | 25 | 25 | 25 | 25 | 26 | 27 | |||
3 | 24 | 23 | 24 | 23 | 24 | 25 | 24 | 25 | |||
4 | 25 | 25 | 27 | 28 | 28 | 29 | 29 | 30 | |||
5 | 24 | 24 | 24 | 25 | 25 | 26 | 26 | 27 | |||
6 | 26 | 27 | 28 | 28 | 28 | 29 | 29 | 30 | |||
7 | 25 | 26 | 26 | 26 | 27 | 27 | 27 | 27 | |||
8 | 24 | 24 | 25 | 25 | 26 | 25 | 26 | 26 | |||
平均 | 24.6 | 24.8 | 25.8 | 25.9 | 26.3 | 26.8 | 26.9 | 27.6 | |||
SEM | 0.3 | 0.5 | 0.5 | 0.6 | 0.5 | 0.6 | 0.6 | 0.7 | |||
4 | MMAE + OBI-888 | 0.191 mg/kg x 4 IP (每周一次) + 10 mg/kg x 4 IV (每周一次) | 1 | 25 | 25 | 26 | 25 | 26 | 26 | 27 | 27 |
2 | 24 | 24 | 27 | 27 | 28 | 29 | 29 | 28 | |||
3 | 24 | 24 | 26 | 25 | 26 | 27 | 26 | 26 | |||
4 | 25 | 22 | 24 | 25 | 26 | 26 | 26 | 27 | |||
5 | 24 | 24 | 26 | 27 | 28 | 28 | 28 | 28 | |||
6 | 25 | 26 | 27 | 27 | 28 | 28 | 28 | 29 | |||
7 | 25 | 26 | 27 | 27 | 28 | 27 | 28 | 29 | |||
8 | 21 | 21 | 23 | 24 | 25 | 25 | 25 | 25 | |||
平均 | 24.1 | 24.0 | 25.8 | 25.9 | 26.9 | 27.0 | 27.1 | 27.4 | |||
SEM | 0.5 | 0.6 | 0.5 | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | |||
5 | MMAE | 0.191 mg/kg x 4 IP (每周一次) | 1 | 24 | 22 | 24 | 24 | 25 | 25 | 24 | 26 |
2 | 25 | 25 | 26 | 28 | 28 | 28 | 28 | 30 | |||
3 | 26 | 27 | 28 | 28 | 28 | 28 | 28 | 29 | |||
4 | 24 | 21 | 21 | 23 | 24 | 24 | 25 | 26 | |||
5 | 24 | 23 | 25 | 24 | 25 | 25 | 25 | 25 | |||
6 | 23 | 23 | 23 | 23 | 23 | 24 | 24 | 25 | |||
7 | 23 | 24 | 24 | 24 | 24 | 24 | 25 | 25 | |||
8 | 22 | 24 | 25 | 25 | 26 | 25 | 25 | 26 | |||
平均 | 23.9 | 23.6 | 24.5 | 24.9 | 25.4 | 25.4 | 25.5 | 26.5 | |||
SEM | 0.4 | 0.7 | 0.7 | 0.7 | 0.7 | 0.6 | 0.6 | 0.7 |
表11-2:異體移植NCI-H526肺癌腫瘤及母裸小鼠(nu/nu)體重(第29天到第45天)
組別 | 治療方式 | 劑量 (mg/kg) (途徑) | 編號 | 體重 (g) | |||||
第29天 | 第31天 | 第36天 | 第39天 | 第43天 | 第45天 | ||||
1 | 溶媒 (PBS, pH 7.4) + 溶媒 (pH 6.5之25 mM 檸檬酸鈉+100 mM NaCl) | 10 mL/kg x 4 (每周一次) IP+IV | 1 | 28 | 29 | NA | NA | NA | NA |
2 | 27 | 28 | NA | NA | NA | NA | |||
3 | 28 | 30 | NA | NA | NA | NA | |||
4 | 30 | 30 | NA | NA | NA | NA | |||
5 | 29 | 30 | NA | NA | NA | NA | |||
6 | 29 | 30 | NA | NA | NA | NA | |||
7 | 28 | 29 | NA | NA | NA | NA | |||
8 | 26 | 28 | NA | NA | NA | NA | |||
平均 | 28.1 | 29.3 | - | - | - | - | |||
SEM | 0.4 | 0.3 | - | - | - | - | |||
2 | 抗體藥物共軛物 (OBI-999) | 10 mg/kg x 4 IV (每周一次) | 1 | 27 | 25 | 24 | 死亡 | 死亡 | 死亡 |
2 | 26 | 26 | 27 | 27 | 27 | 28 | |||
3 | 29 | 29 | 31 | 32 | 34 | 36 | |||
4 | 28 | 27 | 28 | 29 | 28 | 29 | |||
5 | 32 | 31 | 32 | 34 | 33 | 35 | |||
6 | 27 | 27 | 28 | 29 | 30 | 31 | |||
7 | 25 | 25 | 26 | 27 | 26 | 28 | |||
8 | 26 | 26 | 27 | 28 | 27 | 28 | |||
平均 | 27.5 | 27.0 | 27.9 | 29.4 | 29.3 | 30.7 | |||
SEM | 0.8 | 0.7 | 0.9 | 0.9 | 1.1 | 1.2 | |||
3 | OBI-888 | 10 mg/kg x 4 IV (每周一次) | 1 | 32 | 31 | 35 | 36 | NA | NA |
2 | 28 | 28 | 30 | 30 | NA | NA | |||
3 | 26 | 25 | 27 | 28 | NA | NA | |||
4 | 32 | 31 | 33 | 36 | NA | NA | |||
5 | 28 | 27 | 27 | 28 | NA | NA | |||
6 | 31 | 31 | 32 | 34 | NA | NA | |||
7 | 27 | 27 | 29 | 29 | NA | NA | |||
8 | 27 | 27 | 27 | 27 | NA | NA | |||
平均 | 28.9 | 28.4 | 30.0 | 31.0 | - | - | |||
SEM | 0.9 | 0.8 | 1.1 | 1.3 | - | - | |||
4 | MMAE + OBI-888 | 0.191 mg/kg x 4 IP (每周一次) + 10 mg/kg x 4 IV (每周一次) | 1 | 29 | 29 | 31 | 33 | NA | NA |
2 | 30 | 30 | 31 | 32 | NA | NA | |||
3 | 28 | 28 | 31 | 32 | NA | NA | |||
4 | 30 | 30 | 33 | 35 | NA | NA | |||
5 | 30 | 30 | 32 | 34 | NA | NA | |||
6 | 30 | 30 | 30 | 34 | NA | NA | |||
7 | 32 | 32 | 33 | 35 | NA | NA | |||
8 | 27 | 27 | 29 | 33 | NA | NA | |||
平均 | 29.5 | 29.5 | 31.3 | 33.5 | - | - | |||
SEM | 0.5 | 0.5 | 0.5 | 0.4 | - | - | |||
5 | MMAE | 0.191 mg/kg x 4 IP (每周一次) | 1 | 25 | 25 | 26 | 27 | NA | NA |
2 | 32 | 32 | 33 | 38 | NA | NA | |||
3 | 31 | 32 | 33 | 34 | NA | NA | |||
4 | 26 | 26 | 28 | 30 | NA | NA | |||
5 | 27 | 27 | 27 | 27 | NA | NA | |||
6 | 26 | 26 | 26 | 27 | NA | NA | |||
7 | 27 | 27 | 29 | 30 | NA | NA | |||
8 | 27 | 27 | 29 | 29 | NA | NA | |||
平均 | 27.6 | 27.8 | 28.9 | 30.3 | - | - | |||
SEM | 0.9 | 1.0 | 1.0 | 1.4 | - | - |
第二十七圖顯示植入母裸小鼠(nu/nu)之NCI-H526腫瘤生長曲線。實驗過程中,每周經靜脈注射劑量為10 mg/kg的抗體藥物共軛物(OBI-999)一次、為期四周之實驗組,自第15天起即呈現顯著抗腫瘤活性(T/C值≦42%)並持續至第31天,TGI百分比於第25天達最大值85%。
實驗過程中,每周經靜脈注射劑量為10 mg/kg的試驗物質OBI-888之實驗組,相較於溶媒對照組呈現中等抗腫瘤活性;然而,實驗組自第18天起即呈現顯著抗腫瘤活性(T/C值≦42%),TGI百分比於第18天達最大值61%。
實驗過程中,每周經腹腔內注射劑量為0.191 mg/kg的標準製劑MMAE之實驗組,相較於溶媒對照組呈現中等抗腫瘤活性,TGI百分比於第18天達最大值55%。
實驗過程中,施打包含10 mg/kg試驗物質OBI-888及0.191 mg/kg標準製劑MMAE的組合療法之實驗組,相較於溶媒對照組呈現中等抗腫瘤生長效果;然而,實驗組於第18天、第22天及第25天即呈現顯著抗腫瘤活性(T/C值≦42%),TGI百分比於第18天達最大值69%。
第二十八圖顯示被植入NCI-H526腫瘤之母裸小鼠(nu/nu)體重變化。所有試驗物質皆可被受試動物容忍,且實驗過程中,施打試驗物質之組別皆未呈現顯著體重變化。
實施例
6
:測量裸小鼠體內範例抗體之抗腫瘤活性(胰臟癌)
本實驗之目的為評估OBI-888、抗體藥物共軛物(OBI-999)、MMAE以及由OBI-888與MMAE結合之藥劑針對公裸BALB/c小鼠體內之人類胰臟癌細胞(HPAC)異體移植模型,所產生之活體內抗腫瘤效力。
6.1 試驗物質及給藥模式
使用含25 mM檸檬酸鈉、100 mM NaCl緩衝液(pH 6.5)之稀釋原液製備抗體藥物共軛物(OBI-999)、OBI-888等試驗物質及對應溶媒,並透過靜脈(IV)每周對小鼠施打一次,為期四周。每周經腹腔內(IP)對小鼠注射標準製劑、MMAE抗體及對應溶媒(PBS pH 7.4)一次,為期四周,劑量為0.191 mg/kg。某一實驗組接受試驗物質之組合療法,其中包括劑量10 mg/kg之OBI-888及劑量0.191 mg/kg之MMAE。
表12:裸小鼠體內範例抗體之抗腫瘤活性之研究設計(胰臟癌)
組別 | 試驗物質 | 途徑 | 劑量 | 小鼠 c,d (nu/nu) | |
mL/kg | mg/kg | (母) | |||
1 | 溶媒 a+溶媒 b | IP + IV | 10 | N/A | 8 |
2 | 抗體藥物共軛物 (OBI-999) b | IV | 10 | 10 | 8 |
3 | OBI-888 b | IV | 10 | 10 | 8 |
4 | MMAE a+ OBI-888 b | IP + IV | 10 | 0.191 a+ 10 b | 8 |
5 | MMAE a | IP | 10 | 0.191 | 8 |
apH 7.4之PBS(高濃度MMAE儲存於100% 二甲基亞碸中,接著被稀釋為pH 7.4之PBS) bpH 6.5之25mM 檸檬酸鈉+100 mM NaCl c每周施打溶媒及試驗物質一次,為期四周,且於細胞移植後隔天即開始施打(標記為第1天) d將含有 HPAC腫瘤細胞(含3 × 10 6個細胞)之0.2 mL PBS經皮下途徑接種至每隻小鼠體內,以觀察腫瘤生長情形。治療於腫瘤移植後第6天、平均腫瘤尺寸達85 mm 3時開始。 |
6.2 細胞株
使用Dulbecco改良的Eagle培養基與Ham’s F12培養基1:1混合形成培養基,於37°C下、含5%二氧化碳之空氣中在試管內(
in vitro)培養HPAC腫瘤細胞(ATCC CRL-2119),形成一單層培養物。該培養基包含1.2 g/L 碳酸氫鈉、2.5 mM L-麩醯胺酸、15 mM 4-羥乙基乙磺酸(HEPES)及0.5 mM 丙酮酸鈉,並搭配0.002 mg/mL 胰島素、0.005 mg/mL 運鐵蛋白、40 ng/mL 氫羥腎上腺皮質素(hydrocortisone)、10 ng/mL 表皮生長因子及5%胎牛血清,以及100 U/mL盤尼西林及100 μg/mL 鏈黴素。使用胰蛋白酶EDTA進行規律之腫瘤細胞繼代培養,每周兩次。採集指數生長期內之腫瘤細胞,並計算細胞數以進行腫瘤接種。
6.3 受試動物
實驗使用自上海Lingchang公司取得之六至八周齡公裸小鼠(nu/nu)。受試動物皆飼養於恆溫恆濕之個獨立通風籠中,每籠含四隻小鼠(溫度為20-26°C,濕度為40-70%)。通風籠材質為聚碳酸酯,大小為300 mm × 200 mm × 180 mm。籠底墊材為玉米梗,每周更換兩次。實驗過程中,受試動物可自由取用經輻射消毒之乾燥顆粒食物以及飲用水。每籠之標籤包含以下資訊:動物數量、性別、品系、接收日期、治療方式、實驗編號、組別及治療開始日期。
6.4 實驗方法
實驗終點為測定試驗物質之抗腫瘤效力。每周使用游標尺測量兩次腫瘤二維尺寸,以公式V = 0.5 a × b
2計算腫瘤體積,其中a、b分別為腫瘤之長直徑及短直徑,體積單位以mm
3表示。再以腫瘤尺寸計算T/C值。T/C值(以百分比表示)代表抗腫瘤效力;T與C分別為某一天實驗組腫瘤平均體積及對照組腫瘤平均體積。每組之腫瘤生長抑制率(TGI)由以下公式計算:TGI (%) = [1-(Ti-T0)/V1-V0] × 100;Ti為某一天實驗組之平均腫瘤體積,T0為第0天實驗組之平均腫瘤體積,Vi為與Ti同一天的溶媒對照組之平均腫瘤體積,而V0為第0天溶媒對照組之平均腫瘤體積。
每個時間點下每組之腫瘤體積皆使用概述統計(summary statistics)描述,包括平均值與平均標準誤差值。最終輪投藥後(分組後第37天),針對於最佳療效出現時間點所收集之資料,以統計方法分析各組之腫瘤體積差異。使用單因子變異數分析比較各組之腫瘤體積差異,若取得一顯著F統計量(治療變異相對誤差變異之比值),再使用Games-Howell檢定比較各組差異;若否,則使用Dunnett(雙側)檢定。以雙因子變異數分析分析OBI-888及MMAE間之潛在加乘作用。所有資料皆使用SPSS 17.0分析,
p< 0.05 時代表具有統計顯著性。
6.5 實驗結果
表13:植入HPAC細胞之裸小鼠(nu/nu)體內腫瘤體積
治療方法 | 編號 | 腫瘤體積 (mm 3) | |||||||||||
0 a | 3 | 7 | 10 | 14 | 17 | 21 | 24 | 28 | 31 | 35 | 37 | ||
第1組 溶媒A+B IP+IV 10 μL/g+10 μL/g 每周一次、 為期四周 | 1 | 87 | 432 | 503 | 628 | 1060 | 1179 | 1259 | 1508 | 2143 | 2950 | 4426 | 4239 |
2 | 93 | 104 | 203 | 251 | 468 | 654 | 929 | 1287 | 1471 | 1589 | 1560 | 1792 | |
3 | 134 | 176 | 208 | 284 | 485 | 636 | 842 | 939 | 1263 | 1431 | 1465 | 1881 | |
4 | 80 | 124 | 161 | 252 | 341 | 735 | 979 | 1024 | 1729 | 1627 | 1692 | 1866 | |
5 | 61 | 204 | 253 | 378 | 492 | 595 | 896 | 876 | 1079 | 1292 | 1289 | 1953 | |
6 | 111 | 161 | 203 | 343 | 501 | 637 | 670 | 725 | 1078 | 1549 | 1629 | 2178 | |
7 | 54 | 77 | 141 | 188 | 334 | 388 | 513 | 567 | 818 | 1033 | 1161 | 1450 | |
8 | 59 | 71 | 135 | 186 | 320 | 428 | 653 | 762 | 994 | 1227 | 1359 | 1998 | |
平均 | 85 | 169 | 226 | 314 | 500 | 656 | 843 | 961 | 1322 | 1587 | 1823 | 2170 | |
SEM | 10 | 41 | 42 | 51 | 85 | 85 | 82 | 109 | 155 | 207 | 377 | 305 | |
第2組 抗體藥物共軛物(OBI-999) IV 10 mg/kg 每周一次、 為期四周 | 1 | 59 | 75 | 104 | 135 | 53 | 26 | 4 | 1 | 0 | 0 | 0 | 0 |
2 | 80 | 115 | 124 | 116 | 43 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | |
3 | 100 | 74 | 75 | 61 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
4 | 56 | 94 | 115 | 91 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
5 | 101 | 148 | 196 | 178 | 102 | 76 | 15 | 14 | 12 | 4 | 1 | 0 | |
6 | 122 | 149 | 264 | 180 | 134 | 65 | 52 | 22 | 18 | 20 | 4 | 12 | |
7 | 72 | 76 | 101 | 87 | 42 | 16 | 4 | 1 | 1 | 0 | 0 | 0 | |
8 | 89 | 154 | 175 | 79 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
平均 | 85 | 111 | 144 | 116 | 47 | 23 | 9 | 5 | 4 | 3 | 1 | 1 | |
SEM | 8 | 13 | 22 | 16 | 18 | 11 | 6 | 3 | 2 | 2 | 0 | 1 | |
第3組 OBI-888 IV 10 mg/kg 每周一次、 為期四周 | 1 | 140 | 155 | 170 | 251 | 384 | 404 | 781 | 874 | 1471 | 1952 | 2063 | 2073 |
2 | 52 | 61 | 154 | 209 | 412 | 523 | 695 | 952 | 999 | 1489 | 1535 | 1839 | |
3 | 84 | 128 | 169 | 331 | 481 | 571 | 772 | 908 | 1480 | 1722 | 2696 | 2620 | |
4 | 90 | 100 | 140 | 296 | 323 | 442 | 671 | 992 | 1590 | 1915 | 2275 | 2269 | |
5 | 109 | 98 | 129 | 252 | 458 | 615 | 727 | 870 | 1200 | 1627 | 1836 | 1838 | |
6 | 58 | 71 | 116 | 214 | 255 | 303 | 645 | 635 | 1134 | 1175 | 1485 | 1791 | |
7 | 75 | 98 | 219 | 367 | 529 | 641 | 724 | 857 | 1150 | 1422 | 1584 | 1852 | |
8 | 69 | 151 | 164 | 288 | 610 | 706 | 930 | 1132 | 1663 | 1876 | 2046 | 2074 | |
平均 | 85 | 108 | 158 | 276 | 432 | 526 | 743 | 902 | 1336 | 1647 | 1940 | 2044 | |
SEM | 10 | 12 | 11 | 20 | 40 | 48 | 31 | 50 | 86 | 96 | 148 | 101 | |
第4組 MMAE+OBI-888 IP+IV 0.191 mg/kg+ 10 mg/kg 每周一次、 為期四周 | 1 | 128 | 166 | 189 | 302 | 520 | 578 | 656 | 844 | 971 | 1370 | 1440 | 1640 |
2 | 118 | 100 | 108 | 154 | 286 | 366 | 453 | 717 | 863 | 904 | 1332 | 1577 | |
3 | 45 | 79 | 死亡 | ||||||||||
4 | 88 | 93 | 143 | 243 | 371 | 824 | 898 | 1134 | 1606 | 1632 | 1830 | 2226 | |
5 | 71 | 75 | 161 | 200 | 279 | 451 | 486 | 693 | 840 | 1186 | 1218 | 1227 | |
6 | 79 | 112 | 121 | 220 | 288 | 414 | 483 | 577 | 985 | 1063 | 1192 | 1638 | |
7 | 91 | 111 | 244 | 274 | 561 | 653 | 735 | 1292 | 1507 | 2073 | 2400 | 2523 | |
8 | 57 | 53 | 73 | 89 | 110 | 189 | 293 | 359 | 554 | 844 | 940 | 931 | |
平均 | 85 | 99 | 148 | 212 | 345 | 496 | 572 | 802 | 1047 | 1296 | 1479 | 1680 | |
SEM | 10 | 12 | 21 | 27 | 59 | 79 | 77 | 121 | 143 | 165 | 185 | 206 | |
第5組 MMAE IP 0.191 mg/kg 每周一次、 為期四周 | 1 | 58 | 128 | 死亡 | |||||||||
2 | 53 | 76 | 104 | 安樂死 | |||||||||
3 | 132 | 148 | 死亡 | ||||||||||
4 | 72 | 82 | 114 | 444 | 429 | 590 | 649 | 748 | 1080 | 1174 | 1650 | 1652 | |
5 | 86 | 158 | 177 | 196 | 418 | 452 | 692 | 705 | 888 | 1340 | 1656 | 1963 | |
6 | 116 | 128 | 144 | 219 | 418 | 510 | 581 | 822 | 913 | 1439 | 1496 | 1828 | |
7 | 71 | 57 | 97 | 160 | 268 | 321 | 383 | 511 | 623 | 1030 | 1236 | 1196 | |
8 | 91 | 137 | 167 | 207 | 390 | 448 | 451 | 571 | 785 | 989 | 1208 | 1580 | |
平均 | 85 | 114 | 134 | 245 | 385 | 464 | 551 | 672 | 858 | 1194 | 1449 | 1644 | |
SEM | 10 | 13 | 14 | 51 | 30 | 44 | 59 | 57 | 75 | 87 | 97 | 130 |
表14:植入HPAC細胞之裸小鼠(nu/nu)體重
治療方法 | 編號 | 體重 (g) | |||||||||||||
0 a | 3 | 4 | 7 | 9 | 10 | 14 | 17 | 21 | 24 | 28 | 31 | 35 | 37 | ||
第1組 溶媒A+B IP+IV 10 μL/g+10 μL/g 每周一次、 為期四周 | 1 | 24.8 | 24.7 | 24.4 | 25.3 | 25.5 | 25.6 | 26.6 | 26.8 | 27.2 | 27.2 | 27.4 | 26.9 | 27.9 | 28.5 |
2 | 21.9 | 22.0 | 22.2 | 22.7 | 23.0 | 22.9 | 23.5 | 23.6 | 23.8 | 23.9 | 24.5 | 23.7 | 24.4 | 24.8 | |
3 | 24.7 | 24.3 | 24.5 | 25.3 | 25.5 | 25.5 | 26.6 | 26.5 | 26.6 | 26.8 | 27.1 | 26.4 | 28.2 | 28.3 | |
4 | 21.0 | 21.4 | 21.8 | 22.5 | 22.5 | 22.7 | 23.2 | 23.3 | 24.2 | 24.3 | 25.1 | 24.7 | 25.2 | 26.2 | |
5 | 23.3 | 24.1 | 24.6 | 25.4 | 25.0 | 25.0 | 25.5 | 25.4 | 25.6 | 26.0 | 27.0 | 26.2 | 27.0 | 27.2 | |
6 | 21.4 | 22.3 | 22.4 | 23.0 | 23.0 | 23.4 | 23.5 | 23.2 | 23.2 | 23.6 | 23.5 | 23.9 | 23.5 | 24.3 | |
7 | 22.8 | 23.0 | 23.5 | 24.2 | 24.2 | 24.1 | 24.4 | 24.2 | 24.9 | 25.0 | 25.4 | 25.6 | 26.8 | 27.2 | |
8 | 24.4 | 24.8 | 25.0 | 25.7 | 26.9 | 25.7 | 26.3 | 22.2 | 26.6 | 27.0 | 27.4 | 27.5 | 28.3 | 28.5 | |
平均 | 23.0 | 23.3 | 23.5 | 24.2 | 24.4 | 24.4 | 25.0 | 24.4 | 25.3 | 25.5 | 25.9 | 25.6 | 26.4 | 26.9 | |
SEM | 0.5 | 0.5 | 0.4 | 0.5 | 0.6 | 0.4 | 0.5 | 0.6 | 0.5 | 0.5 | 0.5 | 0.5 | 0.6 | 0.6 | |
第2組 抗體藥物共軛物(OBI-999) IV 10 mg/kg 每周一次、 為期四周 | 1 | 24.4 | 24.9 | 24.8 | 25.5 | 25.7 | 25.9 | 26.6 | 26.4 | 26.2 | 26.3 | 26.3 | 26.6 | 26.8 | 27.0 |
2 | 24.1 | 24.9 | 25.5 | 25.6 | 25.8 | 25.7 | 26.9 | 26.7 | 27.3 | 27.4 | 27.1 | 27.7 | 27.9 | 28.1 | |
3 | 23.8 | 23.9 | 23.9 | 24.5 | 24.8 | 24.6 | 25.6 | 25.6 | 25.9 | 26.1 | 26.0 | 26.4 | 27.0 | 27.8 | |
4 | 23.2 | 24.6 | 24.4 | 24.9 | 25.3 | 25.1 | 25.1 | 24.6 | 25.1 | 25.3 | 25.3 | 25.3 | 24.3 | 24.9 | |
5 | 24.5 | 25.1 | 25.3 | 25.9 | 25.8 | 25.8 | 26.5 | 26.8 | 27.4 | 27.4 | 27.4 | 27.5 | 27.6 | 28.9 | |
6 | 24.8 | 24.4 | 25.1 | 25.8 | 26.2 | 26.3 | 27.4 | 26.7 | 26.3 | 26.3 | 26.9 | 26.9 | 27.3 | 27.9 | |
7 | 22.8 | 23.0 | 23.1 | 24.0 | 23.8 | 23.8 | 24.3 | 24.0 | 24.5 | 24.6 | 24.6 | 24.7 | 24.5 | 25.6 | |
8 | 24.6 | 24.3 | 24.4 | 25.4 | 25.4 | 25.3 | 26.1 | 26.3 | 26.4 | 26.1 | 26.4 | 26.4 | 27.1 | 27.6 | |
平均 | 24.0 | 24.4 | 24.6 | 25.2 | 25.3 | 25.3 | 26.1 | 25.9 | 26.1 | 26.2 | 26.3 | 26.4 | 26.6 | 27.2 | |
SEM | 0.3 | 0.2 | 0.3 | 0.2 | 0.3 | 0.3 | 0.4 | 0.4 | 0.3 | 0.3 | 0.3 | 0.4 | 0.5 | 0.5 | |
第3組 OBI-888 IV 10 mg/kg 每周一次、 為期四周 | 1 | 25.1 | 24.3 | 24.5 | 25.5 | 25.4 | 25.8 | 26.5 | 26.9 | 26.4 | 27.3 | 26.9 | 26.8 | 28.8 | 28.4 |
2 | 25.5 | 25.5 | 25.9 | 26.6 | 27.3 | 27.4 | 27.0 | 27.3 | 27.8 | 29.4 | 28.8 | 28.4 | 28.9 | 29.0 | |
3 | 24.9 | 24.4 | 24.9 | 25.5 | 26.2 | 26.5 | 27.0 | 27.6 | 27.7 | 27.9 | 28.5 | 27.8 | 29.1 | 29.1 | |
4 | 25.0 | 25.5 | 26.1 | 27.1 | 27.0 | 27.1 | 24.5 | 27.6 | 27.3 | 26.8 | 27.9 | 27.5 | 28.5 | 27.9 | |
5 | 24.3 | 23.7 | 24.0 | 24.1 | 24.8 | 25.0 | 26.0 | 26.5 | 26.3 | 25.0 | 26.2 | 26.1 | 27.1 | 27.1 | |
6 | 23.9 | 24.5 | 24.7 | 25.2 | 25.3 | 25.1 | 25.6 | 25.6 | 25.7 | 26.7 | 26.9 | 26.2 | 26.8 | 26.9 | |
7 | 24.4 | 24.6 | 24.7 | 25.0 | 25.4 | 25.5 | 25.9 | 26.2 | 26.4 | 26.5 | 27.2 | 26.8 | 27.5 | 27.7 | |
8 | 23.0 | 23.5 | 23.7 | 23.9 | 24.5 | 24.9 | 25.1 | 24.9 | 24.6 | 24.7 | 25.3 | 25.4 | 25.9 | 25.3 | |
平均 | 24.5 | 24.5 | 24.8 | 25.4 | 25.7 | 25.9 | 25.9 | 26.6 | 26.5 | 26.8 | 27.2 | 26.9 | 27.8 | 27.7 | |
SEM | 0.3 | 0.3 | 0.3 | 0.4 | 0.4 | 0.3 | 0.3 | 0.3 | 0.4 | 0.5 | 0.4 | 0.3 | 0.4 | 0.4 | |
第4組 MMAE+OBI-888 IP+IV 0.191 mg/kg+ 10 mg/kg 每周一次、 為期四周 | 1 | 27.2 | 23.6 | 23.9 | 26.9 | 27.1 | 27.5 | 28.3 | 28.0 | 28.2 | 27.8 | 28.3 | 29.7 | 30.4 | 29.9 |
2 | 25.1 | 23.7 | 24.0 | 26.3 | 25.9 | 26.2 | 26.7 | 26.6 | 26.9 | 27.0 | 26.9 | 27.4 | 28.2 | 28.0 | |
3 | 23.6 | 21.6 | 20.7 | 死亡 | |||||||||||
4 | 24.1 | 21.7 | 22.6 | 25.6 | 25.4 | 25.3 | 25.8 | 25.4 | 26.2 | 25.2 | 25.4 | 24.9 | 25.5 | 25.6 | |
5 | 23.9 | 22.6 | 23.6 | 24.3 | 24.0 | 24.3 | 25.1 | 24.6 | 24.5 | 24.7 | 24.3 | 23.8 | 25.0 | 25.1 | |
6 | 25.2 | 23.7 | 25.0 | 27.5 | 27.7 | 27.9 | 28.8 | 26.9 | 28.3 | 28.4 | 28.3 | 28.4 | 29.7 | 30.0 | |
7 | 24.3 | 22.3 | 21.2 | 23.7 | 23.9 | 24.2 | 25.4 | 26.0 | 26.1 | 26.7 | 26.3 | 26.8 | 28.1 | 28.3 | |
8 | 23.3 | 23.7 | 24.1 | 24.6 | 25.2 | 25.6 | 25.2 | 26.0 | 26.1 | 26.7 | 26.3 | 26.8 | 27.5 | 27.6 | |
平均 | 24.6 | 22.8 | 23.1 | 25.5 | 25.6 | 25.8 | 26.5 | 26.2 | 26.6 | 26.6 | 26.5 | 26.8 | 27.8 | 27.8 | |
SEM | 0.4 | 0.3 | 0.5 | 0.5 | 0.5 | 0.5 | 0.6 | 0.4 | 0.5 | 0.5 | 0.6 | 0.7 | 0.8 | 0.7 | |
第5組 MMAE IP 0.191 mg/kg 每周一次、 為期四周 | 1 | 25.4 | 21.8 | 21.0 | 死亡 | ||||||||||
2 | 24.3 | 22.4 | 21.3 | 18.8 | 安樂死 | ||||||||||
3 | 24.8 | 21.5 | 20.5 | 死亡 | |||||||||||
4 | 24.2 | 21.6 | 22.0 | 25.1 | 24.9 | 25.9 | 25.7 | 23.9 | 25.6 | 24.8 | 26.2 | 25.0 | 26.9 | 26.7 | |
5 | 24.5 | 24.0 | 24.9 | 27.0 | 25.9 | 26.0 | 26.2 | 26.0 | 26.2 | 25.7 | 25.3 | 25.2 | 25.6 | 25.3 | |
6 | 23.3 | 20.7 | 19.6 | 21.7 | 22.2 | 26.3 | 24.4 | 24.5 | 24.7 | 24.9 | 24.9 | 25.4 | 25.6 | 25.5 | |
7 | 24.0 | 23.1 | 23.7 | 25.2 | 24.9 | 25.3 | 26.0 | 25.3 | 25.7 | 25.6 | 26.3 | 26.4 | 27.2 | 27.1 | |
8 | 22.7 | 21.6 | 22.1 | 23.8 | 23.5 | 24.1 | 24.5 | 23.6 | 23.8 | 23.7 | 24.1 | 24.1 | 24.5 | 24.0 | |
平均 | 24.2 | 22.1 | 21.9 | 23.6 | 24.3 | 25.5 | 25.3 | 24.6 | 25.2 | 24.9 | 25.4 | 25.2 | 26.0 | 25.7 | |
SEM | 0.3 | 0.4 | 0.6 | 1.2 | 0.7 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.5 | 0.5 |
第三十四圖顯示經植入HPAC的裸小鼠(nu/nu)體內腫瘤之生長曲線。對小鼠施打之10 mg/kg抗體藥物共軛物(OBI-999)試驗物質自第14天起呈現顯著抗腫瘤活性,持續至第37天。施打抗體藥物共軛物(OBI-999)的小鼠之平均腫瘤尺寸為1 mm
3(T/C = 0.1%,TGI = 104.0%,
p< 0.001)。對小鼠單獨施打之10 mg/kg OBI-888製劑並未呈現顯著抗腫瘤活性。施打OBI-888的小鼠之平均腫瘤尺寸為2,044 mm
3(T/C = 94.2%,TGI = 6.0%,
p= 0.967)。對小鼠單獨施打或與10 mg/kgOBI-888合併施打之0.191 mg/kg MMAE製劑呈現微弱抗腫瘤活性,小鼠之平均腫瘤尺寸分別為1,644 mm
3(T/C = 75.8%,TGI = 25.2%,
p= 0.231)及之平均腫瘤尺寸為1,680 mm
3(T/C = 77.4%,TGI = 23.5%,
p= 0.213)。
第三十五圖顯示經植入HPAC的裸小鼠(nu/nu)之體重變化。所有試驗物質皆可被受試動物容忍,且實驗過程中,施打試驗物質之組別皆未呈現顯著體重變化。
除非另外說明,否則本文使用之所有技術及科學詞彙及縮寫,皆與本發明所屬技術領域中具通常知識者所理解之意義相同。雖然任何與本文描述相似或相等之組成物、方法、工具組及資訊傳遞方式可用以實施本發明,但較佳之組成物、方法、工具組及資訊傳遞方式仍如本文所述。
本文列出之所有參考文獻,皆以法律允許最大限度之引用方式併入本文中。針對該些參考文獻之討論,目的僅為概述文獻作者之主張。本文並未認定任何參考文獻(或任何參考文獻之一部分)為相關習知技術。對於任何所列參考文獻之準確性及相關性,申請人保有質疑之權利。
無
在參照說明書所附圖式並搭配實施方式說明後,即可更全面理解本發明內容。附圖詳述之實施例僅為實施本發明之範例,不應被理解為本發明僅限於詳述之實施例。
第一圖為使用疏水性交互作用層析測定OBI-888(第一圖A)及抗體藥物共軛物(OBI-999)(第一圖B)之結果圖。
第二圖為使用粒徑篩析層析法測定OBI-888(第二圖A)及抗體藥物共軛物(OBI-999)(第二圖B)之結果圖。
第三圖為使用十二烷基硫酸鈉聚丙烯醯胺凝膠電泳(SDS-PAGE)分析OBI-888及抗體藥物共軛物(OBI-999)之結果圖。泳道M:Novex Sharp 標準蛋白質;泳道1:配方緩衝液中的原生抗體OBI-888;泳道2:反應緩衝液中的原生抗體OBI-888。泳道3:抗體藥物共軛物(OBI-999)。
第四圖為經植入MCF-7的雌裸小鼠(nu/nu)體內腫瘤之生長曲線。每周對小鼠施用10 mg/kg試驗物質一次,為期兩周(第四圖A),或以較低劑量每周對小鼠施用3、1及0.3 mg/kg,為期六周(第四圖B)。T/C 值≦42% 時,代表相較於對照組,試驗物質對實驗組具備顯著抗腫瘤活性(
#)。使用雙因子變異數分析再進行Bonferroni 事後檢定,以比較對照組及施用試驗物質之實驗組。
p< 0.05時兩組有顯著差異。
第五圖為經植入MCF-7的雌裸小鼠(nu/nu)體重變化曲線。每周對小鼠施用10 mg/kg試驗物質一次,為期兩周(第五圖A),或以較低劑量每周對小鼠施用3、1及0.3 mg/kg,為期六周(第五圖B)。T/C 值≦42% 時,代表相較於對照組,試驗物質對實驗組具備顯著抗腫瘤活性(
#)。使用雙因子變異數分析再進行Bonferroni 事後檢定,以比較對照組及施用試驗物質之實驗組。
p< 0.05時兩組有顯著差異。
第六圖為經植入MCF-7後罹患腫瘤的雌裸小鼠(nu/nu),試驗物質為10 mL/kg溶媒(25 mM 檸檬酸鈉、pH6.5+100 mM NaCl),每周經靜脈注射一次,為期六周。
第七圖為經植入MCF-7後罹患腫瘤的雌裸小鼠(nu/nu),試驗物質為10 mL/kg溶媒(25 mM 檸檬酸鈉、pH6.5+100 mM NaCl),每周經靜脈注射一次,為期兩周。
第八圖為經植入MCF-7後罹患腫瘤的雌裸小鼠(nu/nu),試驗物質為10 mg/kg抗體藥物共軛物(OBI-999),每周經靜脈注射一次,為期兩周。
第九圖為經植入MCF-7後罹患腫瘤的雌裸小鼠(nu/nu),試驗物質為0.3 mg/kg抗體藥物共軛物(OBI-999),每周經靜脈注射一次,為期六周。
第十圖為經植入MCF-7後罹患腫瘤的雌裸小鼠(nu/nu),試驗物質為1 mg/kg抗體藥物共軛物(OBI-999),每周經靜脈注射一次,為期六周。
第十一圖為經植入MCF-7後罹患腫瘤的雌裸小鼠(nu/nu),試驗物質為3 mg/kg抗體藥物共軛物(OBI-999),每周經靜脈注射一次,為期六周。
第十二圖為經植入MCF-7後罹患腫瘤的雌裸小鼠(nu/nu),試驗物質為10 mg/kg之OBI-888,每周經靜脈注射一次,為期兩周。
第十三圖為經植入MCF-7後罹患腫瘤的雌裸小鼠(nu/nu),試驗物質為0.3 mg/kg之OBI-888,每周經靜脈注射一次,為期六周。
第十四圖為經植入MCF-7後罹患腫瘤的雌裸小鼠(nu/nu),試驗物質為1 mg/kg之OBI-888,每周經靜脈注射一次,為期六周。
第十五圖為經植入MCF-7後罹患腫瘤的雌裸小鼠(nu/nu),試驗物質為3 mg/kg之OBI-888,每周經靜脈注射一次,為期六周。
第十六圖為經植入MCF-7後罹患腫瘤的雌裸小鼠(nu/nu),試驗物質為0.057 mg/kg之MMAE,每周經靜脈注射一次,為期兩周。
第十七圖為經植入NCI-N87的雌裸小鼠(nu/nu)體內之腫瘤生長曲線。施用溶媒及試驗物質之方式如前述實驗設計。T/C 值≦42%時,代表相較於對照組,試驗物質對實驗組具備顯著抗腫瘤活性(
#)。使用雙因子變異數分析再進行Bonferroni 事後檢定,以比較對照組及施用試驗物質之實驗組。
p< 0.05時兩組有顯著差異。
第十八圖為經植入NCI-N87的雌裸小鼠(nu/nu)體重變化曲線。施用溶媒及試驗物質之方式如前述實驗設計。每周測量並紀錄小鼠體重兩次,至第100天為止。
第十九圖為經植入NCI-N87後罹患腫瘤的雌裸小鼠(nu/nu),試驗物質為10 mL/kg溶媒(25 mM 檸檬酸鈉、pH6.5+100 mM NaCl),每周經靜脈注射一次,為期四周;以及10 mL/kg溶媒(PBS,pH 7.4),每周經腹腔注射一次,為期四周。
第二十圖為經植入NCI-N87後罹患腫瘤的雌裸小鼠(nu/nu),試驗物質為1 mg/kg抗體藥物共軛物(OBI-999),每周經靜脈注射一次,為期四周。
第二十一圖為經植入NCI-N87後罹患腫瘤的雌裸小鼠(nu/nu),試驗物質為3 mg/kg抗體藥物共軛物(OBI-999),每周經靜脈注射一次,為期四周。
第二十二圖為經植入NCI-N87後罹患腫瘤的雌裸小鼠(nu/nu),試驗物質為10 mg/kg抗體藥物共軛物(OBI-999),每周經靜脈注射一次,為期四周。
第二十三圖為經植入NCI-N87後罹患腫瘤的雌裸小鼠(nu/nu),試驗物質為10 mg/kg之OBI-888,每周經靜脈注射一次,為期四周。
第二十四圖為經植入NCI-N87後罹患腫瘤的雌裸小鼠(nu/nu),試驗物質為3 mg/kg抗體藥物共軛物OBI-910(抗CD30之抗體藥物共軛物),每周經靜脈注射一次,為期四周。
第二十五圖為經植入NCI-N87後罹患腫瘤的雌裸小鼠(nu/nu),試驗物質為0.191 mg/kg之MMAE,每周經腹腔注射一次,為期四周;以及10 mg/kg之OBI-888,每周經靜脈注射一次,為期四周。
第二十六圖為經植入NCI-N87後罹患腫瘤的雌裸小鼠(nu/nu),試驗物質為0.191 mg/kg之MMAE,每周經腹腔注射一次,為期四周。
第二十七圖為經植入NCI-H526的雌裸小鼠(nu/nu)體內之腫瘤生長曲線。施用溶媒及試驗物質之方式如前述實驗設計。T/C 值≦42%時,代表相較於對照組,試驗物質對實驗組具備顯著抗腫瘤活性(
#)。使用雙因子變異數分析再進行Bonferroni 事後檢定,以比較對照組及施用試驗物質之實驗組。
p< 0.05時兩組有顯著差異。
第二十八圖為經植入NCI-H526的雌裸小鼠(nu/nu)體重變化曲線。施用溶媒及試驗物質之方式如前述實驗設計。每周測量並紀錄小鼠體重兩次,至第45天為止。
第二十九圖為經植入NCI-H526後罹患腫瘤的雌裸小鼠(nu/nu),試驗物質為10 mL/kg溶媒(25 mM 檸檬酸鈉、pH6.5+100 mM NaCl),每周經靜脈注射一次,為期四周;以及10 mL/kg溶媒(PBS,pH 7.4),每周經腹腔注射一次,為期四周。
第三十圖為經植入NCI-H526後罹患腫瘤的雌裸小鼠(nu/nu),試驗物質為1 mg/kg抗體藥物共軛物(OBI-999),每周經靜脈注射一次,為期四周。
第三十一圖為經植入NCI-H526後罹患腫瘤的雌裸小鼠(nu/nu),試驗物質為10 mg/kg抗體藥物共軛物(OBI-999),每周經靜脈注射一次,為期四周。
第三十二圖為經植入NCI-H526後罹患腫瘤的雌裸小鼠(nu/nu),試驗物質為0.191 mg/kg之MMAE,每周經腹腔注射一次,為期四周;以及10 mg/kg之OBI-888,每周經靜脈注射一次,為期四周。
第三十三圖為經植入NCI-H526後罹患腫瘤的雌裸小鼠(nu/nu),試驗物質為0.191 mg/kg之MMAE,每周經腹腔注射一次,為期四周。
第三十四圖為不同的BALB/c雄裸小鼠實驗組腫瘤生長曲線,小鼠體內皆已形成胰腺癌腫瘤。施用溶媒及試驗物質之方式如前述實驗設計。資料點代表實驗組平均值。誤差線代表平均值標準誤差(SEM)。
第三十五圖為不同的BALB/c雄裸小鼠實驗組體重變化曲線,小鼠體內皆已形成胰腺癌腫瘤。施用溶媒及試驗物質之方式如前述實驗設計。資料點代表實驗組平均體重。誤差線代表平均值標準誤差(SEM)。
第三十六圖顯示不同的BALB/c雄裸小鼠實驗組中小鼠體內已形成胰腺癌腫瘤的情形。
Claims (15)
- 一種抗體藥物共軛物(ADC),其具有下列化學式:Ab-(L-D)n (I)其中一或多個藥物基團D透過聯結分子L與抗體Ab以共價鍵相連;n為由1到8之整數;其中該抗體Ab為抗SSEA-4(Neu5Acα2→3Galβ1→3GalNAcβ1→3Galα1→4Galβ1→4Glcβ1)抗體,該抗SSEA-4抗體為OBI-898;其中該聯結分子L包含硫醇基,該硫醇基經還原一雙硫鍵而產生;且其中該藥物基團D包含單甲基奧瑞斯他丁(MMAE)。
- 如請求項1之抗體藥物共軛物,其中該抗體Ab之重鏈可變域包含:i.一第一重鏈互補決定域(HCDR1),其具有如SEQ ID NO:29之胺基酸序列;ii.一第二重鏈互補決定域(HCDR2),其具有如SEQ ID NO:31之胺基酸序列;及iii.一第三重鏈互補決定域(HCDR3),其具有如SEQ ID NO:33之胺基酸序列;以及其中該抗體Ab之輕鏈可變域包含:iv.一第一輕鏈互補決定域(LCDR1),其具有如SEQ ID NO:22之胺基酸序列;v.一第二輕鏈互補決定域(LCDR2),其具有如SEQ ID NO:24之胺基酸序列;及vi.一第三重鏈互補決定域(LCDR3),其具有如SEQ ID NO:26之胺基酸序列。
- 一種醫藥組成物,其包含:如請求項1之抗體藥物共軛物,或其醫藥上可接受之一鹽類;以及一醫藥上可接受溶劑、載體或賦形劑。
- 一種製造如請求項1之抗體藥物共軛物的方法,其中該方法包含:使抗體Ab與化學式(I)之聯結分子L試劑反應,以形成抗體-聯結分子中間產物Ab-L,並使抗體Ab與藥物基團D反應,以形成抗體藥物共軛物;或使藥物基團D與聯結分子L試劑反應,以形成一藥物-聯結分子中間產物D-L,並使D-L與抗體Ab反應,以形成抗體藥物共軛物。
- 一種抗體藥物共軛物用於製備治療癌症之藥物的用途,其中該藥物包含對患有癌症之個體施用一有效劑量之如請求項1之抗體藥物共軛物。
- 如請求項5之用途,其中該癌症為表現SSEA-4之癌症。
- 如請求項6之用途,其中該表現SSEA-4之癌症選自由惡性肉瘤、皮膚癌、血癌、淋巴癌、腦癌、膠質母細胞瘤、肺癌、乳癌、口腔癌、頭頸癌、鼻咽癌、食道癌、胃癌、肝癌、膽管癌、膽囊癌、膀胱癌、胰臟癌、腸癌、大腸直腸癌、腎臟癌、子宮頸癌、子宮內膜癌、卵巢癌、睪丸癌、頰癌、口咽癌、喉癌及前列腺癌組成之群組。
- 一種醫藥組成物用於製備誘發或提升有需要的個體體內免疫反應之藥物的用途,其包含:對該個體施用一免疫生成有效劑量之如請求項3之醫藥組成物。
- 如請求項5或8之用途,其中該個體為人類。
- 如請求項5或8之用途,其中該有效劑量為自0.01μg至250mg。
- 如請求項5或8之用途,其中該有效劑量為自0.001μg/kg至250mg/kg。
- 如請求項5或8之用途,其中該有效劑量包含於共同配方或個別配方內。
- 如請求項1之抗體藥物共軛物,其與一有效量之額外製劑組合,該額外製劑選自由抗癌製劑、免疫抑制製劑及抗感染製劑組成之群組,該額外製劑用於治療一癌症,該癌症選自由惡性肉瘤、皮膚癌、血癌、淋巴癌、腦癌、膠質母細胞瘤、肺癌、乳癌、口腔癌、頭頸癌、鼻咽癌、食道癌、胃癌、肝癌、膽管癌、膽囊癌、膀胱癌、胰臟癌、腸癌、大腸直腸癌、腎臟癌、子宮頸癌、子宮內膜癌、卵巢癌、睪丸癌、頰癌、口咽癌、喉癌及前列腺癌組成之群組。
- 一種使用如請求項1之抗體藥物共軛物製造藥物並與一有效量之額外製劑組合的用途,該額外製劑選自由抗癌製劑、免疫抑制製劑及抗感染製劑組成之群組,該額外製劑用於治療一癌症,該癌症選自由惡性肉瘤、皮膚癌、血癌、淋巴癌、腦癌、膠質母細胞瘤、肺癌、乳癌、口腔癌、頭頸癌、鼻咽癌、食道癌、胃癌、肝癌、膽管癌、膽囊癌、膀胱癌、胰臟癌、腸癌、大腸直腸癌、腎臟癌、子宮頸癌、子宮內膜癌、卵巢癌、睪丸癌、頰癌、口咽癌、喉癌及前列腺癌組成之群組。
- 一種測定抗體藥物共軛物針對癌症細胞療效之方法,包含:(a)將細胞與如請求項1之抗體藥物共軛物接觸;(b)根據與該癌症細胞結合之抗體藥物共軛物數量,測量該抗體藥物共軛物之結合程度;及(c)測定癌症細胞對抗體藥物共軛物之結合效力。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662424851P | 2016-11-21 | 2016-11-21 | |
US62/424,851 | 2016-11-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW202233250A TW202233250A (zh) | 2022-09-01 |
TWI822055B true TWI822055B (zh) | 2023-11-11 |
Family
ID=62145860
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW111119282A TWI822055B (zh) | 2016-11-21 | 2017-11-21 | 共軛生物分子、醫藥組成物及方法 |
TW106140308A TWI767959B (zh) | 2016-11-21 | 2017-11-21 | 共軛生物分子、醫藥組成物及方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW106140308A TWI767959B (zh) | 2016-11-21 | 2017-11-21 | 共軛生物分子、醫藥組成物及方法 |
Country Status (12)
Country | Link |
---|---|
US (2) | US11000601B2 (zh) |
EP (1) | EP3541414A4 (zh) |
JP (2) | JP2019535731A (zh) |
KR (1) | KR20190077103A (zh) |
CN (1) | CN110290800A (zh) |
AU (1) | AU2017361549B2 (zh) |
BR (1) | BR112019010356A2 (zh) |
CA (1) | CA3044274A1 (zh) |
IL (1) | IL266693A (zh) |
TW (2) | TWI822055B (zh) |
WO (1) | WO2018094414A1 (zh) |
ZA (1) | ZA201903308B (zh) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
CN105682666B (zh) | 2013-09-06 | 2021-06-01 | 中央研究院 | 使用醣脂激活人类iNKT细胞 |
EP3094352B1 (en) * | 2014-01-16 | 2020-09-23 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
KR20220151036A (ko) | 2014-05-27 | 2022-11-11 | 아카데미아 시니카 | 항-cd20 글리코항체 및 이의 용도 |
AU2015267052A1 (en) | 2014-05-27 | 2016-12-15 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
AU2015267045B2 (en) | 2014-05-27 | 2021-02-25 | Academia Sinica | Anti-HER2 glycoantibodies and uses thereof |
US11332523B2 (en) | 2014-05-28 | 2022-05-17 | Academia Sinica | Anti-TNF-alpha glycoantibodies and uses thereof |
WO2017041027A1 (en) | 2015-09-04 | 2017-03-09 | Obi Pharma, Inc. | Glycan arrays and method of use |
US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
CN109311995A (zh) | 2016-03-29 | 2019-02-05 | 台湾浩鼎生技股份有限公司 | 抗体、药物组合物和方法 |
KR20180128496A (ko) | 2016-04-22 | 2018-12-03 | 오비아이 파머 인코퍼레이티드 | 글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에 의한 암 면역요법 |
CN110072545A (zh) | 2016-07-27 | 2019-07-30 | 台湾浩鼎生技股份有限公司 | 免疫原性/治疗性聚糖组合物及其用途 |
JP7121724B2 (ja) | 2016-07-29 | 2022-08-18 | オービーアイ ファーマ,インコーポレイテッド | ヒト抗体、医薬組成物及び方法 |
CN109963868B (zh) | 2016-08-22 | 2023-11-14 | 醣基生医股份有限公司 | 抗体、结合片段及使用方法 |
CA3044274A1 (en) | 2016-11-21 | 2018-05-24 | Obi Pharma, Inc. | Conjugated biological molecules, pharmaceutical compositions and methods |
US11827703B2 (en) | 2018-05-09 | 2023-11-28 | Legochem Biosciences, Inc. | Compositions and methods related to anti-CD19 antibody drug conjugates |
TW202016147A (zh) * | 2018-06-01 | 2020-05-01 | 台灣浩鼎生技股份有限公司 | 使用抗Globo H或抗SSEA-4抗體與抗負面免疫檢查點抗體之結合醫療 |
TW202035444A (zh) | 2018-06-27 | 2020-10-01 | 台灣浩鼎生技股份有限公司 | 用於糖蛋白工程的糖苷合成酶變體及其使用方法 |
TW202035462A (zh) * | 2018-10-02 | 2020-10-01 | 台灣浩鼎生技股份有限公司 | 使用抗ssea-4抗體結合醫療性腫瘤藥劑的組合醫療 |
KR102503143B1 (ko) * | 2019-03-06 | 2023-02-24 | 주식회사 레고켐 바이오사이언스 | 인간 dlk1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도 |
WO2022173840A1 (en) * | 2021-02-09 | 2022-08-18 | Obi Pharma, Inc. | Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201546092A (zh) * | 2014-04-10 | 2015-12-16 | Obi Pharma Inc | 抗體、產生該抗體之融合瘤、包含該抗體之藥學組成物及其用途 |
US20160102151A1 (en) * | 2014-01-16 | 2016-04-14 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
TW201636363A (zh) * | 2015-01-24 | 2016-10-16 | 中央研究院 | 腫瘤標記及其使用方法 |
Family Cites Families (152)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4601903A (en) | 1985-05-01 | 1986-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
US5811128A (en) | 1986-10-24 | 1998-09-22 | Southern Research Institute | Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US4849222A (en) | 1987-03-24 | 1989-07-18 | The Procter & Gamble Company | Mixtures for treating hypercholesterolemia |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
JP2670680B2 (ja) | 1988-02-24 | 1997-10-29 | 株式会社ビーエムジー | 生理活性物質含有ポリ乳酸系微小球およびその製造法 |
AU632065B2 (en) | 1988-09-23 | 1992-12-17 | Novartis Vaccines And Diagnostics, Inc. | Cell culture medium for enhanced cell growth, culture longevity and product expression |
NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
EP0479909B1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
AU639726B2 (en) | 1989-09-08 | 1993-08-05 | Duke University | Structural alterations of the egf receptor gene in human gliomas |
JP3068180B2 (ja) | 1990-01-12 | 2000-07-24 | アブジェニックス インコーポレイテッド | 異種抗体の生成 |
US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
CA2086417C (en) | 1990-06-29 | 1999-07-06 | Biosource Technologies, Inc. | Melanin production by transformed organisms |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
US5508192A (en) | 1990-11-09 | 1996-04-16 | Board Of Regents, The University Of Texas System | Bacterial host strains for producing proteolytically sensitive polypeptides |
US5264365A (en) | 1990-11-09 | 1993-11-23 | Board Of Regents, The University Of Texas System | Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides |
ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
DE69222303T2 (de) | 1991-04-30 | 1998-01-22 | Eukarion Inc | Kationisierte antikörper gegen intrazelluläre eiweisse |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
DE69229477T2 (de) | 1991-09-23 | 1999-12-09 | Cambridge Antibody Tech | Methoden zur Herstellung humanisierter Antikörper |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
US5288502A (en) | 1991-10-16 | 1994-02-22 | The University Of Texas System | Preparation and uses of multi-phase microspheres |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
DE69333807T2 (de) | 1992-02-06 | 2006-02-02 | Chiron Corp., Emeryville | Marker für krebs und biosynthetisches bindeprotein dafür |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
DE69334095T2 (de) | 1992-07-17 | 2007-04-12 | Dana-Farber Cancer Institute, Boston | Verfahren zur intrazellulären Bindung von zielgerichteten Molekülen |
WO1994002178A1 (en) | 1992-07-27 | 1994-02-03 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Targeting of liposomes to the blood-brain barrier |
CA2140280A1 (en) | 1992-08-17 | 1994-03-03 | Avi J. Ashkenazi | Bispecific immunoadhesins |
WO1994011026A2 (en) | 1992-11-13 | 1994-05-26 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
WO1995011010A1 (en) | 1993-10-22 | 1995-04-27 | Genentech, Inc. | Methods and compositions for microencapsulation of antigens for use as vaccines |
US6544952B1 (en) | 1994-03-15 | 2003-04-08 | Sloan-Kettering Institute For Cancer Research | Synthesis of glycoconjugates of the globo-H epitope and uses thereof |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
WO1996030347A1 (en) | 1995-03-30 | 1996-10-03 | Pfizer Inc. | Quinazoline derivatives |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
CA2761116A1 (en) | 1995-04-27 | 1996-10-31 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
CA2219486A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
JPH11507535A (ja) | 1995-06-07 | 1999-07-06 | イムクローン システムズ インコーポレイテッド | 腫瘍の成長を抑制する抗体および抗体フラグメント類 |
PT1516628E (pt) | 1995-07-27 | 2013-09-24 | Genentech Inc | Formulação de proteína liofilizada isotónica estável |
AU2660397A (en) | 1996-04-05 | 1997-10-29 | Board Of Regents, The University Of Texas System | Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells |
CN100503580C (zh) | 1996-04-12 | 2009-06-24 | 沃尼尔·朗伯公司 | 酪氨酸激酶的不可逆抑制剂 |
US6231859B1 (en) | 1996-12-02 | 2001-05-15 | Aquila Biopharmaceuticals, Inc. | Saponin adjuvant compositions |
KR20080059467A (ko) | 1996-12-03 | 2008-06-27 | 아브게닉스, 인크. | 복수의 vh 및 vk 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체 |
AUPO517897A0 (en) | 1997-02-19 | 1997-04-11 | Csl Limited | Chelating immunostimulating complexes |
UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
US6083715A (en) | 1997-06-09 | 2000-07-04 | Board Of Regents, The University Of Texas System | Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells |
ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
US7018637B2 (en) | 1998-02-23 | 2006-03-28 | Aventis Pasteur, Inc | Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines |
AUPP807399A0 (en) | 1999-01-08 | 1999-02-04 | Csl Limited | Improved immunogenic lhrh composition and methods relating thereto |
EP2204186B1 (en) | 1999-02-17 | 2016-04-06 | CSL Limited | Immunogenic complexes and methods relating thereto |
EP1785726A1 (en) | 1999-02-17 | 2007-05-16 | Carbozyme NT Ltd | Combinatioral complex carbohydrate libraries and methods for the manufacture and uses thereof |
US7824687B2 (en) | 1999-08-20 | 2010-11-02 | Sloan-Kettering Institute For Cancer Research | Clustered multi-antigenic carbohydrate constructs, methods for their preparation, and uses thereof |
US7854934B2 (en) | 1999-08-20 | 2010-12-21 | Sloan-Kettering Institute For Cancer Research | Glycoconjugates, glycoamino acids, intermediates thereto, and uses thereof |
US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
AU2001286930A1 (en) | 2000-08-30 | 2002-03-13 | The Board Of Trustees Of The Leland Stanford Junior University | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
US20030083299A1 (en) | 2000-11-04 | 2003-05-01 | Ferguson Ian A. | Non-invasive delivery of polypeptides through the blood-brain barrier |
US20040018194A1 (en) | 2000-11-28 | 2004-01-29 | Francisco Joseph A. | Recombinant anti-CD30 antibodies and uses thereof |
US20030104402A1 (en) | 2001-01-23 | 2003-06-05 | University Of Rochester | Methods of producing or identifying intrabodies in eukaryotic cells |
DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
WO2003009815A2 (en) | 2001-07-25 | 2003-02-06 | Biomarin Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
EP1429785A4 (en) | 2001-08-14 | 2005-12-14 | Biomira Inc | IMMUNOGENIC CONJUGATE OF GLUCIDIC HAPTENES AND AGREED PROTEIN MEDIUM |
WO2003043583A2 (en) | 2001-11-20 | 2003-05-30 | Seattle Genetics, Inc. | Treatment of immunological disorders using anti-cd30 antibodies |
US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
WO2003077945A1 (en) | 2002-03-14 | 2003-09-25 | Medical Research Council | Intracellular antibodies |
AU2003294210A1 (en) | 2002-07-31 | 2004-05-04 | Seattle Genetics, Inc | Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders |
EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
EP1578447A4 (en) | 2002-10-31 | 2009-06-03 | Genentech Inc | METHODS AND COMPOSITIONS THAT CAN INCREASE ANTIBODY PRODUCTION |
CA2507762C (en) | 2002-12-03 | 2013-02-05 | Blanchette Rockefeller Neurosciences Institute | Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier |
US7575893B2 (en) | 2003-01-23 | 2009-08-18 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
US20060035267A1 (en) | 2003-04-09 | 2006-02-16 | Livingston Philip O | Optimal polyvalent vaccine for cancer |
GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
RU2556128C2 (ru) | 2003-08-25 | 2015-07-10 | ЮниВэкс, ЭлЭлСи | Профилактическая противораковая вакцина |
EP1663239A4 (en) | 2003-09-10 | 2008-07-23 | Cedars Sinai Medical Center | KALIUM CHANNEL-MEDIATED FEEDING OF MEDICINES BY THE BLOOD BRAIN BARRIER |
JP2007527539A (ja) | 2004-03-05 | 2007-09-27 | ザ スクリプス リサーチ インスティテュート | ハイスループットグリカンマイクロアレイ |
KR100958505B1 (ko) | 2004-07-18 | 2010-05-17 | 씨에스엘 리미티드 | 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기위한 올리고뉴클레오티드 제제 |
JP2008506683A (ja) | 2004-07-18 | 2008-03-06 | コーリー ファーマシューティカル グループ, リミテッド | 先天免疫応答を誘導するための方法および組成物 |
CN103361303B (zh) | 2005-03-31 | 2015-09-30 | 斯丹姆涅恩有限公司 | 制备一种高度纯化来自羊膜的细胞群的方法 |
EA032466B1 (ru) | 2005-10-07 | 2019-05-31 | Экселиксис, Инк. | Способы получения ингибиторов mek |
AU2007325283B2 (en) | 2006-11-27 | 2012-08-30 | Diadexus, Inc. | Ovr110 antibody compositions and methods of use |
WO2009035494A2 (en) | 2007-07-30 | 2009-03-19 | The Scripps Research Institute | Methods for producing anti-glycan antibodies, vaccines and methods for treating cancer or infectious disease |
JPWO2009044918A1 (ja) | 2007-10-05 | 2011-02-17 | 武田薬品工業株式会社 | ニューロメジンu誘導体 |
US20110117009A1 (en) | 2008-03-31 | 2011-05-19 | Freie Universität Berlin | Drug conjugates with polyglycerols |
CN102112484B (zh) | 2008-04-08 | 2015-03-04 | 索隆-基特林癌症研究协会 | 三萜皂苷、其合成方法和用途 |
US20090317411A1 (en) * | 2008-06-16 | 2009-12-24 | Academia Sinica | Compositions for inducing immune responses specific to globo h and ssea3 and uses thereof in cancer treatment |
CN102215862B (zh) | 2009-06-16 | 2016-04-06 | 中央研究院 | Globo h及含新颖糖脂质佐剂的相关抗癌疫苗 |
US9180127B2 (en) * | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
EP2347769A1 (en) | 2010-01-20 | 2011-07-27 | Glycotope GmbH | Cancer stem cell markers and uses thereof |
JP6050227B2 (ja) | 2010-06-11 | 2016-12-21 | スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ | 多価糖ペプチド構築物およびその使用 |
EP2500035A1 (en) | 2011-03-15 | 2012-09-19 | Icon Genetics GmbH | Pharmaceutical formulation containing immunglobulin |
TWI597065B (zh) | 2011-06-10 | 2017-09-01 | 梅爾莎納醫療公司 | 蛋白質-聚合物-藥物共軛體 |
SI2817338T1 (sl) | 2012-02-24 | 2017-11-30 | Abbvie Stemcentrx Llc | Modulatorji DLL3 in postopki uporabe |
NO2825156T3 (zh) | 2012-03-16 | 2017-12-23 | ||
US10517936B2 (en) | 2013-01-04 | 2019-12-31 | OBI Pharma., Inc. | Vaccines with higher carbohydrate antigen density and novel saponin adjuvant |
WO2014178195A1 (ja) | 2013-05-02 | 2014-11-06 | 独立行政法人産業技術総合研究所 | 糖鎖抗原の免疫誘導剤 |
BR112015032713B1 (pt) | 2013-09-17 | 2023-03-21 | Obi Pharma, Inc | Composto, composição farmacêutica, uso de uma quantidade terapeuticamente efetiva da composição farmacêutica, e uso do composto |
KR102270428B1 (ko) * | 2013-09-27 | 2021-06-29 | 스미또모 가가꾸 가부시키가이샤 | 적층 필름, 유기 전계 발광 장치, 광전 변환 장치 및 액정 디스플레이 |
EP3094352B1 (en) * | 2014-01-16 | 2020-09-23 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
CN106456766B (zh) | 2014-03-19 | 2020-03-10 | 台湾基督长老教会马偕医疗财团法人马偕纪念医院 | 抗免疫原性糖肽的抗体、包含其的组合物及其用途 |
ES2693035T3 (es) | 2014-04-01 | 2018-12-07 | Miltenyi Biotec Gmbh | SSEA4 y ST3GAL2 como biomarcadores de respuesta a fármacos quimioterapéuticos |
CA2958757C (en) | 2014-08-19 | 2021-04-27 | Miltenyi Biotec Gmbh | Chimeric antigen receptor specific for ssea4 antigen |
KR20230109783A (ko) | 2014-09-15 | 2023-07-20 | 오비아이 파머 인코퍼레이티드 | 면역원성/치료적 당접합체 조성물 및 그의 용도 |
KR102439847B1 (ko) * | 2015-08-25 | 2022-09-01 | 삼성에스디아이 주식회사 | 이차 전지 |
WO2017041027A1 (en) | 2015-09-04 | 2017-03-09 | Obi Pharma, Inc. | Glycan arrays and method of use |
AR106307A1 (es) | 2015-10-07 | 2018-01-03 | Obi Pharma Inc | Anticuerpos de hidratos de carbono, composiciones farmacéuticas y usos de los mismos |
CN109311995A (zh) | 2016-03-29 | 2019-02-05 | 台湾浩鼎生技股份有限公司 | 抗体、药物组合物和方法 |
US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
KR20180128496A (ko) | 2016-04-22 | 2018-12-03 | 오비아이 파머 인코퍼레이티드 | 글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에 의한 암 면역요법 |
CN110072545A (zh) | 2016-07-27 | 2019-07-30 | 台湾浩鼎生技股份有限公司 | 免疫原性/治疗性聚糖组合物及其用途 |
JP7121724B2 (ja) * | 2016-07-29 | 2022-08-18 | オービーアイ ファーマ,インコーポレイテッド | ヒト抗体、医薬組成物及び方法 |
CN109963868B (zh) * | 2016-08-22 | 2023-11-14 | 醣基生医股份有限公司 | 抗体、结合片段及使用方法 |
CA3044274A1 (en) | 2016-11-21 | 2018-05-24 | Obi Pharma, Inc. | Conjugated biological molecules, pharmaceutical compositions and methods |
CA3067380A1 (en) * | 2017-06-15 | 2018-12-20 | Development Center For Biotechnology | Antibody-drug conjugates containing anti-globo h antibodies and uses thereof |
-
2017
- 2017-11-21 CA CA3044274A patent/CA3044274A1/en active Pending
- 2017-11-21 CN CN201780071980.6A patent/CN110290800A/zh active Pending
- 2017-11-21 BR BR112019010356A patent/BR112019010356A2/pt unknown
- 2017-11-21 EP EP17871220.4A patent/EP3541414A4/en active Pending
- 2017-11-21 TW TW111119282A patent/TWI822055B/zh active
- 2017-11-21 AU AU2017361549A patent/AU2017361549B2/en active Active
- 2017-11-21 WO PCT/US2017/062886 patent/WO2018094414A1/en active Application Filing
- 2017-11-21 KR KR1020197017395A patent/KR20190077103A/ko not_active Application Discontinuation
- 2017-11-21 JP JP2019527170A patent/JP2019535731A/ja active Pending
- 2017-11-21 TW TW106140308A patent/TWI767959B/zh active
- 2017-11-21 US US15/820,309 patent/US11000601B2/en active Active
-
2019
- 2019-05-16 IL IL266693A patent/IL266693A/en unknown
- 2019-05-24 ZA ZA2019/03308A patent/ZA201903308B/en unknown
-
2020
- 2020-12-23 US US17/133,388 patent/US20210113711A1/en active Pending
-
2023
- 2023-03-15 JP JP2023040609A patent/JP2023088945A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160102151A1 (en) * | 2014-01-16 | 2016-04-14 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
TW201546092A (zh) * | 2014-04-10 | 2015-12-16 | Obi Pharma Inc | 抗體、產生該抗體之融合瘤、包含該抗體之藥學組成物及其用途 |
TW201636363A (zh) * | 2015-01-24 | 2016-10-16 | 中央研究院 | 腫瘤標記及其使用方法 |
Also Published As
Publication number | Publication date |
---|---|
JP2019535731A (ja) | 2019-12-12 |
AU2017361549B2 (en) | 2023-12-21 |
EP3541414A1 (en) | 2019-09-25 |
US11000601B2 (en) | 2021-05-11 |
IL266693A (en) | 2019-07-31 |
CA3044274A1 (en) | 2018-05-24 |
TWI767959B (zh) | 2022-06-21 |
JP2023088945A (ja) | 2023-06-27 |
US20180193481A1 (en) | 2018-07-12 |
CN110290800A (zh) | 2019-09-27 |
ZA201903308B (en) | 2020-09-30 |
WO2018094414A1 (en) | 2018-05-24 |
TW202233250A (zh) | 2022-09-01 |
TW201834695A (zh) | 2018-10-01 |
EP3541414A4 (en) | 2020-11-11 |
BR112019010356A2 (pt) | 2019-08-27 |
KR20190077103A (ko) | 2019-07-02 |
AU2017361549A1 (en) | 2019-06-06 |
US20210113711A1 (en) | 2021-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI822055B (zh) | 共軛生物分子、醫藥組成物及方法 | |
US10660953B2 (en) | Anti-PD-1 antibodies and methods of use thereof | |
RU2714232C2 (ru) | Антитела к c10orf54 и их применения | |
AU2017316663B2 (en) | Antibodies, binding fragments, and methods of use | |
US20210093733A1 (en) | Conjugated biological molecules, pharmaceutical compositions and methods | |
KR101980554B1 (ko) | 암의 치료 및/또는 예방용 의약 조성물 | |
CN110300601A (zh) | 吡咯并苯并二氮杂*-抗体缀合物 | |
JP6916741B2 (ja) | 抗cd19抗体およびブルトン型チロシンキナーゼ阻害剤の組み合わせ、およびその使用 | |
CN103703027B (zh) | 使用抗cd‑19抗体和嘌呤类似物的联合治疗 | |
CN107050460A (zh) | 用于治疗癌症的涉及针对密蛋白18.2之抗体的联合治疗 | |
CN103732252B (zh) | 使用抗cd‑19抗体和氮芥的联合治疗 | |
CN104379166A (zh) | 用于治疗癌症的涉及针对密蛋白18.2之抗体的联合治疗 | |
CN107614521A (zh) | 增进抗体功效的通用糖型组合物及方法 | |
EP4074732A1 (en) | Fully human antibodies against ox40, method for preparing the same, and use thereof | |
JP2024016220A (ja) | 抗体-薬物コンジュゲートを用いた免疫応答の調節 | |
JP2021113194A (ja) | 組み合わせおよびその使用 | |
KR20200024158A (ko) | Btn1a1에 면역특이적으로 결합하는 항체 및 분자를 사용하여 암을 치료하는 방법 | |
TW202035462A (zh) | 使用抗ssea-4抗體結合醫療性腫瘤藥劑的組合醫療 | |
TW202310871A (zh) | 用莫蘇妥珠單抗及帕羅托珠單抗維多汀治療cd20陽性增生性失調之方法 | |
KR20240052084A (ko) | 조합 및 이의 용도 |